data_2lcl_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lcl _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.412 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 28.0 m-85 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.412 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.34 129.37 17.91 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.723 2.282 . . . . 0.0 111.773 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 104.26 -13.53 51.74 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -69.49 156.69 38.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -1.104 . . . . 0.0 109.445 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.463 ' CB ' HD12 ' A' ' 162' ' ' LEU . 18.2 mttp -86.42 139.63 30.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.561 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.631 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.4 m -127.17 154.14 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -0.911 . . . . 0.0 109.402 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.516 ' HB ' ' CD2' ' A' ' 162' ' ' LEU . 2.7 tp -122.44 139.83 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.57 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.434 HD12 ' HB3' ' A' ' 123' ' ' PHE . 83.6 mt -92.58 139.4 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.482 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.419 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 70.9 p -115.14 -10.8 12.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.458 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.38 157.26 43.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.08 162.08 38.01 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.9 -13.46 45.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.145 . . . . 0.0 109.437 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.556 ' CD1' HD22 ' A' ' 143' ' ' LEU . 96.4 m-85 -86.59 12.67 10.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.419 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.3 tt0 -63.42 137.93 58.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.12 -0.81 76.26 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -102.45 139.3 38.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.576 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -91.48 146.72 23.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.517 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -140.68 162.24 35.87 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 128' ' ' ALA . 35.6 mm -117.48 135.01 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.194 -0.941 . . . . 0.0 109.582 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.631 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.6 m-85 -58.55 104.41 0.22 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.523 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 55.4 p -79.79 -32.1 40.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.897 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 163.68 93.62 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.437 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.18 126.74 13.37 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.667 2.245 . . . . 0.0 111.723 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -66.82 -24.89 66.21 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.251 -0.906 . . . . 0.0 109.539 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.03 -179.41 40.56 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -72.64 -24.94 61.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -1.136 . . . . 0.0 109.452 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -75.29 -51.45 13.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.471 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 55.5 mtt85 -110.52 151.33 27.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 57.1 m -139.74 156.16 46.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.924 . . . . 0.0 109.507 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.457 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 56.2 mtp -106.76 119.39 39.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.572 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.6 mp -116.3 154.03 30.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.509 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.518 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 51.5 tp -106.04 124.95 50.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.216 -0.927 . . . . 0.0 109.464 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.56 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -99.19 116.67 31.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -82.73 129.23 34.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.638 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.499 HD13 ' CD1' ' A' ' 150' ' ' ILE . 42.6 mt -121.09 142.12 50.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.398 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.432 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -49.94 -30.6 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.517 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.432 ' N ' HG13 ' A' ' 146' ' ' ILE . 92.9 m-20 -79.24 -47.71 15.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.27 -0.894 . . . . 0.0 109.681 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.515 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 40.2 ttpt -168.77 168.1 10.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.459 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.515 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.9 mt-10 -87.55 137.29 32.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.252 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.509 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 36.1 pt -126.34 149.16 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.202 -0.936 . . . . 0.0 109.774 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.518 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 62.1 mttp -110.45 131.46 55.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -0.882 . . . . 0.0 109.191 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -142.38 140.62 32.1 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.177 -0.952 . . . . 0.0 109.681 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 21.6 p -88.45 122.0 31.46 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.347 -0.846 . . . . 0.0 109.217 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.512 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 3.3 p -124.07 149.99 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.595 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.48 ' N ' HG22 ' A' ' 154' ' ' VAL . 43.3 mttt -76.64 150.5 36.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.881 . . . . 0.0 109.482 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.559 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.9 m-80 -59.69 -23.49 63.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.335 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 74.8 p -81.62 -25.96 35.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.268 -0.895 . . . . 0.0 109.428 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.512 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 88.6 mt-10 -75.03 -24.81 58.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 0.0 109.519 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.559 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 31.9 p90 -136.36 170.78 15.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.43 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -134.23 159.64 40.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.226 -0.921 . . . . 0.0 109.53 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -83.63 146.76 28.09 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.516 ' CD2' ' HB ' ' A' ' 117' ' ' ILE . 23.8 mt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.432 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 53.1 m-85 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.423 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.3 Cg_endo -69.92 135.16 29.4 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.663 2.242 . . . . 0.0 111.795 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.12 -9.04 65.29 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 82.8 m-20 -81.27 146.74 30.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -1.172 . . . . 0.0 109.523 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.402 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 29.4 mtmt -80.51 144.48 32.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 0.0 109.417 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.639 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.4 m -133.47 152.63 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.196 -0.94 . . . . 0.0 109.595 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.411 ' HB ' ' CD2' ' A' ' 162' ' ' LEU . 2.8 tp -121.74 139.51 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.421 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 123' ' ' PHE . 67.7 mt -92.78 130.76 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 70.4 p -116.72 4.04 13.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -0.925 . . . . 0.0 109.624 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 157' ' ' THR . 92.5 mt-10 -137.7 155.73 48.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 87.54 -168.04 37.74 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.6 -7.07 51.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -1.135 . . . . 0.0 109.502 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.562 ' CD1' HD23 ' A' ' 143' ' ' LEU . 80.4 m-85 -88.86 15.81 7.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.41 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 95.8 mt-10 -61.18 135.07 57.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.64 0.71 69.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -102.95 131.96 49.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -1.207 . . . . 0.0 109.488 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -92.61 140.46 29.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.229 -0.92 . . . . 0.0 109.45 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.451 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -136.77 167.01 22.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.176 -0.952 . . . . 0.0 109.536 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.421 HD13 ' O ' ' A' ' 128' ' ' ALA . 30.7 mm -118.31 138.14 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.3 m-85 -58.49 102.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.254 -0.904 . . . . 0.0 109.579 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.524 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 40.9 p -75.8 -33.39 60.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.6 OUTLIER 163.49 95.41 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.308 -0.87 . . . . 0.0 109.347 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.2 Cg_endo -69.76 117.31 5.0 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.695 2.264 . . . . 0.0 111.791 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 18.1 p-10 -66.91 -31.56 72.23 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -0.935 . . . . 0.0 109.573 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.432 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -155.32 172.85 33.55 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -70.15 -28.85 65.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.307 -1.114 . . . . 0.0 109.485 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.67 -53.6 15.13 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.53 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.422 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 79.4 mtt180 -111.86 146.25 38.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.286 -0.883 . . . . 0.0 109.506 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 70.8 m -134.34 157.94 45.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.472 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.468 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 66.9 mtp -102.07 124.8 48.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.468 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.535 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.3 mp -127.22 143.91 51.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.209 -0.932 . . . . 0.0 109.551 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.507 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 45.4 tp -93.79 121.19 34.99 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.955 . . . . 0.0 109.519 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.562 HD23 ' CD1' ' A' ' 123' ' ' PHE . 4.5 mp -93.03 129.62 38.9 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.429 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -103.59 106.98 17.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.882 . . . . 0.0 109.482 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.492 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 7.0 mp -75.03 -175.7 2.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.207 -0.933 . . . . 0.0 109.477 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.521 HG13 ' N ' ' A' ' 147' ' ' ASN . 10.9 pt -60.44 -46.09 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.18 -0.95 . . . . 0.0 109.449 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.521 ' N ' HG13 ' A' ' 146' ' ' ILE . 28.7 p-10 -139.38 23.1 2.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.286 -0.884 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.453 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 40.8 mttt -140.29 151.14 44.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.742 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -120.63 134.13 55.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.33 -0.856 . . . . 0.0 108.992 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.467 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 37.0 pt -133.6 154.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.125 -0.984 . . . . 0.0 109.892 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.507 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 51.5 mttt -123.16 124.79 43.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.34 -0.85 . . . . 0.0 109.286 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -153.19 150.93 29.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 47.9 p -80.14 140.28 36.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.304 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.467 HG12 ' HB2' ' A' ' 158' ' ' GLU . 14.1 t -122.69 155.67 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.492 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 31.0 mttt -91.16 143.99 26.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.434 ' O ' ' O ' ' A' ' 159' ' ' PHE . 1.0 OUTLIER -51.4 -29.44 15.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.511 179.864 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 120' ' ' GLU . 45.9 p -82.57 -22.82 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.526 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.467 ' HB2' HG12 ' A' ' 154' ' ' VAL . 79.9 mt-10 -78.4 -19.99 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.254 -0.904 . . . . 0.0 109.531 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.47 ' CD1' ' O ' ' A' ' 155' ' ' LYS . 33.4 p90 -145.09 162.25 37.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.938 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -131.83 136.47 47.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.535 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -60.86 134.46 57.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.413 HD12 ' N ' ' A' ' 116' ' ' VAL . 9.2 mt . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.472 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.462 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 48.2 m-85 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.01 137.48 34.82 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.702 2.268 . . . . 0.0 111.829 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.78 -10.07 68.47 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.462 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.8 m-20 -82.39 145.48 29.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.252 -1.146 . . . . 0.0 109.461 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.456 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 30.5 mttm -75.83 142.23 42.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.615 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.5 m -132.45 150.97 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.446 ' HB ' HD11 ' A' ' 162' ' ' LEU . 4.5 tp -123.43 141.75 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.491 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.451 HD11 ' CB ' ' A' ' 123' ' ' PHE . 61.2 mt -92.59 131.12 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.236 -0.915 . . . . 0.0 109.443 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.432 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.2 p -106.95 -8.39 16.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.6 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -137.37 157.29 46.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.23 -0.919 . . . . 0.0 109.572 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.21 165.14 37.75 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.67 -19.87 65.25 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.445 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.543 ' CD1' HD22 ' A' ' 143' ' ' LEU . 94.3 m-85 -86.38 13.48 8.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.454 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.432 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 87.0 tt0 -66.25 137.88 57.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.471 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.51 0.26 73.23 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -106.4 134.72 49.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -1.162 . . . . 0.0 109.484 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -79.93 147.62 31.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.222 -0.924 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.457 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.33 163.63 32.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.456 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 24.0 mm -121.29 139.23 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -0.875 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.615 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 42.2 m-85 -60.92 114.41 3.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.192 -0.943 . . . . 0.0 109.442 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.519 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.3 p -87.37 -30.76 20.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 163.79 82.2 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.896 . . . . 0.0 109.455 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.07 130.74 19.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.723 2.282 . . . . 0.0 111.827 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -67.83 -32.72 73.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.291 -0.88 . . . . 0.0 109.475 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -170.54 -177.48 40.65 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.62 -29.46 70.47 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.272 -1.134 . . . . 0.0 109.521 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -63.68 -60.41 3.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.165 -0.96 . . . . 0.0 109.438 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.453 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.2 mtt180 -112.72 155.74 24.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 53.4 m -146.5 149.07 32.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.434 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.463 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 82.1 mmm -95.31 125.14 39.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.389 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.547 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.3 mp -125.46 140.4 52.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.163 -0.961 . . . . 0.0 109.631 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.524 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 6.0 tt -96.04 123.9 39.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.322 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.58 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.6 mp -99.51 113.65 26.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.652 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -89.52 124.27 34.37 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.494 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 3.5 mm? -85.27 175.22 9.06 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.152 -0.967 . . . . 0.0 109.392 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 147' ' ' ASN . 17.6 pt -58.93 -38.12 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.483 ' N ' HG13 ' A' ' 146' ' ' ILE . 24.2 m120 -138.89 19.61 2.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.958 . . . . 0.0 109.407 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.469 ' O ' ' N ' ' A' ' 145' ' ' LEU . 85.7 mttt -143.64 156.56 44.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.26 -0.9 . . . . 0.0 109.631 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -121.38 124.9 45.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.196 -0.94 . . . . 0.0 109.191 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.47 HD11 ' CE1' ' A' ' 123' ' ' PHE . 32.8 pt -128.73 156.03 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.918 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.524 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.7 mttt -131.56 132.18 43.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.339 -0.851 . . . . 0.0 109.27 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 153' ' ' SER . 57.8 t-80 -152.28 144.79 24.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.141 -0.974 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.429 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 45.9 p -68.7 142.61 54.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.33 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.466 HG11 ' HB2' ' A' ' 158' ' ' GLU . 19.7 t -129.85 150.78 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.537 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 158' ' ' GLU . 90.5 mttt -94.11 139.12 31.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.33 -0.856 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.576 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.0 p30 -46.0 -29.06 1.32 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.169 -0.957 . . . . 0.0 109.582 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 57.9 p -82.24 -21.92 36.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 109.595 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.2 mt-10 -81.22 -20.6 40.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.576 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 27.7 p90 -140.74 172.14 13.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -0.937 . . . . 0.0 109.561 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -130.85 147.73 52.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -78.57 133.54 37.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.273 -0.892 . . . . 0.0 109.504 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.446 HD11 ' HB ' ' A' ' 117' ' ' ILE . 15.9 mt . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.468 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 6.5 m-85 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.64 131.52 23.07 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.73 2.286 . . . . 0.0 111.712 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.65 -11.98 59.5 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.441 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.6 m-20 -77.44 157.43 30.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -1.155 . . . . 0.0 109.497 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.511 ' CB ' HD21 ' A' ' 162' ' ' LEU . 55.9 mttt -80.35 142.12 34.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.299 -0.876 . . . . 0.0 109.448 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.603 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 5.8 m -127.59 159.48 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.506 ' CG2' ' O ' ' A' ' 160' ' ' ARG . 8.3 tp -123.37 147.32 27.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 15.2 mm -91.45 131.63 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.264 -0.897 . . . . 0.0 109.475 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.422 ' C ' ' HG2' ' A' ' 124' ' ' GLU . 72.7 p -121.65 5.5 10.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.267 -0.896 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.411 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -141.73 151.16 42.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -0.936 . . . . 0.0 109.442 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 85.13 -170.27 44.94 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.73 -2.4 58.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -1.201 . . . . 0.0 109.625 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.564 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 93.1 m-85 -87.94 4.78 43.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.63 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.422 ' HG2' ' C ' ' A' ' 119' ' ' THR . 97.5 mt-10 -56.5 142.09 40.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.7 -3.46 83.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.564 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.8 m-30 -102.36 147.71 26.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -1.17 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -100.17 151.03 21.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.387 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -146.74 161.34 40.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.227 -0.92 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.478 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 22.8 mm -114.02 140.54 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.484 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.5 m-85 -61.42 112.86 2.36 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.275 -0.891 . . . . 0.0 109.443 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 46.0 p -82.36 -32.13 29.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.457 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.8 mm-40 164.4 91.72 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.156 -0.965 . . . . 0.0 109.488 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.2 Cg_endo -70.11 122.99 9.55 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.597 2.198 . . . . 0.0 111.771 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -65.81 -31.26 72.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.47 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -163.26 179.84 38.18 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.04 -26.85 63.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.218 -1.166 . . . . 0.0 109.541 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.36 -53.72 15.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.461 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 59.0 mtt180 -112.32 151.44 29.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.516 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 54.4 m -142.32 150.43 40.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.303 -0.873 . . . . 0.0 109.465 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.441 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 48.8 mtp -100.37 127.31 46.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.5 mp -125.38 146.42 49.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.483 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.527 ' O ' ' CB ' ' A' ' 128' ' ' ALA . 9.7 tt -97.44 126.3 42.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.478 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 39.1 mt -97.93 109.88 22.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.542 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.411 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 14.9 p-10 -84.63 122.6 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 0.0 109.621 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.551 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 3.0 mm? -111.23 141.43 44.77 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.383 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.484 HG13 ' N ' ' A' ' 147' ' ' ASN . 21.3 pt -50.03 -35.75 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.499 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 61.3 t30 -72.42 -49.22 35.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.288 -0.882 . . . . 0.0 109.575 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.499 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 67.3 mttt -158.11 173.38 16.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.543 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -103.17 133.21 48.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.924 . . . . 0.0 109.312 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.506 HD12 HG22 ' A' ' 150' ' ' ILE . 17.2 pt -133.99 159.27 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.625 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.517 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 13.3 mttt -119.63 136.95 54.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.282 -0.886 . . . . 0.0 109.33 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -144.31 140.24 29.04 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.585 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 23.5 p -85.1 125.19 32.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.338 -0.851 . . . . 0.0 109.313 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.51 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 4.0 p -127.97 147.92 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.196 -0.94 . . . . 0.0 109.547 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.54 ' O ' ' CD2' ' A' ' 159' ' ' PHE . 88.8 mttt -76.08 155.27 34.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.231 -0.918 . . . . 0.0 109.464 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.573 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 20.3 m-80 -62.71 -27.09 69.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.453 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 64.7 p -77.33 -18.86 57.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.356 -0.84 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.51 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.3 mt-10 -87.72 -19.78 27.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.475 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.573 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 29.8 p90 -138.08 161.03 37.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -0.951 . . . . 0.0 109.583 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.506 ' O ' ' CG2' ' A' ' 117' ' ' ILE . 73.7 mtt180 -129.53 147.77 51.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.317 -0.864 . . . . 0.0 109.475 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 25.7 tttt -73.55 123.88 24.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.511 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.487 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.46 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 52.8 m-85 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.459 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 49.4 Cg_endo -70.2 135.01 28.37 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.675 2.25 . . . . 0.0 111.754 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.82 -10.11 66.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.46 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.2 m-20 -83.99 147.53 27.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -1.123 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.509 ' CB ' HD21 ' A' ' 162' ' ' LEU . 22.7 mttm -72.98 145.08 46.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.902 . . . . 0.0 109.456 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.625 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.3 m -133.79 150.42 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.476 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 1.8 tp -119.95 139.29 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.461 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.452 HD11 HD23 ' A' ' 143' ' ' LEU . 58.8 mt -92.53 130.08 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.287 -0.883 . . . . 0.0 109.501 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.474 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 60.5 p -106.96 -10.26 16.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -132.87 157.36 45.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 109.522 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.66 166.85 36.33 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.59 -22.31 64.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.571 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 96.9 m-85 -82.51 8.13 12.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.224 -0.922 . . . . 0.0 109.52 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.474 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -57.64 139.9 52.51 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.297 -0.877 . . . . 0.0 109.522 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.53 -5.26 73.82 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.571 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.5 m-30 -99.99 145.79 27.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.247 -1.149 . . . . 0.0 109.464 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -94.55 146.45 24.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.935 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.456 ' O ' HG23 ' A' ' 116' ' ' VAL . . . -142.21 160.18 40.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.299 -0.875 . . . . 0.0 109.42 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.449 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 25.8 mm -114.71 140.06 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.48 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.625 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.8 m-85 -61.42 110.15 1.36 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.295 -0.878 . . . . 0.0 109.495 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.52 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 39.3 p -80.46 -32.5 37.18 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.317 -0.864 . . . . 0.0 109.477 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 164.32 86.58 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.267 -0.895 . . . . 0.0 109.398 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.5 Cg_endo -69.79 128.56 16.17 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.773 2.316 . . . . 0.0 111.799 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -69.06 -29.34 67.45 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.517 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -167.92 174.81 42.87 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -62.07 -27.97 69.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.68 -64.93 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.164 -0.96 . . . . 0.0 109.476 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.402 ' O ' ' O ' ' A' ' 135' ' ' GLY . 49.9 mtm-85 -105.08 152.08 23.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.532 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 65.2 m -142.46 152.15 42.44 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.51 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 66.2 mmm -96.58 123.61 40.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.574 HD23 ' CD2' ' A' ' 159' ' ' PHE . 6.5 mp -122.5 142.89 50.11 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.945 . . . . 0.0 109.636 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.505 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 15.1 tp -103.86 119.36 38.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.273 -0.892 . . . . 0.0 109.417 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.577 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -100.57 109.14 21.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.501 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.431 ' O ' ' CG ' ' A' ' 144' ' ' ASN . 11.3 p-10 -83.11 118.86 23.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.567 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.519 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 3.0 mm? -82.03 168.83 17.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.259 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.496 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.2 pt -54.15 -38.27 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.19 -0.944 . . . . 0.0 109.638 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.496 ' N ' HG13 ' A' ' 146' ' ' ILE . 30.3 p-10 -139.19 25.09 2.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -0.984 . . . . 0.0 109.787 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 76.0 mttt -152.61 157.41 40.97 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.0 109.815 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -128.11 130.86 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.383 -0.823 . . . . 0.0 109.112 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.505 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 21.3 pt -131.45 145.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.134 -0.978 . . . . 0.0 109.835 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 19.6 mttp -118.53 126.79 52.75 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 0.0 109.298 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.494 ' CE1' ' O ' ' A' ' 153' ' ' SER . 52.5 t-80 -153.85 145.73 23.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.168 -0.958 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.494 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 52.5 p -74.48 141.48 44.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.216 -0.928 . . . . 0.0 109.356 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.448 HG12 ' HB2' ' A' ' 158' ' ' GLU . 21.3 t -124.78 150.4 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.444 ' HB2' ' HG3' ' A' ' 158' ' ' GLU . 61.3 mttp -86.06 138.46 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -49.96 -22.99 1.75 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.943 . . . . 0.0 109.494 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.7 p -86.62 -25.39 24.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.175 -0.953 . . . . 0.0 109.463 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.448 ' HB2' HG12 ' A' ' 154' ' ' VAL . 97.6 mt-10 -76.63 -23.39 53.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -0.865 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.574 ' CD2' HD23 ' A' ' 141' ' ' LEU . 22.7 p90 -140.62 160.95 38.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 109.491 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -128.89 142.15 51.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.219 -0.925 . . . . 0.0 109.512 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -70.43 124.99 25.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.208 -0.933 . . . . 0.0 109.422 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.509 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.496 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.439 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 65.9 m-85 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.427 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.2 Cg_endo -69.64 132.27 23.16 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.681 2.254 . . . . 0.0 111.756 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.54 -10.55 61.12 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 81.5 m-20 -77.85 150.72 34.15 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.176 -1.191 . . . . 0.0 109.451 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.516 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 28.8 mttt -84.81 141.51 30.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.47 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.598 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.8 m -129.04 158.89 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.463 ' O ' ' HB2' ' A' ' 159' ' ' PHE . 7.3 tp -126.59 148.73 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.151 -0.968 . . . . 0.0 109.505 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.446 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 25.9 mm -90.52 127.84 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.451 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 72.8 p -112.83 -5.36 13.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.275 -0.891 . . . . 0.0 109.502 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.457 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 85.2 tt0 -138.51 156.28 47.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.202 -0.936 . . . . 0.0 109.421 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.457 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 86.5 169.57 46.05 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.22 -14.63 63.13 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -1.163 . . . . 0.0 109.527 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.516 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 85.6 m-85 -82.78 6.85 16.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 84.5 tt0 -59.45 132.84 55.2 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.565 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 99.46 1.17 56.67 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.516 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -103.49 138.58 40.01 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.12 -1.224 . . . . 0.0 109.59 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -93.98 122.58 36.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.211 -0.931 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.48 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -118.52 165.77 13.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.58 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.516 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 41.9 mm -120.43 139.29 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.598 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.6 m-85 -58.65 101.37 0.09 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.906 . . . . 0.0 109.516 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.525 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 49.2 p -77.15 -30.52 55.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.286 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.2 mt-10 163.63 97.15 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.262 -0.899 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.85 114.63 3.78 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.707 2.272 . . . . 0.0 111.763 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -66.55 -33.6 76.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.492 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -145.01 163.0 28.11 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.66 -31.99 72.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -1.146 . . . . 0.0 109.184 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.17 -73.91 0.15 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.6 ptt-85 -84.96 158.32 20.55 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.285 -0.885 . . . . 0.0 109.611 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 71.1 m -145.79 144.58 30.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.514 ' SD ' ' CB ' ' A' ' 153' ' ' SER . 89.8 mmm -86.58 118.89 26.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.251 -0.906 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.521 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.8 mp -122.61 146.07 47.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.521 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.48 ' O ' ' CB ' ' A' ' 128' ' ' ALA . 9.4 tt -99.37 127.44 45.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.434 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.431 HD21 ' HB3' ' A' ' 128' ' ' ALA . 17.9 mt -96.8 115.04 26.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -86.75 126.6 34.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.465 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 9.6 mp -129.46 136.33 49.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.242 -0.911 . . . . 0.0 109.362 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.501 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -50.55 -35.09 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.888 . . . . 0.0 109.614 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.501 ' N ' HG13 ' A' ' 146' ' ' ILE . 47.7 t-20 -68.68 -47.56 66.16 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.915 . . . . 0.0 109.585 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 55.5 tttp -168.09 158.98 10.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.166 -0.959 . . . . 0.0 109.576 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.47 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 97.0 mt-10 -93.81 125.72 38.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.95 . . . . 0.0 109.5 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 27.8 pt -126.34 158.63 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.205 -0.935 . . . . 0.0 109.428 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.438 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 17.1 mttt -124.62 131.55 53.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.543 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -142.6 147.06 35.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 39.3 p -72.18 139.66 48.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.519 HG13 ' CD1' ' A' ' 159' ' ' PHE . 21.8 t -131.08 150.63 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 24.6 mttm -97.16 138.72 34.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 32.1 m-80 -45.06 -30.64 1.11 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 65.9 p -81.15 -25.21 37.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.287 -0.883 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 92.0 mt-10 -76.21 -23.67 54.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.577 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 27.5 p90 -137.41 167.05 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 63.5 mtt85 -130.21 146.84 51.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . 0.426 ' HE3' ' HB3' ' A' ' 114' ' ' ASP . 73.8 tttt -72.8 117.23 14.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.436 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.448 HD22 ' HB3' ' A' ' 115' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.466 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.46 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 43.7 m-85 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 133.61 25.19 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.69 2.26 . . . . 0.0 111.873 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.34 -10.69 61.52 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.46 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.6 m-20 -85.57 144.69 27.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.288 -1.124 . . . . 0.0 109.498 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -75.45 147.02 40.22 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 109.517 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.635 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.8 m -134.9 151.41 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.515 HG21 ' CD2' ' A' ' 162' ' ' LEU . 3.8 tp -123.94 141.07 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.446 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 61.8 mt -92.18 129.95 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.321 -0.862 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.492 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 p -105.65 -7.6 18.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.537 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.435 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 97.8 mt-10 -138.02 158.16 44.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.484 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.4 168.11 38.55 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.95 -22.7 65.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.222 -1.163 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.524 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.9 m-85 -83.47 9.46 11.17 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.244 -0.91 . . . . 0.0 109.417 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.492 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -61.76 140.89 58.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.96 -6.06 76.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.524 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.0 m-85 -99.89 149.8 23.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -1.153 . . . . 0.0 109.557 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -98.45 147.86 24.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.319 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.474 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -143.69 162.61 35.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.898 . . . . 0.0 109.502 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 26.1 mm -113.47 143.87 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.45 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.635 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 33.6 m-85 -66.06 113.01 4.16 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.525 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 18.1 p -82.4 -33.17 28.78 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.952 . . . . 0.0 109.437 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.89 90.3 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.425 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.5 Cg_endo -69.78 122.66 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.686 2.257 . . . . 0.0 111.799 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 21.3 p-10 -65.89 -31.21 72.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.664 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.509 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -164.66 178.6 39.79 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -67.61 -27.05 66.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.308 -1.113 . . . . 0.0 109.543 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.04 -63.2 1.14 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 58.1 mtt180 -108.37 158.53 17.42 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 109.548 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 72.6 m -145.28 155.38 43.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.394 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.455 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 64.6 mtp -102.21 124.27 47.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.56 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.2 mp -122.25 145.79 47.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.525 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 7.8 tt -104.8 120.82 42.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.915 . . . . 0.0 109.521 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.557 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.7 mp -96.37 136.1 37.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.44 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.498 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 92.7 m-20 -106.21 112.41 25.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.541 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.433 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 44.1 mt -100.24 148.08 25.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.495 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -51.13 -40.12 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.495 ' N ' HG13 ' A' ' 146' ' ' ILE . 45.8 t-20 -68.7 -48.08 64.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.54 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.494 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 28.3 ttpp -168.46 164.6 12.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.287 -0.883 . . . . 0.0 109.466 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.494 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 95.1 mt-10 -87.88 139.19 30.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.7 158.18 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.25 -0.906 . . . . 0.0 109.402 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.449 ' HG2' HD12 ' A' ' 142' ' ' LEU . 20.8 mttt -125.84 130.45 51.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.196 -0.94 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.411 ' ND1' ' O ' ' A' ' 153' ' ' SER . 56.5 t-80 -153.17 141.61 20.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 109.436 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.411 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 68.6 m -67.77 142.59 56.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -0.958 . . . . 0.0 109.438 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.462 HG13 ' CD1' ' A' ' 159' ' ' PHE . 16.8 t -131.03 151.6 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.418 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 9.5 mtpm? -92.04 137.29 32.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.893 . . . . 0.0 109.508 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.582 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.0 m-80 -50.66 -24.36 3.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 109.415 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.6 p -84.78 -22.49 29.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.907 . . . . 0.0 109.356 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.414 ' HG2' ' HB2' ' A' ' 155' ' ' LYS . 68.6 mm-40 -81.47 -20.7 39.66 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.582 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.14 178.29 7.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.464 ' HD2' HG22 ' A' ' 119' ' ' THR . 59.1 mtt-85 -134.65 146.63 49.71 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.871 . . . . 0.0 109.402 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -84.71 135.75 34.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.447 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.515 ' CD2' HG21 ' A' ' 117' ' ' ILE . 68.0 mt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.415 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.418 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 33.0 m-85 . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.17 134.04 28.21 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.693 2.262 . . . . 0.0 111.819 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.03 -17.55 54.0 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -68.47 162.71 24.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -1.151 . . . . 0.0 109.38 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.473 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 36.5 mttm -88.01 139.48 30.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.282 -0.886 . . . . 0.0 109.572 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.589 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.7 m -133.48 148.98 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.438 ' CG2' ' HB3' ' A' ' 162' ' ' LEU . 5.1 tp -116.67 141.45 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.556 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.6 mt -92.61 130.72 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.422 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.45 HG23 ' HD2' ' A' ' 160' ' ' ARG . 61.3 p -107.27 -5.02 18.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.462 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 83.9 tt0 -141.41 155.53 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.521 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.462 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 100.33 166.83 28.83 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.37 -22.22 64.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.527 ' CD1' HD13 ' A' ' 143' ' ' LEU . 77.8 m-85 -87.64 12.87 11.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.1 136.94 58.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.254 -0.904 . . . . 0.0 109.432 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.91 66.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -105.68 122.75 46.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -1.168 . . . . 0.0 109.541 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -72.05 137.35 47.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.298 -0.876 . . . . 0.0 109.306 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.461 ' CB ' HD21 ' A' ' 143' ' ' LEU . . . -133.68 158.52 43.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.208 -0.932 . . . . 0.0 109.563 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.473 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 29.5 mm -116.64 136.0 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.444 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.589 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 35.2 m-85 -58.61 101.77 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.519 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 44.8 p -75.05 -39.06 61.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.386 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 131' ' ' THR . 67.9 tt0 172.98 95.77 0.05 OUTLIER Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.9 . . . . 0.0 109.441 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.16 110.72 2.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.718 2.279 . . . . 0.0 111.848 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.5 p-10 -62.68 -34.42 77.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.504 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.417 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -141.85 178.06 20.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -76.91 -30.02 55.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -1.129 . . . . 0.0 109.406 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -69.46 -78.06 0.07 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.407 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.46 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 13.3 ptt180 -89.77 148.13 23.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.248 -0.907 . . . . 0.0 109.743 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.1 m -135.33 155.38 50.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 0.0 109.492 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.488 ' SD ' ' CB ' ' A' ' 153' ' ' SER . 93.6 mmm -89.92 115.55 27.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.519 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.1 mp -119.74 139.52 52.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.892 . . . . 0.0 109.481 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.515 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 9.0 tp -97.48 122.16 40.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.527 HD13 ' CD1' ' A' ' 123' ' ' PHE . 22.1 mt -87.95 146.46 25.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.316 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -115.98 107.96 15.63 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.601 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.523 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.0 mp -105.23 141.18 37.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.938 . . . . 0.0 109.302 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.456 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.0 pt -50.39 -32.5 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.522 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.7 m-20 -73.12 -56.41 5.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.289 -0.882 . . . . 0.0 109.674 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.522 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 60.2 mttm -159.58 171.32 19.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.513 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.58 139.08 38.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.337 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.515 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 20.1 pt -132.8 142.43 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.231 -0.918 . . . . 0.0 109.46 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -96.5 130.02 43.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.24 -0.913 . . . . 0.0 109.474 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -147.52 138.57 23.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.488 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 52.1 p -73.2 141.45 47.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.278 -0.889 . . . . 0.0 109.441 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.499 HG11 ' CD1' ' A' ' 159' ' ' PHE . 12.2 t -128.81 151.56 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -0.91 . . . . 0.0 109.56 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 45.4 mttp -100.87 138.36 38.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.376 -0.828 . . . . 0.0 109.423 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.572 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.1 p30 -46.04 -28.28 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.493 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 72.0 p -84.94 -19.64 31.88 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.25 -0.906 . . . . 0.0 109.629 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.6 mt-10 -83.23 -22.34 33.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.182 -0.949 . . . . 0.0 109.459 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.572 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 29.9 p90 -136.93 173.03 12.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.215 -0.928 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.45 ' HD2' HG23 ' A' ' 119' ' ' THR . 96.6 mtt180 -134.99 145.17 47.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.515 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -69.34 113.59 6.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.53 HD22 ' CA ' ' A' ' 116' ' ' VAL . 1.9 pp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.406 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.7 138.22 37.48 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.722 2.281 . . . . 0.0 111.79 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.85 -11.61 66.12 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.99 151.7 40.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -1.144 . . . . 0.0 109.403 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.524 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.5 mttm -80.26 139.75 36.54 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.7 m -129.23 156.3 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.427 HG21 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.24 146.1 29.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.598 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 20.5 mm -90.13 120.27 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.394 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 58.1 p -103.03 -16.06 15.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.42 155.56 50.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.459 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.94 165.04 35.45 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.95 -15.35 62.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 0.0 109.441 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.546 ' CD1' HD21 ' A' ' 143' ' ' LEU . 88.7 m-85 -86.49 11.75 11.88 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.45 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.1 tt0 -59.04 134.74 57.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.97 67.18 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.464 ' CE2' ' HG ' ' A' ' 145' ' ' LEU . 40.7 m-85 -99.19 137.62 37.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.098 -1.236 . . . . 0.0 109.545 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -90.99 129.38 37.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.323 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -130.08 163.72 25.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.56 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.524 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 31.0 mm -119.42 139.76 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.308 -0.87 . . . . 0.0 109.408 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.594 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 38.0 m-85 -58.6 101.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -0.933 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.501 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 41.0 p -77.58 -28.33 51.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.7 OUTLIER 164.93 98.01 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.484 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.0 Cg_endo -69.82 114.83 3.84 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.733 2.289 . . . . 0.0 111.805 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -60.94 -30.7 70.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 109.506 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -166.15 174.45 41.72 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -67.34 -22.81 65.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -1.144 . . . . 0.0 109.491 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.92 -64.63 1.01 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.45 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 57.5 mtm-85 -107.72 159.61 16.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 55.7 m -144.98 157.93 43.97 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -0.864 . . . . 0.0 109.471 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.429 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 33.8 mtp -101.97 120.91 41.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.57 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.4 mp -120.31 147.31 45.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.514 ' O ' ' CB ' ' A' ' 128' ' ' ALA . 11.9 tp -99.87 124.01 44.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.45 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.573 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.1 mp -100.89 109.51 21.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.195 -0.941 . . . . 0.0 109.457 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -83.24 125.44 31.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.908 . . . . 0.0 109.553 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 7.7 mp -118.3 141.87 48.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.16 -0.962 . . . . 0.0 109.468 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.425 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.4 pt -51.6 -30.93 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.478 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.506 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 95.6 m-20 -74.98 -55.24 5.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.263 -0.898 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.506 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 33.9 mttt -158.68 171.78 19.47 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.223 -0.923 . . . . 0.0 109.622 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -101.01 131.3 46.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.239 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.459 ' O ' HG13 ' A' ' 150' ' ' ILE . 6.9 pt -129.87 144.77 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.742 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.2 mttt -108.47 136.57 47.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.039 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.09 140.02 20.97 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.004 -1.06 . . . . 0.0 109.831 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.4 p -85.19 121.8 28.46 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.39 -0.819 . . . . 0.0 109.047 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.521 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 2.9 p -121.13 151.55 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.15 -0.969 . . . . 0.0 109.638 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.501 ' N ' HG23 ' A' ' 154' ' ' VAL . 35.2 mttt -75.21 149.25 38.97 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.327 -0.858 . . . . 0.0 109.577 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.565 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.1 m-80 -60.56 -26.09 66.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.7 p -78.51 -20.69 50.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.293 -0.88 . . . . 0.0 109.53 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.521 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 72.8 mm-40 -83.28 -22.06 33.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.908 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.565 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 35.4 p90 -138.35 156.19 47.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.427 ' O ' HG21 ' A' ' 117' ' ' ILE . 17.3 ttt85 -127.93 137.08 52.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 16.8 pttt -72.19 161.03 31.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.174 -0.954 . . . . 0.0 109.405 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.54 ' CD1' ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.079 -0.963 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.77 132.34 24.75 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.728 2.285 . . . . 0.0 111.824 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 106.83 -14.79 41.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.49 158.96 25.71 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -1.146 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -92.78 145.92 24.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.278 -0.889 . . . . 0.0 109.48 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.639 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 17.4 m -128.71 152.48 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.476 ' N ' HD11 ' A' ' 162' ' ' LEU . 7.3 tp -123.6 148.59 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.463 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.0 mm -92.58 132.51 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.23 -0.919 . . . . 0.0 109.463 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 52.2 p -121.32 5.39 10.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.196 -0.94 . . . . 0.0 109.619 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.414 ' OE1' ' HA ' ' A' ' 158' ' ' GLU . 94.0 mt-10 -141.36 152.14 44.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.14 -0.975 . . . . 0.0 109.501 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.463 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 84.25 -171.94 48.64 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.25 -5.72 59.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -1.146 . . . . 0.0 109.54 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.57 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 83.1 m-85 -85.46 7.7 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.578 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 121' ' ' GLY . 97.6 mt-10 -58.96 141.1 54.71 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 109.572 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.56 -6.83 80.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 20.6 m-30 -96.97 147.62 23.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.224 -1.162 . . . . 0.0 109.614 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -104.54 154.19 20.23 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.356 -0.84 . . . . 0.0 109.334 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.514 ' O ' ' CG2' ' A' ' 116' ' ' VAL . . . -147.88 162.05 40.06 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.595 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.431 HG22 ' N ' ' A' ' 130' ' ' PHE . 23.9 mm -112.39 144.34 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.587 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 35.1 m-85 -66.48 103.33 1.03 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.382 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.514 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.8 p -76.29 -34.2 59.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.527 ' O ' ' CG ' ' A' ' 140' ' ' MET . 2.2 mt-10 165.14 89.79 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.164 -0.96 . . . . 0.0 109.731 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.1 130.78 19.5 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.608 2.205 . . . . 0.0 111.694 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -68.17 -30.57 69.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -171.18 177.96 43.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -63.45 -25.76 68.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.254 -1.145 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.08 -62.27 1.51 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.7 mtt180 -110.01 157.98 18.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.3 m -142.46 153.05 43.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.527 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 85.7 mmm -99.73 124.0 44.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.555 HD23 ' CE1' ' A' ' 130' ' ' PHE . 42.0 mt -122.94 145.89 48.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.52 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 2.7 tt -101.2 126.39 47.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.168 -0.958 . . . . 0.0 109.646 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.555 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.8 mp -99.55 104.37 16.16 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.223 -0.923 . . . . 0.0 109.157 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -77.54 125.56 29.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.127 -0.983 . . . . 0.0 109.335 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.444 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 69.1 mt -117.72 141.35 48.49 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.32 -0.863 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.5 pt -51.55 -29.04 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.495 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.3 m-20 -78.47 -53.08 7.62 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.495 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 83.5 mttt -158.29 172.57 18.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.3 -0.875 . . . . 0.0 109.469 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -100.89 125.16 47.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.43 HG21 HD11 ' A' ' 145' ' ' LEU . 32.2 pt -120.87 158.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.923 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.52 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 3.2 mtpm? -125.27 132.25 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.428 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -144.67 141.33 29.26 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.505 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 38.5 p -73.33 141.22 47.1 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.887 . . . . 0.0 109.32 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 155' ' ' LYS . 19.4 t -133.09 152.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.114 -0.991 . . . . 0.0 109.618 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 39.0 mtmt -91.28 141.46 28.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.519 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 18.5 m-80 -51.21 -26.2 6.66 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.3 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 45.6 p -83.83 -19.18 35.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.304 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.455 ' HB2' HG13 ' A' ' 154' ' ' VAL . 94.9 mt-10 -84.87 -13.42 50.97 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.353 -0.842 . . . . 0.0 109.45 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.519 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -148.74 173.5 13.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.208 -0.933 . . . . 0.0 109.398 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -131.16 143.99 51.04 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.197 -0.939 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -80.78 135.09 35.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.49 ' CD1' ' N ' ' A' ' 162' ' ' LEU . 6.7 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.495 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 72.0 m-85 . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.485 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 47.9 Cg_endo -69.07 130.72 20.72 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.767 2.311 . . . . 0.0 111.783 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.23 -8.21 55.18 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -83.1 166.41 18.73 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -1.185 . . . . 0.0 109.577 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 28.8 mtpt -90.85 140.36 29.88 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.62 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 9.9 m -129.77 155.92 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.546 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.511 ' HB ' ' CD1' ' A' ' 162' ' ' LEU . 8.6 tp -120.55 145.19 27.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.343 -0.848 . . . . 0.0 109.475 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 15.0 mm -90.25 134.02 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.937 . . . . 0.0 109.463 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.447 HG23 ' HD3' ' A' ' 160' ' ' ARG . 44.4 p -120.67 -0.05 10.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.512 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.46 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 93.9 mt-10 -138.39 153.4 48.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.4 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.427 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.28 -171.51 44.16 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.95 -3.62 58.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -1.13 . . . . 0.0 109.603 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.567 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.2 m-85 -89.13 9.55 25.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.502 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.46 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 98.3 mt-10 -59.23 141.89 53.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.586 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 88.57 -3.59 85.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.567 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.7 m-30 -100.17 143.22 30.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.167 -1.196 . . . . 0.0 109.565 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . 0.406 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 93.6 mt-30 -93.22 149.76 20.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.252 -0.905 . . . . 0.0 109.375 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.527 ' CB ' ' CG2' ' A' ' 116' ' ' VAL . . . -142.23 160.8 39.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 25.8 mm -114.99 136.52 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.18 -0.95 . . . . 0.0 109.453 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.62 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 34.8 m-85 -59.8 109.89 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.219 -0.926 . . . . 0.0 109.708 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.51 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 60.7 p -79.61 -34.85 40.34 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 109.34 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.98 96.9 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -70.83 109.27 2.47 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.653 2.235 . . . . 0.0 111.59 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -76.02 0.11 19.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.736 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -172.48 160.68 32.01 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -66.32 -41.85 89.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -1.152 . . . . 0.0 109.314 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -65.5 -77.51 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.288 -0.882 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.0 ptp180 -80.46 151.53 29.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.91 . . . . 0.0 109.564 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.464 ' OG ' HD12 ' A' ' 141' ' ' LEU . 88.7 p -145.57 156.71 43.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.528 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' MET . . . . . . . . . . . . . 48.7 mtp -100.2 119.25 38.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.569 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 5.1 mp -124.24 148.52 47.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.278 -0.888 . . . . 0.0 109.506 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.513 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.7 tt -97.52 126.74 42.97 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.352 -0.843 . . . . 0.0 109.397 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.53 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 35.3 mt -96.47 110.42 22.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.227 -0.921 . . . . 0.0 109.377 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.417 ' C ' HD21 ' A' ' 145' ' ' LEU . 15.5 p-10 -82.73 124.03 29.86 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.852 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.53 ' CD2' ' O ' ' A' ' 143' ' ' LEU . 3.0 mm? -117.34 144.02 45.35 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.513 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.6 pt -50.08 -35.73 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.438 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.513 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.3 m-20 -71.35 -55.44 7.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.59 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 43.8 mttm -157.58 173.33 17.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.28 -0.887 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -99.12 128.79 45.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.259 -0.901 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.429 HG12 HD22 ' A' ' 145' ' ' LEU . 19.2 pt -125.5 158.02 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.513 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 24.0 mttp -119.26 135.58 54.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.382 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -144.91 145.92 31.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.58 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.2 p -86.17 121.28 28.54 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.349 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.5 HG23 ' N ' ' A' ' 155' ' ' LYS . 4.7 p -124.92 147.86 29.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.208 -0.932 . . . . 0.0 109.591 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.573 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.2 mttt -75.76 150.97 37.67 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.349 -0.844 . . . . 0.0 109.657 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.561 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 13.9 m-80 -61.51 -24.17 66.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.4 p -79.58 -21.08 45.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.246 -0.909 . . . . 0.0 109.495 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.485 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.8 mt-10 -81.18 -22.65 38.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.554 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 155' ' ' LYS . 41.7 p90 -138.47 170.51 15.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.925 . . . . 0.0 109.464 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.465 ' CG ' ' CG2' ' A' ' 117' ' ' ILE . 27.1 ptt180 -134.79 158.72 43.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.181 -0.949 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -88.59 139.26 30.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.511 ' CD1' ' HB ' ' A' ' 117' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.98 134.04 26.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.722 2.281 . . . . 0.0 111.713 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.482 ' HA2' ' CG2' ' A' ' 129' ' ' ILE . . . 89.88 -8.99 78.77 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.467 ' O ' HG22 ' A' ' 129' ' ' ILE . 29.0 p-10 -68.22 -178.85 1.13 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -1.153 . . . . 0.0 109.384 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.448 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 26.9 mttp -103.0 139.75 38.17 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.536 HG13 ' CE2' ' A' ' 130' ' ' PHE . 7.9 m -134.41 154.51 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.865 . . . . 0.0 109.38 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.406 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 2.5 tp -121.6 139.35 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.869 . . . . 0.0 109.617 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.464 ' HA ' ' HB2' ' A' ' 159' ' ' PHE . 66.7 mt -92.68 127.19 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 80.4 p -101.68 -11.77 18.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.421 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.458 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 95.6 mt-10 -130.66 158.97 38.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.01 165.61 36.85 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.78 -27.8 68.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.44 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 97.1 m-85 -82.49 3.61 27.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.326 -0.859 . . . . 0.0 109.582 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -53.76 141.49 26.58 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.177 -0.952 . . . . 0.0 109.48 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 94.06 -9.83 72.35 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.44 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -97.93 148.46 23.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.207 -1.172 . . . . 0.0 109.47 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . 0.439 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 95.3 mt-30 -91.27 143.69 26.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.273 -0.892 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -135.51 160.36 38.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.482 ' CG2' ' HA2' ' A' ' 113' ' ' GLY . 31.2 mm -117.86 136.6 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.536 ' CE2' HG13 ' A' ' 116' ' ' VAL . 19.6 m-85 -66.53 114.84 5.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 47.6 p -90.62 -29.93 17.48 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.337 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 175.46 87.53 0.09 OUTLIER Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.224 -0.922 . . . . 0.0 109.327 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.46 118.02 5.36 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.671 2.247 . . . . 0.0 111.791 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -60.32 -34.71 74.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -164.95 -160.12 12.03 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 70.3 mm-40 -83.41 -26.64 30.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -1.139 . . . . 0.0 109.354 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.29 -80.57 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.223 -0.923 . . . . 0.0 109.372 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.425 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 24.0 ptt180 -89.17 148.38 23.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.631 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 59.2 m -144.44 152.81 41.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.197 -0.939 . . . . 0.0 109.414 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.422 ' C ' HD11 ' A' ' 141' ' ' LEU . 39.5 mtp -96.97 122.33 39.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.44 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.547 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.3 mp -123.83 150.41 44.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.42 HD11 ' O ' ' A' ' 150' ' ' ILE . 32.1 tp -100.07 123.73 44.64 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 109.466 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.571 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -93.94 118.71 31.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.466 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 21.9 p-10 -83.49 114.92 21.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.566 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.528 ' CD2' ' O ' ' A' ' 143' ' ' LEU . 2.9 mm? -114.38 144.16 43.73 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 109.413 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 29.1 pt -55.09 -29.07 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.306 -0.872 . . . . 0.0 109.29 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 34.8 t30 -75.82 -54.29 7.15 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.342 -0.849 . . . . 0.0 109.441 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.508 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 24.7 tttm -168.57 164.84 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.229 -0.919 . . . . 0.0 109.6 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.508 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 93.9 mt-10 -87.94 127.79 35.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.438 ' O ' HG13 ' A' ' 150' ' ' ILE . 7.6 pt -122.23 136.01 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.283 -0.885 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -91.92 127.17 37.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.399 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -139.27 141.36 37.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.638 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.1 p -87.15 119.44 27.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.321 -0.862 . . . . 0.0 109.381 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.494 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 3.9 p -121.97 149.3 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.483 ' N ' HG23 ' A' ' 154' ' ' VAL . 68.2 mttm -83.62 151.89 25.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.556 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 12.3 m-80 -59.45 -25.14 64.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.236 -0.915 . . . . 0.0 109.456 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.4 p -78.77 -20.29 50.21 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.494 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.2 mt-10 -82.09 -22.68 36.16 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.556 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.22 166.89 23.35 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.537 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 76.4 mtt85 -131.87 150.93 52.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -74.0 122.44 22.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.406 ' HB3' ' HB ' ' A' ' 117' ' ' ILE . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.489 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.469 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.5 m-85 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.469 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.4 Cg_endo -69.53 128.94 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.663 2.242 . . . . 0.0 111.688 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.8 -11.15 59.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.455 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 79.3 m-20 -78.99 151.87 31.31 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -1.119 . . . . 0.0 109.457 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.436 ' CB ' HD22 ' A' ' 162' ' ' LEU . 97.2 mttt -80.15 142.0 35.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.592 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 6.1 m -131.9 160.57 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 6.8 tp -124.6 142.19 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.509 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 69.4 mt -92.64 125.59 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.453 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.3 p -102.38 -10.66 19.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.43 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 94.4 mt-10 -131.38 158.44 40.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.525 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 92.68 166.85 39.05 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.53 -19.78 63.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -1.133 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.537 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 95.9 m-85 -83.54 9.48 11.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.47 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 118' ' ' ILE . 85.5 tt0 -58.32 140.41 53.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.391 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.87 -6.04 73.09 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.537 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -99.06 142.36 30.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.475 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -86.71 125.92 34.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.937 . . . . 0.0 109.352 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 142' ' ' LEU . . . -110.57 153.0 25.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.298 -0.876 . . . . 0.0 109.456 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.414 HD11 ' HG2' ' A' ' 115' ' ' LYS . 24.2 mm -118.06 130.67 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.498 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.592 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 32.7 m-85 -62.31 101.7 0.25 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -0.942 . . . . 0.0 109.542 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 43.3 p -78.43 -36.34 45.72 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.225 -0.922 . . . . 0.0 109.262 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.468 ' HB2' ' O ' ' A' ' 131' ' ' THR . 17.2 tp10 171.36 99.35 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.419 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.0 113.86 3.55 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.62 2.213 . . . . 0.0 111.461 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 29.2 p-10 -74.95 -6.3 48.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.628 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.19 169.67 41.6 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -75.3 -26.25 58.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.477 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -76.1 -73.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 109.341 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 9.9 ptp85 -89.32 147.62 23.99 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 65.0 m -134.68 144.91 48.06 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.232 -0.917 . . . . 0.0 109.5 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' MET . . . . . . . . . . . . . 56.2 ttm -87.98 109.66 19.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.224 -0.922 . . . . 0.0 109.504 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.552 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 5.5 mp -115.59 151.61 34.6 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.522 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 48.1 tp -93.47 127.99 39.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.373 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.447 HD21 HD12 ' A' ' 118' ' ' ILE . 51.5 mt -90.73 137.45 32.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -104.16 106.16 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.0 109.432 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.422 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 49.5 mt -104.33 140.88 37.25 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.466 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -50.97 -31.47 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.238 -0.914 . . . . 0.0 109.423 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.49 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 17.1 t-20 -74.17 -56.15 5.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.635 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.49 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 19.9 mttt -158.81 166.75 31.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -0.954 . . . . 0.0 109.489 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -92.83 131.93 37.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -0.893 . . . . 0.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.522 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 13.7 pt -132.56 155.53 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 109.6 -179.695 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.513 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 28.9 mttp -105.55 131.46 52.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -140.52 129.42 23.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.266 -0.896 . . . . 0.0 109.409 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 70.7 m -69.89 118.52 12.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.516 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 5.3 p -121.82 148.35 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.855 . . . . 0.0 109.53 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 33.0 mttp -81.8 151.92 27.17 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.56 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.0 m-80 -60.76 -21.34 62.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.914 . . . . 0.0 109.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.9 p -81.48 -21.58 38.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.516 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 99.8 mt-10 -81.52 -23.14 37.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.316 -0.865 . . . . 0.0 109.473 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.56 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 33.3 p90 -138.53 167.96 20.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.538 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 51.0 mtt-85 -131.12 155.37 47.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.547 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -76.84 125.06 28.64 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.495 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.436 HD22 ' CB ' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.472 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.448 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.4 m-85 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.448 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.71 130.75 19.95 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.609 2.206 . . . . 0.0 111.808 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.0 -15.14 56.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -69.45 153.88 42.86 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.196 -1.179 . . . . 0.0 109.51 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -90.04 147.5 23.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 5.0 m -131.74 154.47 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.502 ' N ' HD13 ' A' ' 162' ' ' LEU . 8.1 tp -124.48 146.98 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.275 -0.891 . . . . 0.0 109.478 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.1 mm -91.16 124.91 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.335 -0.853 . . . . 0.0 109.356 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.451 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 66.2 p -108.99 -8.57 15.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.531 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.92 157.4 45.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.121 -0.987 . . . . 0.0 109.463 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 88.88 166.54 42.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.44 -18.65 64.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.239 -1.154 . . . . 0.0 109.448 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.565 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 88.5 m-85 -82.56 5.75 19.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 109.506 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.6 tt0 -58.67 136.7 57.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.557 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.31 -3.43 66.3 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.565 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -101.11 150.09 23.29 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.17 -1.194 . . . . 0.0 109.48 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -102.21 149.27 24.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.521 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -143.47 166.22 25.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.305 -0.872 . . . . 0.0 109.423 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.446 HD11 ' O ' ' A' ' 128' ' ' ALA . 27.2 mm -116.63 137.66 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.206 -0.934 . . . . 0.0 109.535 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.0 m-85 -59.57 104.0 0.24 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.482 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 39.3 p -78.71 -38.89 37.92 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.344 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 131' ' ' THR . 1.0 OUTLIER 171.68 94.8 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.303 -0.873 . . . . 0.0 109.455 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.38 115.7 4.17 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.776 2.317 . . . . 0.0 111.744 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -61.16 -35.92 78.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.243 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -148.01 175.5 27.3 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.82 -27.43 64.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -1.151 . . . . 0.0 109.495 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.11 -73.54 0.29 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.309 -0.869 . . . . 0.0 109.384 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 21.3 ptt-85 -83.53 147.81 27.56 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.23 -0.919 . . . . 0.0 109.558 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 67.9 m -139.96 153.11 46.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.176 -0.952 . . . . 0.0 109.514 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.434 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 41.6 mtp -99.23 119.48 37.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.262 -0.899 . . . . 0.0 109.429 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.449 HD21 HG22 ' A' ' 116' ' ' VAL . 66.1 mt -117.85 147.73 42.78 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.255 -0.903 . . . . 0.0 109.471 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.503 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.4 tt -97.31 126.46 42.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.263 -0.898 . . . . 0.0 109.438 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.524 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 43.5 mt -97.69 113.87 25.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.183 -0.948 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.422 ' C ' HD21 ' A' ' 145' ' ' LEU . 8.4 p30 -83.45 121.21 26.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.283 -0.885 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.524 ' CD2' ' O ' ' A' ' 143' ' ' LEU . 3.0 mm? -118.72 135.64 54.38 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.357 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.2 pt -49.74 -33.29 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.266 -0.896 . . . . 0.0 109.574 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.475 ' N ' HG13 ' A' ' 146' ' ' ILE . 94.2 m-20 -70.49 -46.44 63.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.517 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 30.3 tttm -168.49 160.75 11.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.517 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.0 mt-10 -87.85 127.24 35.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.927 . . . . 0.0 109.407 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.466 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 19.6 pt -127.67 162.12 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.424 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.503 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.9 mttt -125.72 130.25 51.14 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.446 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -139.12 148.14 42.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.434 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 29.7 p -82.7 141.89 32.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.428 HG11 ' N ' ' A' ' 155' ' ' LYS . 13.7 t -130.91 153.64 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.35 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.501 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 41.3 mttt -91.11 138.3 31.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.913 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.578 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 1.6 p30 -47.75 -30.38 3.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 44.7 p -80.97 -22.18 39.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.898 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 155' ' ' LYS . 94.8 mt-10 -81.69 -19.7 41.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.439 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.578 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.6 p90 -140.45 169.01 18.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.372 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 87.0 mtt-85 -129.44 143.24 50.75 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -78.14 132.74 37.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.321 -0.862 . . . . 0.0 109.473 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.502 HD13 ' N ' ' A' ' 117' ' ' ILE . 6.5 mp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.481 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.408 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 12.6 m-85 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 50.5 Cg_endo -70.25 134.84 27.87 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.724 2.283 . . . . 0.0 111.797 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.21 -12.98 65.12 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 83.4 m-20 -69.97 147.91 49.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.506 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.3 mttm -75.05 139.74 43.05 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.586 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 6.0 m -127.33 155.67 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.942 . . . . 0.0 109.455 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.435 HG21 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.82 147.69 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.235 -0.916 . . . . 0.0 109.48 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.454 ' HB ' ' HA ' ' A' ' 124' ' ' GLU . 21.6 mm -91.66 129.34 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.8 p -114.17 -7.34 13.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.502 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 46.8 tp10 -140.89 153.48 45.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.502 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 92.15 169.05 40.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.92 -15.9 63.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -1.188 . . . . 0.0 109.493 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.594 ' CD1' ' CD2' ' A' ' 143' ' ' LEU . 89.9 m-85 -84.93 11.06 10.1 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.2 -0.938 . . . . 0.0 109.451 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.454 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 85.0 tt0 -60.73 134.08 56.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.636 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.94 66.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.7 m-85 -98.26 140.48 32.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.143 -1.21 . . . . 0.0 109.472 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -94.13 126.52 39.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.525 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.521 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -126.35 161.42 27.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.938 . . . . 0.0 109.533 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.506 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 29.9 mm -120.12 136.96 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.254 -0.904 . . . . 0.0 109.451 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.586 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.5 m-85 -58.58 103.18 0.14 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 63.4 p -77.3 -31.45 54.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 164.74 91.37 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.188 -0.945 . . . . 0.0 109.53 -179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.47 125.99 12.37 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.63 2.22 . . . . 0.0 111.655 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.6 p-10 -68.66 -25.78 64.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 109.538 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -166.09 170.25 40.69 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -64.01 -27.59 69.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.43 -63.63 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.3 -0.875 . . . . 0.0 109.394 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 135' ' ' GLY . 57.7 mtt85 -107.48 153.6 22.59 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.197 -0.939 . . . . 0.0 109.468 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 68.8 m -138.8 156.64 47.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 109.46 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.462 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 34.7 tpp -101.12 117.31 34.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.475 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.54 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.8 mp -118.61 144.07 46.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 9.2 tt -101.52 123.51 45.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.452 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.594 ' CD2' ' CD1' ' A' ' 123' ' ' PHE . 4.7 mp -91.4 138.51 31.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.923 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.47 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 97.6 m-20 -110.86 113.38 25.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.53 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.3 mp -114.61 139.63 49.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.579 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.5 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.1 pt -50.28 -36.25 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.5 ' N ' HG13 ' A' ' 146' ' ' ILE . 15.3 t-20 -68.04 -52.89 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.488 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.458 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 19.3 tttt -166.66 155.11 10.3 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.541 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.458 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.4 mt-10 -89.86 140.21 29.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.407 HG21 ' C ' ' A' ' 149' ' ' GLU . 30.4 pt -131.57 158.61 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.484 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.523 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.3 mttt -125.83 134.18 51.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.66 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.49 ' ND1' ' O ' ' A' ' 153' ' ' SER . 51.7 t-80 -158.31 146.45 18.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.422 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.49 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 42.0 p -69.77 141.34 53.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.924 . . . . 0.0 109.393 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.533 HG13 ' CG ' ' A' ' 158' ' ' GLU . 20.2 t -126.17 152.31 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.182 -0.949 . . . . 0.0 109.61 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.486 ' N ' HG13 ' A' ' 154' ' ' VAL . 86.4 mttt -91.17 131.64 36.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.276 -0.89 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.574 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 33.4 m-80 -53.41 -18.57 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 79.8 p -85.13 -29.66 24.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 110.141 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.533 ' CG ' HG13 ' A' ' 154' ' ' VAL . 10.9 pt-20 -82.84 -18.57 39.93 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.02 -1.05 . . . . 0.0 109.698 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.574 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 20.4 p90 -135.3 157.25 47.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.147 -0.97 . . . . 0.0 109.553 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.435 ' O ' HG21 ' A' ' 117' ' ' ILE . 37.2 ttt-85 -124.07 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.267 -0.896 . . . . 0.0 109.482 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . 0.45 ' CG ' ' O ' ' A' ' 161' ' ' LYS . 16.9 pttp -74.39 124.03 25.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.196 -0.94 . . . . 0.0 109.51 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.997 -1.002 . . . . 0.0 109.48 179.991 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.439 ' N ' ' OD2' ' A' ' 114' ' ' ASP . 50.9 m-85 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.1 Cg_endo -69.73 131.5 21.4 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.696 2.264 . . . . 0.0 111.79 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 98.83 -12.29 62.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' N ' ' A' ' 111' ' ' TYR . 81.5 m-20 -65.56 150.31 48.62 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -1.135 . . . . 0.0 109.491 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.498 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 96.5 mttt -77.98 140.14 39.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.897 . . . . 0.0 109.476 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.566 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.1 m -130.84 153.63 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.438 ' O ' HG21 ' A' ' 117' ' ' ILE . 3.0 tp -122.65 140.67 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.448 HD11 ' HB3' ' A' ' 123' ' ' PHE . 69.4 mt -92.56 131.05 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.5 p -118.42 5.37 11.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.245 -0.909 . . . . 0.0 109.578 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.428 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -136.91 153.6 50.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 109.481 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.403 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.67 -171.08 42.9 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.87 -5.84 57.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -1.134 . . . . 0.0 109.587 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.538 ' CD1' HD21 ' A' ' 143' ' ' LEU . 80.2 m-85 -88.54 14.98 8.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.997 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.428 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 96.9 mt-10 -62.84 136.91 58.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.14 1.09 70.11 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -102.22 131.41 48.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.137 -1.213 . . . . 0.0 109.454 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -86.72 134.44 33.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.461 ' O ' HG23 ' A' ' 116' ' ' VAL . . . -132.18 159.72 38.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.544 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.498 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 33.4 mm -119.2 140.07 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.311 -0.868 . . . . 0.0 109.383 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.566 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.1 m-85 -58.58 101.47 0.09 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.528 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 68.9 p -75.04 -34.41 61.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.369 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.3 mt-10 163.75 88.84 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.294 -0.879 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.435 ' HB3' ' OG ' ' A' ' 139' ' ' SER . 49.9 Cg_endo -69.96 132.35 22.83 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.679 2.253 . . . . 0.0 111.81 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -67.82 -30.03 69.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -0.861 . . . . 0.0 109.444 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -165.18 -174.02 34.4 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -73.32 -26.79 61.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.295 -1.121 . . . . 0.0 109.453 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.82 -58.51 4.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.532 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -109.6 161.12 15.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.158 -0.964 . . . . 0.0 109.425 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.435 ' OG ' ' HB3' ' A' ' 133' ' ' PRO . 4.1 m -147.36 155.38 41.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.262 -0.899 . . . . 0.0 109.566 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.455 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 63.5 mtp -103.06 124.22 48.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.343 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.564 HD23 ' CD2' ' A' ' 159' ' ' PHE . 5.4 mp -126.19 140.78 52.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.175 -0.953 . . . . 0.0 109.607 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.525 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 10.1 tt -96.59 125.82 41.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.304 -0.873 . . . . 0.0 109.413 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.546 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.6 mp -93.47 137.02 33.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.284 -0.885 . . . . 0.0 109.525 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -108.57 104.19 13.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.905 . . . . 0.0 109.422 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.493 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.8 mp -104.45 139.6 39.14 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.149 -0.969 . . . . 0.0 109.56 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.496 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.2 pt -54.32 -35.09 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.445 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.496 ' N ' HG13 ' A' ' 146' ' ' ILE . 52.0 t-20 -65.96 -46.57 77.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.393 -0.817 . . . . 0.0 109.512 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.1 pttt -168.64 169.54 10.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.204 -0.935 . . . . 0.0 109.555 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.484 ' CG ' HD21 ' A' ' 142' ' ' LEU . 86.8 tt0 -98.2 132.32 43.82 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.1 pt -131.88 157.01 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.45 ' HG2' ' HG ' ' A' ' 142' ' ' LEU . 2.3 mtpm? -123.97 134.1 53.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.396 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.466 ' CE1' ' O ' ' A' ' 153' ' ' SER . 55.4 t-80 -152.26 143.73 23.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.466 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 41.6 p -81.66 137.07 35.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.473 HG12 ' HB2' ' A' ' 158' ' ' GLU . 16.4 t -127.6 151.09 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.406 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.522 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 0.6 OUTLIER -87.38 139.97 30.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.272 -0.893 . . . . 0.0 109.559 -179.935 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.505 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 27.4 m-80 -46.17 -27.98 1.12 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.357 -0.839 . . . . 0.0 110.272 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' THR . . . . . 0.512 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 27.0 p -80.14 -19.93 46.1 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.97 -1.081 . . . . 0.0 109.983 -179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.522 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 48.5 mm-40 -89.85 -19.11 25.02 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.068 -1.02 . . . . 0.0 109.201 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.564 ' CD2' HD23 ' A' ' 141' ' ' LEU . 34.5 p90 -139.22 156.03 47.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.793 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 53.2 mtt180 -125.25 147.1 49.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.255 -0.903 . . . . 0.0 109.339 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . 0.464 ' CG ' ' O ' ' A' ' 161' ' ' LYS . 15.9 pttp -82.44 121.52 26.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.489 -179.992 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.407 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 53.0 m-85 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.423 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 46.2 Cg_endo -68.28 137.61 40.65 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.634 2.223 . . . . 0.0 111.701 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . 0.422 ' HA2' HG21 ' A' ' 129' ' ' ILE . . . 90.82 -9.88 76.46 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.508 ' OD2' ' NZ ' ' A' ' 161' ' ' LYS . 36.6 p-10 -74.55 -177.85 3.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -1.149 . . . . 0.0 109.5 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.462 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 76.6 mttt -99.19 141.6 31.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -0.893 . . . . 0.0 109.426 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.503 HG12 ' CE2' ' A' ' 130' ' ' PHE . 11.2 m -138.18 158.1 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.239 -0.913 . . . . 0.0 109.529 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.453 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.2 tp -126.27 141.91 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.466 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 56.1 mt -92.29 129.91 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.209 -0.932 . . . . 0.0 109.695 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.515 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 58.0 p -105.08 -8.39 18.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.484 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 48.0 tp10 -136.26 156.84 48.08 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . 0.484 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 93.77 162.77 36.09 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.26 -19.4 65.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -1.115 . . . . 0.0 109.438 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -86.26 13.16 8.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.379 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.515 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.8 tt0 -63.76 140.12 58.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.38 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 90.32 -0.15 77.63 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -104.99 138.89 40.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -1.193 . . . . 0.0 109.428 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -83.79 148.65 26.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.26 -0.9 . . . . 0.0 109.541 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.461 ' O ' HG21 ' A' ' 116' ' ' VAL . . . -144.83 159.31 43.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.462 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 27.2 mm -119.68 133.06 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.961 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.503 ' CE2' HG12 ' A' ' 116' ' ' VAL . 18.3 m-85 -58.57 115.84 3.29 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.368 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.513 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.0 p -84.18 -29.5 26.56 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.9 86.33 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.326 -0.859 . . . . 0.0 109.545 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.2 Cg_endo -70.0 130.64 19.38 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.694 2.263 . . . . 0.0 111.751 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -68.91 -26.61 65.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.905 . . . . 0.0 109.594 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -170.59 178.31 43.27 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -66.16 -25.94 67.19 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -1.121 . . . . 0.0 109.509 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.53 -63.68 1.01 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.455 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 75.4 mtt180 -107.11 156.89 18.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 69.0 m -148.58 152.42 36.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.175 -0.953 . . . . 0.0 109.51 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.483 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 20.4 mtp -101.62 122.05 43.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.217 -0.927 . . . . 0.0 109.583 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.573 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.8 mp -114.21 147.32 39.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.875 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.526 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 34.5 tp -102.8 125.42 49.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.742 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.529 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -98.32 127.98 44.52 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.257 -0.902 . . . . 0.0 109.25 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -105.02 113.27 26.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.509 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 2.4 mm? -101.01 150.56 22.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.326 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 25.7 pt -65.13 -10.45 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.501 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 48.3 t30 -97.57 -47.55 5.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.59 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.501 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 77.7 mttt -158.55 165.39 34.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.93 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.524 ' OE2' ' CD2' ' A' ' 142' ' ' LEU . 78.4 tt0 -89.57 147.57 23.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.172 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.526 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 30.9 pt -144.44 151.66 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.945 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.522 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.8 mttp -118.01 136.64 53.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.366 -0.834 . . . . 0.0 109.159 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -148.58 134.99 19.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.116 -0.99 . . . . 0.0 109.651 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.8 p -87.12 118.08 26.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.888 . . . . 0.0 109.326 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.513 HG21 ' N ' ' A' ' 155' ' ' LYS . 4.3 p -120.05 150.59 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.565 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 28.0 mttt -77.01 153.69 34.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.891 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.578 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 9.7 m-80 -65.18 -14.95 61.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 70.5 p -88.17 -24.2 23.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.513 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 99.7 mt-10 -78.79 -22.62 46.05 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.258 -0.901 . . . . 0.0 109.51 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.578 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.3 p90 -135.95 174.04 11.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.414 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 52.6 mtp180 -139.45 164.59 29.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.57 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . 0.508 ' NZ ' ' OD2' ' A' ' 114' ' ' ASP . 55.4 tttp -85.59 126.32 33.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.487 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.453 ' HB3' ' HB ' ' A' ' 117' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.519 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.403 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 50.3 m-85 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.96 130.89 19.87 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.63 2.22 . . . . 0.0 111.811 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 101.04 -14.77 58.42 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.47 ' CB ' ' HE2' ' A' ' 161' ' ' LYS . 80.4 m-20 -66.89 153.78 42.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.487 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 95.5 mttt -81.83 140.62 34.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 11.8 m -125.61 152.61 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.459 ' CG2' HD21 ' A' ' 162' ' ' LEU . 8.2 tp -122.64 145.43 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.538 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 126' ' ' PHE . 28.8 mm -91.24 128.82 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.293 -0.88 . . . . 0.0 109.499 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.434 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 69.1 p -114.92 -7.9 12.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.217 -0.927 . . . . 0.0 109.518 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -140.1 151.91 45.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.163 -0.961 . . . . 0.0 109.473 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.56 167.78 38.2 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.41 -13.78 62.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -1.155 . . . . 0.0 109.422 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.547 ' CD1' HD22 ' A' ' 143' ' ' LEU . 69.6 m-85 -87.98 13.93 9.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.462 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.8 tt0 -64.08 132.43 50.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.58 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.17 1.03 59.6 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.466 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.4 m-85 -98.95 136.52 38.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.1 -1.235 . . . . 0.0 109.594 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -88.79 136.07 33.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.291 -0.881 . . . . 0.0 109.279 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.5 ' O ' ' CG2' ' A' ' 116' ' ' VAL . . . -137.95 165.73 25.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.597 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.487 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 28.7 mm -121.01 142.28 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 40.5 m-85 -58.58 104.49 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.936 . . . . 0.0 109.558 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.454 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 71.1 p -78.07 -40.69 37.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 131' ' ' THR . 7.6 tt0 172.32 91.53 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 48.8 Cg_endo -70.1 124.46 10.97 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.718 2.279 . . . . 0.0 111.761 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 23.3 p-10 -75.23 -4.03 36.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.355 -0.84 . . . . 0.0 109.54 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 174.64 173.3 40.44 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.95 -30.48 67.87 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -1.125 . . . . 0.0 109.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.07 -60.03 2.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -0.915 . . . . 0.0 109.431 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.444 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 81.9 mtm180 -103.28 152.93 20.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.395 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 68.5 m -144.97 150.12 36.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.96 . . . . 0.0 109.491 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.49 ' SD ' ' CB ' ' A' ' 153' ' ' SER . 91.6 mmm -96.17 125.91 41.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.323 -0.861 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.515 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.6 mp -128.32 141.27 51.49 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.236 -0.915 . . . . 0.0 109.622 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.52 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.9 tt -99.67 119.51 38.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.395 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.573 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -96.03 108.63 21.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.18 -0.95 . . . . 0.0 109.652 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -88.7 127.5 35.59 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.32 -0.862 . . . . 0.0 109.631 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.563 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.1 mp -108.05 159.37 16.62 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.925 . . . . 0.0 109.425 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 23.6 pt -66.65 -10.22 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.418 ' CG ' ' N ' ' A' ' 148' ' ' LYS . 9.2 p30 -105.34 -45.54 4.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.514 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 62.1 tttm -158.48 147.96 19.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.29 -0.881 . . . . 0.0 109.563 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -87.89 141.23 28.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.371 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.446 HD13 ' CE1' ' A' ' 123' ' ' PHE . 28.7 pt -133.7 162.12 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.917 . . . . 0.0 109.572 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.52 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 29.6 mttt -125.16 136.52 53.68 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.291 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.29 148.47 28.21 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.183 -0.948 . . . . 0.0 109.694 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.49 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 21.9 p -86.88 122.77 31.21 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.251 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.513 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 3.2 p -125.06 148.93 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.493 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 45.0 mttt -79.59 153.53 29.38 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.493 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.8 m-80 -62.52 -19.73 63.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.344 -0.847 . . . . 0.0 109.474 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 63.1 p -82.26 -23.19 35.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.194 -0.941 . . . . 0.0 109.478 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.513 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.6 mt-10 -81.13 -21.11 40.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.226 -0.921 . . . . 0.0 109.524 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.577 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 35.8 p90 -139.53 158.94 43.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -122.15 148.49 44.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.205 -0.934 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . 0.47 ' HE2' ' CB ' ' A' ' 114' ' ' ASP . 64.1 tttm -76.44 135.37 39.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.923 . . . . 0.0 109.487 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.459 HD21 ' CG2' ' A' ' 117' ' ' ILE . 53.5 mt . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.912 -1.042 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -70.22 134.47 27.09 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.695 2.263 . . . . 0.0 111.784 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.24 -11.68 68.85 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.459 ' O ' HD13 ' A' ' 129' ' ' ILE . 23.9 p-10 -67.45 176.23 2.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.168 -1.195 . . . . 0.0 109.473 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.522 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 99.6 mttt -98.34 139.42 34.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.91 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.499 ' HA ' ' CD1' ' A' ' 162' ' ' LEU . 15.0 m -135.14 149.8 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.443 HG21 ' O ' ' A' ' 160' ' ' ARG . 6.4 tp -120.84 142.47 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.511 HD11 ' CD2' ' A' ' 143' ' ' LEU . 62.1 mt -92.37 129.78 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.192 -0.943 . . . . 0.0 109.416 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.478 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 62.7 p -105.6 -9.97 17.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.421 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 75.4 mm-40 -135.73 158.17 45.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.178 -0.951 . . . . 0.0 109.425 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.09 165.48 32.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.93 -20.78 65.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.174 . . . . 0.0 109.43 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.498 ' CG ' HD13 ' A' ' 143' ' ' LEU . 64.1 m-85 -88.12 15.0 8.02 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.478 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 83.2 tt0 -63.22 137.4 58.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.917 . . . . 0.0 109.469 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.7 0.96 62.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -105.67 128.43 53.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -78.04 135.29 37.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.227 -0.921 . . . . 0.0 109.417 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.528 ' CB ' ' HB3' ' A' ' 141' ' ' LEU . . . -132.89 164.35 27.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.237 -0.915 . . . . 0.0 109.593 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.522 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 39.3 mm -122.8 137.81 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.462 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.565 ' CD1' HD21 ' A' ' 141' ' ' LEU . 10.6 m-85 -58.56 102.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.679 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 47.0 p -79.43 -36.01 39.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 109.322 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.466 ' O ' ' HG3' ' A' ' 140' ' ' MET . 1.0 OUTLIER 170.02 87.53 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.308 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.77 131.78 21.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.735 2.29 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -66.51 -32.36 73.66 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.374 -0.828 . . . . 0.0 109.415 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -163.44 -178.4 37.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -70.5 -29.1 65.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -1.165 . . . . 0.0 109.49 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.14 -59.14 4.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.236 -0.915 . . . . 0.0 109.388 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.49 ' HG3' ' NH1' ' A' ' 138' ' ' ARG . 6.8 mtt85 -109.46 157.81 18.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 109.35 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.6 m -146.38 156.8 43.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -0.986 . . . . 0.0 109.611 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.466 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 49.6 mtp -99.46 127.54 45.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.442 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.565 HD21 ' CD1' ' A' ' 130' ' ' PHE . 89.8 mt -126.27 135.73 51.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.516 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.0 tt -92.73 123.84 36.31 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.511 ' CD2' HD11 ' A' ' 118' ' ' ILE . 16.5 mt -97.1 109.06 21.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.922 . . . . 0.0 109.662 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 12.8 p-10 -83.94 125.48 32.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.224 -0.922 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.451 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 8.1 mp -119.24 145.73 45.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.17 -0.956 . . . . 0.0 109.441 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.495 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -53.44 -39.0 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.656 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.495 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.4 m-20 -67.98 -44.88 75.63 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 11.8 pttt -167.17 173.41 9.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.589 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -104.13 129.37 51.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.435 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.445 ' CG2' ' HE3' ' A' ' 148' ' ' LYS . 25.8 pt -125.5 161.59 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.904 . . . . 0.0 109.427 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.516 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.6 mttt -125.34 133.02 52.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -145.87 142.72 29.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 44.9 p -77.17 140.96 40.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.553 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.466 HG13 ' HB3' ' A' ' 159' ' ' PHE . 14.6 t -137.62 146.48 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.528 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 1.3 ptpt -91.05 145.48 24.65 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.313 -0.867 . . . . 0.0 109.801 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.54 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 2.0 p30 -48.96 -29.21 4.52 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.344 -0.847 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' THR . . . . . 0.496 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 17.1 p -78.98 -20.96 47.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.105 -0.997 . . . . 0.0 109.975 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.528 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 44.0 mm-40 -87.64 -20.4 26.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.02 -1.05 . . . . 0.0 109.214 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.54 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 26.8 p90 -135.85 166.86 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.876 . . . . 0.0 109.607 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . 0.443 ' O ' HG21 ' A' ' 117' ' ' ILE . 37.1 ttt180 -130.26 136.96 49.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.469 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.3 pttp -77.45 147.18 36.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.267 -0.895 . . . . 0.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.519 ' CD1' ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' TYR . . . . . 0.447 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 15.7 m-85 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' PRO . . . . . 0.447 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 47.5 Cg_endo -68.93 136.09 34.25 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.713 2.275 . . . . 0.0 111.765 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.4 -8.82 60.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -85.82 159.51 19.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.206 -1.173 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' LYS . . . . . 0.428 ' C ' HD21 ' A' ' 162' ' ' LEU . 24.6 mttm -87.3 145.52 26.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -0.899 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.603 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 14.1 m -132.98 152.18 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.428 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.444 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.8 tp -122.0 140.71 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.281 -0.887 . . . . 0.0 109.55 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.466 HD12 ' CB ' ' A' ' 123' ' ' PHE . 73.4 mt -92.68 132.88 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.252 -0.905 . . . . 0.0 109.405 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.449 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 54.7 p -111.01 0.16 16.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.248 -0.908 . . . . 0.0 109.6 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLU . . . . . 0.433 ' HA ' ' OE1' ' A' ' 120' ' ' GLU . 71.7 mm-40 -143.52 155.73 44.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.174 -0.954 . . . . 0.0 109.484 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.35 164.26 39.65 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.74 -18.71 64.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -1.147 . . . . 0.0 109.473 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD1' HD12 ' A' ' 143' ' ' LEU . 96.9 m-85 -82.93 8.69 11.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.918 . . . . 0.0 109.535 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.0 tt0 -62.7 138.96 58.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.23 0.11 80.68 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -102.99 137.54 41.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.466 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -89.44 143.08 27.1 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.398 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.454 ' O ' HG23 ' A' ' 116' ' ' VAL . . . -142.2 160.36 40.4 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.214 -0.929 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.435 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.2 mm -116.16 137.13 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.278 -0.889 . . . . 0.0 109.528 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 24.7 m-85 -58.77 106.2 0.38 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.584 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.4 p -77.55 -33.64 54.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.256 -0.903 . . . . 0.0 109.249 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.05 96.53 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.428 -0.795 . . . . 0.0 109.326 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.43 123.52 10.29 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.71 2.274 . . . . 0.0 111.773 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -67.94 -33.03 73.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -150.24 174.71 29.58 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -69.57 -29.04 66.5 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.421 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.86 -74.16 0.13 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.161 -0.962 . . . . 0.0 109.344 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 33.0 ptt-85 -89.87 158.14 17.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.326 -0.859 . . . . 0.0 109.72 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 6.1 m -142.7 159.49 42.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' MET . . . . . 0.456 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 64.0 mtp -101.31 120.13 39.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.344 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . 0.565 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.6 mp -118.13 148.79 41.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.605 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' LEU . . . . . 0.519 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 48.9 tp -99.6 123.9 44.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.3 -0.875 . . . . 0.0 109.515 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.561 HD12 ' CD1' ' A' ' 123' ' ' PHE . 41.8 mt -98.18 110.84 23.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.95 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 20.1 p-10 -78.58 120.83 23.83 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.185 -0.947 . . . . 0.0 109.551 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' LEU . . . . . 0.503 HD11 ' CD1' ' A' ' 150' ' ' ILE . 67.9 mt -111.19 142.2 43.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.186 -0.946 . . . . 0.0 109.546 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.443 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.7 pt -51.63 -31.11 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.453 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.52 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 22.9 m120 -75.83 -55.57 5.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.465 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' LYS . . . . . 0.52 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 23.2 mttt -158.98 171.92 19.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.176 -0.952 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -88.34 130.03 35.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.325 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ILE . . . . . 0.503 ' CD1' HD11 ' A' ' 145' ' ' LEU . 42.4 pt -124.1 151.74 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.519 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 90.8 mttt -109.18 128.52 55.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.302 -0.874 . . . . 0.0 109.379 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -141.27 132.18 25.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.549 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 46.1 p -77.94 140.35 39.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.32 -0.862 . . . . 0.0 109.471 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.469 HG12 ' HB3' ' A' ' 159' ' ' PHE . 13.4 t -134.82 148.39 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.525 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 16.2 ptmt -91.27 139.96 30.24 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.227 -0.921 . . . . 0.0 109.625 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.57 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 44.7 m-80 -46.34 -27.27 1.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.397 -0.814 . . . . 0.0 110.067 -179.592 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' THR . . . . . 0.522 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 15.8 p -79.83 -21.02 44.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 0.0 109.766 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' GLU . . . . . 0.525 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 46.3 mm-40 -87.67 -20.51 26.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.052 -1.03 . . . . 0.0 109.229 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 39.3 p90 -136.17 168.68 18.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.339 -0.851 . . . . 0.0 109.667 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -133.09 159.7 39.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -82.51 118.0 22.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.433 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' LEU . . . . . 0.444 ' HB3' ' HB ' ' A' ' 117' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.492 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.24 144.34 55.67 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -1.139 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 87.9 mtp -61.01 -38.77 87.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.432 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -81.63 147.96 27.2 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.42 136.7 31.86 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.692 2.261 . . . . 0.0 111.788 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -63.81 -34.99 79.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.931 . . . . 0.0 109.422 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.9 p30 -142.87 -179.93 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.396 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.31 -43.43 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 39.4 t -115.06 128.58 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.47 164.8 31.13 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.35 53.97 1.36 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.73 2.286 . . . . 0.0 111.807 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.0 -26.61 66.88 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.483 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 61.2 m -55.19 118.25 17.44 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.466 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 49.8 Cg_endo -70.39 142.34 44.91 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.633 2.222 . . . . 0.0 111.793 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.412 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 28.0 m-85 -76.87 161.24 74.49 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.412 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.34 129.37 17.91 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.723 2.282 . . . . 0.0 111.773 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 104.26 -13.53 51.74 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -69.49 156.69 38.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -1.104 . . . . 0.0 109.445 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.463 ' CB ' HD12 ' A' ' 162' ' ' LEU . 18.2 mttp -86.42 139.63 30.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.561 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.631 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.4 m -127.17 154.14 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -0.911 . . . . 0.0 109.402 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.516 ' HB ' ' CD2' ' A' ' 162' ' ' LEU . 2.7 tp -122.44 139.83 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.57 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.434 HD12 ' HB3' ' A' ' 123' ' ' PHE . 83.6 mt -92.58 139.4 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.482 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.419 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 70.9 p -115.14 -10.8 12.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.458 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.38 157.26 43.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.08 162.08 38.01 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.9 -13.46 45.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.145 . . . . 0.0 109.437 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.556 ' CD1' HD22 ' A' ' 143' ' ' LEU . 96.4 m-85 -86.59 12.67 10.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.419 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.3 tt0 -63.42 137.93 58.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.12 -0.81 76.26 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -102.45 139.3 38.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.576 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -91.48 146.72 23.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.517 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -140.68 162.24 35.87 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 128' ' ' ALA . 35.6 mm -117.48 135.01 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.194 -0.941 . . . . 0.0 109.582 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.631 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.6 m-85 -58.55 104.41 0.22 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.523 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 55.4 p -79.79 -32.1 40.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.897 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 163.68 93.62 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.437 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.18 126.74 13.37 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.667 2.245 . . . . 0.0 111.723 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -66.82 -24.89 66.21 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.251 -0.906 . . . . 0.0 109.539 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.03 -179.41 40.56 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -72.64 -24.94 61.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -1.136 . . . . 0.0 109.452 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -75.29 -51.45 13.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.471 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 55.5 mtt85 -110.52 151.33 27.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 57.1 m -139.74 156.16 46.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.924 . . . . 0.0 109.507 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.457 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 56.2 mtp -106.76 119.39 39.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.572 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.6 mp -116.3 154.03 30.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.509 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.518 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 51.5 tp -106.04 124.95 50.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.216 -0.927 . . . . 0.0 109.464 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.56 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -99.19 116.67 31.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -82.73 129.23 34.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.638 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.499 HD13 ' CD1' ' A' ' 150' ' ' ILE . 42.6 mt -121.09 142.12 50.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.398 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.432 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -49.94 -30.6 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.517 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.432 ' N ' HG13 ' A' ' 146' ' ' ILE . 92.9 m-20 -79.24 -47.71 15.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.27 -0.894 . . . . 0.0 109.681 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.515 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 40.2 ttpt -168.77 168.1 10.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.459 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.515 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.9 mt-10 -87.55 137.29 32.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.252 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.509 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 36.1 pt -126.34 149.16 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.202 -0.936 . . . . 0.0 109.774 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.518 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 62.1 mttp -110.45 131.46 55.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -0.882 . . . . 0.0 109.191 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -142.38 140.62 32.1 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.177 -0.952 . . . . 0.0 109.681 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 21.6 p -88.45 122.0 31.46 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.347 -0.846 . . . . 0.0 109.217 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.512 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 3.3 p -124.07 149.99 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.595 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.48 ' N ' HG22 ' A' ' 154' ' ' VAL . 43.3 mttt -76.64 150.5 36.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.881 . . . . 0.0 109.482 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.559 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.9 m-80 -59.69 -23.49 63.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.335 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 74.8 p -81.62 -25.96 35.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.268 -0.895 . . . . 0.0 109.428 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.512 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 88.6 mt-10 -75.03 -24.81 58.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 0.0 109.519 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.559 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 31.9 p90 -136.36 170.78 15.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.43 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -134.23 159.64 40.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.226 -0.921 . . . . 0.0 109.53 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -83.63 146.76 28.09 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.516 ' CD2' ' HB ' ' A' ' 117' ' ' ILE . 23.8 mt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.12 -33.1 73.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.463 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.1 mtm -58.24 -38.42 76.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -68.45 145.16 43.63 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -69.89 -27.19 26.14 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.673 2.249 . . . . 0.0 111.776 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -55.3 -41.06 71.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -80.45 139.63 36.35 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.291 -0.88 . . . . 0.0 109.452 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 57.4 mt -131.78 143.23 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 14.7 p -133.3 137.93 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.446 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -78.01 119.77 78.68 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.338 -0.851 . . . . 0.0 109.577 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -72.24 50.51 1.56 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.594 2.196 . . . . 0.0 111.818 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.25 -35.44 68.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.11 -0.994 . . . . 0.0 109.415 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.467 HG23 ' HD2' ' A' ' 110' ' ' PRO . 26.8 m -66.62 131.61 94.1 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.312 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.574 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 48.0 Cg_endo -69.45 149.6 69.07 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.577 2.185 . . . . 0.0 111.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.432 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 53.1 m-85 -109.4 160.99 25.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.517 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.423 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.3 Cg_endo -69.92 135.16 29.4 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.663 2.242 . . . . 0.0 111.795 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.12 -9.04 65.29 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.432 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 82.8 m-20 -81.27 146.74 30.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -1.172 . . . . 0.0 109.523 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.402 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 29.4 mtmt -80.51 144.48 32.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 0.0 109.417 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.639 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.4 m -133.47 152.63 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.196 -0.94 . . . . 0.0 109.595 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.411 ' HB ' ' CD2' ' A' ' 162' ' ' LEU . 2.8 tp -121.74 139.51 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.421 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 123' ' ' PHE . 67.7 mt -92.78 130.76 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 70.4 p -116.72 4.04 13.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -0.925 . . . . 0.0 109.624 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 157' ' ' THR . 92.5 mt-10 -137.7 155.73 48.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 87.54 -168.04 37.74 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.6 -7.07 51.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -1.135 . . . . 0.0 109.502 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.562 ' CD1' HD23 ' A' ' 143' ' ' LEU . 80.4 m-85 -88.86 15.81 7.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.41 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 95.8 mt-10 -61.18 135.07 57.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.64 0.71 69.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -102.95 131.96 49.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -1.207 . . . . 0.0 109.488 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -92.61 140.46 29.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.229 -0.92 . . . . 0.0 109.45 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.451 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -136.77 167.01 22.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.176 -0.952 . . . . 0.0 109.536 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.421 HD13 ' O ' ' A' ' 128' ' ' ALA . 30.7 mm -118.31 138.14 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.3 m-85 -58.49 102.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.254 -0.904 . . . . 0.0 109.579 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.524 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 40.9 p -75.8 -33.39 60.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.6 OUTLIER 163.49 95.41 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.308 -0.87 . . . . 0.0 109.347 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.2 Cg_endo -69.76 117.31 5.0 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.695 2.264 . . . . 0.0 111.791 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 18.1 p-10 -66.91 -31.56 72.23 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -0.935 . . . . 0.0 109.573 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.432 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -155.32 172.85 33.55 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -70.15 -28.85 65.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.307 -1.114 . . . . 0.0 109.485 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.67 -53.6 15.13 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.53 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.422 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 79.4 mtt180 -111.86 146.25 38.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.286 -0.883 . . . . 0.0 109.506 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 70.8 m -134.34 157.94 45.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.472 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.468 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 66.9 mtp -102.07 124.8 48.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.468 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.535 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.3 mp -127.22 143.91 51.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.209 -0.932 . . . . 0.0 109.551 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.507 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 45.4 tp -93.79 121.19 34.99 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.955 . . . . 0.0 109.519 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.562 HD23 ' CD1' ' A' ' 123' ' ' PHE . 4.5 mp -93.03 129.62 38.9 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.429 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -103.59 106.98 17.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.882 . . . . 0.0 109.482 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.492 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 7.0 mp -75.03 -175.7 2.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.207 -0.933 . . . . 0.0 109.477 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.521 HG13 ' N ' ' A' ' 147' ' ' ASN . 10.9 pt -60.44 -46.09 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.18 -0.95 . . . . 0.0 109.449 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.521 ' N ' HG13 ' A' ' 146' ' ' ILE . 28.7 p-10 -139.38 23.1 2.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.286 -0.884 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.453 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 40.8 mttt -140.29 151.14 44.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.742 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -120.63 134.13 55.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.33 -0.856 . . . . 0.0 108.992 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.467 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 37.0 pt -133.6 154.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.125 -0.984 . . . . 0.0 109.892 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.507 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 51.5 mttt -123.16 124.79 43.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.34 -0.85 . . . . 0.0 109.286 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -153.19 150.93 29.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 47.9 p -80.14 140.28 36.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.304 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.467 HG12 ' HB2' ' A' ' 158' ' ' GLU . 14.1 t -122.69 155.67 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.492 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 31.0 mttt -91.16 143.99 26.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.434 ' O ' ' O ' ' A' ' 159' ' ' PHE . 1.0 OUTLIER -51.4 -29.44 15.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.511 179.864 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 120' ' ' GLU . 45.9 p -82.57 -22.82 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.526 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.467 ' HB2' HG12 ' A' ' 154' ' ' VAL . 79.9 mt-10 -78.4 -19.99 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.254 -0.904 . . . . 0.0 109.531 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.47 ' CD1' ' O ' ' A' ' 155' ' ' LYS . 33.4 p90 -145.09 162.25 37.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.938 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -131.83 136.47 47.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.535 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -60.86 134.46 57.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.413 HD12 ' N ' ' A' ' 116' ' ' VAL . 9.2 mt . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.472 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.56 -32.5 72.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.6 mtt -122.05 151.87 40.4 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.26 -0.9 . . . . 0.0 109.466 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -69.07 150.35 50.17 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.98 148.73 64.25 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.227 . . . . 0.0 111.821 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -83.57 150.88 25.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -54.13 -40.05 67.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.399 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.96 142.56 24.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.494 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 19.5 m -87.23 -16.76 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.566 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.502 ' N ' ' OD1' ' A' ' 106' ' ' ASP . 0.5 OUTLIER -57.98 135.22 83.8 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.39 53.57 1.33 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.676 2.251 . . . . 0.0 111.742 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . 58.98 33.1 22.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.426 HG23 ' HD2' ' A' ' 110' ' ' PRO . 42.2 m -65.78 136.83 95.96 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.572 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.1 Cg_endo -69.91 147.34 61.71 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.72 2.28 . . . . 0.0 111.839 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.462 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 48.2 m-85 -111.1 160.28 29.56 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.01 137.48 34.82 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.702 2.268 . . . . 0.0 111.829 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.78 -10.07 68.47 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.462 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.8 m-20 -82.39 145.48 29.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.252 -1.146 . . . . 0.0 109.461 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.456 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 30.5 mttm -75.83 142.23 42.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.615 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.5 m -132.45 150.97 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.446 ' HB ' HD11 ' A' ' 162' ' ' LEU . 4.5 tp -123.43 141.75 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.491 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.451 HD11 ' CB ' ' A' ' 123' ' ' PHE . 61.2 mt -92.59 131.12 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.236 -0.915 . . . . 0.0 109.443 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.432 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.2 p -106.95 -8.39 16.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.6 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -137.37 157.29 46.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.23 -0.919 . . . . 0.0 109.572 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.21 165.14 37.75 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.67 -19.87 65.25 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.445 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.543 ' CD1' HD22 ' A' ' 143' ' ' LEU . 94.3 m-85 -86.38 13.48 8.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.454 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.432 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 87.0 tt0 -66.25 137.88 57.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.471 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.51 0.26 73.23 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -106.4 134.72 49.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -1.162 . . . . 0.0 109.484 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -79.93 147.62 31.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.222 -0.924 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.457 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.33 163.63 32.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.456 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 24.0 mm -121.29 139.23 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -0.875 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.615 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 42.2 m-85 -60.92 114.41 3.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.192 -0.943 . . . . 0.0 109.442 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.519 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.3 p -87.37 -30.76 20.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 163.79 82.2 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.896 . . . . 0.0 109.455 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.07 130.74 19.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.723 2.282 . . . . 0.0 111.827 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -67.83 -32.72 73.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.291 -0.88 . . . . 0.0 109.475 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -170.54 -177.48 40.65 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.62 -29.46 70.47 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.272 -1.134 . . . . 0.0 109.521 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -63.68 -60.41 3.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.165 -0.96 . . . . 0.0 109.438 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.453 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.2 mtt180 -112.72 155.74 24.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 53.4 m -146.5 149.07 32.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.434 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.463 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 82.1 mmm -95.31 125.14 39.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.389 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.547 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.3 mp -125.46 140.4 52.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.163 -0.961 . . . . 0.0 109.631 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.524 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 6.0 tt -96.04 123.9 39.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.322 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.58 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.6 mp -99.51 113.65 26.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.652 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -89.52 124.27 34.37 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.494 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 3.5 mm? -85.27 175.22 9.06 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.152 -0.967 . . . . 0.0 109.392 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 147' ' ' ASN . 17.6 pt -58.93 -38.12 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.483 ' N ' HG13 ' A' ' 146' ' ' ILE . 24.2 m120 -138.89 19.61 2.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.958 . . . . 0.0 109.407 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.469 ' O ' ' N ' ' A' ' 145' ' ' LEU . 85.7 mttt -143.64 156.56 44.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.26 -0.9 . . . . 0.0 109.631 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -121.38 124.9 45.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.196 -0.94 . . . . 0.0 109.191 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.47 HD11 ' CE1' ' A' ' 123' ' ' PHE . 32.8 pt -128.73 156.03 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.918 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.524 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.7 mttt -131.56 132.18 43.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.339 -0.851 . . . . 0.0 109.27 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 153' ' ' SER . 57.8 t-80 -152.28 144.79 24.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.141 -0.974 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.429 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 45.9 p -68.7 142.61 54.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.33 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.466 HG11 ' HB2' ' A' ' 158' ' ' GLU . 19.7 t -129.85 150.78 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.537 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 158' ' ' GLU . 90.5 mttt -94.11 139.12 31.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.33 -0.856 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.576 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.0 p30 -46.0 -29.06 1.32 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.169 -0.957 . . . . 0.0 109.582 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 57.9 p -82.24 -21.92 36.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 109.595 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.2 mt-10 -81.22 -20.6 40.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.576 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 27.7 p90 -140.74 172.14 13.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -0.937 . . . . 0.0 109.561 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -130.85 147.73 52.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -78.57 133.54 37.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.273 -0.892 . . . . 0.0 109.504 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.446 HD11 ' HB ' ' A' ' 117' ' ' ILE . 15.9 mt . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.468 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.48 -33.03 73.08 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.172 -1.193 . . . . 0.0 109.526 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.6 mtt -125.35 154.4 41.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.925 . . . . 0.0 109.417 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -67.94 151.69 52.11 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -9.08 25.17 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.669 2.246 . . . . 0.0 111.743 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.415 ' O ' ' HB3' ' A' ' 103' ' ' ASP . 93.5 mttt -63.57 -31.22 72.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.6 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 104' ' ' ILE . 46.6 t0 67.0 26.82 8.96 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.292 -0.88 . . . . 0.0 109.39 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' ASP . 78.3 mt -42.98 -37.38 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.631 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 43.5 t -108.25 135.74 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.487 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 106' ' ' ASP . 25.8 p30 -106.89 156.37 37.44 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.894 . . . . 0.0 109.477 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -69.99 63.22 1.93 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.742 2.295 . . . . 0.0 111.854 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.52 -34.28 77.57 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.47 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.426 HG22 ' HD2' ' A' ' 110' ' ' PRO . 32.6 m -64.93 138.2 97.4 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.426 ' HD2' HG22 ' A' ' 109' ' ' THR . 49.9 Cg_endo -70.12 147.07 59.75 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.764 2.309 . . . . 0.0 111.833 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 6.5 m-85 -111.03 161.29 25.62 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.324 -0.86 . . . . 0.0 109.368 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.64 131.52 23.07 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.73 2.286 . . . . 0.0 111.712 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.65 -11.98 59.5 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.441 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.6 m-20 -77.44 157.43 30.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -1.155 . . . . 0.0 109.497 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.511 ' CB ' HD21 ' A' ' 162' ' ' LEU . 55.9 mttt -80.35 142.12 34.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.299 -0.876 . . . . 0.0 109.448 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.603 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 5.8 m -127.59 159.48 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.506 ' CG2' ' O ' ' A' ' 160' ' ' ARG . 8.3 tp -123.37 147.32 27.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.459 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 15.2 mm -91.45 131.63 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.264 -0.897 . . . . 0.0 109.475 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.422 ' C ' ' HG2' ' A' ' 124' ' ' GLU . 72.7 p -121.65 5.5 10.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.267 -0.896 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.411 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -141.73 151.16 42.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -0.936 . . . . 0.0 109.442 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 85.13 -170.27 44.94 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.73 -2.4 58.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -1.201 . . . . 0.0 109.625 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.564 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 93.1 m-85 -87.94 4.78 43.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.63 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.422 ' HG2' ' C ' ' A' ' 119' ' ' THR . 97.5 mt-10 -56.5 142.09 40.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.7 -3.46 83.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.564 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.8 m-30 -102.36 147.71 26.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -1.17 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -100.17 151.03 21.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.387 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -146.74 161.34 40.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.227 -0.92 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.478 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 22.8 mm -114.02 140.54 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.484 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.5 m-85 -61.42 112.86 2.36 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.275 -0.891 . . . . 0.0 109.443 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 46.0 p -82.36 -32.13 29.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.457 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.8 mm-40 164.4 91.72 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.156 -0.965 . . . . 0.0 109.488 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.405 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.2 Cg_endo -70.11 122.99 9.55 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.597 2.198 . . . . 0.0 111.771 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -65.81 -31.26 72.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.47 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -163.26 179.84 38.18 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.04 -26.85 63.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.218 -1.166 . . . . 0.0 109.541 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.36 -53.72 15.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.461 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 59.0 mtt180 -112.32 151.44 29.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.516 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 54.4 m -142.32 150.43 40.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.303 -0.873 . . . . 0.0 109.465 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.441 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 48.8 mtp -100.37 127.31 46.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.5 mp -125.38 146.42 49.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.483 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.527 ' O ' ' CB ' ' A' ' 128' ' ' ALA . 9.7 tt -97.44 126.3 42.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.478 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 39.1 mt -97.93 109.88 22.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.542 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.411 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 14.9 p-10 -84.63 122.6 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 0.0 109.621 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.551 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 3.0 mm? -111.23 141.43 44.77 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.383 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.484 HG13 ' N ' ' A' ' 147' ' ' ASN . 21.3 pt -50.03 -35.75 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.499 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 61.3 t30 -72.42 -49.22 35.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.288 -0.882 . . . . 0.0 109.575 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.499 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 67.3 mttt -158.11 173.38 16.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.543 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -103.17 133.21 48.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.924 . . . . 0.0 109.312 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.506 HD12 HG22 ' A' ' 150' ' ' ILE . 17.2 pt -133.99 159.27 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.625 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.517 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 13.3 mttt -119.63 136.95 54.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.282 -0.886 . . . . 0.0 109.33 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -144.31 140.24 29.04 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.585 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 23.5 p -85.1 125.19 32.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.338 -0.851 . . . . 0.0 109.313 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.51 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 4.0 p -127.97 147.92 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.196 -0.94 . . . . 0.0 109.547 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.54 ' O ' ' CD2' ' A' ' 159' ' ' PHE . 88.8 mttt -76.08 155.27 34.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.231 -0.918 . . . . 0.0 109.464 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.573 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 20.3 m-80 -62.71 -27.09 69.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.453 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 64.7 p -77.33 -18.86 57.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.356 -0.84 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.51 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.3 mt-10 -87.72 -19.78 27.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.475 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.573 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 29.8 p90 -138.08 161.03 37.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -0.951 . . . . 0.0 109.583 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.506 ' O ' ' CG2' ' A' ' 117' ' ' ILE . 73.7 mtt180 -129.53 147.77 51.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.317 -0.864 . . . . 0.0 109.475 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.405 ' NZ ' ' HA ' ' A' ' 110' ' ' PRO . 25.7 tttt -73.55 123.88 24.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.429 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.511 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.487 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.48 146.02 52.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -1.129 . . . . 0.0 109.48 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.8 mtm -111.5 143.21 42.71 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.288 -0.883 . . . . 0.0 109.454 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -74.6 150.77 42.09 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.02 147.53 61.4 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.708 2.272 . . . . 0.0 111.789 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 23.4 tttp -84.24 134.03 34.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -68.32 146.83 52.92 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 109.528 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.478 HG23 HD11 ' A' ' 104' ' ' ILE . 54.6 mt -116.81 138.51 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.202 -0.936 . . . . 0.0 109.468 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.462 ' O ' ' O ' ' A' ' 104' ' ' ILE . 50.8 t 58.99 114.89 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -62.69 138.43 96.83 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.208 -0.932 . . . . 0.0 109.473 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.1 53.64 1.23 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.75 2.3 . . . . 0.0 111.799 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.04 -32.04 72.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.904 . . . . 0.0 109.5 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.512 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 3.0 m -68.05 140.7 93.65 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.565 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.1 Cg_endo -69.98 144.45 52.89 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.679 2.253 . . . . 0.0 111.754 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.46 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 52.8 m-85 -111.55 160.89 27.79 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.459 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 49.4 Cg_endo -70.2 135.01 28.37 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.675 2.25 . . . . 0.0 111.754 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.82 -10.11 66.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.46 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.2 m-20 -83.99 147.53 27.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -1.123 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.509 ' CB ' HD21 ' A' ' 162' ' ' LEU . 22.7 mttm -72.98 145.08 46.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.902 . . . . 0.0 109.456 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.625 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.3 m -133.79 150.42 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.476 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 1.8 tp -119.95 139.29 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.461 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.452 HD11 HD23 ' A' ' 143' ' ' LEU . 58.8 mt -92.53 130.08 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.287 -0.883 . . . . 0.0 109.501 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.474 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 60.5 p -106.96 -10.26 16.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -132.87 157.36 45.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 109.522 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.66 166.85 36.33 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.59 -22.31 64.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.571 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 96.9 m-85 -82.51 8.13 12.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.224 -0.922 . . . . 0.0 109.52 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.474 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -57.64 139.9 52.51 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.297 -0.877 . . . . 0.0 109.522 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.53 -5.26 73.82 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.571 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.5 m-30 -99.99 145.79 27.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.247 -1.149 . . . . 0.0 109.464 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -94.55 146.45 24.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.935 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.456 ' O ' HG23 ' A' ' 116' ' ' VAL . . . -142.21 160.18 40.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.299 -0.875 . . . . 0.0 109.42 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.449 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 25.8 mm -114.71 140.06 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.48 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.625 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.8 m-85 -61.42 110.15 1.36 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.295 -0.878 . . . . 0.0 109.495 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.52 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 39.3 p -80.46 -32.5 37.18 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.317 -0.864 . . . . 0.0 109.477 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 164.32 86.58 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.267 -0.895 . . . . 0.0 109.398 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.5 Cg_endo -69.79 128.56 16.17 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.773 2.316 . . . . 0.0 111.799 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -69.06 -29.34 67.45 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.517 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -167.92 174.81 42.87 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . 0.403 ' HG3' HG23 ' A' ' 109' ' ' THR . 82.7 tt0 -62.07 -27.97 69.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.68 -64.93 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.164 -0.96 . . . . 0.0 109.476 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.402 ' O ' ' O ' ' A' ' 135' ' ' GLY . 49.9 mtm-85 -105.08 152.08 23.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.532 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 65.2 m -142.46 152.15 42.44 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.51 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 66.2 mmm -96.58 123.61 40.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.574 HD23 ' CD2' ' A' ' 159' ' ' PHE . 6.5 mp -122.5 142.89 50.11 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.945 . . . . 0.0 109.636 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.505 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 15.1 tp -103.86 119.36 38.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.273 -0.892 . . . . 0.0 109.417 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.577 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -100.57 109.14 21.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.501 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.431 ' O ' ' CG ' ' A' ' 144' ' ' ASN . 11.3 p-10 -83.11 118.86 23.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.567 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.519 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 3.0 mm? -82.03 168.83 17.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.259 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.496 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.2 pt -54.15 -38.27 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.19 -0.944 . . . . 0.0 109.638 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.496 ' N ' HG13 ' A' ' 146' ' ' ILE . 30.3 p-10 -139.19 25.09 2.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -0.984 . . . . 0.0 109.787 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.472 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 76.0 mttt -152.61 157.41 40.97 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.0 109.815 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -128.11 130.86 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.383 -0.823 . . . . 0.0 109.112 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.505 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 21.3 pt -131.45 145.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.134 -0.978 . . . . 0.0 109.835 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 19.6 mttp -118.53 126.79 52.75 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 0.0 109.298 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.494 ' CE1' ' O ' ' A' ' 153' ' ' SER . 52.5 t-80 -153.85 145.73 23.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.168 -0.958 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.494 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 52.5 p -74.48 141.48 44.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.216 -0.928 . . . . 0.0 109.356 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.448 HG12 ' HB2' ' A' ' 158' ' ' GLU . 21.3 t -124.78 150.4 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.444 ' HB2' ' HG3' ' A' ' 158' ' ' GLU . 61.3 mttp -86.06 138.46 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -49.96 -22.99 1.75 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.943 . . . . 0.0 109.494 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.7 p -86.62 -25.39 24.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.175 -0.953 . . . . 0.0 109.463 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.448 ' HB2' HG12 ' A' ' 154' ' ' VAL . 97.6 mt-10 -76.63 -23.39 53.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -0.865 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.574 ' CD2' HD23 ' A' ' 141' ' ' LEU . 22.7 p90 -140.62 160.95 38.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 109.491 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -128.89 142.15 51.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.219 -0.925 . . . . 0.0 109.512 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -70.43 124.99 25.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.208 -0.933 . . . . 0.0 109.422 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.509 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.496 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.9 143.93 57.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -1.145 . . . . 0.0 109.424 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.1 mtp -56.36 -36.34 68.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -102.37 131.05 10.45 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.94 141.86 45.59 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.639 2.226 . . . . 0.0 111.825 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -58.21 -39.51 79.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.893 . . . . 0.0 109.516 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -84.52 139.24 32.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.3 mt -109.12 141.19 25.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.501 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.5 155.49 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.209 -0.932 . . . . 0.0 109.566 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.448 ' HB2' ' HD2' ' A' ' 107' ' ' PRO . 3.4 p30 -66.76 160.67 67.11 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 106' ' ' ASP . 49.0 Cg_endo -69.94 66.59 1.87 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.634 2.223 . . . . 0.0 111.818 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.61 -31.54 71.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.3 m -55.71 129.16 70.67 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.571 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.3 Cg_endo -70.24 148.17 61.41 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.637 2.225 . . . . 0.0 111.754 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.439 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 65.9 m-85 -109.24 161.11 25.11 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.282 -0.886 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.427 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.2 Cg_endo -69.64 132.27 23.16 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.681 2.254 . . . . 0.0 111.756 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.54 -10.55 61.12 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 81.5 m-20 -77.85 150.72 34.15 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.176 -1.191 . . . . 0.0 109.451 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.516 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 28.8 mttt -84.81 141.51 30.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.47 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.598 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.8 m -129.04 158.89 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.463 ' O ' ' HB2' ' A' ' 159' ' ' PHE . 7.3 tp -126.59 148.73 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.151 -0.968 . . . . 0.0 109.505 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.446 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 25.9 mm -90.52 127.84 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.451 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 72.8 p -112.83 -5.36 13.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.275 -0.891 . . . . 0.0 109.502 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.457 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 85.2 tt0 -138.51 156.28 47.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.202 -0.936 . . . . 0.0 109.421 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.457 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 86.5 169.57 46.05 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.22 -14.63 63.13 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -1.163 . . . . 0.0 109.527 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.516 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 85.6 m-85 -82.78 6.85 16.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 84.5 tt0 -59.45 132.84 55.2 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.565 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 99.46 1.17 56.67 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.516 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -103.49 138.58 40.01 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.12 -1.224 . . . . 0.0 109.59 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -93.98 122.58 36.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.211 -0.931 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.48 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -118.52 165.77 13.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.58 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.516 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 41.9 mm -120.43 139.29 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.598 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.6 m-85 -58.65 101.37 0.09 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.906 . . . . 0.0 109.516 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.525 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 49.2 p -77.15 -30.52 55.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.286 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.2 mt-10 163.63 97.15 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.262 -0.899 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.85 114.63 3.78 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.707 2.272 . . . . 0.0 111.763 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -66.55 -33.6 76.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.492 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -145.01 163.0 28.11 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.66 -31.99 72.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -1.146 . . . . 0.0 109.184 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.17 -73.91 0.15 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.6 ptt-85 -84.96 158.32 20.55 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.285 -0.885 . . . . 0.0 109.611 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 71.1 m -145.79 144.58 30.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.514 ' SD ' ' CB ' ' A' ' 153' ' ' SER . 89.8 mmm -86.58 118.89 26.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.251 -0.906 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.521 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.8 mp -122.61 146.07 47.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.521 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.48 ' O ' ' CB ' ' A' ' 128' ' ' ALA . 9.4 tt -99.37 127.44 45.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.434 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.431 HD21 ' HB3' ' A' ' 128' ' ' ALA . 17.9 mt -96.8 115.04 26.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -86.75 126.6 34.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.465 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 9.6 mp -129.46 136.33 49.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.242 -0.911 . . . . 0.0 109.362 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.501 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -50.55 -35.09 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.888 . . . . 0.0 109.614 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.501 ' N ' HG13 ' A' ' 146' ' ' ILE . 47.7 t-20 -68.68 -47.56 66.16 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.915 . . . . 0.0 109.585 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 55.5 tttp -168.09 158.98 10.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.166 -0.959 . . . . 0.0 109.576 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.47 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 97.0 mt-10 -93.81 125.72 38.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.95 . . . . 0.0 109.5 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 27.8 pt -126.34 158.63 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.205 -0.935 . . . . 0.0 109.428 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.438 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 17.1 mttt -124.62 131.55 53.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.543 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -142.6 147.06 35.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 39.3 p -72.18 139.66 48.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.519 HG13 ' CD1' ' A' ' 159' ' ' PHE . 21.8 t -131.08 150.63 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 24.6 mttm -97.16 138.72 34.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 32.1 m-80 -45.06 -30.64 1.11 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 65.9 p -81.15 -25.21 37.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.287 -0.883 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 92.0 mt-10 -76.21 -23.67 54.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.577 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 27.5 p90 -137.41 167.05 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 63.5 mtt85 -130.21 146.84 51.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.459 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.426 ' HE3' ' HB3' ' A' ' 114' ' ' ASP . 73.8 tttt -72.8 117.23 14.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.436 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.448 HD22 ' HB3' ' A' ' 115' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.466 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -60.65 -31.23 70.45 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.248 -1.148 . . . . 0.0 109.526 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 67.6 mtm -117.18 154.35 31.26 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.505 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -108.98 159.23 14.19 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.6 -21.07 30.09 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.801 2.334 . . . . 0.0 111.719 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -58.3 -38.43 77.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.919 . . . . 0.0 109.515 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -90.3 133.37 35.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.8 mt -124.87 140.2 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.947 . . . . 0.0 109.512 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 41.8 t -138.63 146.24 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.367 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -105.69 164.17 15.57 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -75.78 45.0 1.38 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.624 2.216 . . . . 0.0 111.995 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -83.28 -27.38 29.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.094 -1.004 . . . . 0.0 109.189 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 18.0 m -49.74 125.36 17.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.307 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.618 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 48.6 Cg_endo -69.99 154.77 66.49 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.701 2.267 . . . . 0.0 111.917 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.46 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 43.7 m-85 -120.01 159.45 46.99 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.442 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 133.61 25.19 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.69 2.26 . . . . 0.0 111.873 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.34 -10.69 61.52 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.46 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.6 m-20 -85.57 144.69 27.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.288 -1.124 . . . . 0.0 109.498 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -75.45 147.02 40.22 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 109.517 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.635 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.8 m -134.9 151.41 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.515 HG21 ' CD2' ' A' ' 162' ' ' LEU . 3.8 tp -123.94 141.07 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.446 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 61.8 mt -92.18 129.95 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.321 -0.862 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.492 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 p -105.65 -7.6 18.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.537 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.435 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 97.8 mt-10 -138.02 158.16 44.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.484 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.4 168.11 38.55 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.95 -22.7 65.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.222 -1.163 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.524 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.9 m-85 -83.47 9.46 11.17 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.244 -0.91 . . . . 0.0 109.417 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.492 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -61.76 140.89 58.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.96 -6.06 76.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.524 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.0 m-85 -99.89 149.8 23.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -1.153 . . . . 0.0 109.557 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -98.45 147.86 24.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.319 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.474 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -143.69 162.61 35.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.898 . . . . 0.0 109.502 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 26.1 mm -113.47 143.87 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.45 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.635 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 33.6 m-85 -66.06 113.01 4.16 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.525 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 18.1 p -82.4 -33.17 28.78 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.952 . . . . 0.0 109.437 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.89 90.3 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.425 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.5 Cg_endo -69.78 122.66 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.686 2.257 . . . . 0.0 111.799 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 21.3 p-10 -65.89 -31.21 72.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.664 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.509 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -164.66 178.6 39.79 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -67.61 -27.05 66.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.308 -1.113 . . . . 0.0 109.543 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.04 -63.2 1.14 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 58.1 mtt180 -108.37 158.53 17.42 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 109.548 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 72.6 m -145.28 155.38 43.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.394 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.455 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 64.6 mtp -102.21 124.27 47.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.56 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.2 mp -122.25 145.79 47.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.525 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 7.8 tt -104.8 120.82 42.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.915 . . . . 0.0 109.521 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.557 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.7 mp -96.37 136.1 37.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.44 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.498 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 92.7 m-20 -106.21 112.41 25.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.541 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.433 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 44.1 mt -100.24 148.08 25.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.495 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -51.13 -40.12 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.495 ' N ' HG13 ' A' ' 146' ' ' ILE . 45.8 t-20 -68.7 -48.08 64.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.54 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.494 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 28.3 ttpp -168.46 164.6 12.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.287 -0.883 . . . . 0.0 109.466 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.494 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 95.1 mt-10 -87.88 139.19 30.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.7 158.18 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.25 -0.906 . . . . 0.0 109.402 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.449 ' HG2' HD12 ' A' ' 142' ' ' LEU . 20.8 mttt -125.84 130.45 51.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.196 -0.94 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.411 ' ND1' ' O ' ' A' ' 153' ' ' SER . 56.5 t-80 -153.17 141.61 20.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 109.436 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.411 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 68.6 m -67.77 142.59 56.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -0.958 . . . . 0.0 109.438 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.462 HG13 ' CD1' ' A' ' 159' ' ' PHE . 16.8 t -131.03 151.6 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.418 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 9.5 mtpm? -92.04 137.29 32.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.893 . . . . 0.0 109.508 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.582 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.0 m-80 -50.66 -24.36 3.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 109.415 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.6 p -84.78 -22.49 29.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.907 . . . . 0.0 109.356 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.414 ' HG2' ' HB2' ' A' ' 155' ' ' LYS . 68.6 mm-40 -81.47 -20.7 39.66 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.582 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.14 178.29 7.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.464 ' HD2' HG22 ' A' ' 119' ' ' THR . 59.1 mtt-85 -134.65 146.63 49.71 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.871 . . . . 0.0 109.402 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -84.71 135.75 34.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.447 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.515 ' CD2' HG21 ' A' ' 117' ' ' ILE . 68.0 mt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.415 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . 0.435 ' O ' ' HB3' ' A' ' 98' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 97' ' ' GLY . . . 63.67 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -1.173 . . . . 0.0 109.481 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.0 mmm -60.58 -36.96 79.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.227 -0.92 . . . . 0.0 109.442 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -68.66 145.9 44.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.37 -14.93 34.65 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.707 2.272 . . . . 0.0 111.786 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.4 mttt -57.22 -36.27 70.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.322 -0.862 . . . . 0.0 109.458 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -79.79 135.65 36.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.198 -0.939 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.74 142.26 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.473 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.73 154.99 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.231 -0.918 . . . . 0.0 109.445 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -74.26 122.37 87.38 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.1 57.84 1.67 Allowed 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.687 2.258 . . . . 0.0 111.779 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.1 75.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.311 -0.868 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 77.0 m -99.93 126.89 35.18 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.234 -0.916 . . . . 0.0 109.411 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.25 135.12 28.51 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.697 2.265 . . . . 0.0 111.846 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.418 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 33.0 m-85 -77.58 161.23 72.78 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.323 -0.861 . . . . 0.0 109.479 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.17 134.04 28.21 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.693 2.262 . . . . 0.0 111.819 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.03 -17.55 54.0 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -68.47 162.71 24.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -1.151 . . . . 0.0 109.38 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.473 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 36.5 mttm -88.01 139.48 30.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.282 -0.886 . . . . 0.0 109.572 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.589 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.7 m -133.48 148.98 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.438 ' CG2' ' HB3' ' A' ' 162' ' ' LEU . 5.1 tp -116.67 141.45 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.556 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.6 mt -92.61 130.72 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.422 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.45 HG23 ' HD2' ' A' ' 160' ' ' ARG . 61.3 p -107.27 -5.02 18.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.462 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 83.9 tt0 -141.41 155.53 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.521 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.462 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 100.33 166.83 28.83 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.37 -22.22 64.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.527 ' CD1' HD13 ' A' ' 143' ' ' LEU . 77.8 m-85 -87.64 12.87 11.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.1 136.94 58.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.254 -0.904 . . . . 0.0 109.432 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.91 66.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -105.68 122.75 46.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -1.168 . . . . 0.0 109.541 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -72.05 137.35 47.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.298 -0.876 . . . . 0.0 109.306 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.461 ' CB ' HD21 ' A' ' 143' ' ' LEU . . . -133.68 158.52 43.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.208 -0.932 . . . . 0.0 109.563 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.473 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 29.5 mm -116.64 136.0 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.444 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.589 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 35.2 m-85 -58.61 101.77 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.519 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.458 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 44.8 p -75.05 -39.06 61.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.386 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 131' ' ' THR . 67.9 tt0 172.98 95.77 0.05 OUTLIER Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.9 . . . . 0.0 109.441 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.16 110.72 2.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.718 2.279 . . . . 0.0 111.848 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.5 p-10 -62.68 -34.42 77.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.504 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.417 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -141.85 178.06 20.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -76.91 -30.02 55.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -1.129 . . . . 0.0 109.406 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -69.46 -78.06 0.07 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.407 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.46 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 13.3 ptt180 -89.77 148.13 23.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.248 -0.907 . . . . 0.0 109.743 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.1 m -135.33 155.38 50.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 0.0 109.492 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.488 ' SD ' ' CB ' ' A' ' 153' ' ' SER . 93.6 mmm -89.92 115.55 27.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.519 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.1 mp -119.74 139.52 52.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.892 . . . . 0.0 109.481 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.515 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 9.0 tp -97.48 122.16 40.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.527 HD13 ' CD1' ' A' ' 123' ' ' PHE . 22.1 mt -87.95 146.46 25.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.316 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -115.98 107.96 15.63 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.601 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.523 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.0 mp -105.23 141.18 37.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.938 . . . . 0.0 109.302 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.456 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.0 pt -50.39 -32.5 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.522 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.7 m-20 -73.12 -56.41 5.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.289 -0.882 . . . . 0.0 109.674 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.522 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 60.2 mttm -159.58 171.32 19.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.513 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.58 139.08 38.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.337 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.515 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 20.1 pt -132.8 142.43 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.231 -0.918 . . . . 0.0 109.46 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -96.5 130.02 43.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.24 -0.913 . . . . 0.0 109.474 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -147.52 138.57 23.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.488 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 52.1 p -73.2 141.45 47.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.278 -0.889 . . . . 0.0 109.441 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.499 HG11 ' CD1' ' A' ' 159' ' ' PHE . 12.2 t -128.81 151.56 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -0.91 . . . . 0.0 109.56 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 45.4 mttp -100.87 138.36 38.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.376 -0.828 . . . . 0.0 109.423 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.572 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.1 p30 -46.04 -28.28 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.493 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 72.0 p -84.94 -19.64 31.88 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.25 -0.906 . . . . 0.0 109.629 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.6 mt-10 -83.23 -22.34 33.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.182 -0.949 . . . . 0.0 109.459 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.572 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 29.9 p90 -136.93 173.03 12.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.215 -0.928 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.45 ' HD2' HG23 ' A' ' 119' ' ' THR . 96.6 mtt180 -134.99 145.17 47.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.515 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -69.34 113.59 6.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.53 HD22 ' CA ' ' A' ' 116' ' ' VAL . 1.9 pp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.406 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -65.31 140.44 58.69 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.277 -1.131 . . . . 0.0 109.445 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 71.7 mtm -60.48 -36.34 78.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -0.886 . . . . 0.0 109.47 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -157.34 130.25 2.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.39 -9.24 25.46 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.682 2.255 . . . . 0.0 111.755 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 47.6 mttm -57.24 -33.18 67.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.3 -0.875 . . . . 0.0 109.474 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -63.94 141.77 58.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.443 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.6 -41.76 89.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 33.7 m -131.08 150.0 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.439 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 -107.65 136.06 19.7 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.884 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.37 54.11 1.0 Allowed 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.722 2.282 . . . . 0.0 111.729 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.53 -34.67 77.57 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.223 -0.923 . . . . 0.0 109.532 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.0 m -76.52 123.49 87.73 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.525 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.8 Cg_endo -70.08 139.55 39.38 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.689 2.259 . . . . 0.0 111.856 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -88.26 161.08 44.22 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.903 . . . . 0.0 109.525 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.7 138.22 37.48 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.722 2.281 . . . . 0.0 111.79 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.85 -11.61 66.12 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.99 151.7 40.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -1.144 . . . . 0.0 109.403 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.524 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.5 mttm -80.26 139.75 36.54 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.594 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.7 m -129.23 156.3 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.427 HG21 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.24 146.1 29.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.598 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.46 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 20.5 mm -90.13 120.27 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.394 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 58.1 p -103.03 -16.06 15.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.42 155.56 50.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.459 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.94 165.04 35.45 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.95 -15.35 62.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 0.0 109.441 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.546 ' CD1' HD21 ' A' ' 143' ' ' LEU . 88.7 m-85 -86.49 11.75 11.88 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.45 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.1 tt0 -59.04 134.74 57.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.97 67.18 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.464 ' CE2' ' HG ' ' A' ' 145' ' ' LEU . 40.7 m-85 -99.19 137.62 37.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.098 -1.236 . . . . 0.0 109.545 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -90.99 129.38 37.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.323 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' A' ' 142' ' ' LEU . . . -130.08 163.72 25.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.56 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.524 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 31.0 mm -119.42 139.76 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.308 -0.87 . . . . 0.0 109.408 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.594 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 38.0 m-85 -58.6 101.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -0.933 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.501 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 41.0 p -77.58 -28.33 51.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.7 OUTLIER 164.93 98.01 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.484 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.0 Cg_endo -69.82 114.83 3.84 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.733 2.289 . . . . 0.0 111.805 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -60.94 -30.7 70.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 109.506 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -166.15 174.45 41.72 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -67.34 -22.81 65.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -1.144 . . . . 0.0 109.491 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.92 -64.63 1.01 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.45 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 57.5 mtm-85 -107.72 159.61 16.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 55.7 m -144.98 157.93 43.97 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -0.864 . . . . 0.0 109.471 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.429 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 33.8 mtp -101.97 120.91 41.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.57 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.4 mp -120.31 147.31 45.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.514 ' O ' ' CB ' ' A' ' 128' ' ' ALA . 11.9 tp -99.87 124.01 44.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.45 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.573 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.1 mp -100.89 109.51 21.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.195 -0.941 . . . . 0.0 109.457 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 13.4 p-10 -83.24 125.44 31.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.908 . . . . 0.0 109.553 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.47 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 7.7 mp -118.3 141.87 48.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.16 -0.962 . . . . 0.0 109.468 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.425 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.4 pt -51.6 -30.93 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.478 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.506 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 95.6 m-20 -74.98 -55.24 5.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.263 -0.898 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.506 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 33.9 mttt -158.68 171.78 19.47 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.223 -0.923 . . . . 0.0 109.622 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -101.01 131.3 46.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.239 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.459 ' O ' HG13 ' A' ' 150' ' ' ILE . 6.9 pt -129.87 144.77 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.742 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 31.2 mttt -108.47 136.57 47.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.039 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.09 140.02 20.97 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.004 -1.06 . . . . 0.0 109.831 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.4 p -85.19 121.8 28.46 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.39 -0.819 . . . . 0.0 109.047 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.521 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 2.9 p -121.13 151.55 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.15 -0.969 . . . . 0.0 109.638 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.501 ' N ' HG23 ' A' ' 154' ' ' VAL . 35.2 mttt -75.21 149.25 38.97 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.327 -0.858 . . . . 0.0 109.577 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.565 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.1 m-80 -60.56 -26.09 66.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.7 p -78.51 -20.69 50.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.293 -0.88 . . . . 0.0 109.53 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.521 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 72.8 mm-40 -83.28 -22.06 33.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.908 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.565 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 35.4 p90 -138.35 156.19 47.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.427 ' O ' HG21 ' A' ' 117' ' ' ILE . 17.3 ttt85 -127.93 137.08 52.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 16.8 pttt -72.19 161.03 31.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.174 -0.954 . . . . 0.0 109.405 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.54 ' CD1' ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.079 -0.963 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.63 -31.07 71.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -1.138 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 89.1 mtp -117.58 149.0 41.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.302 -0.874 . . . . 0.0 109.461 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -65.29 155.56 49.17 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.23 141.65 43.86 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 122.684 2.256 . . . . 0.0 111.833 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.0 tttm -57.82 -39.95 78.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.346 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.11 137.94 47.41 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.428 HD12 HG21 ' A' ' 104' ' ' ILE . 62.9 mt -113.89 141.36 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.178 -0.951 . . . . 0.0 109.542 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 36.8 t -119.15 126.84 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 109.394 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 106' ' ' ASP . 0.4 OUTLIER -98.8 119.66 60.61 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.631 -179.864 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -77.13 42.32 1.1 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.601 2.201 . . . . 0.0 111.999 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -80.77 -31.72 35.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.451 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.44 HG23 ' HD2' ' A' ' 110' ' ' PRO . 21.1 m -58.17 129.92 83.25 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.331 -0.856 . . . . 0.0 109.515 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.638 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 48.5 Cg_endo -70.32 145.14 53.08 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.639 2.226 . . . . 0.0 111.789 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -109.03 161.33 24.13 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.528 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.77 132.34 24.75 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.728 2.285 . . . . 0.0 111.824 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 106.83 -14.79 41.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.49 158.96 25.71 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -1.146 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -92.78 145.92 24.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.278 -0.889 . . . . 0.0 109.48 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.639 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 17.4 m -128.71 152.48 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.476 ' N ' HD11 ' A' ' 162' ' ' LEU . 7.3 tp -123.6 148.59 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.463 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.0 mm -92.58 132.51 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.23 -0.919 . . . . 0.0 109.463 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 52.2 p -121.32 5.39 10.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.196 -0.94 . . . . 0.0 109.619 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.414 ' OE1' ' HA ' ' A' ' 158' ' ' GLU . 94.0 mt-10 -141.36 152.14 44.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.14 -0.975 . . . . 0.0 109.501 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.463 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 84.25 -171.94 48.64 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.25 -5.72 59.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -1.146 . . . . 0.0 109.54 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.57 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 83.1 m-85 -85.46 7.7 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.578 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.463 ' HG3' ' O ' ' A' ' 121' ' ' GLY . 97.6 mt-10 -58.96 141.1 54.71 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 109.572 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.56 -6.83 80.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 20.6 m-30 -96.97 147.62 23.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.224 -1.162 . . . . 0.0 109.614 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -104.54 154.19 20.23 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.356 -0.84 . . . . 0.0 109.334 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.514 ' O ' ' CG2' ' A' ' 116' ' ' VAL . . . -147.88 162.05 40.06 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.595 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.431 HG22 ' N ' ' A' ' 130' ' ' PHE . 23.9 mm -112.39 144.34 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.587 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 35.1 m-85 -66.48 103.33 1.03 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.382 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.514 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.8 p -76.29 -34.2 59.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.527 ' O ' ' CG ' ' A' ' 140' ' ' MET . 2.2 mt-10 165.14 89.79 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.164 -0.96 . . . . 0.0 109.731 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.1 130.78 19.5 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.608 2.205 . . . . 0.0 111.694 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -68.17 -30.57 69.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -171.18 177.96 43.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -63.45 -25.76 68.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.254 -1.145 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.08 -62.27 1.51 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.7 mtt180 -110.01 157.98 18.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.3 m -142.46 153.05 43.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.527 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 85.7 mmm -99.73 124.0 44.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.555 HD23 ' CE1' ' A' ' 130' ' ' PHE . 42.0 mt -122.94 145.89 48.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.52 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 2.7 tt -101.2 126.39 47.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.168 -0.958 . . . . 0.0 109.646 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.555 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.8 mp -99.55 104.37 16.16 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.223 -0.923 . . . . 0.0 109.157 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -77.54 125.56 29.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.127 -0.983 . . . . 0.0 109.335 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.444 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 69.1 mt -117.72 141.35 48.49 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.32 -0.863 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.5 pt -51.55 -29.04 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.495 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.3 m-20 -78.47 -53.08 7.62 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.495 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 83.5 mttt -158.29 172.57 18.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.3 -0.875 . . . . 0.0 109.469 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -100.89 125.16 47.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.43 HG21 HD11 ' A' ' 145' ' ' LEU . 32.2 pt -120.87 158.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.923 . . . . 0.0 109.5 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.52 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 3.2 mtpm? -125.27 132.25 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.428 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -144.67 141.33 29.26 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.505 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 38.5 p -73.33 141.22 47.1 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.887 . . . . 0.0 109.32 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.466 HG13 ' N ' ' A' ' 155' ' ' LYS . 19.4 t -133.09 152.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.114 -0.991 . . . . 0.0 109.618 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 39.0 mtmt -91.28 141.46 28.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.519 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 18.5 m-80 -51.21 -26.2 6.66 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.3 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 45.6 p -83.83 -19.18 35.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.304 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.455 ' HB2' HG13 ' A' ' 154' ' ' VAL . 94.9 mt-10 -84.87 -13.42 50.97 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.353 -0.842 . . . . 0.0 109.45 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.519 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -148.74 173.5 13.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.208 -0.933 . . . . 0.0 109.398 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -131.16 143.99 51.04 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.197 -0.939 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -80.78 135.09 35.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.49 ' CD1' ' N ' ' A' ' 162' ' ' LEU . 6.7 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.495 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.13 143.79 56.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -1.155 . . . . 0.0 109.512 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.5 mtt -124.02 150.7 44.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.429 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -78.72 161.26 47.82 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.16 -16.74 35.95 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 122.673 2.248 . . . . 0.0 111.754 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 105' ' ' VAL . 37.1 mttt -62.29 -32.78 73.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.905 . . . . 0.0 109.44 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -60.07 -26.99 66.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.206 -0.934 . . . . 0.0 109.44 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 85.3 mt -55.97 -44.49 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' A' ' 102' ' ' LYS . 46.7 t -129.52 148.87 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.478 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.05 140.69 40.0 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.485 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.06 42.75 1.03 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.712 2.275 . . . . 0.0 112.081 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -78.87 -32.76 46.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.072 -1.018 . . . . 0.0 109.124 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.445 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 26.5 m -58.09 138.84 83.85 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.569 ' HB2' ' CZ ' ' A' ' 130' ' ' PHE . 48.9 Cg_endo -69.73 148.04 64.4 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.662 2.242 . . . . 0.0 111.958 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 72.0 m-85 -118.39 161.18 36.58 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.319 -0.863 . . . . 0.0 109.341 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.485 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 47.9 Cg_endo -69.07 130.72 20.72 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.767 2.311 . . . . 0.0 111.783 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.23 -8.21 55.18 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -83.1 166.41 18.73 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -1.185 . . . . 0.0 109.577 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 28.8 mtpt -90.85 140.36 29.88 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.62 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 9.9 m -129.77 155.92 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.546 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.511 ' HB ' ' CD1' ' A' ' 162' ' ' LEU . 8.6 tp -120.55 145.19 27.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.343 -0.848 . . . . 0.0 109.475 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.464 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 15.0 mm -90.25 134.02 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.937 . . . . 0.0 109.463 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.447 HG23 ' HD3' ' A' ' 160' ' ' ARG . 44.4 p -120.67 -0.05 10.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.512 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.46 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 93.9 mt-10 -138.39 153.4 48.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.4 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.427 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.28 -171.51 44.16 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.95 -3.62 58.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -1.13 . . . . 0.0 109.603 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.567 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.2 m-85 -89.13 9.55 25.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.502 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.46 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 98.3 mt-10 -59.23 141.89 53.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.586 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 88.57 -3.59 85.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.567 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.7 m-30 -100.17 143.22 30.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.167 -1.196 . . . . 0.0 109.565 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . 0.406 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 93.6 mt-30 -93.22 149.76 20.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.252 -0.905 . . . . 0.0 109.375 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.527 ' CB ' ' CG2' ' A' ' 116' ' ' VAL . . . -142.23 160.8 39.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 25.8 mm -114.99 136.52 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.18 -0.95 . . . . 0.0 109.453 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.62 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 34.8 m-85 -59.8 109.89 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.219 -0.926 . . . . 0.0 109.708 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.51 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 60.7 p -79.61 -34.85 40.34 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 109.34 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.98 96.9 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -70.83 109.27 2.47 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.653 2.235 . . . . 0.0 111.59 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 24.7 p-10 -76.02 0.11 19.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.736 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -172.48 160.68 32.01 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -66.32 -41.85 89.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -1.152 . . . . 0.0 109.314 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -65.5 -77.51 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.288 -0.882 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.0 ptp180 -80.46 151.53 29.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.91 . . . . 0.0 109.564 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.464 ' OG ' HD12 ' A' ' 141' ' ' LEU . 88.7 p -145.57 156.71 43.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.528 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' MET . . . . . . . . . . . . . 48.7 mtp -100.2 119.25 38.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.569 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 5.1 mp -124.24 148.52 47.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.278 -0.888 . . . . 0.0 109.506 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.513 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.7 tt -97.52 126.74 42.97 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.352 -0.843 . . . . 0.0 109.397 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.53 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 35.3 mt -96.47 110.42 22.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.227 -0.921 . . . . 0.0 109.377 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.417 ' C ' HD21 ' A' ' 145' ' ' LEU . 15.5 p-10 -82.73 124.03 29.86 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.852 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.53 ' CD2' ' O ' ' A' ' 143' ' ' LEU . 3.0 mm? -117.34 144.02 45.35 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.513 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.6 pt -50.08 -35.73 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.438 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.513 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.3 m-20 -71.35 -55.44 7.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.59 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 43.8 mttm -157.58 173.33 17.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.28 -0.887 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -99.12 128.79 45.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.259 -0.901 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.429 HG12 HD22 ' A' ' 145' ' ' LEU . 19.2 pt -125.5 158.02 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.513 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 24.0 mttp -119.26 135.58 54.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.382 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -144.91 145.92 31.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.58 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.2 p -86.17 121.28 28.54 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.349 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.5 HG23 ' N ' ' A' ' 155' ' ' LYS . 4.7 p -124.92 147.86 29.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.208 -0.932 . . . . 0.0 109.591 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.573 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.2 mttt -75.76 150.97 37.67 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.349 -0.844 . . . . 0.0 109.657 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.561 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 13.9 m-80 -61.51 -24.17 66.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.4 p -79.58 -21.08 45.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.246 -0.909 . . . . 0.0 109.495 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.485 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.8 mt-10 -81.18 -22.65 38.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.554 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 155' ' ' LYS . 41.7 p90 -138.47 170.51 15.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.925 . . . . 0.0 109.464 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.465 ' CG ' ' CG2' ' A' ' 117' ' ' ILE . 27.1 ptt180 -134.79 158.72 43.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.181 -0.949 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -88.59 139.26 30.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.511 ' CD1' ' HB ' ' A' ' 117' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . 0.424 ' O ' ' HB3' ' A' ' 98' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 97' ' ' GLY . . . 64.04 -89.02 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.166 -1.196 . . . . 0.0 109.469 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.0 mtm -62.21 -36.94 83.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.298 -0.876 . . . . 0.0 109.5 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -80.28 160.43 44.08 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.84 144.57 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.637 2.225 . . . . 0.0 111.841 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -58.16 -37.12 74.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -0.927 . . . . 0.0 109.421 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 104' ' ' ILE . 51.4 t0 -160.55 168.64 24.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.279 -0.888 . . . . 0.0 109.504 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.483 ' N ' ' OD1' ' A' ' 103' ' ' ASP . 70.3 mt -110.07 146.13 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.921 . . . . 0.0 109.52 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.468 ' N ' HG23 ' A' ' 104' ' ' ILE . 63.9 t -64.51 -36.51 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.306 -0.871 . . . . 0.0 109.516 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.96 121.58 69.62 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.198 -0.939 . . . . 0.0 109.537 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -71.17 51.44 1.34 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.707 2.271 . . . . 0.0 111.885 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.96 -34.78 66.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.203 -0.935 . . . . 0.0 109.315 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.0 m -87.37 130.55 47.15 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.231 179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.449 ' HB3' ' HD2' ' A' ' 161' ' ' LYS . 47.6 Cg_endo -68.58 137.89 40.36 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.595 2.197 . . . . 0.0 111.949 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -77.84 157.63 78.98 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 109.486 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -69.98 134.04 26.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.722 2.281 . . . . 0.0 111.713 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.482 ' HA2' ' CG2' ' A' ' 129' ' ' ILE . . . 89.88 -8.99 78.77 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.467 ' O ' HG22 ' A' ' 129' ' ' ILE . 29.0 p-10 -68.22 -178.85 1.13 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -1.153 . . . . 0.0 109.384 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.448 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 26.9 mttp -103.0 139.75 38.17 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.536 HG13 ' CE2' ' A' ' 130' ' ' PHE . 7.9 m -134.41 154.51 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.865 . . . . 0.0 109.38 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.406 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 2.5 tp -121.6 139.35 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.869 . . . . 0.0 109.617 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.464 ' HA ' ' HB2' ' A' ' 159' ' ' PHE . 66.7 mt -92.68 127.19 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 80.4 p -101.68 -11.77 18.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.421 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.458 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 95.6 mt-10 -130.66 158.97 38.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.01 165.61 36.85 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.78 -27.8 68.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.44 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 97.1 m-85 -82.49 3.61 27.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.326 -0.859 . . . . 0.0 109.582 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -53.76 141.49 26.58 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.177 -0.952 . . . . 0.0 109.48 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 94.06 -9.83 72.35 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.44 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -97.93 148.46 23.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.207 -1.172 . . . . 0.0 109.47 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . 0.439 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 95.3 mt-30 -91.27 143.69 26.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.273 -0.892 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -135.51 160.36 38.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.482 ' CG2' ' HA2' ' A' ' 113' ' ' GLY . 31.2 mm -117.86 136.6 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.536 ' CE2' HG13 ' A' ' 116' ' ' VAL . 19.6 m-85 -66.53 114.84 5.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 47.6 p -90.62 -29.93 17.48 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.337 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 175.46 87.53 0.09 OUTLIER Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.224 -0.922 . . . . 0.0 109.327 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.46 118.02 5.36 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.671 2.247 . . . . 0.0 111.791 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -60.32 -34.71 74.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -164.95 -160.12 12.03 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 70.3 mm-40 -83.41 -26.64 30.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -1.139 . . . . 0.0 109.354 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.29 -80.57 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.223 -0.923 . . . . 0.0 109.372 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.425 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 24.0 ptt180 -89.17 148.38 23.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.631 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 59.2 m -144.44 152.81 41.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.197 -0.939 . . . . 0.0 109.414 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.422 ' C ' HD11 ' A' ' 141' ' ' LEU . 39.5 mtp -96.97 122.33 39.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.44 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.547 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.3 mp -123.83 150.41 44.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.42 HD11 ' O ' ' A' ' 150' ' ' ILE . 32.1 tp -100.07 123.73 44.64 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 109.466 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.571 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -93.94 118.71 31.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.466 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 21.9 p-10 -83.49 114.92 21.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.566 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.528 ' CD2' ' O ' ' A' ' 143' ' ' LEU . 2.9 mm? -114.38 144.16 43.73 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 109.413 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 29.1 pt -55.09 -29.07 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.306 -0.872 . . . . 0.0 109.29 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 34.8 t30 -75.82 -54.29 7.15 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.342 -0.849 . . . . 0.0 109.441 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.508 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 24.7 tttm -168.57 164.84 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.229 -0.919 . . . . 0.0 109.6 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.508 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 93.9 mt-10 -87.94 127.79 35.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.438 ' O ' HG13 ' A' ' 150' ' ' ILE . 7.6 pt -122.23 136.01 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.283 -0.885 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 17.3 mttp -91.92 127.17 37.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.399 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -139.27 141.36 37.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.638 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.1 p -87.15 119.44 27.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.321 -0.862 . . . . 0.0 109.381 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.494 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 3.9 p -121.97 149.3 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.483 ' N ' HG23 ' A' ' 154' ' ' VAL . 68.2 mttm -83.62 151.89 25.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.556 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 12.3 m-80 -59.45 -25.14 64.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.236 -0.915 . . . . 0.0 109.456 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.4 p -78.77 -20.29 50.21 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.494 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.2 mt-10 -82.09 -22.68 36.16 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.556 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.22 166.89 23.35 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.537 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 76.4 mtt85 -131.87 150.93 52.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.449 ' HD2' ' HB3' ' A' ' 110' ' ' PRO . 63.8 tttt -74.0 122.44 22.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.406 ' HB3' ' HB ' ' A' ' 117' ' ' ILE . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.489 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.23 -33.41 74.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.194 -1.18 . . . . 0.0 109.467 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 9.1 tpt -57.79 -35.6 71.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.426 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.53 149.24 5.07 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.26 -37.19 10.73 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.699 2.266 . . . . 0.0 111.726 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 60.8 mttm 58.14 42.97 21.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.647 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 84.8 m-20 45.59 -165.77 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.568 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.0 mt -109.28 141.51 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.499 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 40.3 t -131.83 135.78 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.24 -0.913 . . . . 0.0 109.522 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.97 137.56 97.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 109.641 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . 0.459 ' HG2' ' OG1' ' A' ' 109' ' ' THR . 53.0 Cg_endo -73.67 49.97 1.94 Allowed 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.716 2.277 . . . . 0.0 111.76 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 107' ' ' PRO . . . 43.88 37.47 1.71 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.885 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.459 ' OG1' ' HG2' ' A' ' 107' ' ' PRO . 11.6 m -64.32 130.41 94.6 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.485 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.571 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.0 Cg_endo -70.13 147.72 61.13 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.644 2.229 . . . . 0.0 111.822 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.469 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.5 m-85 -99.55 160.17 28.11 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.469 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.4 Cg_endo -69.53 128.94 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.663 2.242 . . . . 0.0 111.688 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.8 -11.15 59.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.455 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 79.3 m-20 -78.99 151.87 31.31 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -1.119 . . . . 0.0 109.457 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.436 ' CB ' HD22 ' A' ' 162' ' ' LEU . 97.2 mttt -80.15 142.0 35.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.592 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 6.1 m -131.9 160.57 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 6.8 tp -124.6 142.19 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.509 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 69.4 mt -92.64 125.59 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.453 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.3 p -102.38 -10.66 19.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.43 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 94.4 mt-10 -131.38 158.44 40.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.525 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 92.68 166.85 39.05 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.53 -19.78 63.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -1.133 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.537 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 95.9 m-85 -83.54 9.48 11.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.47 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 118' ' ' ILE . 85.5 tt0 -58.32 140.41 53.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.391 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.87 -6.04 73.09 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.537 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -99.06 142.36 30.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.475 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -86.71 125.92 34.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.937 . . . . 0.0 109.352 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 142' ' ' LEU . . . -110.57 153.0 25.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.298 -0.876 . . . . 0.0 109.456 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.414 HD11 ' HG2' ' A' ' 115' ' ' LYS . 24.2 mm -118.06 130.67 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.498 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.592 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 32.7 m-85 -62.31 101.7 0.25 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -0.942 . . . . 0.0 109.542 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 43.3 p -78.43 -36.34 45.72 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.225 -0.922 . . . . 0.0 109.262 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.468 ' HB2' ' O ' ' A' ' 131' ' ' THR . 17.2 tp10 171.36 99.35 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.419 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.0 113.86 3.55 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.62 2.213 . . . . 0.0 111.461 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 29.2 p-10 -74.95 -6.3 48.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.628 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.19 169.67 41.6 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -75.3 -26.25 58.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.477 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -76.1 -73.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 109.341 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 9.9 ptp85 -89.32 147.62 23.99 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 65.0 m -134.68 144.91 48.06 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.232 -0.917 . . . . 0.0 109.5 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' MET . . . . . . . . . . . . . 56.2 ttm -87.98 109.66 19.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.224 -0.922 . . . . 0.0 109.504 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.552 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 5.5 mp -115.59 151.61 34.6 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.522 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 48.1 tp -93.47 127.99 39.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.373 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.447 HD21 HD12 ' A' ' 118' ' ' ILE . 51.5 mt -90.73 137.45 32.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -104.16 106.16 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.0 109.432 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.422 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 49.5 mt -104.33 140.88 37.25 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.466 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -50.97 -31.47 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.238 -0.914 . . . . 0.0 109.423 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.49 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 17.1 t-20 -74.17 -56.15 5.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.635 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.49 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 19.9 mttt -158.81 166.75 31.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -0.954 . . . . 0.0 109.489 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -92.83 131.93 37.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -0.893 . . . . 0.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.522 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 13.7 pt -132.56 155.53 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 109.6 -179.695 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.513 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 28.9 mttp -105.55 131.46 52.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -140.52 129.42 23.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.266 -0.896 . . . . 0.0 109.409 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 70.7 m -69.89 118.52 12.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.516 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 5.3 p -121.82 148.35 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.855 . . . . 0.0 109.53 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 33.0 mttp -81.8 151.92 27.17 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.56 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.0 m-80 -60.76 -21.34 62.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.914 . . . . 0.0 109.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.9 p -81.48 -21.58 38.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.516 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 99.8 mt-10 -81.52 -23.14 37.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.316 -0.865 . . . . 0.0 109.473 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.56 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 33.3 p90 -138.53 167.96 20.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.538 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 51.0 mtt-85 -131.12 155.37 47.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.547 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -76.84 125.06 28.64 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.495 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.436 HD22 ' CB ' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.472 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -144.05 152.19 40.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -1.127 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 94.7 mmm -58.99 -35.2 72.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.67 130.93 1.6 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.26 148.67 62.36 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.732 2.288 . . . . 0.0 111.784 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 83.3 tttt -54.83 -36.87 65.48 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.432 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 49.7 p30 -148.43 173.93 12.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.478 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 83.0 mt -59.83 -41.64 86.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -0.925 . . . . 0.0 109.543 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.416 ' O ' ' OD1' ' A' ' 103' ' ' ASP . 40.6 t -117.09 126.68 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' A' ' 106' ' ' ASP . 7.5 p30 -59.2 135.5 88.14 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.632 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -78.41 38.62 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.653 2.235 . . . . 0.0 112.075 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -80.76 -36.68 31.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.237 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.458 HG21 ' HD2' ' A' ' 110' ' ' PRO . 88.4 m -75.61 129.54 81.46 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.325 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.628 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 50.5 Cg_endo -70.26 138.05 35.38 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.638 2.225 . . . . 0.0 111.866 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.448 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.4 m-85 -88.5 160.92 43.9 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.207 -0.933 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.448 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.71 130.75 19.95 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.609 2.206 . . . . 0.0 111.808 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.0 -15.14 56.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -69.45 153.88 42.86 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.196 -1.179 . . . . 0.0 109.51 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -90.04 147.5 23.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 5.0 m -131.74 154.47 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.502 ' N ' HD13 ' A' ' 162' ' ' LEU . 8.1 tp -124.48 146.98 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.275 -0.891 . . . . 0.0 109.478 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.1 mm -91.16 124.91 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.335 -0.853 . . . . 0.0 109.356 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.451 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 66.2 p -108.99 -8.57 15.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.531 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.92 157.4 45.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.121 -0.987 . . . . 0.0 109.463 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 88.88 166.54 42.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.44 -18.65 64.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.239 -1.154 . . . . 0.0 109.448 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.565 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 88.5 m-85 -82.56 5.75 19.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 109.506 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.6 tt0 -58.67 136.7 57.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.557 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.31 -3.43 66.3 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.565 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -101.11 150.09 23.29 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.17 -1.194 . . . . 0.0 109.48 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -102.21 149.27 24.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.521 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -143.47 166.22 25.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.305 -0.872 . . . . 0.0 109.423 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.446 HD11 ' O ' ' A' ' 128' ' ' ALA . 27.2 mm -116.63 137.66 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.206 -0.934 . . . . 0.0 109.535 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.0 m-85 -59.57 104.0 0.24 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.482 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 39.3 p -78.71 -38.89 37.92 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.344 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 131' ' ' THR . 1.0 OUTLIER 171.68 94.8 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.303 -0.873 . . . . 0.0 109.455 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.38 115.7 4.17 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.776 2.317 . . . . 0.0 111.744 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -61.16 -35.92 78.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.243 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -148.01 175.5 27.3 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.82 -27.43 64.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -1.151 . . . . 0.0 109.495 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.11 -73.54 0.29 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.309 -0.869 . . . . 0.0 109.384 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 21.3 ptt-85 -83.53 147.81 27.56 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.23 -0.919 . . . . 0.0 109.558 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 67.9 m -139.96 153.11 46.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.176 -0.952 . . . . 0.0 109.514 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.434 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 41.6 mtp -99.23 119.48 37.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.262 -0.899 . . . . 0.0 109.429 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.449 HD21 HG22 ' A' ' 116' ' ' VAL . 66.1 mt -117.85 147.73 42.78 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.255 -0.903 . . . . 0.0 109.471 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.503 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.4 tt -97.31 126.46 42.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.263 -0.898 . . . . 0.0 109.438 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.524 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 43.5 mt -97.69 113.87 25.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.183 -0.948 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.422 ' C ' HD21 ' A' ' 145' ' ' LEU . 8.4 p30 -83.45 121.21 26.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.283 -0.885 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.524 ' CD2' ' O ' ' A' ' 143' ' ' LEU . 3.0 mm? -118.72 135.64 54.38 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.357 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.475 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.2 pt -49.74 -33.29 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.266 -0.896 . . . . 0.0 109.574 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.475 ' N ' HG13 ' A' ' 146' ' ' ILE . 94.2 m-20 -70.49 -46.44 63.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.517 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 30.3 tttm -168.49 160.75 11.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.517 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.0 mt-10 -87.85 127.24 35.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.927 . . . . 0.0 109.407 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.466 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 19.6 pt -127.67 162.12 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.424 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.503 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.9 mttt -125.72 130.25 51.14 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.446 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -139.12 148.14 42.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.434 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 29.7 p -82.7 141.89 32.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.428 HG11 ' N ' ' A' ' 155' ' ' LYS . 13.7 t -130.91 153.64 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.35 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.501 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 41.3 mttt -91.11 138.3 31.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.913 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.578 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 1.6 p30 -47.75 -30.38 3.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 44.7 p -80.97 -22.18 39.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.898 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 155' ' ' LYS . 94.8 mt-10 -81.69 -19.7 41.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.439 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.578 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.6 p90 -140.45 169.01 18.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.372 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 87.0 mtt-85 -129.44 143.24 50.75 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -78.14 132.74 37.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.321 -0.862 . . . . 0.0 109.473 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.502 HD13 ' N ' ' A' ' 117' ' ' ILE . 6.5 mp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.481 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.7 -31.73 72.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -1.116 . . . . 0.0 109.445 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.6 mtp -58.36 -36.99 74.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 109.488 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -151.58 139.47 7.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.4 143.31 47.42 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.744 2.296 . . . . 0.0 111.755 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -112.39 144.76 41.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.9 . . . . 0.0 109.523 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 103' ' ' ASP . 45.6 p30 -74.5 151.83 39.47 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.243 -0.91 . . . . 0.0 109.494 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -122.88 143.58 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.25 -0.906 . . . . 0.0 109.523 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.6 t -115.92 134.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.251 -0.906 . . . . 0.0 109.505 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -67.01 130.59 93.87 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.628 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -71.71 50.59 1.4 Allowed 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.682 2.255 . . . . 0.0 111.875 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.37 -27.65 59.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 0.0 109.376 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.462 HG23 ' HD2' ' A' ' 110' ' ' PRO . 23.1 m -63.9 127.15 91.35 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.353 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.462 ' HD2' HG23 ' A' ' 109' ' ' THR . 49.3 Cg_endo -69.75 140.74 43.47 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.656 2.238 . . . . 0.0 111.797 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.408 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 12.6 m-85 -81.5 161.0 63.33 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 50.5 Cg_endo -70.25 134.84 27.87 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.724 2.283 . . . . 0.0 111.797 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.21 -12.98 65.12 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 83.4 m-20 -69.97 147.91 49.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.506 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.3 mttm -75.05 139.74 43.05 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.586 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 6.0 m -127.33 155.67 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.942 . . . . 0.0 109.455 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.435 HG21 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.82 147.69 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.235 -0.916 . . . . 0.0 109.48 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.454 ' HB ' ' HA ' ' A' ' 124' ' ' GLU . 21.6 mm -91.66 129.34 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.8 p -114.17 -7.34 13.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.502 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 46.8 tp10 -140.89 153.48 45.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.502 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 92.15 169.05 40.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.92 -15.9 63.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -1.188 . . . . 0.0 109.493 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.594 ' CD1' ' CD2' ' A' ' 143' ' ' LEU . 89.9 m-85 -84.93 11.06 10.1 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.2 -0.938 . . . . 0.0 109.451 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.454 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 85.0 tt0 -60.73 134.08 56.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.636 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.94 66.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.446 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.7 m-85 -98.26 140.48 32.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.143 -1.21 . . . . 0.0 109.472 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -94.13 126.52 39.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.525 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.521 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -126.35 161.42 27.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.938 . . . . 0.0 109.533 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.506 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 29.9 mm -120.12 136.96 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.254 -0.904 . . . . 0.0 109.451 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.586 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.5 m-85 -58.58 103.18 0.14 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 63.4 p -77.3 -31.45 54.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 164.74 91.37 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.188 -0.945 . . . . 0.0 109.53 -179.987 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.47 125.99 12.37 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.63 2.22 . . . . 0.0 111.655 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.6 p-10 -68.66 -25.78 64.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 109.538 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -166.09 170.25 40.69 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -64.01 -27.59 69.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.43 -63.63 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.3 -0.875 . . . . 0.0 109.394 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 135' ' ' GLY . 57.7 mtt85 -107.48 153.6 22.59 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.197 -0.939 . . . . 0.0 109.468 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 68.8 m -138.8 156.64 47.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 109.46 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.462 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 34.7 tpp -101.12 117.31 34.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.475 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.54 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.8 mp -118.61 144.07 46.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 9.2 tt -101.52 123.51 45.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.452 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.594 ' CD2' ' CD1' ' A' ' 123' ' ' PHE . 4.7 mp -91.4 138.51 31.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.923 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.47 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 97.6 m-20 -110.86 113.38 25.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.53 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.3 mp -114.61 139.63 49.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.579 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.5 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.1 pt -50.28 -36.25 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.5 ' N ' HG13 ' A' ' 146' ' ' ILE . 15.3 t-20 -68.04 -52.89 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.488 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.458 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 19.3 tttt -166.66 155.11 10.3 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.541 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.458 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.4 mt-10 -89.86 140.21 29.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.407 HG21 ' C ' ' A' ' 149' ' ' GLU . 30.4 pt -131.57 158.61 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.484 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.523 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.3 mttt -125.83 134.18 51.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.66 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.49 ' ND1' ' O ' ' A' ' 153' ' ' SER . 51.7 t-80 -158.31 146.45 18.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.422 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.49 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 42.0 p -69.77 141.34 53.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.924 . . . . 0.0 109.393 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.533 HG13 ' CG ' ' A' ' 158' ' ' GLU . 20.2 t -126.17 152.31 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.182 -0.949 . . . . 0.0 109.61 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.486 ' N ' HG13 ' A' ' 154' ' ' VAL . 86.4 mttt -91.17 131.64 36.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.276 -0.89 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.574 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 33.4 m-80 -53.41 -18.57 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 79.8 p -85.13 -29.66 24.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 110.141 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.533 ' CG ' HG13 ' A' ' 154' ' ' VAL . 10.9 pt-20 -82.84 -18.57 39.93 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.02 -1.05 . . . . 0.0 109.698 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.574 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 20.4 p90 -135.3 157.25 47.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.147 -0.97 . . . . 0.0 109.553 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.435 ' O ' HG21 ' A' ' 117' ' ' ILE . 37.2 ttt-85 -124.07 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.267 -0.896 . . . . 0.0 109.482 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.45 ' CG ' ' O ' ' A' ' 161' ' ' LYS . 16.9 pttp -74.39 124.03 25.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.196 -0.94 . . . . 0.0 109.51 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.997 -1.002 . . . . 0.0 109.48 179.991 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.26 -31.09 70.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.48 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.4 mtt -121.43 156.21 33.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.129 -0.982 . . . . 0.0 109.444 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -122.37 167.24 14.85 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.99 -23.73 29.43 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.841 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.2 tttm -77.3 133.49 38.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.9 . . . . 0.0 109.449 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -80.89 135.38 35.9 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.28 -0.888 . . . . 0.0 109.409 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.4 mt -125.81 143.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.454 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 25.8 m -126.57 160.36 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.231 -0.918 . . . . 0.0 109.475 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.29 130.37 94.57 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.89 53.27 1.12 Allowed 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.729 2.286 . . . . 0.0 111.831 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . 46.03 26.23 0.39 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.406 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 45.1 m -107.09 124.73 34.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.238 -0.914 . . . . 0.0 109.444 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.23 143.84 49.77 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.682 2.255 . . . . 0.0 111.82 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.439 ' N ' ' OD2' ' A' ' 114' ' ' ASP . 50.9 m-85 -76.14 161.14 76.35 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.245 -0.91 . . . . 0.0 109.475 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.1 Cg_endo -69.73 131.5 21.4 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.696 2.264 . . . . 0.0 111.79 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 98.83 -12.29 62.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' N ' ' A' ' 111' ' ' TYR . 81.5 m-20 -65.56 150.31 48.62 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -1.135 . . . . 0.0 109.491 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.498 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 96.5 mttt -77.98 140.14 39.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.897 . . . . 0.0 109.476 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.566 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 4.1 m -130.84 153.63 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.438 ' O ' HG21 ' A' ' 117' ' ' ILE . 3.0 tp -122.65 140.67 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.448 HD11 ' HB3' ' A' ' 123' ' ' PHE . 69.4 mt -92.56 131.05 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.5 p -118.42 5.37 11.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.245 -0.909 . . . . 0.0 109.578 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.428 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -136.91 153.6 50.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 109.481 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.403 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.67 -171.08 42.9 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.87 -5.84 57.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -1.134 . . . . 0.0 109.587 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.538 ' CD1' HD21 ' A' ' 143' ' ' LEU . 80.2 m-85 -88.54 14.98 8.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.997 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.428 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 96.9 mt-10 -62.84 136.91 58.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.14 1.09 70.11 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -102.22 131.41 48.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.137 -1.213 . . . . 0.0 109.454 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -86.72 134.44 33.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.461 ' O ' HG23 ' A' ' 116' ' ' VAL . . . -132.18 159.72 38.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.544 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.498 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 33.4 mm -119.2 140.07 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.311 -0.868 . . . . 0.0 109.383 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.566 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.1 m-85 -58.58 101.47 0.09 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.528 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 68.9 p -75.04 -34.41 61.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.369 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.3 mt-10 163.75 88.84 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.294 -0.879 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.435 ' HB3' ' OG ' ' A' ' 139' ' ' SER . 49.9 Cg_endo -69.96 132.35 22.83 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.679 2.253 . . . . 0.0 111.81 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -67.82 -30.03 69.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -0.861 . . . . 0.0 109.444 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -165.18 -174.02 34.4 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -73.32 -26.79 61.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.295 -1.121 . . . . 0.0 109.453 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.82 -58.51 4.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.532 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -109.6 161.12 15.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.158 -0.964 . . . . 0.0 109.425 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.435 ' OG ' ' HB3' ' A' ' 133' ' ' PRO . 4.1 m -147.36 155.38 41.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.262 -0.899 . . . . 0.0 109.566 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.455 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 63.5 mtp -103.06 124.22 48.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.343 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.564 HD23 ' CD2' ' A' ' 159' ' ' PHE . 5.4 mp -126.19 140.78 52.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.175 -0.953 . . . . 0.0 109.607 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.525 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 10.1 tt -96.59 125.82 41.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.304 -0.873 . . . . 0.0 109.413 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.546 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.6 mp -93.47 137.02 33.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.284 -0.885 . . . . 0.0 109.525 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -108.57 104.19 13.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.905 . . . . 0.0 109.422 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.493 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.8 mp -104.45 139.6 39.14 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.149 -0.969 . . . . 0.0 109.56 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.496 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.2 pt -54.32 -35.09 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.445 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.496 ' N ' HG13 ' A' ' 146' ' ' ILE . 52.0 t-20 -65.96 -46.57 77.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.393 -0.817 . . . . 0.0 109.512 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.1 pttt -168.64 169.54 10.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.204 -0.935 . . . . 0.0 109.555 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.484 ' CG ' HD21 ' A' ' 142' ' ' LEU . 86.8 tt0 -98.2 132.32 43.82 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.1 pt -131.88 157.01 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.45 ' HG2' ' HG ' ' A' ' 142' ' ' LEU . 2.3 mtpm? -123.97 134.1 53.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.396 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.466 ' CE1' ' O ' ' A' ' 153' ' ' SER . 55.4 t-80 -152.26 143.73 23.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.466 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 41.6 p -81.66 137.07 35.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.473 HG12 ' HB2' ' A' ' 158' ' ' GLU . 16.4 t -127.6 151.09 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.406 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.522 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 0.6 OUTLIER -87.38 139.97 30.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.272 -0.893 . . . . 0.0 109.559 -179.935 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.505 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 27.4 m-80 -46.17 -27.98 1.12 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.357 -0.839 . . . . 0.0 110.272 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' THR . . . . . 0.512 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 27.0 p -80.14 -19.93 46.1 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.97 -1.081 . . . . 0.0 109.983 -179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.522 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 48.5 mm-40 -89.85 -19.11 25.02 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.068 -1.02 . . . . 0.0 109.201 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.564 ' CD2' HD23 ' A' ' 141' ' ' LEU . 34.5 p90 -139.22 156.03 47.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.793 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 53.2 mtt180 -125.25 147.1 49.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.255 -0.903 . . . . 0.0 109.339 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.464 ' CG ' ' O ' ' A' ' 161' ' ' LYS . 15.9 pttp -82.44 121.52 26.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.489 -179.992 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.12 -36.3 79.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -1.173 . . . . 0.0 109.527 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 65.1 mtt -58.64 -35.19 72.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.426 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -144.93 130.4 3.87 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.17 140.67 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.736 2.29 . . . . 0.0 111.736 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -123.92 150.11 45.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -52.38 -36.8 54.83 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.31 -0.869 . . . . 0.0 109.413 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.2 mt -107.75 143.17 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.511 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.1 t -122.48 130.26 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.508 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -65.08 149.83 96.26 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.295 -0.878 . . . . 0.0 109.527 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -76.35 43.47 1.19 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.633 2.222 . . . . 0.0 112.069 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.38 -42.74 61.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.05 -1.031 . . . . 0.0 109.109 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.3 m -103.24 120.39 52.18 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.366 -0.834 . . . . 0.0 109.187 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.4 149.47 69.2 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.663 2.242 . . . . 0.0 111.93 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.407 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 53.0 m-85 -102.8 161.46 23.11 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.448 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.423 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 46.2 Cg_endo -68.28 137.61 40.65 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.634 2.223 . . . . 0.0 111.701 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . 0.422 ' HA2' HG21 ' A' ' 129' ' ' ILE . . . 90.82 -9.88 76.46 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.508 ' OD2' ' NZ ' ' A' ' 161' ' ' LYS . 36.6 p-10 -74.55 -177.85 3.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -1.149 . . . . 0.0 109.5 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.462 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 76.6 mttt -99.19 141.6 31.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -0.893 . . . . 0.0 109.426 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.503 HG12 ' CE2' ' A' ' 130' ' ' PHE . 11.2 m -138.18 158.1 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.239 -0.913 . . . . 0.0 109.529 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.453 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.2 tp -126.27 141.91 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.466 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 56.1 mt -92.29 129.91 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.209 -0.932 . . . . 0.0 109.695 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.515 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 58.0 p -105.08 -8.39 18.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.484 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 48.0 tp10 -136.26 156.84 48.08 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . 0.484 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 93.77 162.77 36.09 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.26 -19.4 65.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -1.115 . . . . 0.0 109.438 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -86.26 13.16 8.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.379 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.515 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.8 tt0 -63.76 140.12 58.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.38 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 90.32 -0.15 77.63 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -104.99 138.89 40.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -1.193 . . . . 0.0 109.428 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -83.79 148.65 26.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.26 -0.9 . . . . 0.0 109.541 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.461 ' O ' HG21 ' A' ' 116' ' ' VAL . . . -144.83 159.31 43.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.462 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 27.2 mm -119.68 133.06 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.961 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.503 ' CE2' HG12 ' A' ' 116' ' ' VAL . 18.3 m-85 -58.57 115.84 3.29 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.368 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.513 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.0 p -84.18 -29.5 26.56 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.9 86.33 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.326 -0.859 . . . . 0.0 109.545 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 49.2 Cg_endo -70.0 130.64 19.38 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.694 2.263 . . . . 0.0 111.751 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -68.91 -26.61 65.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.905 . . . . 0.0 109.594 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -170.59 178.31 43.27 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -66.16 -25.94 67.19 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -1.121 . . . . 0.0 109.509 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.53 -63.68 1.01 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.455 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 75.4 mtt180 -107.11 156.89 18.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.412 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 69.0 m -148.58 152.42 36.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.175 -0.953 . . . . 0.0 109.51 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.483 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 20.4 mtp -101.62 122.05 43.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.217 -0.927 . . . . 0.0 109.583 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.573 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.8 mp -114.21 147.32 39.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.875 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.526 ' CD1' ' O ' ' A' ' 150' ' ' ILE . 34.5 tp -102.8 125.42 49.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.742 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.529 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -98.32 127.98 44.52 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.257 -0.902 . . . . 0.0 109.25 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -105.02 113.27 26.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.509 ' N ' ' CD2' ' A' ' 145' ' ' LEU . 2.4 mm? -101.01 150.56 22.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.326 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 25.7 pt -65.13 -10.45 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.501 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 48.3 t30 -97.57 -47.55 5.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.59 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.501 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 77.7 mttt -158.55 165.39 34.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.93 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.524 ' OE2' ' CD2' ' A' ' 142' ' ' LEU . 78.4 tt0 -89.57 147.57 23.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.172 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.526 ' O ' ' CD1' ' A' ' 142' ' ' LEU . 30.9 pt -144.44 151.66 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.945 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.522 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.8 mttp -118.01 136.64 53.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.366 -0.834 . . . . 0.0 109.159 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -148.58 134.99 19.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.116 -0.99 . . . . 0.0 109.651 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.8 p -87.12 118.08 26.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.888 . . . . 0.0 109.326 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.513 HG21 ' N ' ' A' ' 155' ' ' LYS . 4.3 p -120.05 150.59 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.565 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 28.0 mttt -77.01 153.69 34.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.891 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.578 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 9.7 m-80 -65.18 -14.95 61.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 70.5 p -88.17 -24.2 23.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.513 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 99.7 mt-10 -78.79 -22.62 46.05 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.258 -0.901 . . . . 0.0 109.51 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.578 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.3 p90 -135.95 174.04 11.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.414 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 52.6 mtp180 -139.45 164.59 29.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.57 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.508 ' NZ ' ' OD2' ' A' ' 114' ' ' ASP . 55.4 tttp -85.59 126.32 33.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.487 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.453 ' HB3' ' HB ' ' A' ' 117' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.519 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -64.69 142.05 58.56 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.229 -1.159 . . . . 0.0 109.405 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 65.1 mtt -61.58 -34.15 75.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 0.0 109.538 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -110.94 173.82 16.37 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.77 152.43 69.26 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.748 2.299 . . . . 0.0 111.818 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 105' ' ' VAL . 94.1 mttt -83.28 145.73 28.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.515 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -61.56 -32.65 72.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.197 -0.94 . . . . 0.0 109.353 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 83.9 mt -49.25 -45.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 102' ' ' LYS . 18.0 m -130.44 143.23 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.295 -0.878 . . . . 0.0 109.435 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.443 ' HB2' ' HD2' ' A' ' 107' ' ' PRO . 1.8 p30 -98.7 164.49 16.87 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.239 -0.913 . . . . 0.0 109.399 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 106' ' ' ASP . 55.8 Cg_endo -80.57 34.04 0.53 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.725 2.283 . . . . 0.0 112.052 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -99.54 -26.71 14.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.122 -0.986 . . . . 0.0 109.447 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 76.7 m -66.39 132.09 94.3 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.353 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.573 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 51.1 Cg_endo -70.19 131.95 21.65 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.916 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.403 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 50.3 m-85 -79.75 157.93 73.72 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.379 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.96 130.89 19.87 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.63 2.22 . . . . 0.0 111.811 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 101.04 -14.77 58.42 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.47 ' CB ' ' HE2' ' A' ' 161' ' ' LYS . 80.4 m-20 -66.89 153.78 42.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.487 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 95.5 mttt -81.83 140.62 34.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.638 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 11.8 m -125.61 152.61 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.459 ' CG2' HD21 ' A' ' 162' ' ' LEU . 8.2 tp -122.64 145.43 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.538 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 126' ' ' PHE . 28.8 mm -91.24 128.82 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.293 -0.88 . . . . 0.0 109.499 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.434 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 69.1 p -114.92 -7.9 12.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.217 -0.927 . . . . 0.0 109.518 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -140.1 151.91 45.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.163 -0.961 . . . . 0.0 109.473 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.56 167.78 38.2 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.41 -13.78 62.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -1.155 . . . . 0.0 109.422 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.547 ' CD1' HD22 ' A' ' 143' ' ' LEU . 69.6 m-85 -87.98 13.93 9.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.462 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.8 tt0 -64.08 132.43 50.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.58 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.17 1.03 59.6 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.466 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.4 m-85 -98.95 136.52 38.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.1 -1.235 . . . . 0.0 109.594 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -88.79 136.07 33.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.291 -0.881 . . . . 0.0 109.279 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.5 ' O ' ' CG2' ' A' ' 116' ' ' VAL . . . -137.95 165.73 25.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.597 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.487 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 28.7 mm -121.01 142.28 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.638 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 40.5 m-85 -58.58 104.49 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.936 . . . . 0.0 109.558 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.454 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 71.1 p -78.07 -40.69 37.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 131' ' ' THR . 7.6 tt0 172.32 91.53 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . 0.442 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 48.8 Cg_endo -70.1 124.46 10.97 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.718 2.279 . . . . 0.0 111.761 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 23.3 p-10 -75.23 -4.03 36.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.355 -0.84 . . . . 0.0 109.54 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 174.64 173.3 40.44 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.95 -30.48 67.87 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -1.125 . . . . 0.0 109.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.07 -60.03 2.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -0.915 . . . . 0.0 109.431 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.444 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 81.9 mtm180 -103.28 152.93 20.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.395 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 68.5 m -144.97 150.12 36.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.96 . . . . 0.0 109.491 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.49 ' SD ' ' CB ' ' A' ' 153' ' ' SER . 91.6 mmm -96.17 125.91 41.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.323 -0.861 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.515 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.6 mp -128.32 141.27 51.49 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.236 -0.915 . . . . 0.0 109.622 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.52 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.9 tt -99.67 119.51 38.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.395 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.573 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -96.03 108.63 21.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.18 -0.95 . . . . 0.0 109.652 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -88.7 127.5 35.59 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.32 -0.862 . . . . 0.0 109.631 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.563 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 6.1 mp -108.05 159.37 16.62 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.925 . . . . 0.0 109.425 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 23.6 pt -66.65 -10.22 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.418 ' CG ' ' N ' ' A' ' 148' ' ' LYS . 9.2 p30 -105.34 -45.54 4.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.514 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.448 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 62.1 tttm -158.48 147.96 19.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.29 -0.881 . . . . 0.0 109.563 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -87.89 141.23 28.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.371 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.446 HD13 ' CE1' ' A' ' 123' ' ' PHE . 28.7 pt -133.7 162.12 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.917 . . . . 0.0 109.572 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.52 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 29.6 mttt -125.16 136.52 53.68 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.291 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.29 148.47 28.21 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.183 -0.948 . . . . 0.0 109.694 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.49 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 21.9 p -86.88 122.77 31.21 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.251 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.513 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 3.2 p -125.06 148.93 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.493 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 45.0 mttt -79.59 153.53 29.38 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.493 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.8 m-80 -62.52 -19.73 63.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.344 -0.847 . . . . 0.0 109.474 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 63.1 p -82.26 -23.19 35.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.194 -0.941 . . . . 0.0 109.478 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.513 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.6 mt-10 -81.13 -21.11 40.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.226 -0.921 . . . . 0.0 109.524 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.577 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 35.8 p90 -139.53 158.94 43.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -122.15 148.49 44.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.205 -0.934 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.47 ' HE2' ' CB ' ' A' ' 114' ' ' ASP . 64.1 tttm -76.44 135.37 39.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.923 . . . . 0.0 109.487 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.459 HD21 ' CG2' ' A' ' 117' ' ' ILE . 53.5 mt . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.912 -1.042 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -63.05 143.7 57.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.263 -1.139 . . . . 0.0 109.479 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 71.4 mtm -57.73 -37.75 74.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -79.4 163.83 48.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.07 140.2 40.97 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.699 2.266 . . . . 0.0 111.744 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.0 mtmt -107.28 141.85 37.97 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.202 -0.936 . . . . 0.0 109.494 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -81.58 138.5 35.37 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.305 -0.872 . . . . 0.0 109.424 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.406 HG21 HD11 ' A' ' 104' ' ' ILE . 81.9 mt -62.86 -36.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 44.3 t -122.55 130.54 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.476 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 63.0 m-20 -78.99 146.9 68.99 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.898 . . . . 0.0 109.496 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.08 65.24 1.99 Allowed 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.706 2.271 . . . . 0.0 111.783 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.27 -38.49 77.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.495 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.0 m -71.42 130.66 87.32 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.244 -0.91 . . . . 0.0 109.406 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.453 ' HB3' ' HD2' ' A' ' 161' ' ' LYS . 49.9 Cg_endo -70.05 151.97 67.63 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.754 2.303 . . . . 0.0 111.879 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -90.99 158.8 41.21 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.906 . . . . 0.0 109.366 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -70.22 134.47 27.09 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.695 2.263 . . . . 0.0 111.784 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.24 -11.68 68.85 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.459 ' O ' HD13 ' A' ' 129' ' ' ILE . 23.9 p-10 -67.45 176.23 2.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.168 -1.195 . . . . 0.0 109.473 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.522 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 99.6 mttt -98.34 139.42 34.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.91 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.499 ' HA ' ' CD1' ' A' ' 162' ' ' LEU . 15.0 m -135.14 149.8 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.443 HG21 ' O ' ' A' ' 160' ' ' ARG . 6.4 tp -120.84 142.47 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.511 HD11 ' CD2' ' A' ' 143' ' ' LEU . 62.1 mt -92.37 129.78 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.192 -0.943 . . . . 0.0 109.416 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.478 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 62.7 p -105.6 -9.97 17.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.421 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 75.4 mm-40 -135.73 158.17 45.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.178 -0.951 . . . . 0.0 109.425 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.09 165.48 32.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.93 -20.78 65.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.174 . . . . 0.0 109.43 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.498 ' CG ' HD13 ' A' ' 143' ' ' LEU . 64.1 m-85 -88.12 15.0 8.02 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.478 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 83.2 tt0 -63.22 137.4 58.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.917 . . . . 0.0 109.469 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.7 0.96 62.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -105.67 128.43 53.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -78.04 135.29 37.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.227 -0.921 . . . . 0.0 109.417 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.528 ' CB ' ' HB3' ' A' ' 141' ' ' LEU . . . -132.89 164.35 27.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.237 -0.915 . . . . 0.0 109.593 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.522 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 39.3 mm -122.8 137.81 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.462 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.565 ' CD1' HD21 ' A' ' 141' ' ' LEU . 10.6 m-85 -58.56 102.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.679 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 47.0 p -79.43 -36.01 39.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 109.322 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.466 ' O ' ' HG3' ' A' ' 140' ' ' MET . 1.0 OUTLIER 170.02 87.53 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.308 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.77 131.78 21.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.735 2.29 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -66.51 -32.36 73.66 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.374 -0.828 . . . . 0.0 109.415 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -163.44 -178.4 37.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -70.5 -29.1 65.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -1.165 . . . . 0.0 109.49 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.14 -59.14 4.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.236 -0.915 . . . . 0.0 109.388 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.49 ' HG3' ' NH1' ' A' ' 138' ' ' ARG . 6.8 mtt85 -109.46 157.81 18.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 109.35 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.6 m -146.38 156.8 43.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -0.986 . . . . 0.0 109.611 -179.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.466 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 49.6 mtp -99.46 127.54 45.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.442 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.565 HD21 ' CD1' ' A' ' 130' ' ' PHE . 89.8 mt -126.27 135.73 51.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.516 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.0 tt -92.73 123.84 36.31 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.511 ' CD2' HD11 ' A' ' 118' ' ' ILE . 16.5 mt -97.1 109.06 21.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.922 . . . . 0.0 109.662 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 12.8 p-10 -83.94 125.48 32.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.224 -0.922 . . . . 0.0 109.577 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.451 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 8.1 mp -119.24 145.73 45.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.17 -0.956 . . . . 0.0 109.441 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.495 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -53.44 -39.0 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.656 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.495 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.4 m-20 -67.98 -44.88 75.63 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 11.8 pttt -167.17 173.41 9.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.589 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -104.13 129.37 51.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.435 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.445 ' CG2' ' HE3' ' A' ' 148' ' ' LYS . 25.8 pt -125.5 161.59 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.904 . . . . 0.0 109.427 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.516 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.6 mttt -125.34 133.02 52.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -145.87 142.72 29.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 44.9 p -77.17 140.96 40.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.553 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.466 HG13 ' HB3' ' A' ' 159' ' ' PHE . 14.6 t -137.62 146.48 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.528 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 1.3 ptpt -91.05 145.48 24.65 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.313 -0.867 . . . . 0.0 109.801 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.54 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 2.0 p30 -48.96 -29.21 4.52 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.344 -0.847 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' THR . . . . . 0.496 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 17.1 p -78.98 -20.96 47.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.105 -0.997 . . . . 0.0 109.975 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.528 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 44.0 mm-40 -87.64 -20.4 26.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.02 -1.05 . . . . 0.0 109.214 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.54 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 26.8 p90 -135.85 166.86 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.876 . . . . 0.0 109.607 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . 0.443 ' O ' HG21 ' A' ' 117' ' ' ILE . 37.1 ttt180 -130.26 136.96 49.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.469 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . 0.453 ' HD2' ' HB3' ' A' ' 110' ' ' PRO . 18.3 pttp -77.45 147.18 36.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.267 -0.895 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.519 ' CD1' ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.57 -34.32 75.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.252 -1.146 . . . . 0.0 109.466 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 72.7 mtm -56.12 -37.77 69.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.202 -0.936 . . . . 0.0 109.422 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . 0.46 ' O ' ' OD1' ' A' ' 103' ' ' ASP . . . -65.45 146.32 49.66 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.435 ' O ' ' HB2' ' A' ' 102' ' ' LYS . 50.1 Cg_endo -69.95 158.11 57.81 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.699 2.266 . . . . 0.0 111.849 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.474 ' HB3' ' CG2' ' A' ' 105' ' ' VAL . 62.6 mttp 61.63 53.32 3.31 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.301 -0.874 . . . . 0.0 109.499 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 100' ' ' GLY . 98.5 m-20 -59.85 -35.52 74.95 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.169 -0.957 . . . . 0.0 109.554 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 88.0 mt -63.64 -31.54 53.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.474 ' CG2' ' HB3' ' A' ' 102' ' ' LYS . 53.4 t -63.91 -40.61 89.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.471 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -94.64 109.99 46.66 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.298 -0.876 . . . . 0.0 109.487 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.9 52.93 1.09 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.654 2.236 . . . . 0.0 111.816 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -71.32 -33.04 69.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.453 HG21 ' HD2' ' A' ' 110' ' ' PRO . 29.3 m -72.53 138.79 80.73 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.567 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.8 Cg_endo -70.18 146.89 58.89 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.736 2.291 . . . . 0.0 111.854 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' TYR . . . . . 0.447 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 15.7 m-85 -108.76 161.15 24.68 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.877 . . . . 0.0 109.411 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' PRO . . . . . 0.447 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 47.5 Cg_endo -68.93 136.09 34.25 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.713 2.275 . . . . 0.0 111.765 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.4 -8.82 60.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -85.82 159.51 19.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.206 -1.173 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.428 ' C ' HD21 ' A' ' 162' ' ' LEU . 24.6 mttm -87.3 145.52 26.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -0.899 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.603 ' CG1' ' CE2' ' A' ' 130' ' ' PHE . 14.1 m -132.98 152.18 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.428 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.444 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.8 tp -122.0 140.71 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.281 -0.887 . . . . 0.0 109.55 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.466 HD12 ' CB ' ' A' ' 123' ' ' PHE . 73.4 mt -92.68 132.88 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.252 -0.905 . . . . 0.0 109.405 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.449 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 54.7 p -111.01 0.16 16.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.248 -0.908 . . . . 0.0 109.6 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.433 ' HA ' ' OE1' ' A' ' 120' ' ' GLU . 71.7 mm-40 -143.52 155.73 44.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.174 -0.954 . . . . 0.0 109.484 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.35 164.26 39.65 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.74 -18.71 64.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -1.147 . . . . 0.0 109.473 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD1' HD12 ' A' ' 143' ' ' LEU . 96.9 m-85 -82.93 8.69 11.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.918 . . . . 0.0 109.535 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.449 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.0 tt0 -62.7 138.96 58.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.23 0.11 80.68 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -102.99 137.54 41.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.466 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -89.44 143.08 27.1 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.398 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.454 ' O ' HG23 ' A' ' 116' ' ' VAL . . . -142.2 160.36 40.4 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.214 -0.929 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.435 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.2 mm -116.16 137.13 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.278 -0.889 . . . . 0.0 109.528 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 24.7 m-85 -58.77 106.2 0.38 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.584 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.4 p -77.55 -33.64 54.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.256 -0.903 . . . . 0.0 109.249 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.05 96.53 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.428 -0.795 . . . . 0.0 109.326 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.43 123.52 10.29 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.71 2.274 . . . . 0.0 111.773 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -67.94 -33.03 73.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -150.24 174.71 29.58 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -69.57 -29.04 66.5 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.421 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.86 -74.16 0.13 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.161 -0.962 . . . . 0.0 109.344 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 33.0 ptt-85 -89.87 158.14 17.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.326 -0.859 . . . . 0.0 109.72 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 6.1 m -142.7 159.49 42.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' MET . . . . . 0.456 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 64.0 mtp -101.31 120.13 39.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.344 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . 0.565 ' CD1' ' N ' ' A' ' 141' ' ' LEU . 6.6 mp -118.13 148.79 41.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.605 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' LEU . . . . . 0.519 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 48.9 tp -99.6 123.9 44.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.3 -0.875 . . . . 0.0 109.515 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.561 HD12 ' CD1' ' A' ' 123' ' ' PHE . 41.8 mt -98.18 110.84 23.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.95 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 20.1 p-10 -78.58 120.83 23.83 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.185 -0.947 . . . . 0.0 109.551 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' LEU . . . . . 0.503 HD11 ' CD1' ' A' ' 150' ' ' ILE . 67.9 mt -111.19 142.2 43.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.186 -0.946 . . . . 0.0 109.546 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.443 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.7 pt -51.63 -31.11 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.453 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.52 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 22.9 m120 -75.83 -55.57 5.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.465 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' LYS . . . . . 0.52 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 23.2 mttt -158.98 171.92 19.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.176 -0.952 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -88.34 130.03 35.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.325 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ILE . . . . . 0.503 ' CD1' HD11 ' A' ' 145' ' ' LEU . 42.4 pt -124.1 151.74 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.519 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 90.8 mttt -109.18 128.52 55.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.302 -0.874 . . . . 0.0 109.379 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -141.27 132.18 25.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.549 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 46.1 p -77.94 140.35 39.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.32 -0.862 . . . . 0.0 109.471 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.469 HG12 ' HB3' ' A' ' 159' ' ' PHE . 13.4 t -134.82 148.39 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.525 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 16.2 ptmt -91.27 139.96 30.24 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.227 -0.921 . . . . 0.0 109.625 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.57 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 44.7 m-80 -46.34 -27.27 1.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.397 -0.814 . . . . 0.0 110.067 -179.592 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' THR . . . . . 0.522 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 15.8 p -79.83 -21.02 44.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 0.0 109.766 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' GLU . . . . . 0.525 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 46.3 mm-40 -87.67 -20.51 26.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.052 -1.03 . . . . 0.0 109.229 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' PHE . . . . . 0.57 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 39.3 p90 -136.17 168.68 18.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.339 -0.851 . . . . 0.0 109.667 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -133.09 159.7 39.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -82.51 118.0 22.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.433 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' LEU . . . . . 0.444 ' HB3' ' HB ' ' A' ' 117' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.492 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.406 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 28.0 m-85 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.406 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.34 129.37 17.91 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.723 2.282 . . . . 0.0 111.773 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 104.26 -13.53 51.74 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -69.49 156.69 38.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -1.104 . . . . 0.0 109.445 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.487 ' HB2' HD12 ' A' ' 162' ' ' LEU . 18.2 mttp -86.42 139.63 30.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.561 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.04 HG21 HD23 ' A' ' 141' ' ' LEU . 4.4 m -127.17 154.14 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -0.911 . . . . 0.0 109.402 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.577 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.7 tp -122.44 139.83 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.57 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 83.6 mt -92.58 139.4 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.482 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.435 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 70.9 p -115.14 -10.8 12.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.458 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.38 157.26 43.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.08 162.08 38.01 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.9 -13.46 45.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.145 . . . . 0.0 109.437 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.461 ' CD1' HD23 ' A' ' 143' ' ' LEU . 96.4 m-85 -86.59 12.67 10.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.435 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.3 tt0 -63.42 137.93 58.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.12 -0.81 76.26 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -102.45 139.3 38.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.576 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -91.48 146.72 23.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.72 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -140.68 162.24 35.87 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.448 HD13 ' O ' ' A' ' 128' ' ' ALA . 35.6 mm -117.48 135.01 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.194 -0.941 . . . . 0.0 109.582 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.631 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.6 m-85 -58.55 104.41 0.22 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.523 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 55.4 p -79.79 -32.1 40.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.897 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 163.68 93.62 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.437 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 126.74 13.37 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.667 2.245 . . . . 0.0 111.723 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -66.82 -24.89 66.21 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.251 -0.906 . . . . 0.0 109.539 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.03 -179.41 40.56 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -72.64 -24.94 61.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -1.136 . . . . 0.0 109.452 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -75.29 -51.45 13.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.471 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 55.5 mtt85 -110.52 151.33 27.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 57.1 m -139.74 156.16 46.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.924 . . . . 0.0 109.507 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.821 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 mtp -106.76 119.39 39.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.04 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -116.3 154.03 30.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.509 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.865 HD12 ' O ' ' A' ' 150' ' ' ILE . 51.5 tp -106.04 124.95 50.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.216 -0.927 . . . . 0.0 109.464 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.841 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -99.19 116.67 31.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -82.73 129.23 34.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.638 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.743 HD11 HD13 ' A' ' 150' ' ' ILE . 42.6 mt -121.09 142.12 50.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.398 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.45 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -49.94 -30.6 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.517 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.45 ' N ' HG13 ' A' ' 146' ' ' ILE . 92.9 m-20 -79.24 -47.71 15.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.27 -0.894 . . . . 0.0 109.681 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.529 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 40.2 ttpt -168.77 168.1 10.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.459 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.529 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.9 mt-10 -87.55 137.29 32.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.252 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.865 ' O ' HD12 ' A' ' 142' ' ' LEU . 36.1 pt -126.34 149.16 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.202 -0.936 . . . . 0.0 109.774 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.823 ' HG2' HD13 ' A' ' 142' ' ' LEU . 62.1 mttp -110.45 131.46 55.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -0.882 . . . . 0.0 109.191 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -142.38 140.62 32.1 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.177 -0.952 . . . . 0.0 109.681 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 21.6 p -88.45 122.0 31.46 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.347 -0.846 . . . . 0.0 109.217 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.724 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.3 p -124.07 149.99 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.595 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.3 mttt -76.64 150.5 36.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.881 . . . . 0.0 109.482 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.567 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.9 m-80 -59.69 -23.49 63.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.335 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 74.8 p -81.62 -25.96 35.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.268 -0.895 . . . . 0.0 109.428 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.601 ' OE1' HG23 ' A' ' 154' ' ' VAL . 88.6 mt-10 -75.03 -24.81 58.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 0.0 109.519 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.724 ' CE2' HD21 ' A' ' 141' ' ' LEU . 31.9 p90 -136.36 170.78 15.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.43 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -134.23 159.64 40.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.226 -0.921 . . . . 0.0 109.53 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -83.63 146.76 28.09 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 117' ' ' ILE . 23.8 mt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.436 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 53.1 m-85 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.3 Cg_endo -69.92 135.16 29.4 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.663 2.242 . . . . 0.0 111.795 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.12 -9.04 65.29 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.436 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 82.8 m-20 -81.27 146.74 30.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -1.172 . . . . 0.0 109.523 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.676 ' C ' HD12 ' A' ' 162' ' ' LEU . 29.4 mtmt -80.51 144.48 32.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 0.0 109.417 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.977 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.4 m -133.47 152.63 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.196 -0.94 . . . . 0.0 109.595 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.69 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.8 tp -121.74 139.51 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.421 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.557 HD12 ' HB3' ' A' ' 123' ' ' PHE . 67.7 mt -92.78 130.76 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 70.4 p -116.72 4.04 13.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -0.925 . . . . 0.0 109.624 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 157' ' ' THR . 92.5 mt-10 -137.7 155.73 48.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 87.54 -168.04 37.74 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.6 -7.07 51.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -1.135 . . . . 0.0 109.502 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.557 ' HB3' HD12 ' A' ' 118' ' ' ILE . 80.4 m-85 -88.86 15.81 7.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.418 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 95.8 mt-10 -61.18 135.07 57.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.64 0.71 69.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -102.95 131.96 49.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -1.207 . . . . 0.0 109.488 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -92.61 140.46 29.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.229 -0.92 . . . . 0.0 109.45 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.778 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -136.77 167.01 22.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.176 -0.952 . . . . 0.0 109.536 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.519 HD13 ' O ' ' A' ' 128' ' ' ALA . 30.7 mm -118.31 138.14 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.3 m-85 -58.49 102.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.254 -0.904 . . . . 0.0 109.579 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.524 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 40.9 p -75.8 -33.39 60.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.6 OUTLIER 163.49 95.41 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.308 -0.87 . . . . 0.0 109.347 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.76 117.31 5.0 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.695 2.264 . . . . 0.0 111.791 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 18.1 p-10 -66.91 -31.56 72.23 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -0.935 . . . . 0.0 109.573 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.432 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -155.32 172.85 33.55 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -70.15 -28.85 65.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.307 -1.114 . . . . 0.0 109.485 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.67 -53.6 15.13 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.53 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.44 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 79.4 mtt180 -111.86 146.25 38.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.286 -0.883 . . . . 0.0 109.506 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.8 m -134.34 157.94 45.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.472 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.937 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.9 mtp -102.07 124.8 48.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.468 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.977 HD23 ' CG2' ' A' ' 116' ' ' VAL . 6.3 mp -127.22 143.91 51.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.209 -0.932 . . . . 0.0 109.551 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.809 HD12 ' O ' ' A' ' 150' ' ' ILE . 45.4 tp -93.79 121.19 34.99 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.955 . . . . 0.0 109.519 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.801 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.5 mp -93.03 129.62 38.9 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.429 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -103.59 106.98 17.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.882 . . . . 0.0 109.482 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.492 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 7.0 mp -75.03 -175.7 2.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.207 -0.933 . . . . 0.0 109.477 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.54 HG13 ' N ' ' A' ' 147' ' ' ASN . 10.9 pt -60.44 -46.09 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.18 -0.95 . . . . 0.0 109.449 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.54 ' N ' HG13 ' A' ' 146' ' ' ILE . 28.7 p-10 -139.38 23.1 2.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.286 -0.884 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.452 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 40.8 mttt -140.29 151.14 44.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.742 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -120.63 134.13 55.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.33 -0.856 . . . . 0.0 108.992 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.809 ' O ' HD12 ' A' ' 142' ' ' LEU . 37.0 pt -133.6 154.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.125 -0.984 . . . . 0.0 109.892 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.747 ' HG2' HD13 ' A' ' 142' ' ' LEU . 51.5 mttt -123.16 124.79 43.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.34 -0.85 . . . . 0.0 109.286 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -153.19 150.93 29.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 47.9 p -80.14 140.28 36.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.304 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.506 HG12 ' HD1' ' A' ' 159' ' ' PHE . 14.1 t -122.69 155.67 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.492 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 31.0 mttt -91.16 143.99 26.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.434 ' O ' ' O ' ' A' ' 159' ' ' PHE . 4.2 m-20 -51.4 -29.44 15.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.511 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 120' ' ' GLU . 45.9 p -82.57 -22.82 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.526 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -78.4 -19.99 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.254 -0.904 . . . . 0.0 109.531 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.575 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.4 p90 -145.09 162.25 37.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.938 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -131.83 136.47 47.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.535 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -60.86 134.46 57.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.69 HD21 ' HB ' ' A' ' 117' ' ' ILE . 9.2 mt . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.472 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.468 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 48.2 m-85 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.01 137.48 34.82 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.702 2.268 . . . . 0.0 111.829 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.78 -10.07 68.47 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.468 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.8 m-20 -82.39 145.48 29.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.252 -1.146 . . . . 0.0 109.461 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.464 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 30.5 mttm -75.83 142.23 42.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.912 HG21 HD23 ' A' ' 141' ' ' LEU . 4.5 m -132.45 150.97 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.444 ' HB ' HD11 ' A' ' 162' ' ' LEU . 4.5 tp -123.43 141.75 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.491 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.535 HD12 ' HB3' ' A' ' 123' ' ' PHE . 61.2 mt -92.59 131.12 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.236 -0.915 . . . . 0.0 109.443 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.451 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.2 p -106.95 -8.39 16.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.6 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -137.37 157.29 46.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.23 -0.919 . . . . 0.0 109.572 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.21 165.14 37.75 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.67 -19.87 65.25 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.445 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.535 ' HB3' HD12 ' A' ' 118' ' ' ILE . 94.3 m-85 -86.38 13.48 8.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.454 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 87.0 tt0 -66.25 137.88 57.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.471 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.51 0.26 73.23 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -106.4 134.72 49.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -1.162 . . . . 0.0 109.484 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -79.93 147.62 31.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.222 -0.924 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.33 163.63 32.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.676 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.0 mm -121.29 139.23 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -0.875 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.615 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 42.2 m-85 -60.92 114.41 3.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.192 -0.943 . . . . 0.0 109.442 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.519 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.3 p -87.37 -30.76 20.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 163.79 82.2 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.896 . . . . 0.0 109.455 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.417 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.07 130.74 19.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.723 2.282 . . . . 0.0 111.827 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -67.83 -32.72 73.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.291 -0.88 . . . . 0.0 109.475 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -170.54 -177.48 40.65 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.62 -29.46 70.47 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.272 -1.134 . . . . 0.0 109.521 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -63.68 -60.41 3.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.165 -0.96 . . . . 0.0 109.438 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.453 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.2 mtt180 -112.72 155.74 24.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 53.4 m -146.5 149.07 32.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.434 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.932 ' C ' HD12 ' A' ' 141' ' ' LEU . 82.1 mmm -95.31 125.14 39.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.389 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.932 HD12 ' C ' ' A' ' 140' ' ' MET . 6.3 mp -125.46 140.4 52.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.163 -0.961 . . . . 0.0 109.631 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.604 HD12 ' HG2' ' A' ' 151' ' ' LYS . 6.0 tt -96.04 123.9 39.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.322 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.858 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.6 mp -99.51 113.65 26.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.652 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -89.52 124.27 34.37 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.703 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.5 mm? -85.27 175.22 9.06 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.152 -0.967 . . . . 0.0 109.392 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.501 HG13 ' N ' ' A' ' 147' ' ' ASN . 17.6 pt -58.93 -38.12 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.501 ' N ' HG13 ' A' ' 146' ' ' ILE . 78.3 m-20 -138.89 19.61 2.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.958 . . . . 0.0 109.407 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 85.7 mttt -143.64 156.56 44.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.26 -0.9 . . . . 0.0 109.631 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -121.38 124.9 45.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.196 -0.94 . . . . 0.0 109.191 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 145' ' ' LEU . 32.8 pt -128.73 156.03 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.918 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.604 ' HG2' HD12 ' A' ' 142' ' ' LEU . 22.7 mttt -131.56 132.18 43.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.339 -0.851 . . . . 0.0 109.27 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 153' ' ' SER . 57.8 t-80 -152.28 144.79 24.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.141 -0.974 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.429 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 45.9 p -68.7 142.61 54.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.33 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.832 ' HB ' HD13 ' A' ' 141' ' ' LEU . 19.7 t -129.85 150.78 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.537 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 158' ' ' GLU . 90.5 mttt -94.11 139.12 31.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.33 -0.856 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.0 p30 -46.0 -29.06 1.32 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.169 -0.957 . . . . 0.0 109.582 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 57.9 p -82.24 -21.92 36.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 109.595 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.2 mt-10 -81.22 -20.6 40.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.658 ' CD2' HD21 ' A' ' 141' ' ' LEU . 27.7 p90 -140.74 172.14 13.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -0.937 . . . . 0.0 109.561 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -130.85 147.73 52.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -78.57 133.54 37.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.273 -0.892 . . . . 0.0 109.504 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.444 HD11 ' HB ' ' A' ' 117' ' ' ILE . 15.9 mt . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.468 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.443 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 6.5 m-85 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.64 131.52 23.07 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.73 2.286 . . . . 0.0 111.712 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.65 -11.98 59.5 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.6 m-20 -77.44 157.43 30.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -1.155 . . . . 0.0 109.497 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.568 ' HB3' HD21 ' A' ' 162' ' ' LEU . 55.9 mttt -80.35 142.12 34.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.299 -0.876 . . . . 0.0 109.448 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.011 HG21 HD23 ' A' ' 141' ' ' LEU . 5.8 m -127.59 159.48 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.836 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.3 tp -123.37 147.32 27.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.607 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.2 mm -91.45 131.63 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.264 -0.897 . . . . 0.0 109.475 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.429 ' C ' ' HG2' ' A' ' 124' ' ' GLU . 72.7 p -121.65 5.5 10.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.267 -0.896 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.426 ' N ' ' HG2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -141.73 151.16 42.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -0.936 . . . . 0.0 109.442 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 85.13 -170.27 44.94 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.73 -2.4 58.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -1.201 . . . . 0.0 109.625 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.607 ' HB2' HG21 ' A' ' 118' ' ' ILE . 93.1 m-85 -87.94 4.78 43.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.63 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 119' ' ' THR . 97.5 mt-10 -56.5 142.09 40.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.7 -3.46 83.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.594 ' O ' HD12 ' A' ' 117' ' ' ILE . 19.8 m-30 -102.36 147.71 26.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -1.17 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -100.17 151.03 21.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.387 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.966 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -146.74 161.34 40.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.227 -0.92 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.487 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 22.8 mm -114.02 140.54 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.484 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.5 m-85 -61.42 112.86 2.36 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.275 -0.891 . . . . 0.0 109.443 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 46.0 p -82.36 -32.13 29.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.457 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.8 mm-40 164.4 91.72 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.156 -0.965 . . . . 0.0 109.488 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.11 122.99 9.55 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.597 2.198 . . . . 0.0 111.771 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -65.81 -31.26 72.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.47 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -163.26 179.84 38.18 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.04 -26.85 63.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.218 -1.166 . . . . 0.0 109.541 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.36 -53.72 15.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.461 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 59.0 mtt180 -112.32 151.44 29.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.516 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 54.4 m -142.32 150.43 40.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.303 -0.873 . . . . 0.0 109.465 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.931 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.8 mtp -100.37 127.31 46.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.011 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -125.38 146.42 49.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.483 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.576 ' O ' ' HB1' ' A' ' 128' ' ' ALA . 9.7 tt -97.44 126.3 42.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.641 HD23 ' HB2' ' A' ' 128' ' ' ALA . 39.1 mt -97.93 109.88 22.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.542 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.625 ' C ' HD22 ' A' ' 145' ' ' LEU . 14.9 p-10 -84.63 122.6 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 0.0 109.621 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -111.23 141.43 44.77 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.383 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.499 HG13 ' N ' ' A' ' 147' ' ' ASN . 21.3 pt -50.03 -35.75 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.499 ' N ' HG13 ' A' ' 146' ' ' ILE . 61.3 t30 -72.42 -49.22 35.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.288 -0.882 . . . . 0.0 109.575 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.499 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 67.3 mttt -158.11 173.38 16.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.543 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -103.17 133.21 48.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.924 . . . . 0.0 109.312 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.451 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 17.2 pt -133.99 159.27 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.625 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.523 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 13.3 mttt -119.63 136.95 54.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.282 -0.886 . . . . 0.0 109.33 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -144.31 140.24 29.04 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.585 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 23.5 p -85.1 125.19 32.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.338 -0.851 . . . . 0.0 109.313 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.722 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.0 p -127.97 147.92 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.196 -0.94 . . . . 0.0 109.547 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.54 ' O ' ' CD2' ' A' ' 159' ' ' PHE . 88.8 mttt -76.08 155.27 34.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.231 -0.918 . . . . 0.0 109.464 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 20.3 m-80 -62.71 -27.09 69.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.453 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 64.7 p -77.33 -18.86 57.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.356 -0.84 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.536 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.3 mt-10 -87.72 -19.78 27.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.475 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.581 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 29.8 p90 -138.08 161.03 37.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -0.951 . . . . 0.0 109.583 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.836 ' O ' HG22 ' A' ' 117' ' ' ILE . 73.7 mtt180 -129.53 147.77 51.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.317 -0.864 . . . . 0.0 109.475 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 25.7 tttt -73.55 123.88 24.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.612 ' OXT' HD12 ' A' ' 162' ' ' LEU . 1.1 pp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.487 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.462 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 52.8 m-85 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 49.4 Cg_endo -70.2 135.01 28.37 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.675 2.25 . . . . 0.0 111.754 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.82 -10.11 66.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.462 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.2 m-20 -83.99 147.53 27.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -1.123 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.516 ' CB ' HD21 ' A' ' 162' ' ' LEU . 22.7 mttm -72.98 145.08 46.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.902 . . . . 0.0 109.456 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 141' ' ' LEU . 4.3 m -133.79 150.42 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.476 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 1.8 tp -119.95 139.29 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.461 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.585 HD11 HD21 ' A' ' 143' ' ' LEU . 58.8 mt -92.53 130.08 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.287 -0.883 . . . . 0.0 109.501 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.482 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 60.5 p -106.96 -10.26 16.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -132.87 157.36 45.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 109.522 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.66 166.85 36.33 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.59 -22.31 64.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 96.9 m-85 -82.51 8.13 12.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.224 -0.922 . . . . 0.0 109.52 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -57.64 139.9 52.51 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.297 -0.877 . . . . 0.0 109.522 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.53 -5.26 73.82 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.5 m-30 -99.99 145.79 27.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.247 -1.149 . . . . 0.0 109.464 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -94.55 146.45 24.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.935 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.812 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.21 160.18 40.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.299 -0.875 . . . . 0.0 109.42 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.71 140.06 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.48 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.625 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.8 m-85 -61.42 110.15 1.36 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.295 -0.878 . . . . 0.0 109.495 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.52 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 39.3 p -80.46 -32.5 37.18 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.317 -0.864 . . . . 0.0 109.477 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 164.32 86.58 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.267 -0.895 . . . . 0.0 109.398 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.79 128.56 16.17 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.773 2.316 . . . . 0.0 111.799 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -69.06 -29.34 67.45 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.517 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -167.92 174.81 42.87 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -62.07 -27.97 69.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.68 -64.93 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.164 -0.96 . . . . 0.0 109.476 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.402 ' O ' ' O ' ' A' ' 135' ' ' GLY . 49.9 mtm-85 -105.08 152.08 23.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.532 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 65.2 m -142.46 152.15 42.44 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.51 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.917 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.2 mmm -96.58 123.61 40.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -122.5 142.89 50.11 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.945 . . . . 0.0 109.636 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.833 HD13 ' HG2' ' A' ' 151' ' ' LYS . 15.1 tp -103.86 119.36 38.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.273 -0.892 . . . . 0.0 109.417 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -100.57 109.14 21.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.501 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.431 ' O ' ' CG ' ' A' ' 144' ' ' ASN . 11.3 p-10 -83.11 118.86 23.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.567 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.765 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -82.03 168.83 17.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.259 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.515 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.2 pt -54.15 -38.27 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.19 -0.944 . . . . 0.0 109.638 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.515 ' N ' HG13 ' A' ' 146' ' ' ILE . 30.3 p-10 -139.19 25.09 2.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -0.984 . . . . 0.0 109.787 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.461 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 76.0 mttt -152.61 157.41 40.97 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.0 109.815 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -128.11 130.86 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.383 -0.823 . . . . 0.0 109.112 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.618 ' O ' HD12 ' A' ' 142' ' ' LEU . 21.3 pt -131.45 145.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.134 -0.978 . . . . 0.0 109.835 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.833 ' HG2' HD13 ' A' ' 142' ' ' LEU . 19.6 mttp -118.53 126.79 52.75 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 0.0 109.298 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.494 ' CE1' ' O ' ' A' ' 153' ' ' SER . 52.5 t-80 -153.85 145.73 23.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.168 -0.958 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.494 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 52.5 p -74.48 141.48 44.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.216 -0.928 . . . . 0.0 109.356 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.601 HG12 ' HD1' ' A' ' 159' ' ' PHE . 21.3 t -124.78 150.4 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.442 ' HB2' ' HG3' ' A' ' 158' ' ' GLU . 61.3 mttp -86.06 138.46 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -49.96 -22.99 1.75 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.943 . . . . 0.0 109.494 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.7 p -86.62 -25.39 24.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.175 -0.953 . . . . 0.0 109.463 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG3' ' HB2' ' A' ' 155' ' ' LYS . 97.6 mt-10 -76.63 -23.39 53.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -0.865 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.926 ' CE2' HD21 ' A' ' 141' ' ' LEU . 22.7 p90 -140.62 160.95 38.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 109.491 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -128.89 142.15 51.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.219 -0.925 . . . . 0.0 109.512 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -70.43 124.99 25.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.208 -0.933 . . . . 0.0 109.422 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.516 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.496 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 65.9 m-85 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.2 Cg_endo -69.64 132.27 23.16 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.681 2.254 . . . . 0.0 111.756 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.54 -10.55 61.12 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.45 ' HB3' ' HE3' ' A' ' 161' ' ' LYS . 81.5 m-20 -77.85 150.72 34.15 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.176 -1.191 . . . . 0.0 109.451 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.549 ' HB3' HD21 ' A' ' 162' ' ' LEU . 28.8 mttt -84.81 141.51 30.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.47 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -129.04 158.89 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 160' ' ' ARG . 7.3 tp -126.59 148.73 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.151 -0.968 . . . . 0.0 109.505 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.453 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 25.9 mm -90.52 127.84 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 72.8 p -112.83 -5.36 13.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.275 -0.891 . . . . 0.0 109.502 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.468 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 85.2 tt0 -138.51 156.28 47.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.202 -0.936 . . . . 0.0 109.421 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.468 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 86.5 169.57 46.05 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.22 -14.63 63.13 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -1.163 . . . . 0.0 109.527 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.553 ' CD1' HD13 ' A' ' 143' ' ' LEU . 85.6 m-85 -82.78 6.85 16.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 84.5 tt0 -59.45 132.84 55.2 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.565 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 99.46 1.17 56.67 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.521 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -103.49 138.58 40.01 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.12 -1.224 . . . . 0.0 109.59 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -93.98 122.58 36.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.211 -0.931 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.922 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -118.52 165.77 13.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.58 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.525 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 41.9 mm -120.43 139.29 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.598 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.6 m-85 -58.65 101.37 0.09 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.906 . . . . 0.0 109.516 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.525 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 49.2 p -77.15 -30.52 55.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.286 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.2 mt-10 163.63 97.15 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.262 -0.899 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.85 114.63 3.78 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.707 2.272 . . . . 0.0 111.763 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -66.55 -33.6 76.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.492 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -145.01 163.0 28.11 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.66 -31.99 72.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -1.146 . . . . 0.0 109.184 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.17 -73.91 0.15 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.6 ptt-85 -84.96 158.32 20.55 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.285 -0.885 . . . . 0.0 109.611 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 71.1 m -145.79 144.58 30.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.871 ' C ' HD12 ' A' ' 141' ' ' LEU . 89.8 mmm -86.58 118.89 26.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.251 -0.906 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -122.61 146.07 47.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.521 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.72 HD12 ' CE ' ' A' ' 151' ' ' LYS . 9.4 tt -99.37 127.44 45.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.434 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.553 HD13 ' CD1' ' A' ' 123' ' ' PHE . 17.9 mt -96.8 115.04 26.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.863 ' C ' HD12 ' A' ' 145' ' ' LEU . 6.9 p30 -86.75 126.6 34.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.6 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.863 HD12 ' C ' ' A' ' 144' ' ' ASN . 9.6 mp -129.46 136.33 49.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.242 -0.911 . . . . 0.0 109.362 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.514 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -50.55 -35.09 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.888 . . . . 0.0 109.614 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.514 ' N ' HG13 ' A' ' 146' ' ' ILE . 47.7 t-20 -68.68 -47.56 66.16 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.915 . . . . 0.0 109.585 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.482 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 55.5 tttp -168.09 158.98 10.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.166 -0.959 . . . . 0.0 109.576 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.482 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 97.0 mt-10 -93.81 125.72 38.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.95 . . . . 0.0 109.5 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.474 HD11 ' CE1' ' A' ' 123' ' ' PHE . 27.8 pt -126.34 158.63 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.205 -0.935 . . . . 0.0 109.428 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.72 ' CE ' HD12 ' A' ' 142' ' ' LEU . 17.1 mttt -124.62 131.55 53.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.543 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -142.6 147.06 35.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 39.3 p -72.18 139.66 48.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.692 ' HB ' HD13 ' A' ' 141' ' ' LEU . 21.8 t -131.08 150.63 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 24.6 mttm -97.16 138.72 34.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.585 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 32.1 m-80 -45.06 -30.64 1.11 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 65.9 p -81.15 -25.21 37.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.287 -0.883 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 92.0 mt-10 -76.21 -23.67 54.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.642 ' HD1' HG12 ' A' ' 154' ' ' VAL . 27.5 p90 -137.41 167.05 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 117' ' ' ILE . 63.5 mtt85 -130.21 146.84 51.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' LYS . . . . . 0.45 ' HE3' ' HB3' ' A' ' 114' ' ' ASP . 73.8 tttt -72.8 117.23 14.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.436 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.549 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.466 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.47 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 43.7 m-85 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 133.61 25.19 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.69 2.26 . . . . 0.0 111.873 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.34 -10.69 61.52 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.47 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.6 m-20 -85.57 144.69 27.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.288 -1.124 . . . . 0.0 109.498 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -75.45 147.02 40.22 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 109.517 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.058 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -134.9 151.41 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.912 HG21 HD21 ' A' ' 162' ' ' LEU . 3.8 tp -123.94 141.07 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.446 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 61.8 mt -92.18 129.95 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.321 -0.862 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.508 HG21 ' CD ' ' A' ' 160' ' ' ARG . 75.0 p -105.65 -7.6 18.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.537 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.435 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 97.8 mt-10 -138.02 158.16 44.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.484 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.4 168.11 38.55 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.95 -22.7 65.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.222 -1.163 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.9 m-85 -83.47 9.46 11.17 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.244 -0.91 . . . . 0.0 109.417 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.502 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -61.76 140.89 58.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.96 -6.06 76.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.0 m-85 -99.89 149.8 23.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -1.153 . . . . 0.0 109.557 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -98.45 147.86 24.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.319 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.817 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.69 162.61 35.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.898 . . . . 0.0 109.502 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.41 HD13 ' O ' ' A' ' 128' ' ' ALA . 26.1 mm -113.47 143.87 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.635 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 33.6 m-85 -66.06 113.01 4.16 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.531 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 18.1 p -82.4 -33.17 28.78 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.952 . . . . 0.0 109.437 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.89 90.3 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.78 122.66 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.686 2.257 . . . . 0.0 111.799 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 21.3 p-10 -65.89 -31.21 72.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.664 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.509 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -164.66 178.6 39.79 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -67.61 -27.05 66.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.308 -1.113 . . . . 0.0 109.543 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.04 -63.2 1.14 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 58.1 mtt180 -108.37 158.53 17.42 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 109.548 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 72.6 m -145.28 155.38 43.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.394 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.896 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.6 mtp -102.21 124.27 47.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.058 HD23 HG21 ' A' ' 116' ' ' VAL . 6.2 mp -122.25 145.79 47.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 7.8 tt -104.8 120.82 42.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.915 . . . . 0.0 109.521 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.7 mp -96.37 136.1 37.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.44 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.498 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 92.7 m-20 -106.21 112.41 25.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.541 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 44.1 mt -100.24 148.08 25.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.512 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -51.13 -40.12 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.512 ' N ' HG13 ' A' ' 146' ' ' ILE . 45.8 t-20 -68.7 -48.08 64.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.54 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.505 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 28.3 ttpp -168.46 164.6 12.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.287 -0.883 . . . . 0.0 109.466 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.505 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 95.1 mt-10 -87.88 139.19 30.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.7 158.18 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.25 -0.906 . . . . 0.0 109.402 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.447 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.8 mttt -125.84 130.45 51.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.196 -0.94 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.411 ' ND1' ' O ' ' A' ' 153' ' ' SER . 56.5 t-80 -153.17 141.61 20.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 109.436 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.411 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 68.6 m -67.77 142.59 56.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -0.958 . . . . 0.0 109.438 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.651 ' HB ' HD13 ' A' ' 141' ' ' LEU . 16.8 t -131.03 151.6 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.418 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 9.5 mtpm? -92.04 137.29 32.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.893 . . . . 0.0 109.508 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.587 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.0 m-80 -50.66 -24.36 3.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 109.415 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.6 p -84.78 -22.49 29.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.907 . . . . 0.0 109.356 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG2' ' HB2' ' A' ' 155' ' ' LYS . 68.6 mm-40 -81.47 -20.7 39.66 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.623 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -139.14 178.29 7.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.508 ' CD ' HG21 ' A' ' 119' ' ' THR . 59.1 mtt-85 -134.65 146.63 49.71 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.871 . . . . 0.0 109.402 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -84.71 135.75 34.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.447 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.912 HD21 HG21 ' A' ' 117' ' ' ILE . 68.0 mt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.415 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.407 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 33.0 m-85 . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.17 134.04 28.21 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.693 2.262 . . . . 0.0 111.819 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.03 -17.55 54.0 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -68.47 162.71 24.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -1.151 . . . . 0.0 109.38 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.483 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 36.5 mttm -88.01 139.48 30.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.282 -0.886 . . . . 0.0 109.572 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -133.48 148.98 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.447 ' CG2' ' HB3' ' A' ' 162' ' ' LEU . 5.1 tp -116.67 141.45 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.556 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.443 HD11 HD21 ' A' ' 143' ' ' LEU . 72.6 mt -92.61 130.72 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.422 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.454 HG21 ' HD2' ' A' ' 160' ' ' ARG . 61.3 p -107.27 -5.02 18.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.472 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 83.9 tt0 -141.41 155.53 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.521 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 100.33 166.83 28.83 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.37 -22.22 64.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.578 ' CE1' HD11 ' A' ' 150' ' ' ILE . 77.8 m-85 -87.64 12.87 11.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.1 136.94 58.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.254 -0.904 . . . . 0.0 109.432 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.91 66.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -105.68 122.75 46.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -1.168 . . . . 0.0 109.541 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -72.05 137.35 47.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.298 -0.876 . . . . 0.0 109.306 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.83 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -133.68 158.52 43.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.208 -0.932 . . . . 0.0 109.563 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.5 mm -116.64 136.0 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.444 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.842 ' CE2' HG11 ' A' ' 116' ' ' VAL . 35.2 m-85 -58.61 101.77 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.519 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.467 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 44.8 p -75.05 -39.06 61.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.386 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 131' ' ' THR . 67.9 tt0 172.98 95.77 0.05 OUTLIER Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.9 . . . . 0.0 109.441 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.16 110.72 2.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.718 2.279 . . . . 0.0 111.848 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.5 p-10 -62.68 -34.42 77.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.504 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.417 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -141.85 178.06 20.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -76.91 -30.02 55.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -1.129 . . . . 0.0 109.406 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -69.46 -78.06 0.07 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.407 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 13.3 ptt180 -89.77 148.13 23.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.248 -0.907 . . . . 0.0 109.743 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.1 m -135.33 155.38 50.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 0.0 109.492 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.76 ' C ' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -89.92 115.55 27.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.1 mp -119.74 139.52 52.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.892 . . . . 0.0 109.481 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.603 HD12 ' N ' ' A' ' 143' ' ' LEU . 9.0 tp -97.48 122.16 40.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.776 HD23 ' HB2' ' A' ' 128' ' ' ALA . 22.1 mt -87.95 146.46 25.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.316 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.503 ' C ' HD12 ' A' ' 145' ' ' LEU . 99.2 m-20 -115.98 107.96 15.63 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.601 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.77 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.0 mp -105.23 141.18 37.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.938 . . . . 0.0 109.302 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.0 pt -50.39 -32.5 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.522 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.7 m-20 -73.12 -56.41 5.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.289 -0.882 . . . . 0.0 109.674 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.522 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 60.2 mttm -159.58 171.32 19.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.513 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.58 139.08 38.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.337 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.598 ' O ' HD12 ' A' ' 142' ' ' LEU . 20.1 pt -132.8 142.43 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.231 -0.918 . . . . 0.0 109.46 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.445 ' HG2' HD13 ' A' ' 142' ' ' LEU . 98.1 mttt -96.5 130.02 43.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.24 -0.913 . . . . 0.0 109.474 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -147.52 138.57 23.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.488 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 52.1 p -73.2 141.45 47.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.278 -0.889 . . . . 0.0 109.441 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.729 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.2 t -128.81 151.56 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -0.91 . . . . 0.0 109.56 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 45.4 mttp -100.87 138.36 38.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.376 -0.828 . . . . 0.0 109.423 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.1 p30 -46.04 -28.28 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.493 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 72.0 p -84.94 -19.64 31.88 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.25 -0.906 . . . . 0.0 109.629 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.6 mt-10 -83.23 -22.34 33.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.182 -0.949 . . . . 0.0 109.459 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.655 ' HD1' HG12 ' A' ' 154' ' ' VAL . 29.9 p90 -136.93 173.03 12.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.215 -0.928 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.454 ' HD2' HG21 ' A' ' 119' ' ' THR . 96.6 mtt180 -134.99 145.17 47.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.515 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -69.34 113.59 6.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.616 HD23 ' C ' ' A' ' 116' ' ' VAL . 1.9 pp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.406 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.7 138.22 37.48 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.722 2.281 . . . . 0.0 111.79 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.85 -11.61 66.12 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.99 151.7 40.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -1.144 . . . . 0.0 109.403 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.534 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.5 mttm -80.26 139.75 36.54 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.031 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -129.23 156.3 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.655 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.24 146.1 29.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.598 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 20.5 mm -90.13 120.27 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.394 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 58.1 p -103.03 -16.06 15.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.42 155.56 50.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.459 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.94 165.04 35.45 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.95 -15.35 62.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 0.0 109.441 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.698 ' HB3' HD23 ' A' ' 143' ' ' LEU . 88.7 m-85 -86.49 11.75 11.88 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.459 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.1 tt0 -59.04 134.74 57.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.97 67.18 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.475 ' CE2' ' HG ' ' A' ' 145' ' ' LEU . 40.7 m-85 -99.19 137.62 37.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.098 -1.236 . . . . 0.0 109.545 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -90.99 129.38 37.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.323 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.972 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -130.08 163.72 25.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.56 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 128' ' ' ALA . 31.0 mm -119.42 139.76 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.308 -0.87 . . . . 0.0 109.408 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.594 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 38.0 m-85 -58.6 101.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -0.933 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.501 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 41.0 p -77.58 -28.33 51.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.7 OUTLIER 164.93 98.01 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.484 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.0 Cg_endo -69.82 114.83 3.84 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.733 2.289 . . . . 0.0 111.805 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -60.94 -30.7 70.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 109.506 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -166.15 174.45 41.72 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -67.34 -22.81 65.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -1.144 . . . . 0.0 109.491 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.92 -64.63 1.01 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.452 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 57.5 mtm-85 -107.72 159.61 16.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 55.7 m -144.98 157.93 43.97 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -0.864 . . . . 0.0 109.471 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.893 ' C ' HD12 ' A' ' 141' ' ' LEU . 33.8 mtp -101.97 120.91 41.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.031 HD23 HG21 ' A' ' 116' ' ' VAL . 6.4 mp -120.31 147.31 45.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.772 HD13 ' HG2' ' A' ' 151' ' ' LYS . 11.9 tp -99.87 124.01 44.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.45 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.843 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.1 mp -100.89 109.51 21.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.195 -0.941 . . . . 0.0 109.457 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.726 ' C ' HD12 ' A' ' 145' ' ' LEU . 13.4 p-10 -83.24 125.44 31.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.908 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 144' ' ' ASN . 7.7 mp -118.3 141.87 48.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.16 -0.962 . . . . 0.0 109.468 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.44 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.4 pt -51.6 -30.93 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.478 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.506 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 95.6 m-20 -74.98 -55.24 5.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.263 -0.898 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.506 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 33.9 mttt -158.68 171.78 19.47 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.223 -0.923 . . . . 0.0 109.622 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -101.01 131.3 46.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.239 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 142' ' ' LEU . 6.9 pt -129.87 144.77 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.742 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.772 ' HG2' HD13 ' A' ' 142' ' ' LEU . 31.2 mttt -108.47 136.57 47.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.039 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.09 140.02 20.97 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.004 -1.06 . . . . 0.0 109.831 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.402 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.4 p -85.19 121.8 28.46 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.39 -0.819 . . . . 0.0 109.047 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.544 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 2.9 p -121.13 151.55 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.15 -0.969 . . . . 0.0 109.638 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 35.2 mttt -75.21 149.25 38.97 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.327 -0.858 . . . . 0.0 109.577 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.573 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.1 m-80 -60.56 -26.09 66.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.7 p -78.51 -20.69 50.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.293 -0.88 . . . . 0.0 109.53 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.544 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 72.8 mm-40 -83.28 -22.06 33.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.908 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.977 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.4 p90 -138.35 156.19 47.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.655 ' O ' HG22 ' A' ' 117' ' ' ILE . 17.3 ttt85 -127.93 137.08 52.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 16.8 pttt -72.19 161.03 31.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.174 -0.954 . . . . 0.0 109.405 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.791 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.079 -0.963 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.77 132.34 24.75 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.728 2.285 . . . . 0.0 111.824 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 106.83 -14.79 41.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.49 158.96 25.71 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -1.146 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -92.78 145.92 24.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.278 -0.889 . . . . 0.0 109.48 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.041 HG22 ' O ' ' A' ' 128' ' ' ALA . 17.4 m -128.71 152.48 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.662 ' HB ' HD11 ' A' ' 162' ' ' LEU . 7.3 tp -123.6 148.59 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.493 HG21 ' HB2' ' A' ' 123' ' ' PHE . 18.0 mm -92.58 132.51 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.23 -0.919 . . . . 0.0 109.463 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 52.2 p -121.32 5.39 10.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.196 -0.94 . . . . 0.0 109.619 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.424 ' OE1' ' HA ' ' A' ' 158' ' ' GLU . 94.0 mt-10 -141.36 152.14 44.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.14 -0.975 . . . . 0.0 109.501 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 84.25 -171.94 48.64 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.25 -5.72 59.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -1.146 . . . . 0.0 109.54 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.576 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 83.1 m-85 -85.46 7.7 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.578 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 121' ' ' GLY . 97.6 mt-10 -58.96 141.1 54.71 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 109.572 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.56 -6.83 80.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.612 ' O ' HD12 ' A' ' 117' ' ' ILE . 20.6 m-30 -96.97 147.62 23.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.224 -1.162 . . . . 0.0 109.614 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -104.54 154.19 20.23 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.356 -0.84 . . . . 0.0 109.334 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 1.041 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -147.88 162.05 40.06 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.595 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.9 mm -112.39 144.34 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.587 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.728 ' CE1' HD21 ' A' ' 141' ' ' LEU . 35.1 m-85 -66.48 103.33 1.03 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.382 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.604 HG21 ' HE2' ' A' ' 151' ' ' LYS . 43.8 p -76.29 -34.2 59.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.527 ' O ' ' CG ' ' A' ' 140' ' ' MET . 2.2 mt-10 165.14 89.79 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.164 -0.96 . . . . 0.0 109.731 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.1 130.78 19.5 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.608 2.205 . . . . 0.0 111.694 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -68.17 -30.57 69.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -171.18 177.96 43.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -63.45 -25.76 68.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.254 -1.145 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.08 -62.27 1.51 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.7 mtt180 -110.01 157.98 18.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.3 m -142.46 153.05 43.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.527 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 85.7 mmm -99.73 124.0 44.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.872 HD22 HG21 ' A' ' 116' ' ' VAL . 42.0 mt -122.94 145.89 48.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.948 HD12 ' HG2' ' A' ' 151' ' ' LYS . 2.7 tt -101.2 126.39 47.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.168 -0.958 . . . . 0.0 109.646 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.807 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.8 mp -99.55 104.37 16.16 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.223 -0.923 . . . . 0.0 109.157 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -77.54 125.56 29.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.127 -0.983 . . . . 0.0 109.335 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 69.1 mt -117.72 141.35 48.49 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.32 -0.863 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.434 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.5 pt -51.55 -29.04 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.495 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.3 m-20 -78.47 -53.08 7.62 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.495 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 83.5 mttt -158.29 172.57 18.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.3 -0.875 . . . . 0.0 109.469 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -100.89 125.16 47.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 32.2 pt -120.87 158.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.923 . . . . 0.0 109.5 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.948 ' HG2' HD12 ' A' ' 142' ' ' LEU . 3.2 mtpm? -125.27 132.25 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.428 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -144.67 141.33 29.26 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.505 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 38.5 p -73.33 141.22 47.1 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.887 . . . . 0.0 109.32 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.577 HG12 ' HD1' ' A' ' 159' ' ' PHE . 19.4 t -133.09 152.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.114 -0.991 . . . . 0.0 109.618 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 39.0 mtmt -91.28 141.46 28.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 18.5 m-80 -51.21 -26.2 6.66 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.3 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 45.6 p -83.83 -19.18 35.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.304 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.444 ' OE2' ' HE2' ' A' ' 155' ' ' LYS . 94.9 mt-10 -84.87 -13.42 50.97 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.353 -0.842 . . . . 0.0 109.45 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.577 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -148.74 173.5 13.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.208 -0.933 . . . . 0.0 109.398 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.471 ' O ' HG22 ' A' ' 117' ' ' ILE . 97.2 mtt180 -131.16 143.99 51.04 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.197 -0.939 . . . . 0.0 109.607 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -80.78 135.09 35.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.738 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.7 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.495 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.44 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 72.0 m-85 . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.513 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 47.9 Cg_endo -69.07 130.72 20.72 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.767 2.311 . . . . 0.0 111.783 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.23 -8.21 55.18 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 129' ' ' ILE . 76.6 m-20 -83.1 166.41 18.73 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -1.185 . . . . 0.0 109.577 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 28.8 mtpt -90.85 140.36 29.88 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.032 HG21 HD23 ' A' ' 141' ' ' LEU . 9.9 m -129.77 155.92 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.546 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.791 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.6 tp -120.55 145.19 27.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.343 -0.848 . . . . 0.0 109.475 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.504 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.0 mm -90.25 134.02 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.937 . . . . 0.0 109.463 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.45 HG21 ' HD3' ' A' ' 160' ' ' ARG . 44.4 p -120.67 -0.05 10.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.512 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.465 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 93.9 mt-10 -138.39 153.4 48.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.4 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.422 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.28 -171.51 44.16 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.95 -3.62 58.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -1.13 . . . . 0.0 109.603 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.573 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.2 m-85 -89.13 9.55 25.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.502 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.465 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 98.3 mt-10 -59.23 141.89 53.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.586 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 88.57 -3.59 85.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.573 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.7 m-30 -100.17 143.22 30.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.167 -1.196 . . . . 0.0 109.565 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLN . . . . . 0.413 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 93.6 mt-30 -93.22 149.76 20.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.252 -0.905 . . . . 0.0 109.375 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.976 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -142.23 160.8 39.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.463 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.99 136.52 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.18 -0.95 . . . . 0.0 109.453 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.62 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 34.8 m-85 -59.8 109.89 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.219 -0.926 . . . . 0.0 109.708 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.51 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 60.7 p -79.61 -34.85 40.34 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 109.34 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.98 96.9 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -70.83 109.27 2.47 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.653 2.235 . . . . 0.0 111.59 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' ASP . . . . . 0.418 ' OD1' ' HG3' ' A' ' 138' ' ' ARG . 24.7 p-10 -76.02 0.11 19.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.736 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -172.48 160.68 32.01 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -66.32 -41.85 89.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -1.152 . . . . 0.0 109.314 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -65.5 -77.51 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.288 -0.882 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.488 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.0 ptp180 -80.46 151.53 29.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.91 . . . . 0.0 109.564 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.768 ' OG ' HD11 ' A' ' 141' ' ' LEU . 88.7 p -145.57 156.71 43.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.528 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.848 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.7 mtp -100.2 119.25 38.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.032 HD23 HG21 ' A' ' 116' ' ' VAL . 5.1 mp -124.24 148.52 47.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.278 -0.888 . . . . 0.0 109.506 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.522 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.7 tt -97.52 126.74 42.97 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.352 -0.843 . . . . 0.0 109.397 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.53 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 35.3 mt -96.47 110.42 22.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.227 -0.921 . . . . 0.0 109.377 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.663 ' C ' HD22 ' A' ' 145' ' ' LEU . 15.5 p-10 -82.73 124.03 29.86 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.852 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.735 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -117.34 144.02 45.35 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.527 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.6 pt -50.08 -35.73 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.438 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.527 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.3 m-20 -71.35 -55.44 7.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.59 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 43.8 mttm -157.58 173.33 17.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.28 -0.887 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -99.12 128.79 45.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.259 -0.901 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.42 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 19.2 pt -125.5 158.02 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.522 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 24.0 mttp -119.26 135.58 54.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.382 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -144.91 145.92 31.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.58 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.2 p -86.17 121.28 28.54 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.349 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.866 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.7 p -124.92 147.86 29.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.208 -0.932 . . . . 0.0 109.591 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.573 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.2 mttt -75.76 150.97 37.67 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.349 -0.844 . . . . 0.0 109.657 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.568 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 13.9 m-80 -61.51 -24.17 66.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.4 p -79.58 -21.08 45.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.246 -0.909 . . . . 0.0 109.495 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.646 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.8 mt-10 -81.18 -22.65 38.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.554 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.881 ' CE2' HD21 ' A' ' 141' ' ' LEU . 41.7 p90 -138.47 170.51 15.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.925 . . . . 0.0 109.464 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ARG . . . . . 0.548 ' O ' HG22 ' A' ' 117' ' ' ILE . 27.1 ptt180 -134.79 158.72 43.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.181 -0.949 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -88.59 139.26 30.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.791 HD11 ' HB ' ' A' ' 117' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.401 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 85.6 m-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 50.4 Cg_endo -69.98 134.04 26.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.722 2.281 . . . . 0.0 111.713 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 89.88 -8.99 78.77 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.594 ' O ' HG23 ' A' ' 129' ' ' ILE . 29.0 p-10 -68.22 -178.85 1.13 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -1.153 . . . . 0.0 109.384 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.458 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 26.9 mttp -103.0 139.75 38.17 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.933 HG21 HD23 ' A' ' 141' ' ' LEU . 7.9 m -134.41 154.51 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.865 . . . . 0.0 109.38 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.427 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 2.5 tp -121.6 139.35 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.869 . . . . 0.0 109.617 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 120' ' ' GLU . 66.7 mt -92.68 127.19 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 80.4 p -101.68 -11.77 18.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.421 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.49 ' O ' HG22 ' A' ' 118' ' ' ILE . 95.6 mt-10 -130.66 158.97 38.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.01 165.61 36.85 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.78 -27.8 68.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.45 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 97.1 m-85 -82.49 3.61 27.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.326 -0.859 . . . . 0.0 109.582 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -53.76 141.49 26.58 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.177 -0.952 . . . . 0.0 109.48 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 94.06 -9.83 72.35 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.45 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -97.93 148.46 23.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.207 -1.172 . . . . 0.0 109.47 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLN . . . . . 0.446 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 95.3 mt-30 -91.27 143.69 26.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.273 -0.892 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.885 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -135.51 160.36 38.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.594 HG23 ' O ' ' A' ' 114' ' ' ASP . 31.2 mm -117.86 136.6 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.649 ' HE1' HD11 ' A' ' 141' ' ' LEU . 19.6 m-85 -66.53 114.84 5.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 47.6 p -90.62 -29.93 17.48 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.337 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 175.46 87.53 0.09 OUTLIER Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.224 -0.922 . . . . 0.0 109.327 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.46 118.02 5.36 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.671 2.247 . . . . 0.0 111.791 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -60.32 -34.71 74.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -164.95 -160.12 12.03 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 70.3 mm-40 -83.41 -26.64 30.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -1.139 . . . . 0.0 109.354 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.29 -80.57 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.223 -0.923 . . . . 0.0 109.372 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.446 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 24.0 ptt180 -89.17 148.38 23.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.631 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 59.2 m -144.44 152.81 41.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.197 -0.939 . . . . 0.0 109.414 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.914 ' C ' HD12 ' A' ' 141' ' ' LEU . 39.5 mtp -96.97 122.33 39.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.44 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.933 HD23 HG21 ' A' ' 116' ' ' VAL . 6.3 mp -123.83 150.41 44.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.521 HD12 ' O ' ' A' ' 150' ' ' ILE . 32.1 tp -100.07 123.73 44.64 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 109.466 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.84 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -93.94 118.71 31.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.579 ' C ' HD22 ' A' ' 145' ' ' LEU . 21.9 p-10 -83.49 114.92 21.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.566 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.749 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.9 mm? -114.38 144.16 43.73 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 109.413 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -55.09 -29.07 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.306 -0.872 . . . . 0.0 109.29 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.417 ' N ' HG13 ' A' ' 146' ' ' ILE . 34.8 t30 -75.82 -54.29 7.15 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.342 -0.849 . . . . 0.0 109.441 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.52 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 24.7 tttm -168.57 164.84 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.229 -0.919 . . . . 0.0 109.6 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.52 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 93.9 mt-10 -87.94 127.79 35.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.521 ' O ' HD12 ' A' ' 142' ' ' LEU . 7.6 pt -122.23 136.01 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.283 -0.885 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.512 ' HG2' HD13 ' A' ' 142' ' ' LEU . 17.3 mttp -91.92 127.17 37.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.399 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -139.27 141.36 37.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.638 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.1 p -87.15 119.44 27.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.321 -0.862 . . . . 0.0 109.381 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.789 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.9 p -121.97 149.3 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 68.2 mttm -83.62 151.89 25.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 12.3 m-80 -59.45 -25.14 64.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.236 -0.915 . . . . 0.0 109.456 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.4 p -78.77 -20.29 50.21 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.622 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.2 mt-10 -82.09 -22.68 36.16 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.564 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.22 166.89 23.35 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.537 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 76.4 mtt85 -131.87 150.93 52.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -74.0 122.44 22.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.435 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.489 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.469 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.5 m-85 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.469 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.4 Cg_endo -69.53 128.94 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.663 2.242 . . . . 0.0 111.688 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.8 -11.15 59.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.45 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 79.3 m-20 -78.99 151.87 31.31 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -1.119 . . . . 0.0 109.457 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.462 ' CB ' HD21 ' A' ' 162' ' ' LEU . 97.2 mttt -80.15 142.0 35.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.034 HG21 HD23 ' A' ' 141' ' ' LEU . 6.1 m -131.9 160.57 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 6.8 tp -124.6 142.19 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.509 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.477 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 69.4 mt -92.64 125.59 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.469 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.3 p -102.38 -10.66 19.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.432 ' O ' HG22 ' A' ' 118' ' ' ILE . 94.4 mt-10 -131.38 158.44 40.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.525 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 92.68 166.85 39.05 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.53 -19.78 63.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -1.133 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.546 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 95.9 m-85 -83.54 9.48 11.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.47 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.477 ' HG3' ' O ' ' A' ' 118' ' ' ILE . 85.5 tt0 -58.32 140.41 53.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.391 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.87 -6.04 73.09 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -99.06 142.36 30.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.475 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -86.71 125.92 34.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.937 . . . . 0.0 109.352 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.949 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -110.57 153.0 25.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.298 -0.876 . . . . 0.0 109.456 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.582 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.2 mm -118.06 130.67 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.498 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.847 ' CE2' HG11 ' A' ' 116' ' ' VAL . 32.7 m-85 -62.31 101.7 0.25 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -0.942 . . . . 0.0 109.542 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.478 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 43.3 p -78.43 -36.34 45.72 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.225 -0.922 . . . . 0.0 109.262 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 131' ' ' THR . 17.2 tp10 171.36 99.35 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.419 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.0 113.86 3.55 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.62 2.213 . . . . 0.0 111.461 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 29.2 p-10 -74.95 -6.3 48.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.628 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.19 169.67 41.6 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -75.3 -26.25 58.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.477 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -76.1 -73.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 109.341 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.438 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 9.9 ptp85 -89.32 147.62 23.99 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.483 ' HB2' HD11 ' A' ' 141' ' ' LEU . 65.0 m -134.68 144.91 48.06 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.232 -0.917 . . . . 0.0 109.5 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.709 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 ttm -87.98 109.66 19.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.224 -0.922 . . . . 0.0 109.504 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.034 HD23 HG21 ' A' ' 116' ' ' VAL . 5.5 mp -115.59 151.61 34.6 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.831 HD12 ' O ' ' A' ' 150' ' ' ILE . 48.1 tp -93.47 127.99 39.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.373 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.5 mt -90.73 137.45 32.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -104.16 106.16 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.0 109.432 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.414 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 49.5 mt -104.33 140.88 37.25 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -50.97 -31.47 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.238 -0.914 . . . . 0.0 109.423 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.49 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 17.1 t-20 -74.17 -56.15 5.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.635 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.49 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 19.9 mttt -158.81 166.75 31.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -0.954 . . . . 0.0 109.489 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -92.83 131.93 37.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -0.893 . . . . 0.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.831 ' O ' HD12 ' A' ' 142' ' ' LEU . 13.7 pt -132.56 155.53 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 109.6 -179.695 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.753 ' HG2' HD13 ' A' ' 142' ' ' LEU . 28.9 mttp -105.55 131.46 52.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -140.52 129.42 23.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.266 -0.896 . . . . 0.0 109.409 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 70.7 m -69.89 118.52 12.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.783 ' CG1' HD13 ' A' ' 141' ' ' LEU . 5.3 p -121.82 148.35 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.855 . . . . 0.0 109.53 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 33.0 mttp -81.8 151.92 27.17 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.566 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.0 m-80 -60.76 -21.34 62.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.914 . . . . 0.0 109.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.9 p -81.48 -21.58 38.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.629 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.8 mt-10 -81.52 -23.14 37.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.316 -0.865 . . . . 0.0 109.473 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.663 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.3 p90 -138.53 167.96 20.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.538 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 51.0 mtt-85 -131.12 155.37 47.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.547 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -76.84 125.06 28.64 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.495 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.462 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.472 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.453 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.4 m-85 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.71 130.75 19.95 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.609 2.206 . . . . 0.0 111.808 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.0 -15.14 56.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -69.45 153.88 42.86 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.196 -1.179 . . . . 0.0 109.51 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -90.04 147.5 23.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.797 HG22 ' O ' ' A' ' 128' ' ' ALA . 5.0 m -131.74 154.47 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.628 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.1 tp -124.48 146.98 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.275 -0.891 . . . . 0.0 109.478 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.461 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.1 mm -91.16 124.91 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.335 -0.853 . . . . 0.0 109.356 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.46 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 66.2 p -108.99 -8.57 15.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.531 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.92 157.4 45.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.121 -0.987 . . . . 0.0 109.463 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 88.88 166.54 42.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.44 -18.65 64.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.239 -1.154 . . . . 0.0 109.448 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.57 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 88.5 m-85 -82.56 5.75 19.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 109.506 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.46 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.6 tt0 -58.67 136.7 57.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.557 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.31 -3.43 66.3 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -101.11 150.09 23.29 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.17 -1.194 . . . . 0.0 109.48 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -102.21 149.27 24.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.47 166.22 25.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.305 -0.872 . . . . 0.0 109.423 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.501 HD13 ' O ' ' A' ' 128' ' ' ALA . 27.2 mm -116.63 137.66 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.206 -0.934 . . . . 0.0 109.535 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.698 ' CE2' HG12 ' A' ' 116' ' ' VAL . 36.0 m-85 -59.57 104.0 0.24 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.495 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 39.3 p -78.71 -38.89 37.92 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.344 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 131' ' ' THR . 1.0 OUTLIER 171.68 94.8 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.303 -0.873 . . . . 0.0 109.455 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.38 115.7 4.17 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.776 2.317 . . . . 0.0 111.744 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -61.16 -35.92 78.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.243 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -148.01 175.5 27.3 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.82 -27.43 64.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -1.151 . . . . 0.0 109.495 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.11 -73.54 0.29 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.309 -0.869 . . . . 0.0 109.384 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 21.3 ptt-85 -83.53 147.81 27.56 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.23 -0.919 . . . . 0.0 109.558 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 67.9 m -139.96 153.11 46.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.176 -0.952 . . . . 0.0 109.514 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.453 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 41.6 mtp -99.23 119.48 37.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.262 -0.899 . . . . 0.0 109.429 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.661 HD13 HG21 ' A' ' 116' ' ' VAL . 66.1 mt -117.85 147.73 42.78 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.255 -0.903 . . . . 0.0 109.471 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.612 HD12 ' CE ' ' A' ' 151' ' ' LYS . 8.4 tt -97.31 126.46 42.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.263 -0.898 . . . . 0.0 109.438 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.524 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 43.5 mt -97.69 113.87 25.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.183 -0.948 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.717 ' C ' HD22 ' A' ' 145' ' ' LEU . 8.4 p30 -83.45 121.21 26.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.283 -0.885 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.75 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -118.72 135.64 54.38 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.357 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.2 pt -49.74 -33.29 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.266 -0.896 . . . . 0.0 109.574 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.487 ' N ' HG13 ' A' ' 146' ' ' ILE . 94.2 m-20 -70.49 -46.44 63.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 30.3 tttm -168.49 160.75 11.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.527 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.0 mt-10 -87.85 127.24 35.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.927 . . . . 0.0 109.407 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.506 HG12 HD23 ' A' ' 145' ' ' LEU . 19.6 pt -127.67 162.12 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.424 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.612 ' CE ' HD12 ' A' ' 142' ' ' LEU . 20.9 mttt -125.72 130.25 51.14 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.446 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -139.12 148.14 42.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 29.7 p -82.7 141.89 32.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.578 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.7 t -130.91 153.64 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.35 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.501 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 41.3 mttt -91.11 138.3 31.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.913 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 8.6 p-10 -47.75 -30.38 3.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 44.7 p -80.97 -22.18 39.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.898 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 155' ' ' LYS . 94.8 mt-10 -81.69 -19.7 41.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.439 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.584 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.6 p90 -140.45 169.01 18.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.372 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 87.0 mtt-85 -129.44 143.24 50.75 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -78.14 132.74 37.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.321 -0.862 . . . . 0.0 109.473 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.5 mp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.481 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.408 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 12.6 m-85 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 134.84 27.87 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.724 2.283 . . . . 0.0 111.797 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.21 -12.98 65.12 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 83.4 m-20 -69.97 147.91 49.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.515 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.3 mttm -75.05 139.74 43.05 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.036 HG21 HD23 ' A' ' 141' ' ' LEU . 6.0 m -127.33 155.67 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.942 . . . . 0.0 109.455 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.446 HD12 ' HA ' ' A' ' 117' ' ' ILE . 8.2 tp -123.82 147.69 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.235 -0.916 . . . . 0.0 109.48 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.466 ' HB ' ' HA ' ' A' ' 124' ' ' GLU . 21.6 mm -91.66 129.34 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.8 p -114.17 -7.34 13.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.486 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 46.8 tp10 -140.89 153.48 45.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.486 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 92.15 169.05 40.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.92 -15.9 63.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -1.188 . . . . 0.0 109.493 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.633 ' CD1' HD23 ' A' ' 143' ' ' LEU . 89.9 m-85 -84.93 11.06 10.1 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.2 -0.938 . . . . 0.0 109.451 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.466 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 85.0 tt0 -60.73 134.08 56.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.636 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.94 66.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.454 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.7 m-85 -98.26 140.48 32.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.143 -1.21 . . . . 0.0 109.472 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -94.13 126.52 39.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.525 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.994 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -126.35 161.42 27.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.938 . . . . 0.0 109.533 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.585 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.9 mm -120.12 136.96 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.254 -0.904 . . . . 0.0 109.451 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.586 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.5 m-85 -58.58 103.18 0.14 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 63.4 p -77.3 -31.45 54.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 164.74 91.37 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.188 -0.945 . . . . 0.0 109.53 -179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.47 125.99 12.37 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.63 2.22 . . . . 0.0 111.655 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.6 p-10 -68.66 -25.78 64.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 109.538 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -166.09 170.25 40.69 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -64.01 -27.59 69.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.43 -63.63 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.3 -0.875 . . . . 0.0 109.394 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 135' ' ' GLY . 57.7 mtt85 -107.48 153.6 22.59 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.197 -0.939 . . . . 0.0 109.468 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 68.8 m -138.8 156.64 47.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 109.46 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.819 ' C ' HD12 ' A' ' 141' ' ' LEU . 34.7 tpp -101.12 117.31 34.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.475 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.036 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -118.61 144.07 46.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 9.2 tt -101.52 123.51 45.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.452 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.835 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -91.4 138.51 31.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.923 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.684 ' C ' HD12 ' A' ' 145' ' ' LEU . 97.6 m-20 -110.86 113.38 25.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.768 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.3 mp -114.61 139.63 49.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.579 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.516 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.1 pt -50.28 -36.25 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.516 ' N ' HG13 ' A' ' 146' ' ' ILE . 15.3 t-20 -68.04 -52.89 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.488 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 19.3 tttt -166.66 155.11 10.3 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.541 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.47 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.4 mt-10 -89.86 140.21 29.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.4 pt -131.57 158.61 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.523 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.3 mttt -125.83 134.18 51.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.66 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.49 ' ND1' ' O ' ' A' ' 153' ' ' SER . 51.7 t-80 -158.31 146.45 18.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.422 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.49 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 42.0 p -69.77 141.34 53.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.924 . . . . 0.0 109.393 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.686 HG13 ' CD ' ' A' ' 158' ' ' GLU . 20.2 t -126.17 152.31 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.182 -0.949 . . . . 0.0 109.61 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.504 ' O ' ' HG2' ' A' ' 158' ' ' GLU . 86.4 mttt -91.17 131.64 36.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.276 -0.89 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.582 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 33.4 m-80 -53.41 -18.57 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 79.8 p -85.13 -29.66 24.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 110.141 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.686 ' CD ' HG13 ' A' ' 154' ' ' VAL . 10.9 pt-20 -82.84 -18.57 39.93 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.02 -1.05 . . . . 0.0 109.698 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.642 ' CE2' HD21 ' A' ' 141' ' ' LEU . 20.4 p90 -135.3 157.25 47.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.147 -0.97 . . . . 0.0 109.553 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.2 ttt-85 -124.07 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.267 -0.896 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 16.9 pttp -74.39 124.03 25.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.196 -0.94 . . . . 0.0 109.51 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.497 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.997 -1.002 . . . . 0.0 109.48 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.439 ' N ' ' OD2' ' A' ' 114' ' ' ASP . 50.9 m-85 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.1 Cg_endo -69.73 131.5 21.4 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.696 2.264 . . . . 0.0 111.79 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 98.83 -12.29 62.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' N ' ' A' ' 111' ' ' TYR . 81.5 m-20 -65.56 150.31 48.62 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -1.135 . . . . 0.0 109.491 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.508 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 96.5 mttt -77.98 140.14 39.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.897 . . . . 0.0 109.476 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.947 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.1 m -130.84 153.63 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 3.0 tp -122.65 140.67 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.473 HD12 ' HB3' ' A' ' 123' ' ' PHE . 69.4 mt -92.56 131.05 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.5 p -118.42 5.37 11.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.245 -0.909 . . . . 0.0 109.578 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.433 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -136.91 153.6 50.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 109.481 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.4 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.67 -171.08 42.9 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.87 -5.84 57.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -1.134 . . . . 0.0 109.587 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.557 ' CD1' HD23 ' A' ' 143' ' ' LEU . 80.2 m-85 -88.54 14.98 8.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.997 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.433 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 96.9 mt-10 -62.84 136.91 58.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.14 1.09 70.11 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -102.22 131.41 48.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.137 -1.213 . . . . 0.0 109.454 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -86.72 134.44 33.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.909 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.18 159.72 38.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.544 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.518 HD13 ' O ' ' A' ' 128' ' ' ALA . 33.4 mm -119.2 140.07 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.311 -0.868 . . . . 0.0 109.383 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.566 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.1 m-85 -58.58 101.47 0.09 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.538 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 68.9 p -75.04 -34.41 61.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.369 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.3 mt-10 163.75 88.84 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.294 -0.879 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.463 ' HB3' ' OG ' ' A' ' 139' ' ' SER . 49.9 Cg_endo -69.96 132.35 22.83 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.679 2.253 . . . . 0.0 111.81 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -67.82 -30.03 69.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -0.861 . . . . 0.0 109.444 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -165.18 -174.02 34.4 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -73.32 -26.79 61.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.295 -1.121 . . . . 0.0 109.453 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.82 -58.51 4.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.532 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -109.6 161.12 15.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.158 -0.964 . . . . 0.0 109.425 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 133' ' ' PRO . 4.1 m -147.36 155.38 41.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.262 -0.899 . . . . 0.0 109.566 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.906 ' C ' HD12 ' A' ' 141' ' ' LEU . 63.5 mtp -103.06 124.22 48.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.343 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.947 HD23 ' CG2' ' A' ' 116' ' ' VAL . 5.4 mp -126.19 140.78 52.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.175 -0.953 . . . . 0.0 109.607 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.569 HD23 ' C ' ' A' ' 142' ' ' LEU . 10.1 tt -96.59 125.82 41.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.304 -0.873 . . . . 0.0 109.413 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.829 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.6 mp -93.47 137.02 33.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.284 -0.885 . . . . 0.0 109.525 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.477 ' C ' HD12 ' A' ' 145' ' ' LEU . 83.0 m-20 -108.57 104.19 13.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.905 . . . . 0.0 109.422 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.725 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.8 mp -104.45 139.6 39.14 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.149 -0.969 . . . . 0.0 109.56 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.2 pt -54.32 -35.09 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.445 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 52.0 t-20 -65.96 -46.57 77.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.393 -0.817 . . . . 0.0 109.512 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.1 pttt -168.64 169.54 10.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.204 -0.935 . . . . 0.0 109.555 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CG ' HD21 ' A' ' 142' ' ' LEU . 86.8 tt0 -98.2 132.32 43.82 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.1 pt -131.88 157.01 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.475 ' HG2' ' HG ' ' A' ' 142' ' ' LEU . 2.3 mtpm? -123.97 134.1 53.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.396 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.466 ' CE1' ' O ' ' A' ' 153' ' ' SER . 55.4 t-80 -152.26 143.73 23.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 41.6 p -81.66 137.07 35.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.512 HG12 ' HD1' ' A' ' 159' ' ' PHE . 16.4 t -127.6 151.09 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.406 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.528 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 0.6 OUTLIER -87.38 139.97 30.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.272 -0.893 . . . . 0.0 109.559 -179.935 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.515 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 27.4 m-80 -46.17 -27.98 1.12 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.357 -0.839 . . . . 0.0 110.272 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' THR . . . . . 0.512 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 27.0 p -80.14 -19.93 46.1 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.97 -1.081 . . . . 0.0 109.983 -179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.528 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 48.5 mm-40 -89.85 -19.11 25.02 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.068 -1.02 . . . . 0.0 109.201 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.721 ' CE2' HD21 ' A' ' 141' ' ' LEU . 34.5 p90 -139.22 156.03 47.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.793 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 53.2 mtt180 -125.25 147.1 49.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.255 -0.903 . . . . 0.0 109.339 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' LYS . . . . . 0.477 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 15.9 pttp -82.44 121.52 26.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.492 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.489 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.4 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 53.0 m-85 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.5 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 46.2 Cg_endo -68.28 137.61 40.65 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.634 2.223 . . . . 0.0 111.701 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 90.82 -9.88 76.46 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.744 ' O ' HG23 ' A' ' 129' ' ' ILE . 36.6 p-10 -74.55 -177.85 3.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -1.149 . . . . 0.0 109.5 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.499 ' HA ' HD13 ' A' ' 129' ' ' ILE . 76.6 mttt -99.19 141.6 31.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -0.893 . . . . 0.0 109.426 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.927 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.2 m -138.18 158.1 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.239 -0.913 . . . . 0.0 109.529 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.2 tp -126.27 141.91 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.482 ' HA ' ' HB2' ' A' ' 159' ' ' PHE . 56.1 mt -92.29 129.91 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.209 -0.932 . . . . 0.0 109.695 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.525 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 58.0 p -105.08 -8.39 18.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.474 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 48.0 tp10 -136.26 156.84 48.08 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLY . . . . . 0.474 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 93.77 162.77 36.09 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.26 -19.4 65.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -1.115 . . . . 0.0 109.438 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.497 ' CD1' HD23 ' A' ' 143' ' ' LEU . 84.5 m-85 -86.26 13.16 8.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.379 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.525 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.8 tt0 -63.76 140.12 58.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.38 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 90.32 -0.15 77.63 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -104.99 138.89 40.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -1.193 . . . . 0.0 109.428 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -83.79 148.65 26.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.26 -0.9 . . . . 0.0 109.541 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.927 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -144.83 159.31 43.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.744 HG23 ' O ' ' A' ' 114' ' ' ASP . 27.2 mm -119.68 133.06 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.961 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.788 ' HE1' HD11 ' A' ' 141' ' ' LEU . 18.3 m-85 -58.57 115.84 3.29 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.368 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.516 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 44.0 p -84.18 -29.5 26.56 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.9 86.33 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.326 -0.859 . . . . 0.0 109.545 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.415 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.2 Cg_endo -70.0 130.64 19.38 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.694 2.263 . . . . 0.0 111.751 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -68.91 -26.61 65.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.905 . . . . 0.0 109.594 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -170.59 178.31 43.27 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -66.16 -25.94 67.19 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -1.121 . . . . 0.0 109.509 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.53 -63.68 1.01 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.476 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 75.4 mtt180 -107.11 156.89 18.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.43 ' HB3' ' CE1' ' A' ' 130' ' ' PHE . 69.0 m -148.58 152.42 36.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.175 -0.953 . . . . 0.0 109.51 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.806 ' C ' HD12 ' A' ' 141' ' ' LEU . 20.4 mtp -101.62 122.05 43.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.217 -0.927 . . . . 0.0 109.583 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.818 HD13 ' CG1' ' A' ' 154' ' ' VAL . 6.8 mp -114.21 147.32 39.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.875 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.926 HD21 ' OE2' ' A' ' 149' ' ' GLU . 34.5 tp -102.8 125.42 49.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.742 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.806 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -98.32 127.98 44.52 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.257 -0.902 . . . . 0.0 109.25 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -105.02 113.27 26.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.771 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.4 mm? -101.01 150.56 22.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.326 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 25.7 pt -65.13 -10.45 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.501 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 48.3 t30 -97.57 -47.55 5.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.59 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.501 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 77.7 mttt -158.55 165.39 34.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.93 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.926 ' OE2' HD21 ' A' ' 142' ' ' LEU . 78.4 tt0 -89.57 147.57 23.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.172 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 142' ' ' LEU . 30.9 pt -144.44 151.66 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.945 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.814 ' HG2' HD13 ' A' ' 142' ' ' LEU . 20.8 mttp -118.01 136.64 53.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.366 -0.834 . . . . 0.0 109.159 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -148.58 134.99 19.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.116 -0.99 . . . . 0.0 109.651 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.8 p -87.12 118.08 26.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.888 . . . . 0.0 109.326 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.818 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.3 p -120.05 150.59 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.565 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 28.0 mttt -77.01 153.69 34.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.891 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 9.7 m-80 -65.18 -14.95 61.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 70.5 p -88.17 -24.2 23.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.593 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.7 mt-10 -78.79 -22.62 46.05 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.258 -0.901 . . . . 0.0 109.51 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.769 ' CE2' HD21 ' A' ' 141' ' ' LEU . 38.3 p90 -135.95 174.04 11.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.414 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 52.6 mtp180 -139.45 164.59 29.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.57 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' LYS . . . . . 0.508 ' NZ ' ' OD2' ' A' ' 114' ' ' ASP . 55.4 tttp -85.59 126.32 33.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.487 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.475 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.519 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.404 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 50.3 m-85 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.96 130.89 19.87 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.63 2.22 . . . . 0.0 111.811 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 101.04 -14.77 58.42 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.483 ' CB ' ' HE2' ' A' ' 161' ' ' LYS . 80.4 m-20 -66.89 153.78 42.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.497 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 95.5 mttt -81.83 140.62 34.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.8 m -125.61 152.61 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.712 ' HB ' HD21 ' A' ' 162' ' ' LEU . 8.2 tp -122.64 145.43 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.538 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.48 HG12 ' O ' ' A' ' 126' ' ' PHE . 28.8 mm -91.24 128.82 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.293 -0.88 . . . . 0.0 109.499 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.453 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 69.1 p -114.92 -7.9 12.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.217 -0.927 . . . . 0.0 109.518 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -140.1 151.91 45.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.163 -0.961 . . . . 0.0 109.473 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.56 167.78 38.2 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.41 -13.78 62.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -1.155 . . . . 0.0 109.422 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.599 ' HB3' HD23 ' A' ' 143' ' ' LEU . 69.6 m-85 -87.98 13.93 9.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.475 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.8 tt0 -64.08 132.43 50.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.58 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.17 1.03 59.6 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.48 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.4 m-85 -98.95 136.52 38.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.1 -1.235 . . . . 0.0 109.594 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -88.79 136.07 33.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.291 -0.881 . . . . 0.0 109.279 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 1.018 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -137.95 165.73 25.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.597 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.7 mm -121.01 142.28 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CE2' HG12 ' A' ' 116' ' ' VAL . 40.5 m-85 -58.58 104.49 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.936 . . . . 0.0 109.558 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.462 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 71.1 p -78.07 -40.69 37.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' THR . 7.6 tt0 172.32 91.53 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 48.8 Cg_endo -70.1 124.46 10.97 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.718 2.279 . . . . 0.0 111.761 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 23.3 p-10 -75.23 -4.03 36.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.355 -0.84 . . . . 0.0 109.54 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 174.64 173.3 40.44 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.95 -30.48 67.87 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -1.125 . . . . 0.0 109.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.07 -60.03 2.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -0.915 . . . . 0.0 109.431 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.463 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 81.9 mtm180 -103.28 152.93 20.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.395 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 68.5 m -144.97 150.12 36.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.96 . . . . 0.0 109.491 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.941 ' C ' HD12 ' A' ' 141' ' ' LEU . 91.6 mmm -96.17 125.91 41.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.323 -0.861 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -128.32 141.27 51.49 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.236 -0.915 . . . . 0.0 109.622 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.527 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.9 tt -99.67 119.51 38.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.395 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -96.03 108.63 21.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.18 -0.95 . . . . 0.0 109.652 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 145' ' ' LEU . 5.8 p30 -88.7 127.5 35.59 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.32 -0.862 . . . . 0.0 109.631 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.793 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.1 mp -108.05 159.37 16.62 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.925 . . . . 0.0 109.425 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 23.6 pt -66.65 -10.22 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.418 ' CG ' ' N ' ' A' ' 148' ' ' LYS . 9.2 p30 -105.34 -45.54 4.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.514 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 62.1 tttm -158.48 147.96 19.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.29 -0.881 . . . . 0.0 109.563 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -87.89 141.23 28.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.371 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.564 HD11 ' CE1' ' A' ' 123' ' ' PHE . 28.7 pt -133.7 162.12 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.917 . . . . 0.0 109.572 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.527 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 29.6 mttt -125.16 136.52 53.68 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.291 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.29 148.47 28.21 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.183 -0.948 . . . . 0.0 109.694 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.49 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 21.9 p -86.88 122.77 31.21 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.251 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.986 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.2 p -125.06 148.93 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.493 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 45.0 mttt -79.59 153.53 29.38 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.493 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 11.9 m120 -62.52 -19.73 63.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.344 -0.847 . . . . 0.0 109.474 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 63.1 p -82.26 -23.19 35.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.194 -0.941 . . . . 0.0 109.478 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.579 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.6 mt-10 -81.13 -21.11 40.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.226 -0.921 . . . . 0.0 109.524 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.874 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.8 p90 -139.53 158.94 43.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -122.15 148.49 44.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.205 -0.934 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' LYS . . . . . 0.483 ' HE2' ' CB ' ' A' ' 114' ' ' ASP . 64.1 tttm -76.44 135.37 39.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.923 . . . . 0.0 109.487 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.712 HD21 ' HB ' ' A' ' 117' ' ' ILE . 53.5 mt . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.912 -1.042 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -70.22 134.47 27.09 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.695 2.263 . . . . 0.0 111.784 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.24 -11.68 68.85 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.648 ' O ' HG23 ' A' ' 129' ' ' ILE . 23.9 p-10 -67.45 176.23 2.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.168 -1.195 . . . . 0.0 109.473 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.546 ' HA ' HD13 ' A' ' 129' ' ' ILE . 99.6 mttt -98.34 139.42 34.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.91 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.971 HG21 HD22 ' A' ' 141' ' ' LEU . 15.0 m -135.14 149.8 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.631 ' N ' HD11 ' A' ' 162' ' ' LEU . 6.4 tp -120.84 142.47 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.444 HD11 HD21 ' A' ' 143' ' ' LEU . 62.1 mt -92.37 129.78 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.192 -0.943 . . . . 0.0 109.416 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.487 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 62.7 p -105.6 -9.97 17.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.421 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 75.4 mm-40 -135.73 158.17 45.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.178 -0.951 . . . . 0.0 109.425 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.09 165.48 32.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.93 -20.78 65.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.174 . . . . 0.0 109.43 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.515 ' CG ' HD13 ' A' ' 143' ' ' LEU . 64.1 m-85 -88.12 15.0 8.02 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.487 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 83.2 tt0 -63.22 137.4 58.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.917 . . . . 0.0 109.469 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.7 0.96 62.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -105.67 128.43 53.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -78.04 135.29 37.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.227 -0.921 . . . . 0.0 109.417 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.843 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.89 164.35 27.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.237 -0.915 . . . . 0.0 109.593 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 114' ' ' ASP . 39.3 mm -122.8 137.81 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.462 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.833 ' CE1' HD21 ' A' ' 141' ' ' LEU . 10.6 m-85 -58.56 102.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.679 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 47.0 p -79.43 -36.01 39.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 109.322 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.454 ' O ' ' HG3' ' A' ' 140' ' ' MET . 1.0 OUTLIER 170.02 87.53 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.308 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 133' ' ' PRO . . . . . 0.406 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.5 Cg_endo -69.77 131.78 21.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.735 2.29 . . . . 0.0 111.871 -179.817 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -66.51 -32.36 73.66 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.374 -0.828 . . . . 0.0 109.415 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -163.44 -178.4 37.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -70.5 -29.1 65.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -1.165 . . . . 0.0 109.49 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.14 -59.14 4.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.236 -0.915 . . . . 0.0 109.388 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.505 ' HG3' ' NH1' ' A' ' 138' ' ' ARG . 6.8 mtt85 -109.46 157.81 18.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 109.35 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.406 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 35.6 m -146.38 156.8 43.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -0.986 . . . . 0.0 109.611 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.484 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 49.6 mtp -99.46 127.54 45.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.442 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.971 HD22 HG21 ' A' ' 116' ' ' VAL . 89.8 mt -126.27 135.73 51.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.524 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.0 tt -92.73 123.84 36.31 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.633 HD23 ' HB2' ' A' ' 128' ' ' ALA . 16.5 mt -97.1 109.06 21.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.922 . . . . 0.0 109.662 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.724 ' C ' HD12 ' A' ' 145' ' ' LEU . 12.8 p-10 -83.94 125.48 32.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.224 -0.922 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.724 HD12 ' C ' ' A' ' 144' ' ' ASN . 8.1 mp -119.24 145.73 45.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.17 -0.956 . . . . 0.0 109.441 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -53.44 -39.0 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.656 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.4 m-20 -67.98 -44.88 75.63 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HE3' ' CG2' ' A' ' 150' ' ' ILE . 11.8 pttt -167.17 173.41 9.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.589 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -104.13 129.37 51.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.435 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.451 ' CG2' ' HE3' ' A' ' 148' ' ' LYS . 25.8 pt -125.5 161.59 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.904 . . . . 0.0 109.427 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.524 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.6 mttt -125.34 133.02 52.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -145.87 142.72 29.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 44.9 p -77.17 140.96 40.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.553 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.463 HG12 ' HD2' ' A' ' 159' ' ' PHE . 14.6 t -137.62 146.48 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.534 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 1.3 ptpt -91.05 145.48 24.65 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.313 -0.867 . . . . 0.0 109.801 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.552 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 2.0 p30 -48.96 -29.21 4.52 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.344 -0.847 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' THR . . . . . 0.496 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 17.1 p -78.98 -20.96 47.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.105 -0.997 . . . . 0.0 109.975 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.534 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 44.0 mm-40 -87.64 -20.4 26.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.02 -1.05 . . . . 0.0 109.214 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.552 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 26.8 p90 -135.85 166.86 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.876 . . . . 0.0 109.607 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -130.26 136.96 49.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.469 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.3 pttp -77.45 147.18 36.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.267 -0.895 . . . . 0.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.775 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' TYR . . . . . 0.445 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 15.7 m-85 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' PRO . . . . . 0.445 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 47.5 Cg_endo -68.93 136.09 34.25 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.713 2.275 . . . . 0.0 111.765 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.4 -8.82 60.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -85.82 159.51 19.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.206 -1.173 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' LYS . . . . . 0.559 ' HB3' HD21 ' A' ' 162' ' ' LEU . 24.6 mttm -87.3 145.52 26.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -0.899 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.995 HG21 HD23 ' A' ' 141' ' ' LEU . 14.1 m -132.98 152.18 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.428 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.467 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.8 tp -122.0 140.71 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.281 -0.887 . . . . 0.0 109.55 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.459 HD12 ' HB3' ' A' ' 123' ' ' PHE . 73.4 mt -92.68 132.88 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.252 -0.905 . . . . 0.0 109.405 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 54.7 p -111.01 0.16 16.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.248 -0.908 . . . . 0.0 109.6 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLU . . . . . 0.439 ' HA ' ' OE1' ' A' ' 120' ' ' GLU . 71.7 mm-40 -143.52 155.73 44.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.174 -0.954 . . . . 0.0 109.484 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.35 164.26 39.65 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.74 -18.71 64.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -1.147 . . . . 0.0 109.473 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.752 ' CD1' HD13 ' A' ' 143' ' ' LEU . 96.9 m-85 -82.93 8.69 11.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.918 . . . . 0.0 109.535 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.0 tt0 -62.7 138.96 58.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.23 0.11 80.68 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -102.99 137.54 41.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.466 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -89.44 143.08 27.1 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.398 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.731 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.2 160.36 40.4 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.214 -0.929 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.2 mm -116.16 137.13 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.278 -0.889 . . . . 0.0 109.528 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' PHE . . . . . 0.676 ' CE2' HG11 ' A' ' 116' ' ' VAL . 24.7 m-85 -58.77 106.2 0.38 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.584 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.4 p -77.55 -33.64 54.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.256 -0.903 . . . . 0.0 109.249 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.05 96.53 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.428 -0.795 . . . . 0.0 109.326 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.43 123.52 10.29 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.71 2.274 . . . . 0.0 111.773 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -67.94 -33.03 73.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -150.24 174.71 29.58 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -69.57 -29.04 66.5 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.421 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.86 -74.16 0.13 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.161 -0.962 . . . . 0.0 109.344 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 33.0 ptt-85 -89.87 158.14 17.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.326 -0.859 . . . . 0.0 109.72 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 6.1 m -142.7 159.49 42.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' MET . . . . . 0.857 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.0 mtp -101.31 120.13 39.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.344 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.995 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -118.13 148.79 41.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.605 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' LEU . . . . . 0.741 HD13 ' HG2' ' A' ' 151' ' ' LYS . 48.9 tp -99.6 123.9 44.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.3 -0.875 . . . . 0.0 109.515 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.752 HD13 ' CD1' ' A' ' 123' ' ' PHE . 41.8 mt -98.18 110.84 23.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.95 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 20.1 p-10 -78.58 120.83 23.83 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.185 -0.947 . . . . 0.0 109.551 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' LEU . . . . . 0.843 HD11 HD13 ' A' ' 150' ' ' ILE . 67.9 mt -111.19 142.2 43.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.186 -0.946 . . . . 0.0 109.546 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.455 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.7 pt -51.63 -31.11 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.453 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASN . . . . . 0.52 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 87.2 m-20 -75.83 -55.57 5.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.465 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' LYS . . . . . 0.52 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 23.2 mttt -158.98 171.92 19.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.176 -0.952 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -88.34 130.03 35.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.325 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ILE . . . . . 0.843 HD13 HD11 ' A' ' 145' ' ' LEU . 42.4 pt -124.1 151.74 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.741 ' HG2' HD13 ' A' ' 142' ' ' LEU . 90.8 mttt -109.18 128.52 55.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.302 -0.874 . . . . 0.0 109.379 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -141.27 132.18 25.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.549 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 46.1 p -77.94 140.35 39.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.32 -0.862 . . . . 0.0 109.471 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.566 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.4 t -134.82 148.39 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.545 ' CD ' ' HG2' ' A' ' 158' ' ' GLU . 16.2 ptmt -91.27 139.96 30.24 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.227 -0.921 . . . . 0.0 109.625 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.583 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 44.7 m-80 -46.34 -27.27 1.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.397 -0.814 . . . . 0.0 110.067 -179.592 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' THR . . . . . 0.522 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 15.8 p -79.83 -21.02 44.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 0.0 109.766 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' GLU . . . . . 0.545 ' HG2' ' CD ' ' A' ' 155' ' ' LYS . 46.3 mm-40 -87.67 -20.51 26.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.052 -1.03 . . . . 0.0 109.229 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 39.3 p90 -136.17 168.68 18.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.339 -0.851 . . . . 0.0 109.667 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -133.09 159.7 39.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -82.51 118.0 22.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.433 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' LEU . . . . . 0.559 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.492 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.24 144.34 55.67 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -1.139 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 87.9 mtp -61.01 -38.77 87.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.432 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -81.63 147.96 27.2 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.42 136.7 31.86 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.692 2.261 . . . . 0.0 111.788 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -63.81 -34.99 79.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.931 . . . . 0.0 109.422 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.9 p30 -142.87 -179.93 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.396 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.31 -43.43 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 39.4 t -115.06 128.58 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.47 164.8 31.13 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.35 53.97 1.36 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.73 2.286 . . . . 0.0 111.807 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.0 -26.61 66.88 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.483 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 61.2 m -55.19 118.25 17.44 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.466 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 49.8 Cg_endo -70.39 142.34 44.91 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.633 2.222 . . . . 0.0 111.793 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.406 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 28.0 m-85 -76.87 161.24 74.49 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.406 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.34 129.37 17.91 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.723 2.282 . . . . 0.0 111.773 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 104.26 -13.53 51.74 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -69.49 156.69 38.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -1.104 . . . . 0.0 109.445 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.487 ' HB2' HD12 ' A' ' 162' ' ' LEU . 18.2 mttp -86.42 139.63 30.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.561 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.04 HG21 HD23 ' A' ' 141' ' ' LEU . 4.4 m -127.17 154.14 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -0.911 . . . . 0.0 109.402 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.577 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.7 tp -122.44 139.83 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.57 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 83.6 mt -92.58 139.4 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.482 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.435 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 70.9 p -115.14 -10.8 12.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.458 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.38 157.26 43.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.08 162.08 38.01 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.9 -13.46 45.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.145 . . . . 0.0 109.437 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.461 ' CD1' HD23 ' A' ' 143' ' ' LEU . 96.4 m-85 -86.59 12.67 10.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.435 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.3 tt0 -63.42 137.93 58.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.12 -0.81 76.26 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -102.45 139.3 38.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.576 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -91.48 146.72 23.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.72 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -140.68 162.24 35.87 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.448 HD13 ' O ' ' A' ' 128' ' ' ALA . 35.6 mm -117.48 135.01 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.194 -0.941 . . . . 0.0 109.582 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.631 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.6 m-85 -58.55 104.41 0.22 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.523 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 55.4 p -79.79 -32.1 40.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.897 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 163.68 93.62 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.437 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 126.74 13.37 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.667 2.245 . . . . 0.0 111.723 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -66.82 -24.89 66.21 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.251 -0.906 . . . . 0.0 109.539 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.03 -179.41 40.56 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -72.64 -24.94 61.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -1.136 . . . . 0.0 109.452 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -75.29 -51.45 13.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.471 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 55.5 mtt85 -110.52 151.33 27.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 57.1 m -139.74 156.16 46.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.924 . . . . 0.0 109.507 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.821 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 mtp -106.76 119.39 39.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.04 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -116.3 154.03 30.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.509 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.865 HD12 ' O ' ' A' ' 150' ' ' ILE . 51.5 tp -106.04 124.95 50.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.216 -0.927 . . . . 0.0 109.464 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.841 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -99.19 116.67 31.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -82.73 129.23 34.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.638 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.743 HD11 HD13 ' A' ' 150' ' ' ILE . 42.6 mt -121.09 142.12 50.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.398 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.45 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -49.94 -30.6 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.517 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.45 ' N ' HG13 ' A' ' 146' ' ' ILE . 92.9 m-20 -79.24 -47.71 15.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.27 -0.894 . . . . 0.0 109.681 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.529 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 40.2 ttpt -168.77 168.1 10.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.459 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.529 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.9 mt-10 -87.55 137.29 32.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.252 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.865 ' O ' HD12 ' A' ' 142' ' ' LEU . 36.1 pt -126.34 149.16 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.202 -0.936 . . . . 0.0 109.774 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.823 ' HG2' HD13 ' A' ' 142' ' ' LEU . 62.1 mttp -110.45 131.46 55.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -0.882 . . . . 0.0 109.191 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -142.38 140.62 32.1 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.177 -0.952 . . . . 0.0 109.681 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 21.6 p -88.45 122.0 31.46 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.347 -0.846 . . . . 0.0 109.217 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.724 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.3 p -124.07 149.99 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.595 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.3 mttt -76.64 150.5 36.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.881 . . . . 0.0 109.482 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.567 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.9 m-80 -59.69 -23.49 63.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.335 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 74.8 p -81.62 -25.96 35.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.268 -0.895 . . . . 0.0 109.428 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.601 ' OE1' HG23 ' A' ' 154' ' ' VAL . 88.6 mt-10 -75.03 -24.81 58.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 0.0 109.519 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.724 ' CE2' HD21 ' A' ' 141' ' ' LEU . 31.9 p90 -136.36 170.78 15.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.43 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -134.23 159.64 40.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.226 -0.921 . . . . 0.0 109.53 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -83.63 146.76 28.09 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 117' ' ' ILE . 23.8 mt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.12 -33.1 73.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.463 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.1 mtm -58.24 -38.42 76.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -68.45 145.16 43.63 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -69.89 -27.19 26.14 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.673 2.249 . . . . 0.0 111.776 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -55.3 -41.06 71.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -80.45 139.63 36.35 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.291 -0.88 . . . . 0.0 109.452 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 57.4 mt -131.78 143.23 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 14.7 p -133.3 137.93 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.446 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -78.01 119.77 78.68 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.338 -0.851 . . . . 0.0 109.577 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -72.24 50.51 1.56 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.594 2.196 . . . . 0.0 111.818 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.25 -35.44 68.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.11 -0.994 . . . . 0.0 109.415 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 26.8 m -66.62 131.61 94.1 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.312 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.606 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 48.0 Cg_endo -69.45 149.6 69.07 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.577 2.185 . . . . 0.0 111.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.436 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 53.1 m-85 -109.4 160.99 25.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.517 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.3 Cg_endo -69.92 135.16 29.4 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.663 2.242 . . . . 0.0 111.795 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.12 -9.04 65.29 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.436 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 82.8 m-20 -81.27 146.74 30.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -1.172 . . . . 0.0 109.523 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.676 ' C ' HD12 ' A' ' 162' ' ' LEU . 29.4 mtmt -80.51 144.48 32.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 0.0 109.417 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.977 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.4 m -133.47 152.63 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.196 -0.94 . . . . 0.0 109.595 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.69 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.8 tp -121.74 139.51 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.421 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.557 HD12 ' HB3' ' A' ' 123' ' ' PHE . 67.7 mt -92.78 130.76 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 70.4 p -116.72 4.04 13.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -0.925 . . . . 0.0 109.624 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 157' ' ' THR . 92.5 mt-10 -137.7 155.73 48.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 87.54 -168.04 37.74 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.6 -7.07 51.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -1.135 . . . . 0.0 109.502 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.557 ' HB3' HD12 ' A' ' 118' ' ' ILE . 80.4 m-85 -88.86 15.81 7.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.418 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 95.8 mt-10 -61.18 135.07 57.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.64 0.71 69.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -102.95 131.96 49.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -1.207 . . . . 0.0 109.488 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -92.61 140.46 29.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.229 -0.92 . . . . 0.0 109.45 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.778 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -136.77 167.01 22.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.176 -0.952 . . . . 0.0 109.536 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.519 HD13 ' O ' ' A' ' 128' ' ' ALA . 30.7 mm -118.31 138.14 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.3 m-85 -58.49 102.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.254 -0.904 . . . . 0.0 109.579 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.524 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 40.9 p -75.8 -33.39 60.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.6 OUTLIER 163.49 95.41 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.308 -0.87 . . . . 0.0 109.347 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.76 117.31 5.0 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.695 2.264 . . . . 0.0 111.791 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 18.1 p-10 -66.91 -31.56 72.23 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -0.935 . . . . 0.0 109.573 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.432 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -155.32 172.85 33.55 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -70.15 -28.85 65.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.307 -1.114 . . . . 0.0 109.485 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.67 -53.6 15.13 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.53 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.44 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 79.4 mtt180 -111.86 146.25 38.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.286 -0.883 . . . . 0.0 109.506 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.8 m -134.34 157.94 45.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.472 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.937 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.9 mtp -102.07 124.8 48.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.468 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.977 HD23 ' CG2' ' A' ' 116' ' ' VAL . 6.3 mp -127.22 143.91 51.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.209 -0.932 . . . . 0.0 109.551 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.809 HD12 ' O ' ' A' ' 150' ' ' ILE . 45.4 tp -93.79 121.19 34.99 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.955 . . . . 0.0 109.519 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.801 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.5 mp -93.03 129.62 38.9 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.429 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -103.59 106.98 17.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.882 . . . . 0.0 109.482 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.492 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 7.0 mp -75.03 -175.7 2.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.207 -0.933 . . . . 0.0 109.477 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.54 HG13 ' N ' ' A' ' 147' ' ' ASN . 10.9 pt -60.44 -46.09 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.18 -0.95 . . . . 0.0 109.449 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.54 ' N ' HG13 ' A' ' 146' ' ' ILE . 28.7 p-10 -139.38 23.1 2.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.286 -0.884 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.452 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 40.8 mttt -140.29 151.14 44.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.742 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -120.63 134.13 55.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.33 -0.856 . . . . 0.0 108.992 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.809 ' O ' HD12 ' A' ' 142' ' ' LEU . 37.0 pt -133.6 154.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.125 -0.984 . . . . 0.0 109.892 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.747 ' HG2' HD13 ' A' ' 142' ' ' LEU . 51.5 mttt -123.16 124.79 43.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.34 -0.85 . . . . 0.0 109.286 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -153.19 150.93 29.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 47.9 p -80.14 140.28 36.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.304 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.506 HG12 ' HD1' ' A' ' 159' ' ' PHE . 14.1 t -122.69 155.67 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.492 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 31.0 mttt -91.16 143.99 26.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.434 ' O ' ' O ' ' A' ' 159' ' ' PHE . 4.2 m-20 -51.4 -29.44 15.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.511 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 120' ' ' GLU . 45.9 p -82.57 -22.82 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.526 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -78.4 -19.99 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.254 -0.904 . . . . 0.0 109.531 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.575 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.4 p90 -145.09 162.25 37.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.938 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -131.83 136.47 47.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.535 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -60.86 134.46 57.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.69 HD21 ' HB ' ' A' ' 117' ' ' ILE . 9.2 mt . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.472 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.56 -32.5 72.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.6 mtt -122.05 151.87 40.4 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.26 -0.9 . . . . 0.0 109.466 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -69.07 150.35 50.17 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.98 148.73 64.25 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.227 . . . . 0.0 111.821 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -83.57 150.88 25.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -54.13 -40.05 67.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.399 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.723 HG22 ' H ' ' A' ' 106' ' ' ASP . 55.6 mt -112.96 142.56 24.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.494 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 19.5 m -87.23 -16.76 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.566 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.723 ' H ' HG22 ' A' ' 104' ' ' ILE . 0.5 OUTLIER -57.98 135.22 83.8 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.39 53.57 1.33 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.676 2.251 . . . . 0.0 111.742 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . 58.98 33.1 22.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 42.2 m -65.78 136.83 95.96 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.599 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.1 Cg_endo -69.91 147.34 61.71 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.72 2.28 . . . . 0.0 111.839 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.468 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 48.2 m-85 -111.1 160.28 29.56 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.01 137.48 34.82 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.702 2.268 . . . . 0.0 111.829 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.78 -10.07 68.47 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.468 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.8 m-20 -82.39 145.48 29.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.252 -1.146 . . . . 0.0 109.461 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.464 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 30.5 mttm -75.83 142.23 42.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.912 HG21 HD23 ' A' ' 141' ' ' LEU . 4.5 m -132.45 150.97 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.444 ' HB ' HD11 ' A' ' 162' ' ' LEU . 4.5 tp -123.43 141.75 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.491 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.535 HD12 ' HB3' ' A' ' 123' ' ' PHE . 61.2 mt -92.59 131.12 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.236 -0.915 . . . . 0.0 109.443 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.451 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.2 p -106.95 -8.39 16.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.6 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -137.37 157.29 46.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.23 -0.919 . . . . 0.0 109.572 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.21 165.14 37.75 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.67 -19.87 65.25 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.445 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.535 ' HB3' HD12 ' A' ' 118' ' ' ILE . 94.3 m-85 -86.38 13.48 8.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.454 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 87.0 tt0 -66.25 137.88 57.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.471 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.51 0.26 73.23 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -106.4 134.72 49.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -1.162 . . . . 0.0 109.484 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -79.93 147.62 31.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.222 -0.924 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.33 163.63 32.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.676 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.0 mm -121.29 139.23 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -0.875 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.615 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 42.2 m-85 -60.92 114.41 3.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.192 -0.943 . . . . 0.0 109.442 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.519 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.3 p -87.37 -30.76 20.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 163.79 82.2 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.896 . . . . 0.0 109.455 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.417 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.07 130.74 19.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.723 2.282 . . . . 0.0 111.827 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -67.83 -32.72 73.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.291 -0.88 . . . . 0.0 109.475 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -170.54 -177.48 40.65 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.62 -29.46 70.47 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.272 -1.134 . . . . 0.0 109.521 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -63.68 -60.41 3.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.165 -0.96 . . . . 0.0 109.438 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.453 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.2 mtt180 -112.72 155.74 24.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 53.4 m -146.5 149.07 32.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.434 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.932 ' C ' HD12 ' A' ' 141' ' ' LEU . 82.1 mmm -95.31 125.14 39.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.389 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.932 HD12 ' C ' ' A' ' 140' ' ' MET . 6.3 mp -125.46 140.4 52.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.163 -0.961 . . . . 0.0 109.631 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.604 HD12 ' HG2' ' A' ' 151' ' ' LYS . 6.0 tt -96.04 123.9 39.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.322 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.858 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.6 mp -99.51 113.65 26.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.652 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -89.52 124.27 34.37 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.703 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.5 mm? -85.27 175.22 9.06 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.152 -0.967 . . . . 0.0 109.392 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.501 HG13 ' N ' ' A' ' 147' ' ' ASN . 17.6 pt -58.93 -38.12 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.501 ' N ' HG13 ' A' ' 146' ' ' ILE . 78.3 m-20 -138.89 19.61 2.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.958 . . . . 0.0 109.407 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 85.7 mttt -143.64 156.56 44.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.26 -0.9 . . . . 0.0 109.631 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -121.38 124.9 45.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.196 -0.94 . . . . 0.0 109.191 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 145' ' ' LEU . 32.8 pt -128.73 156.03 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.918 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.604 ' HG2' HD12 ' A' ' 142' ' ' LEU . 22.7 mttt -131.56 132.18 43.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.339 -0.851 . . . . 0.0 109.27 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 153' ' ' SER . 57.8 t-80 -152.28 144.79 24.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.141 -0.974 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.429 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 45.9 p -68.7 142.61 54.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.33 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.832 ' HB ' HD13 ' A' ' 141' ' ' LEU . 19.7 t -129.85 150.78 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.537 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 158' ' ' GLU . 90.5 mttt -94.11 139.12 31.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.33 -0.856 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.0 p30 -46.0 -29.06 1.32 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.169 -0.957 . . . . 0.0 109.582 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 57.9 p -82.24 -21.92 36.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 109.595 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.2 mt-10 -81.22 -20.6 40.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.658 ' CD2' HD21 ' A' ' 141' ' ' LEU . 27.7 p90 -140.74 172.14 13.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -0.937 . . . . 0.0 109.561 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -130.85 147.73 52.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -78.57 133.54 37.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.273 -0.892 . . . . 0.0 109.504 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.444 HD11 ' HB ' ' A' ' 117' ' ' ILE . 15.9 mt . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.468 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.48 -33.03 73.08 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.172 -1.193 . . . . 0.0 109.526 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.6 mtt -125.35 154.4 41.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.925 . . . . 0.0 109.417 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -67.94 151.69 52.11 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -9.08 25.17 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.669 2.246 . . . . 0.0 111.743 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.419 ' O ' ' HB3' ' A' ' 103' ' ' ASP . 93.5 mttt -63.57 -31.22 72.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.6 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 104' ' ' ILE . 46.6 t0 67.0 26.82 8.96 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.292 -0.88 . . . . 0.0 109.39 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' ASP . 78.3 mt -42.98 -37.38 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.631 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 43.5 t -108.25 135.74 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.487 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 106' ' ' ASP . 25.8 p30 -106.89 156.37 37.44 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.894 . . . . 0.0 109.477 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -69.99 63.22 1.93 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.742 2.295 . . . . 0.0 111.854 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.52 -34.28 77.57 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.47 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.42 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 32.6 m -64.93 138.2 97.4 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.42 ' HD2' ' CG2' ' A' ' 109' ' ' THR . 49.9 Cg_endo -70.12 147.07 59.75 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.764 2.309 . . . . 0.0 111.833 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.443 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 6.5 m-85 -111.03 161.29 25.62 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.324 -0.86 . . . . 0.0 109.368 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.64 131.52 23.07 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.73 2.286 . . . . 0.0 111.712 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.65 -11.98 59.5 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.6 m-20 -77.44 157.43 30.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -1.155 . . . . 0.0 109.497 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.568 ' HB3' HD21 ' A' ' 162' ' ' LEU . 55.9 mttt -80.35 142.12 34.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.299 -0.876 . . . . 0.0 109.448 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.011 HG21 HD23 ' A' ' 141' ' ' LEU . 5.8 m -127.59 159.48 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.836 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.3 tp -123.37 147.32 27.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.607 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.2 mm -91.45 131.63 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.264 -0.897 . . . . 0.0 109.475 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.429 ' C ' ' HG2' ' A' ' 124' ' ' GLU . 72.7 p -121.65 5.5 10.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.267 -0.896 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.426 ' N ' ' HG2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -141.73 151.16 42.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -0.936 . . . . 0.0 109.442 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 85.13 -170.27 44.94 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.73 -2.4 58.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -1.201 . . . . 0.0 109.625 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.607 ' HB2' HG21 ' A' ' 118' ' ' ILE . 93.1 m-85 -87.94 4.78 43.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.63 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 119' ' ' THR . 97.5 mt-10 -56.5 142.09 40.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.7 -3.46 83.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.594 ' O ' HD12 ' A' ' 117' ' ' ILE . 19.8 m-30 -102.36 147.71 26.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -1.17 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -100.17 151.03 21.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.387 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.966 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -146.74 161.34 40.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.227 -0.92 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.487 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 22.8 mm -114.02 140.54 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.484 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.5 m-85 -61.42 112.86 2.36 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.275 -0.891 . . . . 0.0 109.443 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 46.0 p -82.36 -32.13 29.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.457 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.8 mm-40 164.4 91.72 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.156 -0.965 . . . . 0.0 109.488 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.11 122.99 9.55 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.597 2.198 . . . . 0.0 111.771 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -65.81 -31.26 72.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.47 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -163.26 179.84 38.18 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.04 -26.85 63.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.218 -1.166 . . . . 0.0 109.541 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.36 -53.72 15.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.461 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 59.0 mtt180 -112.32 151.44 29.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.516 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 54.4 m -142.32 150.43 40.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.303 -0.873 . . . . 0.0 109.465 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.931 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.8 mtp -100.37 127.31 46.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.011 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -125.38 146.42 49.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.483 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.576 ' O ' ' HB1' ' A' ' 128' ' ' ALA . 9.7 tt -97.44 126.3 42.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.641 HD23 ' HB2' ' A' ' 128' ' ' ALA . 39.1 mt -97.93 109.88 22.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.542 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.625 ' C ' HD22 ' A' ' 145' ' ' LEU . 14.9 p-10 -84.63 122.6 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 0.0 109.621 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -111.23 141.43 44.77 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.383 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.499 HG13 ' N ' ' A' ' 147' ' ' ASN . 21.3 pt -50.03 -35.75 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.499 ' N ' HG13 ' A' ' 146' ' ' ILE . 61.3 t30 -72.42 -49.22 35.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.288 -0.882 . . . . 0.0 109.575 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.499 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 67.3 mttt -158.11 173.38 16.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.543 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -103.17 133.21 48.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.924 . . . . 0.0 109.312 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.451 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 17.2 pt -133.99 159.27 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.625 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.523 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 13.3 mttt -119.63 136.95 54.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.282 -0.886 . . . . 0.0 109.33 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -144.31 140.24 29.04 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.585 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 23.5 p -85.1 125.19 32.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.338 -0.851 . . . . 0.0 109.313 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.722 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.0 p -127.97 147.92 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.196 -0.94 . . . . 0.0 109.547 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.54 ' O ' ' CD2' ' A' ' 159' ' ' PHE . 88.8 mttt -76.08 155.27 34.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.231 -0.918 . . . . 0.0 109.464 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 20.3 m-80 -62.71 -27.09 69.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.453 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 64.7 p -77.33 -18.86 57.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.356 -0.84 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.536 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.3 mt-10 -87.72 -19.78 27.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.475 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.581 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 29.8 p90 -138.08 161.03 37.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -0.951 . . . . 0.0 109.583 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.836 ' O ' HG22 ' A' ' 117' ' ' ILE . 73.7 mtt180 -129.53 147.77 51.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.317 -0.864 . . . . 0.0 109.475 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.405 ' NZ ' ' HA ' ' A' ' 110' ' ' PRO . 25.7 tttt -73.55 123.88 24.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.429 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.612 ' OXT' HD12 ' A' ' 162' ' ' LEU . 1.1 pp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.487 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.48 146.02 52.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -1.129 . . . . 0.0 109.48 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.8 mtm -111.5 143.21 42.71 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.288 -0.883 . . . . 0.0 109.454 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -74.6 150.77 42.09 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.02 147.53 61.4 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.708 2.272 . . . . 0.0 111.789 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 23.4 tttp -84.24 134.03 34.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -68.32 146.83 52.92 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 109.528 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' A' ' 105' ' ' VAL . 54.6 mt -116.81 138.51 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.202 -0.936 . . . . 0.0 109.468 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.462 ' O ' ' O ' ' A' ' 104' ' ' ILE . 50.8 t 58.99 114.89 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -62.69 138.43 96.83 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.208 -0.932 . . . . 0.0 109.473 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.1 53.64 1.23 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.75 2.3 . . . . 0.0 111.799 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.04 -32.04 72.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.904 . . . . 0.0 109.5 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.522 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 3.0 m -68.05 140.7 93.65 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.589 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.1 Cg_endo -69.98 144.45 52.89 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.679 2.253 . . . . 0.0 111.754 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.462 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 52.8 m-85 -111.55 160.89 27.79 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 49.4 Cg_endo -70.2 135.01 28.37 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.675 2.25 . . . . 0.0 111.754 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.82 -10.11 66.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.462 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.2 m-20 -83.99 147.53 27.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -1.123 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.516 ' CB ' HD21 ' A' ' 162' ' ' LEU . 22.7 mttm -72.98 145.08 46.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.902 . . . . 0.0 109.456 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 141' ' ' LEU . 4.3 m -133.79 150.42 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.476 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 1.8 tp -119.95 139.29 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.461 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.585 HD11 HD21 ' A' ' 143' ' ' LEU . 58.8 mt -92.53 130.08 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.287 -0.883 . . . . 0.0 109.501 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.482 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 60.5 p -106.96 -10.26 16.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -132.87 157.36 45.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 109.522 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.66 166.85 36.33 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.59 -22.31 64.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 96.9 m-85 -82.51 8.13 12.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.224 -0.922 . . . . 0.0 109.52 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -57.64 139.9 52.51 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.297 -0.877 . . . . 0.0 109.522 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.53 -5.26 73.82 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.5 m-30 -99.99 145.79 27.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.247 -1.149 . . . . 0.0 109.464 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -94.55 146.45 24.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.935 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.812 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.21 160.18 40.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.299 -0.875 . . . . 0.0 109.42 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.71 140.06 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.48 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.625 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.8 m-85 -61.42 110.15 1.36 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.295 -0.878 . . . . 0.0 109.495 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.52 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 39.3 p -80.46 -32.5 37.18 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.317 -0.864 . . . . 0.0 109.477 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 164.32 86.58 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.267 -0.895 . . . . 0.0 109.398 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.79 128.56 16.17 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.773 2.316 . . . . 0.0 111.799 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -69.06 -29.34 67.45 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.517 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -167.92 174.81 42.87 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLU . . . . . 0.41 ' HG3' HG23 ' A' ' 109' ' ' THR . 82.7 tt0 -62.07 -27.97 69.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.68 -64.93 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.164 -0.96 . . . . 0.0 109.476 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.402 ' O ' ' O ' ' A' ' 135' ' ' GLY . 49.9 mtm-85 -105.08 152.08 23.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.532 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 65.2 m -142.46 152.15 42.44 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.51 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.917 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.2 mmm -96.58 123.61 40.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -122.5 142.89 50.11 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.945 . . . . 0.0 109.636 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.833 HD13 ' HG2' ' A' ' 151' ' ' LYS . 15.1 tp -103.86 119.36 38.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.273 -0.892 . . . . 0.0 109.417 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -100.57 109.14 21.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.501 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.431 ' O ' ' CG ' ' A' ' 144' ' ' ASN . 11.3 p-10 -83.11 118.86 23.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.567 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.765 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -82.03 168.83 17.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.259 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.515 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.2 pt -54.15 -38.27 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.19 -0.944 . . . . 0.0 109.638 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.515 ' N ' HG13 ' A' ' 146' ' ' ILE . 30.3 p-10 -139.19 25.09 2.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -0.984 . . . . 0.0 109.787 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.461 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 76.0 mttt -152.61 157.41 40.97 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.0 109.815 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -128.11 130.86 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.383 -0.823 . . . . 0.0 109.112 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.618 ' O ' HD12 ' A' ' 142' ' ' LEU . 21.3 pt -131.45 145.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.134 -0.978 . . . . 0.0 109.835 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.833 ' HG2' HD13 ' A' ' 142' ' ' LEU . 19.6 mttp -118.53 126.79 52.75 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 0.0 109.298 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.494 ' CE1' ' O ' ' A' ' 153' ' ' SER . 52.5 t-80 -153.85 145.73 23.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.168 -0.958 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.494 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 52.5 p -74.48 141.48 44.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.216 -0.928 . . . . 0.0 109.356 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.601 HG12 ' HD1' ' A' ' 159' ' ' PHE . 21.3 t -124.78 150.4 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.442 ' HB2' ' HG3' ' A' ' 158' ' ' GLU . 61.3 mttp -86.06 138.46 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -49.96 -22.99 1.75 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.943 . . . . 0.0 109.494 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.7 p -86.62 -25.39 24.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.175 -0.953 . . . . 0.0 109.463 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG3' ' HB2' ' A' ' 155' ' ' LYS . 97.6 mt-10 -76.63 -23.39 53.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -0.865 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.926 ' CE2' HD21 ' A' ' 141' ' ' LEU . 22.7 p90 -140.62 160.95 38.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 109.491 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -128.89 142.15 51.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.219 -0.925 . . . . 0.0 109.512 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -70.43 124.99 25.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.208 -0.933 . . . . 0.0 109.422 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.516 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.496 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.9 143.93 57.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -1.145 . . . . 0.0 109.424 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.1 mtp -56.36 -36.34 68.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -102.37 131.05 10.45 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.94 141.86 45.59 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.639 2.226 . . . . 0.0 111.825 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -58.21 -39.51 79.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.893 . . . . 0.0 109.516 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -84.52 139.24 32.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.3 mt -109.12 141.19 25.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.501 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.5 155.49 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.209 -0.932 . . . . 0.0 109.566 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.456 ' HB2' ' HD2' ' A' ' 107' ' ' PRO . 3.4 p30 -66.76 160.67 67.11 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' PRO . . . . . 0.456 ' HD2' ' HB2' ' A' ' 106' ' ' ASP . 49.0 Cg_endo -69.94 66.59 1.87 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.634 2.223 . . . . 0.0 111.818 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.61 -31.54 71.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.3 m -55.71 129.16 70.67 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.603 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.3 Cg_endo -70.24 148.17 61.41 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.637 2.225 . . . . 0.0 111.754 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 65.9 m-85 -109.24 161.11 25.11 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.282 -0.886 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.2 Cg_endo -69.64 132.27 23.16 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.681 2.254 . . . . 0.0 111.756 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.54 -10.55 61.12 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.45 ' HB3' ' HE3' ' A' ' 161' ' ' LYS . 81.5 m-20 -77.85 150.72 34.15 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.176 -1.191 . . . . 0.0 109.451 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.549 ' HB3' HD21 ' A' ' 162' ' ' LEU . 28.8 mttt -84.81 141.51 30.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.47 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -129.04 158.89 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 160' ' ' ARG . 7.3 tp -126.59 148.73 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.151 -0.968 . . . . 0.0 109.505 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.453 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 25.9 mm -90.52 127.84 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 72.8 p -112.83 -5.36 13.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.275 -0.891 . . . . 0.0 109.502 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.468 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 85.2 tt0 -138.51 156.28 47.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.202 -0.936 . . . . 0.0 109.421 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.468 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 86.5 169.57 46.05 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.22 -14.63 63.13 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -1.163 . . . . 0.0 109.527 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.553 ' CD1' HD13 ' A' ' 143' ' ' LEU . 85.6 m-85 -82.78 6.85 16.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 84.5 tt0 -59.45 132.84 55.2 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.565 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 99.46 1.17 56.67 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.521 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -103.49 138.58 40.01 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.12 -1.224 . . . . 0.0 109.59 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -93.98 122.58 36.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.211 -0.931 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.922 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -118.52 165.77 13.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.58 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.525 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 41.9 mm -120.43 139.29 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' HB2' ' A' ' 110' ' ' PRO . 37.6 m-85 -58.65 101.37 0.09 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.906 . . . . 0.0 109.516 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.525 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 49.2 p -77.15 -30.52 55.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.286 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.2 mt-10 163.63 97.15 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.262 -0.899 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.85 114.63 3.78 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.707 2.272 . . . . 0.0 111.763 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -66.55 -33.6 76.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.492 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -145.01 163.0 28.11 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.66 -31.99 72.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -1.146 . . . . 0.0 109.184 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.17 -73.91 0.15 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.6 ptt-85 -84.96 158.32 20.55 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.285 -0.885 . . . . 0.0 109.611 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 71.1 m -145.79 144.58 30.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.871 ' C ' HD12 ' A' ' 141' ' ' LEU . 89.8 mmm -86.58 118.89 26.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.251 -0.906 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -122.61 146.07 47.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.521 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.72 HD12 ' CE ' ' A' ' 151' ' ' LYS . 9.4 tt -99.37 127.44 45.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.434 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.553 HD13 ' CD1' ' A' ' 123' ' ' PHE . 17.9 mt -96.8 115.04 26.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.863 ' C ' HD12 ' A' ' 145' ' ' LEU . 6.9 p30 -86.75 126.6 34.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.6 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.863 HD12 ' C ' ' A' ' 144' ' ' ASN . 9.6 mp -129.46 136.33 49.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.242 -0.911 . . . . 0.0 109.362 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.514 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -50.55 -35.09 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.888 . . . . 0.0 109.614 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.514 ' N ' HG13 ' A' ' 146' ' ' ILE . 47.7 t-20 -68.68 -47.56 66.16 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.915 . . . . 0.0 109.585 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.482 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 55.5 tttp -168.09 158.98 10.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.166 -0.959 . . . . 0.0 109.576 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.482 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 97.0 mt-10 -93.81 125.72 38.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.95 . . . . 0.0 109.5 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.474 HD11 ' CE1' ' A' ' 123' ' ' PHE . 27.8 pt -126.34 158.63 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.205 -0.935 . . . . 0.0 109.428 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.72 ' CE ' HD12 ' A' ' 142' ' ' LEU . 17.1 mttt -124.62 131.55 53.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.543 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -142.6 147.06 35.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 39.3 p -72.18 139.66 48.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.692 ' HB ' HD13 ' A' ' 141' ' ' LEU . 21.8 t -131.08 150.63 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 24.6 mttm -97.16 138.72 34.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.585 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 32.1 m-80 -45.06 -30.64 1.11 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 65.9 p -81.15 -25.21 37.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.287 -0.883 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 92.0 mt-10 -76.21 -23.67 54.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.642 ' HD1' HG12 ' A' ' 154' ' ' VAL . 27.5 p90 -137.41 167.05 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 117' ' ' ILE . 63.5 mtt85 -130.21 146.84 51.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.45 ' HE3' ' HB3' ' A' ' 114' ' ' ASP . 73.8 tttt -72.8 117.23 14.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.436 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.549 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.466 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -60.65 -31.23 70.45 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.248 -1.148 . . . . 0.0 109.526 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 67.6 mtm -117.18 154.35 31.26 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.505 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -108.98 159.23 14.19 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.6 -21.07 30.09 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.801 2.334 . . . . 0.0 111.719 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -58.3 -38.43 77.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.919 . . . . 0.0 109.515 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -90.3 133.37 35.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.8 mt -124.87 140.2 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.947 . . . . 0.0 109.512 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 41.8 t -138.63 146.24 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.367 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -105.69 164.17 15.57 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -75.78 45.0 1.38 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.624 2.216 . . . . 0.0 111.995 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -83.28 -27.38 29.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.094 -1.004 . . . . 0.0 109.189 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 18.0 m -49.74 125.36 17.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.307 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.618 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 48.6 Cg_endo -69.99 154.77 66.49 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.701 2.267 . . . . 0.0 111.917 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.47 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 43.7 m-85 -120.01 159.45 46.99 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.442 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 133.61 25.19 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.69 2.26 . . . . 0.0 111.873 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.34 -10.69 61.52 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.47 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.6 m-20 -85.57 144.69 27.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.288 -1.124 . . . . 0.0 109.498 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -75.45 147.02 40.22 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 109.517 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.058 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -134.9 151.41 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.912 HG21 HD21 ' A' ' 162' ' ' LEU . 3.8 tp -123.94 141.07 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.446 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 61.8 mt -92.18 129.95 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.321 -0.862 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.508 HG21 ' CD ' ' A' ' 160' ' ' ARG . 75.0 p -105.65 -7.6 18.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.537 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.435 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 97.8 mt-10 -138.02 158.16 44.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.484 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.4 168.11 38.55 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.95 -22.7 65.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.222 -1.163 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.528 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.9 m-85 -83.47 9.46 11.17 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.244 -0.91 . . . . 0.0 109.417 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.502 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -61.76 140.89 58.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.96 -6.06 76.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.0 m-85 -99.89 149.8 23.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -1.153 . . . . 0.0 109.557 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -98.45 147.86 24.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.319 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.817 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.69 162.61 35.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.898 . . . . 0.0 109.502 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.41 HD13 ' O ' ' A' ' 128' ' ' ALA . 26.1 mm -113.47 143.87 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.635 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 33.6 m-85 -66.06 113.01 4.16 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.531 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 18.1 p -82.4 -33.17 28.78 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.952 . . . . 0.0 109.437 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.89 90.3 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.78 122.66 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.686 2.257 . . . . 0.0 111.799 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 21.3 p-10 -65.89 -31.21 72.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.664 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.509 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -164.66 178.6 39.79 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -67.61 -27.05 66.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.308 -1.113 . . . . 0.0 109.543 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.04 -63.2 1.14 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 58.1 mtt180 -108.37 158.53 17.42 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 109.548 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 72.6 m -145.28 155.38 43.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.394 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.896 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.6 mtp -102.21 124.27 47.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.058 HD23 HG21 ' A' ' 116' ' ' VAL . 6.2 mp -122.25 145.79 47.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 7.8 tt -104.8 120.82 42.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.915 . . . . 0.0 109.521 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.7 mp -96.37 136.1 37.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.44 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.498 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 92.7 m-20 -106.21 112.41 25.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.541 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 44.1 mt -100.24 148.08 25.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.512 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -51.13 -40.12 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.512 ' N ' HG13 ' A' ' 146' ' ' ILE . 45.8 t-20 -68.7 -48.08 64.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.54 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.505 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 28.3 ttpp -168.46 164.6 12.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.287 -0.883 . . . . 0.0 109.466 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.505 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 95.1 mt-10 -87.88 139.19 30.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.7 158.18 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.25 -0.906 . . . . 0.0 109.402 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.447 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.8 mttt -125.84 130.45 51.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.196 -0.94 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.411 ' ND1' ' O ' ' A' ' 153' ' ' SER . 56.5 t-80 -153.17 141.61 20.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 109.436 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.411 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 68.6 m -67.77 142.59 56.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -0.958 . . . . 0.0 109.438 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.651 ' HB ' HD13 ' A' ' 141' ' ' LEU . 16.8 t -131.03 151.6 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.418 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 9.5 mtpm? -92.04 137.29 32.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.893 . . . . 0.0 109.508 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.587 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.0 m-80 -50.66 -24.36 3.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 109.415 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.6 p -84.78 -22.49 29.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.907 . . . . 0.0 109.356 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG2' ' HB2' ' A' ' 155' ' ' LYS . 68.6 mm-40 -81.47 -20.7 39.66 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.623 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -139.14 178.29 7.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.508 ' CD ' HG21 ' A' ' 119' ' ' THR . 59.1 mtt-85 -134.65 146.63 49.71 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.871 . . . . 0.0 109.402 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -84.71 135.75 34.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.447 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.912 HD21 HG21 ' A' ' 117' ' ' ILE . 68.0 mt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.415 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 98' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 97' ' ' GLY . . . 63.67 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -1.173 . . . . 0.0 109.481 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.0 mmm -60.58 -36.96 79.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.227 -0.92 . . . . 0.0 109.442 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -68.66 145.9 44.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.37 -14.93 34.65 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.707 2.272 . . . . 0.0 111.786 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.4 mttt -57.22 -36.27 70.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.322 -0.862 . . . . 0.0 109.458 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -79.79 135.65 36.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.198 -0.939 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.74 142.26 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.473 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.73 154.99 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.231 -0.918 . . . . 0.0 109.445 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -74.26 122.37 87.38 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.1 57.84 1.67 Allowed 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.687 2.258 . . . . 0.0 111.779 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.1 75.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.311 -0.868 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 77.0 m -99.93 126.89 35.18 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.234 -0.916 . . . . 0.0 109.411 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.25 135.12 28.51 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.697 2.265 . . . . 0.0 111.846 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.407 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 33.0 m-85 -77.58 161.23 72.78 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.323 -0.861 . . . . 0.0 109.479 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.17 134.04 28.21 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.693 2.262 . . . . 0.0 111.819 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.03 -17.55 54.0 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -68.47 162.71 24.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -1.151 . . . . 0.0 109.38 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.483 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 36.5 mttm -88.01 139.48 30.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.282 -0.886 . . . . 0.0 109.572 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -133.48 148.98 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.447 ' CG2' ' HB3' ' A' ' 162' ' ' LEU . 5.1 tp -116.67 141.45 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.556 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.443 HD11 HD21 ' A' ' 143' ' ' LEU . 72.6 mt -92.61 130.72 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.422 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.454 HG21 ' HD2' ' A' ' 160' ' ' ARG . 61.3 p -107.27 -5.02 18.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.472 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 83.9 tt0 -141.41 155.53 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.521 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 100.33 166.83 28.83 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.37 -22.22 64.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.578 ' CE1' HD11 ' A' ' 150' ' ' ILE . 77.8 m-85 -87.64 12.87 11.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.1 136.94 58.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.254 -0.904 . . . . 0.0 109.432 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.91 66.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -105.68 122.75 46.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -1.168 . . . . 0.0 109.541 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -72.05 137.35 47.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.298 -0.876 . . . . 0.0 109.306 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.83 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -133.68 158.52 43.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.208 -0.932 . . . . 0.0 109.563 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.5 mm -116.64 136.0 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.444 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.842 ' CE2' HG11 ' A' ' 116' ' ' VAL . 35.2 m-85 -58.61 101.77 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.519 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.467 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 44.8 p -75.05 -39.06 61.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.386 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 131' ' ' THR . 67.9 tt0 172.98 95.77 0.05 OUTLIER Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.9 . . . . 0.0 109.441 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.16 110.72 2.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.718 2.279 . . . . 0.0 111.848 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.5 p-10 -62.68 -34.42 77.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.504 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.417 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -141.85 178.06 20.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -76.91 -30.02 55.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -1.129 . . . . 0.0 109.406 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -69.46 -78.06 0.07 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.407 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 13.3 ptt180 -89.77 148.13 23.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.248 -0.907 . . . . 0.0 109.743 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.1 m -135.33 155.38 50.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 0.0 109.492 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.76 ' C ' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -89.92 115.55 27.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.1 mp -119.74 139.52 52.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.892 . . . . 0.0 109.481 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.603 HD12 ' N ' ' A' ' 143' ' ' LEU . 9.0 tp -97.48 122.16 40.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.776 HD23 ' HB2' ' A' ' 128' ' ' ALA . 22.1 mt -87.95 146.46 25.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.316 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.503 ' C ' HD12 ' A' ' 145' ' ' LEU . 99.2 m-20 -115.98 107.96 15.63 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.601 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.77 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.0 mp -105.23 141.18 37.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.938 . . . . 0.0 109.302 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.0 pt -50.39 -32.5 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.522 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.7 m-20 -73.12 -56.41 5.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.289 -0.882 . . . . 0.0 109.674 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.522 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 60.2 mttm -159.58 171.32 19.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.513 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.58 139.08 38.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.337 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.598 ' O ' HD12 ' A' ' 142' ' ' LEU . 20.1 pt -132.8 142.43 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.231 -0.918 . . . . 0.0 109.46 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.445 ' HG2' HD13 ' A' ' 142' ' ' LEU . 98.1 mttt -96.5 130.02 43.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.24 -0.913 . . . . 0.0 109.474 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -147.52 138.57 23.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.488 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 52.1 p -73.2 141.45 47.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.278 -0.889 . . . . 0.0 109.441 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.729 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.2 t -128.81 151.56 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -0.91 . . . . 0.0 109.56 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 45.4 mttp -100.87 138.36 38.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.376 -0.828 . . . . 0.0 109.423 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.1 p30 -46.04 -28.28 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.493 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 72.0 p -84.94 -19.64 31.88 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.25 -0.906 . . . . 0.0 109.629 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.6 mt-10 -83.23 -22.34 33.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.182 -0.949 . . . . 0.0 109.459 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.655 ' HD1' HG12 ' A' ' 154' ' ' VAL . 29.9 p90 -136.93 173.03 12.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.215 -0.928 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.454 ' HD2' HG21 ' A' ' 119' ' ' THR . 96.6 mtt180 -134.99 145.17 47.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.515 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -69.34 113.59 6.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.616 HD23 ' C ' ' A' ' 116' ' ' VAL . 1.9 pp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.406 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -65.31 140.44 58.69 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.277 -1.131 . . . . 0.0 109.445 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 71.7 mtm -60.48 -36.34 78.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -0.886 . . . . 0.0 109.47 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -157.34 130.25 2.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.39 -9.24 25.46 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.682 2.255 . . . . 0.0 111.755 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 47.6 mttm -57.24 -33.18 67.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.3 -0.875 . . . . 0.0 109.474 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -63.94 141.77 58.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.443 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.6 -41.76 89.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 33.7 m -131.08 150.0 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.439 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 -107.65 136.06 19.7 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.884 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.37 54.11 1.0 Allowed 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.722 2.282 . . . . 0.0 111.729 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.53 -34.67 77.57 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.223 -0.923 . . . . 0.0 109.532 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.0 m -76.52 123.49 87.73 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.559 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.8 Cg_endo -70.08 139.55 39.38 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.689 2.259 . . . . 0.0 111.856 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -88.26 161.08 44.22 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.903 . . . . 0.0 109.525 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.7 138.22 37.48 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.722 2.281 . . . . 0.0 111.79 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.85 -11.61 66.12 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.99 151.7 40.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -1.144 . . . . 0.0 109.403 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.534 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.5 mttm -80.26 139.75 36.54 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.031 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -129.23 156.3 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.655 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.24 146.1 29.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.598 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 20.5 mm -90.13 120.27 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.394 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 58.1 p -103.03 -16.06 15.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.42 155.56 50.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.459 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.94 165.04 35.45 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.95 -15.35 62.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 0.0 109.441 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.698 ' HB3' HD23 ' A' ' 143' ' ' LEU . 88.7 m-85 -86.49 11.75 11.88 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.459 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.1 tt0 -59.04 134.74 57.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.97 67.18 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.475 ' CE2' ' HG ' ' A' ' 145' ' ' LEU . 40.7 m-85 -99.19 137.62 37.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.098 -1.236 . . . . 0.0 109.545 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -90.99 129.38 37.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.323 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.972 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -130.08 163.72 25.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.56 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 128' ' ' ALA . 31.0 mm -119.42 139.76 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.308 -0.87 . . . . 0.0 109.408 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.594 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 38.0 m-85 -58.6 101.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -0.933 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.501 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 41.0 p -77.58 -28.33 51.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.7 OUTLIER 164.93 98.01 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.484 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.0 Cg_endo -69.82 114.83 3.84 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.733 2.289 . . . . 0.0 111.805 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -60.94 -30.7 70.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 109.506 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -166.15 174.45 41.72 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -67.34 -22.81 65.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -1.144 . . . . 0.0 109.491 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.92 -64.63 1.01 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.452 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 57.5 mtm-85 -107.72 159.61 16.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 55.7 m -144.98 157.93 43.97 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -0.864 . . . . 0.0 109.471 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.893 ' C ' HD12 ' A' ' 141' ' ' LEU . 33.8 mtp -101.97 120.91 41.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.031 HD23 HG21 ' A' ' 116' ' ' VAL . 6.4 mp -120.31 147.31 45.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.772 HD13 ' HG2' ' A' ' 151' ' ' LYS . 11.9 tp -99.87 124.01 44.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.45 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.843 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.1 mp -100.89 109.51 21.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.195 -0.941 . . . . 0.0 109.457 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.726 ' C ' HD12 ' A' ' 145' ' ' LEU . 13.4 p-10 -83.24 125.44 31.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.908 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 144' ' ' ASN . 7.7 mp -118.3 141.87 48.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.16 -0.962 . . . . 0.0 109.468 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.44 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.4 pt -51.6 -30.93 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.478 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.506 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 95.6 m-20 -74.98 -55.24 5.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.263 -0.898 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.506 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 33.9 mttt -158.68 171.78 19.47 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.223 -0.923 . . . . 0.0 109.622 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -101.01 131.3 46.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.239 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 142' ' ' LEU . 6.9 pt -129.87 144.77 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.742 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.772 ' HG2' HD13 ' A' ' 142' ' ' LEU . 31.2 mttt -108.47 136.57 47.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.039 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.09 140.02 20.97 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.004 -1.06 . . . . 0.0 109.831 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.402 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.4 p -85.19 121.8 28.46 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.39 -0.819 . . . . 0.0 109.047 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.544 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 2.9 p -121.13 151.55 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.15 -0.969 . . . . 0.0 109.638 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 35.2 mttt -75.21 149.25 38.97 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.327 -0.858 . . . . 0.0 109.577 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.573 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.1 m-80 -60.56 -26.09 66.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.7 p -78.51 -20.69 50.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.293 -0.88 . . . . 0.0 109.53 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.544 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 72.8 mm-40 -83.28 -22.06 33.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.908 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.977 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.4 p90 -138.35 156.19 47.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.655 ' O ' HG22 ' A' ' 117' ' ' ILE . 17.3 ttt85 -127.93 137.08 52.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 16.8 pttt -72.19 161.03 31.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.174 -0.954 . . . . 0.0 109.405 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.791 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.079 -0.963 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.63 -31.07 71.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -1.138 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 89.1 mtp -117.58 149.0 41.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.302 -0.874 . . . . 0.0 109.461 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -65.29 155.56 49.17 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.23 141.65 43.86 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 122.684 2.256 . . . . 0.0 111.833 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.0 tttm -57.82 -39.95 78.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.346 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.11 137.94 47.41 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.9 mt -113.89 141.36 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.178 -0.951 . . . . 0.0 109.542 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 36.8 t -119.15 126.84 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 109.394 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 106' ' ' ASP . 0.4 OUTLIER -98.8 119.66 60.61 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.631 -179.864 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -77.13 42.32 1.1 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.601 2.201 . . . . 0.0 111.999 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -80.77 -31.72 35.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.451 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 21.1 m -58.17 129.92 83.25 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.331 -0.856 . . . . 0.0 109.515 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.638 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 48.5 Cg_endo -70.32 145.14 53.08 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.639 2.226 . . . . 0.0 111.789 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -109.03 161.33 24.13 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.528 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.77 132.34 24.75 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.728 2.285 . . . . 0.0 111.824 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 106.83 -14.79 41.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.49 158.96 25.71 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -1.146 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -92.78 145.92 24.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.278 -0.889 . . . . 0.0 109.48 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.041 HG22 ' O ' ' A' ' 128' ' ' ALA . 17.4 m -128.71 152.48 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.662 ' HB ' HD11 ' A' ' 162' ' ' LEU . 7.3 tp -123.6 148.59 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.493 HG21 ' HB2' ' A' ' 123' ' ' PHE . 18.0 mm -92.58 132.51 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.23 -0.919 . . . . 0.0 109.463 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 52.2 p -121.32 5.39 10.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.196 -0.94 . . . . 0.0 109.619 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.424 ' OE1' ' HA ' ' A' ' 158' ' ' GLU . 94.0 mt-10 -141.36 152.14 44.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.14 -0.975 . . . . 0.0 109.501 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 84.25 -171.94 48.64 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.25 -5.72 59.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -1.146 . . . . 0.0 109.54 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.576 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 83.1 m-85 -85.46 7.7 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.578 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 121' ' ' GLY . 97.6 mt-10 -58.96 141.1 54.71 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 109.572 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.56 -6.83 80.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.612 ' O ' HD12 ' A' ' 117' ' ' ILE . 20.6 m-30 -96.97 147.62 23.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.224 -1.162 . . . . 0.0 109.614 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -104.54 154.19 20.23 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.356 -0.84 . . . . 0.0 109.334 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 1.041 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -147.88 162.05 40.06 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.595 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.9 mm -112.39 144.34 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.587 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.728 ' CE1' HD21 ' A' ' 141' ' ' LEU . 35.1 m-85 -66.48 103.33 1.03 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.382 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.604 HG21 ' HE2' ' A' ' 151' ' ' LYS . 43.8 p -76.29 -34.2 59.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.527 ' O ' ' CG ' ' A' ' 140' ' ' MET . 2.2 mt-10 165.14 89.79 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.164 -0.96 . . . . 0.0 109.731 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.1 130.78 19.5 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.608 2.205 . . . . 0.0 111.694 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -68.17 -30.57 69.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -171.18 177.96 43.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -63.45 -25.76 68.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.254 -1.145 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.08 -62.27 1.51 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.7 mtt180 -110.01 157.98 18.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.3 m -142.46 153.05 43.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.527 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 85.7 mmm -99.73 124.0 44.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.872 HD22 HG21 ' A' ' 116' ' ' VAL . 42.0 mt -122.94 145.89 48.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.948 HD12 ' HG2' ' A' ' 151' ' ' LYS . 2.7 tt -101.2 126.39 47.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.168 -0.958 . . . . 0.0 109.646 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.807 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.8 mp -99.55 104.37 16.16 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.223 -0.923 . . . . 0.0 109.157 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -77.54 125.56 29.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.127 -0.983 . . . . 0.0 109.335 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 69.1 mt -117.72 141.35 48.49 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.32 -0.863 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.434 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.5 pt -51.55 -29.04 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.495 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.3 m-20 -78.47 -53.08 7.62 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.495 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 83.5 mttt -158.29 172.57 18.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.3 -0.875 . . . . 0.0 109.469 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -100.89 125.16 47.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 32.2 pt -120.87 158.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.923 . . . . 0.0 109.5 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.948 ' HG2' HD12 ' A' ' 142' ' ' LEU . 3.2 mtpm? -125.27 132.25 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.428 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -144.67 141.33 29.26 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.505 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 38.5 p -73.33 141.22 47.1 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.887 . . . . 0.0 109.32 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.577 HG12 ' HD1' ' A' ' 159' ' ' PHE . 19.4 t -133.09 152.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.114 -0.991 . . . . 0.0 109.618 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 39.0 mtmt -91.28 141.46 28.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 18.5 m-80 -51.21 -26.2 6.66 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.3 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 45.6 p -83.83 -19.18 35.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.304 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.444 ' OE2' ' HE2' ' A' ' 155' ' ' LYS . 94.9 mt-10 -84.87 -13.42 50.97 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.353 -0.842 . . . . 0.0 109.45 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.577 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -148.74 173.5 13.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.208 -0.933 . . . . 0.0 109.398 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.471 ' O ' HG22 ' A' ' 117' ' ' ILE . 97.2 mtt180 -131.16 143.99 51.04 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.197 -0.939 . . . . 0.0 109.607 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -80.78 135.09 35.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.738 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.7 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.495 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.13 143.79 56.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -1.155 . . . . 0.0 109.512 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.5 mtt -124.02 150.7 44.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.429 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -78.72 161.26 47.82 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.16 -16.74 35.95 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 122.673 2.248 . . . . 0.0 111.754 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 105' ' ' VAL . 37.1 mttt -62.29 -32.78 73.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.905 . . . . 0.0 109.44 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -60.07 -26.99 66.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.206 -0.934 . . . . 0.0 109.44 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 85.3 mt -55.97 -44.49 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' A' ' 102' ' ' LYS . 46.7 t -129.52 148.87 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.478 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.05 140.69 40.0 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.485 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.06 42.75 1.03 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.712 2.275 . . . . 0.0 112.081 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -78.87 -32.76 46.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.072 -1.018 . . . . 0.0 109.124 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.452 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 26.5 m -58.09 138.84 83.85 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.603 ' HB2' ' CZ ' ' A' ' 130' ' ' PHE . 48.9 Cg_endo -69.73 148.04 64.4 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.662 2.242 . . . . 0.0 111.958 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.44 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 72.0 m-85 -118.39 161.18 36.58 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.319 -0.863 . . . . 0.0 109.341 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.513 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 47.9 Cg_endo -69.07 130.72 20.72 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.767 2.311 . . . . 0.0 111.783 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.23 -8.21 55.18 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 129' ' ' ILE . 76.6 m-20 -83.1 166.41 18.73 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -1.185 . . . . 0.0 109.577 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 28.8 mtpt -90.85 140.36 29.88 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.032 HG21 HD23 ' A' ' 141' ' ' LEU . 9.9 m -129.77 155.92 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.546 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.791 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.6 tp -120.55 145.19 27.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.343 -0.848 . . . . 0.0 109.475 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.504 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.0 mm -90.25 134.02 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.937 . . . . 0.0 109.463 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.45 HG21 ' HD3' ' A' ' 160' ' ' ARG . 44.4 p -120.67 -0.05 10.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.512 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.465 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 93.9 mt-10 -138.39 153.4 48.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.4 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.422 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.28 -171.51 44.16 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.95 -3.62 58.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -1.13 . . . . 0.0 109.603 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.573 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.2 m-85 -89.13 9.55 25.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.502 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.465 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 98.3 mt-10 -59.23 141.89 53.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.586 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 88.57 -3.59 85.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.573 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.7 m-30 -100.17 143.22 30.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.167 -1.196 . . . . 0.0 109.565 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLN . . . . . 0.413 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 93.6 mt-30 -93.22 149.76 20.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.252 -0.905 . . . . 0.0 109.375 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.976 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -142.23 160.8 39.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.463 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.99 136.52 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.18 -0.95 . . . . 0.0 109.453 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.62 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 34.8 m-85 -59.8 109.89 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.219 -0.926 . . . . 0.0 109.708 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.51 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 60.7 p -79.61 -34.85 40.34 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 109.34 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.98 96.9 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -70.83 109.27 2.47 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.653 2.235 . . . . 0.0 111.59 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ASP . . . . . 0.418 ' OD1' ' HG3' ' A' ' 138' ' ' ARG . 24.7 p-10 -76.02 0.11 19.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.736 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -172.48 160.68 32.01 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -66.32 -41.85 89.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -1.152 . . . . 0.0 109.314 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -65.5 -77.51 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.288 -0.882 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.488 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.0 ptp180 -80.46 151.53 29.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.91 . . . . 0.0 109.564 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.768 ' OG ' HD11 ' A' ' 141' ' ' LEU . 88.7 p -145.57 156.71 43.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.528 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.848 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.7 mtp -100.2 119.25 38.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.032 HD23 HG21 ' A' ' 116' ' ' VAL . 5.1 mp -124.24 148.52 47.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.278 -0.888 . . . . 0.0 109.506 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.522 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.7 tt -97.52 126.74 42.97 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.352 -0.843 . . . . 0.0 109.397 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.53 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 35.3 mt -96.47 110.42 22.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.227 -0.921 . . . . 0.0 109.377 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.663 ' C ' HD22 ' A' ' 145' ' ' LEU . 15.5 p-10 -82.73 124.03 29.86 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.852 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.735 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -117.34 144.02 45.35 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.527 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.6 pt -50.08 -35.73 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.438 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.527 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.3 m-20 -71.35 -55.44 7.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.59 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 43.8 mttm -157.58 173.33 17.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.28 -0.887 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -99.12 128.79 45.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.259 -0.901 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.42 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 19.2 pt -125.5 158.02 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.522 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 24.0 mttp -119.26 135.58 54.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.382 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -144.91 145.92 31.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.58 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.2 p -86.17 121.28 28.54 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.349 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.866 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.7 p -124.92 147.86 29.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.208 -0.932 . . . . 0.0 109.591 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.573 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.2 mttt -75.76 150.97 37.67 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.349 -0.844 . . . . 0.0 109.657 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.568 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 13.9 m-80 -61.51 -24.17 66.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.4 p -79.58 -21.08 45.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.246 -0.909 . . . . 0.0 109.495 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.646 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.8 mt-10 -81.18 -22.65 38.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.554 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.881 ' CE2' HD21 ' A' ' 141' ' ' LEU . 41.7 p90 -138.47 170.51 15.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.925 . . . . 0.0 109.464 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ARG . . . . . 0.548 ' O ' HG22 ' A' ' 117' ' ' ILE . 27.1 ptt180 -134.79 158.72 43.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.181 -0.949 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -88.59 139.26 30.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.791 HD11 ' HB ' ' A' ' 117' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 98' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 97' ' ' GLY . . . 64.04 -89.02 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.166 -1.196 . . . . 0.0 109.469 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.0 mtm -62.21 -36.94 83.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.298 -0.876 . . . . 0.0 109.5 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -80.28 160.43 44.08 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.84 144.57 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.637 2.225 . . . . 0.0 111.841 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -58.16 -37.12 74.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -0.927 . . . . 0.0 109.421 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 104' ' ' ILE . 51.4 t0 -160.55 168.64 24.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.279 -0.888 . . . . 0.0 109.504 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.547 HG22 ' H ' ' A' ' 106' ' ' ASP . 70.3 mt -110.07 146.13 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.921 . . . . 0.0 109.52 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.51 -36.51 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.306 -0.871 . . . . 0.0 109.516 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.547 ' H ' HG22 ' A' ' 104' ' ' ILE . 3.8 m-20 -62.96 121.58 69.62 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.198 -0.939 . . . . 0.0 109.537 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -71.17 51.44 1.34 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.707 2.271 . . . . 0.0 111.885 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.96 -34.78 66.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.203 -0.935 . . . . 0.0 109.315 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.0 m -87.37 130.55 47.15 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.231 179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.431 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 47.6 Cg_endo -68.58 137.89 40.36 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.595 2.197 . . . . 0.0 111.949 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.401 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 85.6 m-85 -77.84 157.63 78.98 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 109.486 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 50.4 Cg_endo -69.98 134.04 26.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.722 2.281 . . . . 0.0 111.713 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 89.88 -8.99 78.77 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.594 ' O ' HG23 ' A' ' 129' ' ' ILE . 29.0 p-10 -68.22 -178.85 1.13 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -1.153 . . . . 0.0 109.384 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.458 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 26.9 mttp -103.0 139.75 38.17 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.933 HG21 HD23 ' A' ' 141' ' ' LEU . 7.9 m -134.41 154.51 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.865 . . . . 0.0 109.38 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.427 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 2.5 tp -121.6 139.35 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.869 . . . . 0.0 109.617 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 120' ' ' GLU . 66.7 mt -92.68 127.19 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 80.4 p -101.68 -11.77 18.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.421 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.49 ' O ' HG22 ' A' ' 118' ' ' ILE . 95.6 mt-10 -130.66 158.97 38.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.01 165.61 36.85 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.78 -27.8 68.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.45 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 97.1 m-85 -82.49 3.61 27.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.326 -0.859 . . . . 0.0 109.582 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -53.76 141.49 26.58 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.177 -0.952 . . . . 0.0 109.48 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 94.06 -9.83 72.35 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.45 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -97.93 148.46 23.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.207 -1.172 . . . . 0.0 109.47 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLN . . . . . 0.446 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 95.3 mt-30 -91.27 143.69 26.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.273 -0.892 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.885 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -135.51 160.36 38.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.594 HG23 ' O ' ' A' ' 114' ' ' ASP . 31.2 mm -117.86 136.6 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.649 ' HE1' HD11 ' A' ' 141' ' ' LEU . 19.6 m-85 -66.53 114.84 5.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 47.6 p -90.62 -29.93 17.48 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.337 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 175.46 87.53 0.09 OUTLIER Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.224 -0.922 . . . . 0.0 109.327 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.46 118.02 5.36 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.671 2.247 . . . . 0.0 111.791 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -60.32 -34.71 74.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -164.95 -160.12 12.03 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 70.3 mm-40 -83.41 -26.64 30.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -1.139 . . . . 0.0 109.354 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.29 -80.57 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.223 -0.923 . . . . 0.0 109.372 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.446 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 24.0 ptt180 -89.17 148.38 23.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.631 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 59.2 m -144.44 152.81 41.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.197 -0.939 . . . . 0.0 109.414 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.914 ' C ' HD12 ' A' ' 141' ' ' LEU . 39.5 mtp -96.97 122.33 39.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.44 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.933 HD23 HG21 ' A' ' 116' ' ' VAL . 6.3 mp -123.83 150.41 44.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.521 HD12 ' O ' ' A' ' 150' ' ' ILE . 32.1 tp -100.07 123.73 44.64 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 109.466 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.84 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -93.94 118.71 31.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.579 ' C ' HD22 ' A' ' 145' ' ' LEU . 21.9 p-10 -83.49 114.92 21.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.566 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.749 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.9 mm? -114.38 144.16 43.73 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 109.413 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -55.09 -29.07 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.306 -0.872 . . . . 0.0 109.29 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.417 ' N ' HG13 ' A' ' 146' ' ' ILE . 34.8 t30 -75.82 -54.29 7.15 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.342 -0.849 . . . . 0.0 109.441 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.52 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 24.7 tttm -168.57 164.84 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.229 -0.919 . . . . 0.0 109.6 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.52 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 93.9 mt-10 -87.94 127.79 35.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.521 ' O ' HD12 ' A' ' 142' ' ' LEU . 7.6 pt -122.23 136.01 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.283 -0.885 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.512 ' HG2' HD13 ' A' ' 142' ' ' LEU . 17.3 mttp -91.92 127.17 37.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.399 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -139.27 141.36 37.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.638 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.1 p -87.15 119.44 27.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.321 -0.862 . . . . 0.0 109.381 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.789 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.9 p -121.97 149.3 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 68.2 mttm -83.62 151.89 25.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 12.3 m-80 -59.45 -25.14 64.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.236 -0.915 . . . . 0.0 109.456 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.4 p -78.77 -20.29 50.21 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.622 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.2 mt-10 -82.09 -22.68 36.16 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.564 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.22 166.89 23.35 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.537 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 76.4 mtt85 -131.87 150.93 52.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.426 ' HD2' ' HB3' ' A' ' 110' ' ' PRO . 63.8 tttt -74.0 122.44 22.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.435 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.489 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.23 -33.41 74.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.194 -1.18 . . . . 0.0 109.467 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 9.1 tpt -57.79 -35.6 71.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.426 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.53 149.24 5.07 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.26 -37.19 10.73 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.699 2.266 . . . . 0.0 111.726 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 60.8 mttm 58.14 42.97 21.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.647 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 84.8 m-20 45.59 -165.77 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.568 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.0 mt -109.28 141.51 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.499 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 40.3 t -131.83 135.78 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.24 -0.913 . . . . 0.0 109.522 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.97 137.56 97.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 109.641 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' PRO . . . . . 0.468 ' HG2' ' OG1' ' A' ' 109' ' ' THR . 53.0 Cg_endo -73.67 49.97 1.94 Allowed 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.716 2.277 . . . . 0.0 111.76 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 107' ' ' PRO . . . 43.88 37.47 1.71 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.885 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.468 ' OG1' ' HG2' ' A' ' 107' ' ' PRO . 11.6 m -64.32 130.41 94.6 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.485 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.601 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.0 Cg_endo -70.13 147.72 61.13 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.644 2.229 . . . . 0.0 111.822 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.469 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.5 m-85 -99.55 160.17 28.11 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.469 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.4 Cg_endo -69.53 128.94 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.663 2.242 . . . . 0.0 111.688 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.8 -11.15 59.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.45 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 79.3 m-20 -78.99 151.87 31.31 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -1.119 . . . . 0.0 109.457 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.462 ' CB ' HD21 ' A' ' 162' ' ' LEU . 97.2 mttt -80.15 142.0 35.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.034 HG21 HD23 ' A' ' 141' ' ' LEU . 6.1 m -131.9 160.57 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 6.8 tp -124.6 142.19 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.509 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.477 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 69.4 mt -92.64 125.59 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.469 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.3 p -102.38 -10.66 19.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.432 ' O ' HG22 ' A' ' 118' ' ' ILE . 94.4 mt-10 -131.38 158.44 40.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.525 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 92.68 166.85 39.05 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.53 -19.78 63.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -1.133 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.546 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 95.9 m-85 -83.54 9.48 11.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.47 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.477 ' HG3' ' O ' ' A' ' 118' ' ' ILE . 85.5 tt0 -58.32 140.41 53.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.391 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.87 -6.04 73.09 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -99.06 142.36 30.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.475 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -86.71 125.92 34.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.937 . . . . 0.0 109.352 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.949 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -110.57 153.0 25.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.298 -0.876 . . . . 0.0 109.456 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.582 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.2 mm -118.06 130.67 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.498 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.847 ' CE2' HG11 ' A' ' 116' ' ' VAL . 32.7 m-85 -62.31 101.7 0.25 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -0.942 . . . . 0.0 109.542 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.478 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 43.3 p -78.43 -36.34 45.72 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.225 -0.922 . . . . 0.0 109.262 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 131' ' ' THR . 17.2 tp10 171.36 99.35 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.419 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.0 113.86 3.55 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.62 2.213 . . . . 0.0 111.461 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 29.2 p-10 -74.95 -6.3 48.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.628 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.19 169.67 41.6 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -75.3 -26.25 58.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.477 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -76.1 -73.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 109.341 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.438 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 9.9 ptp85 -89.32 147.62 23.99 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.483 ' HB2' HD11 ' A' ' 141' ' ' LEU . 65.0 m -134.68 144.91 48.06 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.232 -0.917 . . . . 0.0 109.5 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.709 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 ttm -87.98 109.66 19.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.224 -0.922 . . . . 0.0 109.504 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.034 HD23 HG21 ' A' ' 116' ' ' VAL . 5.5 mp -115.59 151.61 34.6 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.831 HD12 ' O ' ' A' ' 150' ' ' ILE . 48.1 tp -93.47 127.99 39.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.373 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.5 mt -90.73 137.45 32.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -104.16 106.16 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.0 109.432 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.414 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 49.5 mt -104.33 140.88 37.25 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -50.97 -31.47 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.238 -0.914 . . . . 0.0 109.423 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.49 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 17.1 t-20 -74.17 -56.15 5.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.635 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.49 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 19.9 mttt -158.81 166.75 31.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -0.954 . . . . 0.0 109.489 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -92.83 131.93 37.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -0.893 . . . . 0.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.831 ' O ' HD12 ' A' ' 142' ' ' LEU . 13.7 pt -132.56 155.53 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 109.6 -179.695 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.753 ' HG2' HD13 ' A' ' 142' ' ' LEU . 28.9 mttp -105.55 131.46 52.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -140.52 129.42 23.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.266 -0.896 . . . . 0.0 109.409 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 70.7 m -69.89 118.52 12.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.783 ' CG1' HD13 ' A' ' 141' ' ' LEU . 5.3 p -121.82 148.35 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.855 . . . . 0.0 109.53 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 33.0 mttp -81.8 151.92 27.17 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.566 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.0 m-80 -60.76 -21.34 62.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.914 . . . . 0.0 109.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.9 p -81.48 -21.58 38.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.629 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.8 mt-10 -81.52 -23.14 37.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.316 -0.865 . . . . 0.0 109.473 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.663 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.3 p90 -138.53 167.96 20.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.538 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 51.0 mtt-85 -131.12 155.37 47.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.547 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -76.84 125.06 28.64 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.495 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.462 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.472 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -144.05 152.19 40.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -1.127 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 94.7 mmm -58.99 -35.2 72.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.67 130.93 1.6 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.26 148.67 62.36 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.732 2.288 . . . . 0.0 111.784 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 83.3 tttt -54.83 -36.87 65.48 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.432 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 49.7 p30 -148.43 173.93 12.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.478 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 83.0 mt -59.83 -41.64 86.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -0.925 . . . . 0.0 109.543 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.416 ' O ' ' OD1' ' A' ' 103' ' ' ASP . 40.6 t -117.09 126.68 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' A' ' 106' ' ' ASP . 7.5 p30 -59.2 135.5 88.14 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.632 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -78.41 38.62 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.653 2.235 . . . . 0.0 112.075 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -80.76 -36.68 31.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.237 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 88.4 m -75.61 129.54 81.46 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.325 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.628 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 50.5 Cg_endo -70.26 138.05 35.38 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.638 2.225 . . . . 0.0 111.866 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.453 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.4 m-85 -88.5 160.92 43.9 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.207 -0.933 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.71 130.75 19.95 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.609 2.206 . . . . 0.0 111.808 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.0 -15.14 56.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -69.45 153.88 42.86 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.196 -1.179 . . . . 0.0 109.51 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -90.04 147.5 23.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.797 HG22 ' O ' ' A' ' 128' ' ' ALA . 5.0 m -131.74 154.47 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.628 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.1 tp -124.48 146.98 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.275 -0.891 . . . . 0.0 109.478 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.461 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.1 mm -91.16 124.91 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.335 -0.853 . . . . 0.0 109.356 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.46 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 66.2 p -108.99 -8.57 15.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.531 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.92 157.4 45.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.121 -0.987 . . . . 0.0 109.463 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 88.88 166.54 42.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.44 -18.65 64.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.239 -1.154 . . . . 0.0 109.448 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.57 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 88.5 m-85 -82.56 5.75 19.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 109.506 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.46 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.6 tt0 -58.67 136.7 57.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.557 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.31 -3.43 66.3 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -101.11 150.09 23.29 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.17 -1.194 . . . . 0.0 109.48 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -102.21 149.27 24.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.47 166.22 25.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.305 -0.872 . . . . 0.0 109.423 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.501 HD13 ' O ' ' A' ' 128' ' ' ALA . 27.2 mm -116.63 137.66 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.206 -0.934 . . . . 0.0 109.535 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.698 ' CE2' HG12 ' A' ' 116' ' ' VAL . 36.0 m-85 -59.57 104.0 0.24 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.495 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 39.3 p -78.71 -38.89 37.92 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.344 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 131' ' ' THR . 1.0 OUTLIER 171.68 94.8 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.303 -0.873 . . . . 0.0 109.455 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.38 115.7 4.17 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.776 2.317 . . . . 0.0 111.744 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -61.16 -35.92 78.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.243 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -148.01 175.5 27.3 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.82 -27.43 64.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -1.151 . . . . 0.0 109.495 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.11 -73.54 0.29 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.309 -0.869 . . . . 0.0 109.384 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 21.3 ptt-85 -83.53 147.81 27.56 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.23 -0.919 . . . . 0.0 109.558 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 67.9 m -139.96 153.11 46.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.176 -0.952 . . . . 0.0 109.514 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.453 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 41.6 mtp -99.23 119.48 37.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.262 -0.899 . . . . 0.0 109.429 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.661 HD13 HG21 ' A' ' 116' ' ' VAL . 66.1 mt -117.85 147.73 42.78 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.255 -0.903 . . . . 0.0 109.471 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.612 HD12 ' CE ' ' A' ' 151' ' ' LYS . 8.4 tt -97.31 126.46 42.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.263 -0.898 . . . . 0.0 109.438 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.524 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 43.5 mt -97.69 113.87 25.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.183 -0.948 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.717 ' C ' HD22 ' A' ' 145' ' ' LEU . 8.4 p30 -83.45 121.21 26.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.283 -0.885 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.75 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -118.72 135.64 54.38 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.357 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.2 pt -49.74 -33.29 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.266 -0.896 . . . . 0.0 109.574 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.487 ' N ' HG13 ' A' ' 146' ' ' ILE . 94.2 m-20 -70.49 -46.44 63.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 30.3 tttm -168.49 160.75 11.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.527 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.0 mt-10 -87.85 127.24 35.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.927 . . . . 0.0 109.407 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.506 HG12 HD23 ' A' ' 145' ' ' LEU . 19.6 pt -127.67 162.12 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.424 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.612 ' CE ' HD12 ' A' ' 142' ' ' LEU . 20.9 mttt -125.72 130.25 51.14 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.446 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -139.12 148.14 42.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 29.7 p -82.7 141.89 32.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.578 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.7 t -130.91 153.64 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.35 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.501 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 41.3 mttt -91.11 138.3 31.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.913 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 8.6 p-10 -47.75 -30.38 3.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 44.7 p -80.97 -22.18 39.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.898 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 155' ' ' LYS . 94.8 mt-10 -81.69 -19.7 41.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.439 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.584 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.6 p90 -140.45 169.01 18.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.372 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 87.0 mtt-85 -129.44 143.24 50.75 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -78.14 132.74 37.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.321 -0.862 . . . . 0.0 109.473 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.5 mp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.481 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.7 -31.73 72.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -1.116 . . . . 0.0 109.445 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.6 mtp -58.36 -36.99 74.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 109.488 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -151.58 139.47 7.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.4 143.31 47.42 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.744 2.296 . . . . 0.0 111.755 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -112.39 144.76 41.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.9 . . . . 0.0 109.523 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 103' ' ' ASP . 45.6 p30 -74.5 151.83 39.47 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.243 -0.91 . . . . 0.0 109.494 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -122.88 143.58 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.25 -0.906 . . . . 0.0 109.523 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.6 t -115.92 134.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.251 -0.906 . . . . 0.0 109.505 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -67.01 130.59 93.87 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.628 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -71.71 50.59 1.4 Allowed 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.682 2.255 . . . . 0.0 111.875 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.37 -27.65 59.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 0.0 109.376 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.1 m -63.9 127.15 91.35 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.353 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.414 ' HB3' ' HD2' ' A' ' 161' ' ' LYS . 49.3 Cg_endo -69.75 140.74 43.47 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.656 2.238 . . . . 0.0 111.797 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.408 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 12.6 m-85 -81.5 161.0 63.33 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 134.84 27.87 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.724 2.283 . . . . 0.0 111.797 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.21 -12.98 65.12 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 83.4 m-20 -69.97 147.91 49.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.515 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.3 mttm -75.05 139.74 43.05 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.036 HG21 HD23 ' A' ' 141' ' ' LEU . 6.0 m -127.33 155.67 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.942 . . . . 0.0 109.455 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.446 HD12 ' HA ' ' A' ' 117' ' ' ILE . 8.2 tp -123.82 147.69 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.235 -0.916 . . . . 0.0 109.48 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.466 ' HB ' ' HA ' ' A' ' 124' ' ' GLU . 21.6 mm -91.66 129.34 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.8 p -114.17 -7.34 13.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.486 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 46.8 tp10 -140.89 153.48 45.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.486 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 92.15 169.05 40.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.92 -15.9 63.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -1.188 . . . . 0.0 109.493 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.633 ' CD1' HD23 ' A' ' 143' ' ' LEU . 89.9 m-85 -84.93 11.06 10.1 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.2 -0.938 . . . . 0.0 109.451 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.466 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 85.0 tt0 -60.73 134.08 56.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.636 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.94 66.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.454 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.7 m-85 -98.26 140.48 32.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.143 -1.21 . . . . 0.0 109.472 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -94.13 126.52 39.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.525 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.994 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -126.35 161.42 27.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.938 . . . . 0.0 109.533 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.585 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.9 mm -120.12 136.96 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.254 -0.904 . . . . 0.0 109.451 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.586 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.5 m-85 -58.58 103.18 0.14 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 63.4 p -77.3 -31.45 54.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 164.74 91.37 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.188 -0.945 . . . . 0.0 109.53 -179.987 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.47 125.99 12.37 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.63 2.22 . . . . 0.0 111.655 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.6 p-10 -68.66 -25.78 64.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 109.538 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -166.09 170.25 40.69 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -64.01 -27.59 69.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.43 -63.63 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.3 -0.875 . . . . 0.0 109.394 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 135' ' ' GLY . 57.7 mtt85 -107.48 153.6 22.59 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.197 -0.939 . . . . 0.0 109.468 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 68.8 m -138.8 156.64 47.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 109.46 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.819 ' C ' HD12 ' A' ' 141' ' ' LEU . 34.7 tpp -101.12 117.31 34.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.475 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.036 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -118.61 144.07 46.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 9.2 tt -101.52 123.51 45.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.452 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.835 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -91.4 138.51 31.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.923 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.684 ' C ' HD12 ' A' ' 145' ' ' LEU . 97.6 m-20 -110.86 113.38 25.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.768 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.3 mp -114.61 139.63 49.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.579 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.516 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.1 pt -50.28 -36.25 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.516 ' N ' HG13 ' A' ' 146' ' ' ILE . 15.3 t-20 -68.04 -52.89 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.488 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 19.3 tttt -166.66 155.11 10.3 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.541 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.47 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.4 mt-10 -89.86 140.21 29.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.4 pt -131.57 158.61 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.523 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.3 mttt -125.83 134.18 51.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.66 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.49 ' ND1' ' O ' ' A' ' 153' ' ' SER . 51.7 t-80 -158.31 146.45 18.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.422 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.49 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 42.0 p -69.77 141.34 53.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.924 . . . . 0.0 109.393 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.686 HG13 ' CD ' ' A' ' 158' ' ' GLU . 20.2 t -126.17 152.31 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.182 -0.949 . . . . 0.0 109.61 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.504 ' O ' ' HG2' ' A' ' 158' ' ' GLU . 86.4 mttt -91.17 131.64 36.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.276 -0.89 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.582 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 33.4 m-80 -53.41 -18.57 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 79.8 p -85.13 -29.66 24.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 110.141 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.686 ' CD ' HG13 ' A' ' 154' ' ' VAL . 10.9 pt-20 -82.84 -18.57 39.93 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.02 -1.05 . . . . 0.0 109.698 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.642 ' CE2' HD21 ' A' ' 141' ' ' LEU . 20.4 p90 -135.3 157.25 47.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.147 -0.97 . . . . 0.0 109.553 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.2 ttt-85 -124.07 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.267 -0.896 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 16.9 pttp -74.39 124.03 25.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.196 -0.94 . . . . 0.0 109.51 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.497 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.997 -1.002 . . . . 0.0 109.48 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.26 -31.09 70.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.48 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.4 mtt -121.43 156.21 33.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.129 -0.982 . . . . 0.0 109.444 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -122.37 167.24 14.85 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.99 -23.73 29.43 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.841 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.2 tttm -77.3 133.49 38.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.9 . . . . 0.0 109.449 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -80.89 135.38 35.9 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.28 -0.888 . . . . 0.0 109.409 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.4 mt -125.81 143.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.454 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 25.8 m -126.57 160.36 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.231 -0.918 . . . . 0.0 109.475 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.29 130.37 94.57 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.89 53.27 1.12 Allowed 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.729 2.286 . . . . 0.0 111.831 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . 46.03 26.23 0.39 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.406 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 45.1 m -107.09 124.73 34.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.238 -0.914 . . . . 0.0 109.444 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.23 143.84 49.77 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.682 2.255 . . . . 0.0 111.82 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.439 ' N ' ' OD2' ' A' ' 114' ' ' ASP . 50.9 m-85 -76.14 161.14 76.35 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.245 -0.91 . . . . 0.0 109.475 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.1 Cg_endo -69.73 131.5 21.4 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.696 2.264 . . . . 0.0 111.79 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 98.83 -12.29 62.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' N ' ' A' ' 111' ' ' TYR . 81.5 m-20 -65.56 150.31 48.62 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -1.135 . . . . 0.0 109.491 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.508 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 96.5 mttt -77.98 140.14 39.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.897 . . . . 0.0 109.476 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.947 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.1 m -130.84 153.63 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 3.0 tp -122.65 140.67 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.473 HD12 ' HB3' ' A' ' 123' ' ' PHE . 69.4 mt -92.56 131.05 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.5 p -118.42 5.37 11.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.245 -0.909 . . . . 0.0 109.578 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.433 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -136.91 153.6 50.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 109.481 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.4 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.67 -171.08 42.9 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.87 -5.84 57.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -1.134 . . . . 0.0 109.587 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.557 ' CD1' HD23 ' A' ' 143' ' ' LEU . 80.2 m-85 -88.54 14.98 8.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.997 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.433 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 96.9 mt-10 -62.84 136.91 58.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.14 1.09 70.11 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -102.22 131.41 48.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.137 -1.213 . . . . 0.0 109.454 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -86.72 134.44 33.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.909 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.18 159.72 38.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.544 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.518 HD13 ' O ' ' A' ' 128' ' ' ALA . 33.4 mm -119.2 140.07 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.311 -0.868 . . . . 0.0 109.383 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.566 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.1 m-85 -58.58 101.47 0.09 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.538 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 68.9 p -75.04 -34.41 61.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.369 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.3 mt-10 163.75 88.84 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.294 -0.879 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.463 ' HB3' ' OG ' ' A' ' 139' ' ' SER . 49.9 Cg_endo -69.96 132.35 22.83 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.679 2.253 . . . . 0.0 111.81 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -67.82 -30.03 69.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -0.861 . . . . 0.0 109.444 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -165.18 -174.02 34.4 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -73.32 -26.79 61.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.295 -1.121 . . . . 0.0 109.453 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.82 -58.51 4.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.532 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -109.6 161.12 15.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.158 -0.964 . . . . 0.0 109.425 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 133' ' ' PRO . 4.1 m -147.36 155.38 41.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.262 -0.899 . . . . 0.0 109.566 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.906 ' C ' HD12 ' A' ' 141' ' ' LEU . 63.5 mtp -103.06 124.22 48.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.343 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.947 HD23 ' CG2' ' A' ' 116' ' ' VAL . 5.4 mp -126.19 140.78 52.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.175 -0.953 . . . . 0.0 109.607 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.569 HD23 ' C ' ' A' ' 142' ' ' LEU . 10.1 tt -96.59 125.82 41.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.304 -0.873 . . . . 0.0 109.413 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.829 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.6 mp -93.47 137.02 33.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.284 -0.885 . . . . 0.0 109.525 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.477 ' C ' HD12 ' A' ' 145' ' ' LEU . 83.0 m-20 -108.57 104.19 13.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.905 . . . . 0.0 109.422 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.725 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.8 mp -104.45 139.6 39.14 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.149 -0.969 . . . . 0.0 109.56 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.2 pt -54.32 -35.09 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.445 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 52.0 t-20 -65.96 -46.57 77.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.393 -0.817 . . . . 0.0 109.512 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.1 pttt -168.64 169.54 10.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.204 -0.935 . . . . 0.0 109.555 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CG ' HD21 ' A' ' 142' ' ' LEU . 86.8 tt0 -98.2 132.32 43.82 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.1 pt -131.88 157.01 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.475 ' HG2' ' HG ' ' A' ' 142' ' ' LEU . 2.3 mtpm? -123.97 134.1 53.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.396 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.466 ' CE1' ' O ' ' A' ' 153' ' ' SER . 55.4 t-80 -152.26 143.73 23.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 41.6 p -81.66 137.07 35.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.512 HG12 ' HD1' ' A' ' 159' ' ' PHE . 16.4 t -127.6 151.09 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.406 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.528 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 0.6 OUTLIER -87.38 139.97 30.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.272 -0.893 . . . . 0.0 109.559 -179.935 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.515 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 27.4 m-80 -46.17 -27.98 1.12 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.357 -0.839 . . . . 0.0 110.272 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' THR . . . . . 0.512 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 27.0 p -80.14 -19.93 46.1 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.97 -1.081 . . . . 0.0 109.983 -179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.528 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 48.5 mm-40 -89.85 -19.11 25.02 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.068 -1.02 . . . . 0.0 109.201 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.721 ' CE2' HD21 ' A' ' 141' ' ' LEU . 34.5 p90 -139.22 156.03 47.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.793 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 53.2 mtt180 -125.25 147.1 49.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.255 -0.903 . . . . 0.0 109.339 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.477 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 15.9 pttp -82.44 121.52 26.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.492 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.489 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.12 -36.3 79.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -1.173 . . . . 0.0 109.527 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 65.1 mtt -58.64 -35.19 72.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.426 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -144.93 130.4 3.87 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.17 140.67 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.736 2.29 . . . . 0.0 111.736 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -123.92 150.11 45.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -52.38 -36.8 54.83 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.31 -0.869 . . . . 0.0 109.413 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.2 mt -107.75 143.17 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.511 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.1 t -122.48 130.26 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.508 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -65.08 149.83 96.26 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.295 -0.878 . . . . 0.0 109.527 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -76.35 43.47 1.19 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.633 2.222 . . . . 0.0 112.069 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.38 -42.74 61.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.05 -1.031 . . . . 0.0 109.109 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.3 m -103.24 120.39 52.18 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.366 -0.834 . . . . 0.0 109.187 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.4 149.47 69.2 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.663 2.242 . . . . 0.0 111.93 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.4 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 53.0 m-85 -102.8 161.46 23.11 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.448 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.5 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 46.2 Cg_endo -68.28 137.61 40.65 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.634 2.223 . . . . 0.0 111.701 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 90.82 -9.88 76.46 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.744 ' O ' HG23 ' A' ' 129' ' ' ILE . 36.6 p-10 -74.55 -177.85 3.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -1.149 . . . . 0.0 109.5 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.499 ' HA ' HD13 ' A' ' 129' ' ' ILE . 76.6 mttt -99.19 141.6 31.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -0.893 . . . . 0.0 109.426 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.927 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.2 m -138.18 158.1 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.239 -0.913 . . . . 0.0 109.529 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.2 tp -126.27 141.91 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.482 ' HA ' ' HB2' ' A' ' 159' ' ' PHE . 56.1 mt -92.29 129.91 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.209 -0.932 . . . . 0.0 109.695 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.525 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 58.0 p -105.08 -8.39 18.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.474 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 48.0 tp10 -136.26 156.84 48.08 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLY . . . . . 0.474 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 93.77 162.77 36.09 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.26 -19.4 65.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -1.115 . . . . 0.0 109.438 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.497 ' CD1' HD23 ' A' ' 143' ' ' LEU . 84.5 m-85 -86.26 13.16 8.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.379 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.525 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.8 tt0 -63.76 140.12 58.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.38 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 90.32 -0.15 77.63 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -104.99 138.89 40.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -1.193 . . . . 0.0 109.428 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -83.79 148.65 26.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.26 -0.9 . . . . 0.0 109.541 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.927 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -144.83 159.31 43.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.744 HG23 ' O ' ' A' ' 114' ' ' ASP . 27.2 mm -119.68 133.06 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.961 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.788 ' HE1' HD11 ' A' ' 141' ' ' LEU . 18.3 m-85 -58.57 115.84 3.29 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.368 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.516 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 44.0 p -84.18 -29.5 26.56 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.9 86.33 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.326 -0.859 . . . . 0.0 109.545 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.415 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.2 Cg_endo -70.0 130.64 19.38 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.694 2.263 . . . . 0.0 111.751 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -68.91 -26.61 65.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.905 . . . . 0.0 109.594 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -170.59 178.31 43.27 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -66.16 -25.94 67.19 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -1.121 . . . . 0.0 109.509 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.53 -63.68 1.01 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.476 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 75.4 mtt180 -107.11 156.89 18.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.43 ' HB3' ' CE1' ' A' ' 130' ' ' PHE . 69.0 m -148.58 152.42 36.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.175 -0.953 . . . . 0.0 109.51 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.806 ' C ' HD12 ' A' ' 141' ' ' LEU . 20.4 mtp -101.62 122.05 43.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.217 -0.927 . . . . 0.0 109.583 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.818 HD13 ' CG1' ' A' ' 154' ' ' VAL . 6.8 mp -114.21 147.32 39.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.875 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.926 HD21 ' OE2' ' A' ' 149' ' ' GLU . 34.5 tp -102.8 125.42 49.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.742 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.806 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -98.32 127.98 44.52 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.257 -0.902 . . . . 0.0 109.25 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -105.02 113.27 26.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.771 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.4 mm? -101.01 150.56 22.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.326 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 25.7 pt -65.13 -10.45 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.501 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 48.3 t30 -97.57 -47.55 5.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.59 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.501 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 77.7 mttt -158.55 165.39 34.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.93 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.926 ' OE2' HD21 ' A' ' 142' ' ' LEU . 78.4 tt0 -89.57 147.57 23.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.172 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 142' ' ' LEU . 30.9 pt -144.44 151.66 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.945 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.814 ' HG2' HD13 ' A' ' 142' ' ' LEU . 20.8 mttp -118.01 136.64 53.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.366 -0.834 . . . . 0.0 109.159 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -148.58 134.99 19.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.116 -0.99 . . . . 0.0 109.651 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.8 p -87.12 118.08 26.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.888 . . . . 0.0 109.326 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.818 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.3 p -120.05 150.59 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.565 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 28.0 mttt -77.01 153.69 34.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.891 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 9.7 m-80 -65.18 -14.95 61.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 70.5 p -88.17 -24.2 23.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.593 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.7 mt-10 -78.79 -22.62 46.05 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.258 -0.901 . . . . 0.0 109.51 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.769 ' CE2' HD21 ' A' ' 141' ' ' LEU . 38.3 p90 -135.95 174.04 11.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.414 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 52.6 mtp180 -139.45 164.59 29.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.57 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.508 ' NZ ' ' OD2' ' A' ' 114' ' ' ASP . 55.4 tttp -85.59 126.32 33.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.487 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.475 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.519 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -64.69 142.05 58.56 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.229 -1.159 . . . . 0.0 109.405 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 65.1 mtt -61.58 -34.15 75.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 0.0 109.538 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -110.94 173.82 16.37 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.77 152.43 69.26 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.748 2.299 . . . . 0.0 111.818 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 105' ' ' VAL . 94.1 mttt -83.28 145.73 28.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.515 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -61.56 -32.65 72.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.197 -0.94 . . . . 0.0 109.353 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 83.9 mt -49.25 -45.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 102' ' ' LYS . 18.0 m -130.44 143.23 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.295 -0.878 . . . . 0.0 109.435 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.464 ' HB2' ' HD2' ' A' ' 107' ' ' PRO . 1.8 p30 -98.7 164.49 16.87 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.239 -0.913 . . . . 0.0 109.399 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' A' ' 106' ' ' ASP . 55.8 Cg_endo -80.57 34.04 0.53 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.725 2.283 . . . . 0.0 112.052 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -99.54 -26.71 14.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.122 -0.986 . . . . 0.0 109.447 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 76.7 m -66.39 132.09 94.3 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.353 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.605 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 51.1 Cg_endo -70.19 131.95 21.65 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.916 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.404 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 50.3 m-85 -79.75 157.93 73.72 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.379 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.96 130.89 19.87 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.63 2.22 . . . . 0.0 111.811 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 101.04 -14.77 58.42 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.483 ' CB ' ' HE2' ' A' ' 161' ' ' LYS . 80.4 m-20 -66.89 153.78 42.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.497 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 95.5 mttt -81.83 140.62 34.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.8 m -125.61 152.61 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.712 ' HB ' HD21 ' A' ' 162' ' ' LEU . 8.2 tp -122.64 145.43 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.538 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.48 HG12 ' O ' ' A' ' 126' ' ' PHE . 28.8 mm -91.24 128.82 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.293 -0.88 . . . . 0.0 109.499 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.453 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 69.1 p -114.92 -7.9 12.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.217 -0.927 . . . . 0.0 109.518 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -140.1 151.91 45.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.163 -0.961 . . . . 0.0 109.473 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.56 167.78 38.2 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.41 -13.78 62.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -1.155 . . . . 0.0 109.422 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.599 ' HB3' HD23 ' A' ' 143' ' ' LEU . 69.6 m-85 -87.98 13.93 9.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.475 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.8 tt0 -64.08 132.43 50.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.58 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.17 1.03 59.6 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.48 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.4 m-85 -98.95 136.52 38.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.1 -1.235 . . . . 0.0 109.594 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -88.79 136.07 33.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.291 -0.881 . . . . 0.0 109.279 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 1.018 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -137.95 165.73 25.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.597 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.7 mm -121.01 142.28 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CE2' HG12 ' A' ' 116' ' ' VAL . 40.5 m-85 -58.58 104.49 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.936 . . . . 0.0 109.558 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.462 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 71.1 p -78.07 -40.69 37.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' THR . 7.6 tt0 172.32 91.53 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 48.8 Cg_endo -70.1 124.46 10.97 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.718 2.279 . . . . 0.0 111.761 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 23.3 p-10 -75.23 -4.03 36.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.355 -0.84 . . . . 0.0 109.54 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 174.64 173.3 40.44 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.95 -30.48 67.87 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -1.125 . . . . 0.0 109.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.07 -60.03 2.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -0.915 . . . . 0.0 109.431 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.463 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 81.9 mtm180 -103.28 152.93 20.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.395 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 68.5 m -144.97 150.12 36.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.96 . . . . 0.0 109.491 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.941 ' C ' HD12 ' A' ' 141' ' ' LEU . 91.6 mmm -96.17 125.91 41.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.323 -0.861 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -128.32 141.27 51.49 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.236 -0.915 . . . . 0.0 109.622 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.527 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.9 tt -99.67 119.51 38.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.395 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -96.03 108.63 21.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.18 -0.95 . . . . 0.0 109.652 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 145' ' ' LEU . 5.8 p30 -88.7 127.5 35.59 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.32 -0.862 . . . . 0.0 109.631 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.793 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.1 mp -108.05 159.37 16.62 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.925 . . . . 0.0 109.425 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 23.6 pt -66.65 -10.22 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.418 ' CG ' ' N ' ' A' ' 148' ' ' LYS . 9.2 p30 -105.34 -45.54 4.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.514 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 62.1 tttm -158.48 147.96 19.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.29 -0.881 . . . . 0.0 109.563 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -87.89 141.23 28.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.371 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.564 HD11 ' CE1' ' A' ' 123' ' ' PHE . 28.7 pt -133.7 162.12 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.917 . . . . 0.0 109.572 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.527 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 29.6 mttt -125.16 136.52 53.68 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.291 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.29 148.47 28.21 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.183 -0.948 . . . . 0.0 109.694 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.49 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 21.9 p -86.88 122.77 31.21 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.251 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.986 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.2 p -125.06 148.93 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.493 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 45.0 mttt -79.59 153.53 29.38 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.493 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 11.9 m120 -62.52 -19.73 63.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.344 -0.847 . . . . 0.0 109.474 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 63.1 p -82.26 -23.19 35.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.194 -0.941 . . . . 0.0 109.478 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.579 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.6 mt-10 -81.13 -21.11 40.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.226 -0.921 . . . . 0.0 109.524 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.874 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.8 p90 -139.53 158.94 43.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -122.15 148.49 44.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.205 -0.934 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.483 ' HE2' ' CB ' ' A' ' 114' ' ' ASP . 64.1 tttm -76.44 135.37 39.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.923 . . . . 0.0 109.487 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.712 HD21 ' HB ' ' A' ' 117' ' ' ILE . 53.5 mt . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.912 -1.042 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -63.05 143.7 57.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.263 -1.139 . . . . 0.0 109.479 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 71.4 mtm -57.73 -37.75 74.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -79.4 163.83 48.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.07 140.2 40.97 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.699 2.266 . . . . 0.0 111.744 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.0 mtmt -107.28 141.85 37.97 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.202 -0.936 . . . . 0.0 109.494 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -81.58 138.5 35.37 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.305 -0.872 . . . . 0.0 109.424 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.86 -36.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 44.3 t -122.55 130.54 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.476 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 63.0 m-20 -78.99 146.9 68.99 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.898 . . . . 0.0 109.496 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.08 65.24 1.99 Allowed 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.706 2.271 . . . . 0.0 111.783 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.27 -38.49 77.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.495 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.0 m -71.42 130.66 87.32 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.244 -0.91 . . . . 0.0 109.406 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.468 ' HB3' ' HD2' ' A' ' 161' ' ' LYS . 49.9 Cg_endo -70.05 151.97 67.63 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.754 2.303 . . . . 0.0 111.879 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -90.99 158.8 41.21 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.906 . . . . 0.0 109.366 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -70.22 134.47 27.09 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.695 2.263 . . . . 0.0 111.784 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.24 -11.68 68.85 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.648 ' O ' HG23 ' A' ' 129' ' ' ILE . 23.9 p-10 -67.45 176.23 2.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.168 -1.195 . . . . 0.0 109.473 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.546 ' HA ' HD13 ' A' ' 129' ' ' ILE . 99.6 mttt -98.34 139.42 34.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.91 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.971 HG21 HD22 ' A' ' 141' ' ' LEU . 15.0 m -135.14 149.8 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.631 ' N ' HD11 ' A' ' 162' ' ' LEU . 6.4 tp -120.84 142.47 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.444 HD11 HD21 ' A' ' 143' ' ' LEU . 62.1 mt -92.37 129.78 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.192 -0.943 . . . . 0.0 109.416 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.487 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 62.7 p -105.6 -9.97 17.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.421 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 75.4 mm-40 -135.73 158.17 45.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.178 -0.951 . . . . 0.0 109.425 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.09 165.48 32.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.93 -20.78 65.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.174 . . . . 0.0 109.43 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.515 ' CG ' HD13 ' A' ' 143' ' ' LEU . 64.1 m-85 -88.12 15.0 8.02 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.487 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 83.2 tt0 -63.22 137.4 58.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.917 . . . . 0.0 109.469 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.7 0.96 62.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -105.67 128.43 53.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -78.04 135.29 37.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.227 -0.921 . . . . 0.0 109.417 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.843 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.89 164.35 27.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.237 -0.915 . . . . 0.0 109.593 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 114' ' ' ASP . 39.3 mm -122.8 137.81 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.462 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.833 ' CE1' HD21 ' A' ' 141' ' ' LEU . 10.6 m-85 -58.56 102.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.679 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 47.0 p -79.43 -36.01 39.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 109.322 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.454 ' O ' ' HG3' ' A' ' 140' ' ' MET . 1.0 OUTLIER 170.02 87.53 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.308 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 133' ' ' PRO . . . . . 0.406 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.5 Cg_endo -69.77 131.78 21.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.735 2.29 . . . . 0.0 111.871 -179.817 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -66.51 -32.36 73.66 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.374 -0.828 . . . . 0.0 109.415 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -163.44 -178.4 37.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -70.5 -29.1 65.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -1.165 . . . . 0.0 109.49 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.14 -59.14 4.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.236 -0.915 . . . . 0.0 109.388 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.505 ' HG3' ' NH1' ' A' ' 138' ' ' ARG . 6.8 mtt85 -109.46 157.81 18.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 109.35 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.406 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 35.6 m -146.38 156.8 43.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -0.986 . . . . 0.0 109.611 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.484 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 49.6 mtp -99.46 127.54 45.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.442 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.971 HD22 HG21 ' A' ' 116' ' ' VAL . 89.8 mt -126.27 135.73 51.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.524 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.0 tt -92.73 123.84 36.31 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.633 HD23 ' HB2' ' A' ' 128' ' ' ALA . 16.5 mt -97.1 109.06 21.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.922 . . . . 0.0 109.662 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.724 ' C ' HD12 ' A' ' 145' ' ' LEU . 12.8 p-10 -83.94 125.48 32.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.224 -0.922 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.724 HD12 ' C ' ' A' ' 144' ' ' ASN . 8.1 mp -119.24 145.73 45.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.17 -0.956 . . . . 0.0 109.441 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -53.44 -39.0 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.656 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.4 m-20 -67.98 -44.88 75.63 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HE3' ' CG2' ' A' ' 150' ' ' ILE . 11.8 pttt -167.17 173.41 9.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.589 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -104.13 129.37 51.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.435 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.451 ' CG2' ' HE3' ' A' ' 148' ' ' LYS . 25.8 pt -125.5 161.59 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.904 . . . . 0.0 109.427 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.524 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.6 mttt -125.34 133.02 52.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -145.87 142.72 29.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 44.9 p -77.17 140.96 40.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.553 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.463 HG12 ' HD2' ' A' ' 159' ' ' PHE . 14.6 t -137.62 146.48 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.534 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 1.3 ptpt -91.05 145.48 24.65 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.313 -0.867 . . . . 0.0 109.801 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.552 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 2.0 p30 -48.96 -29.21 4.52 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.344 -0.847 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' THR . . . . . 0.496 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 17.1 p -78.98 -20.96 47.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.105 -0.997 . . . . 0.0 109.975 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.534 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 44.0 mm-40 -87.64 -20.4 26.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.02 -1.05 . . . . 0.0 109.214 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.552 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 26.8 p90 -135.85 166.86 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.876 . . . . 0.0 109.607 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -130.26 136.96 49.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.469 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' LYS . . . . . 0.468 ' HD2' ' HB3' ' A' ' 110' ' ' PRO . 18.3 pttp -77.45 147.18 36.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.267 -0.895 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.775 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.57 -34.32 75.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.252 -1.146 . . . . 0.0 109.466 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 72.7 mtm -56.12 -37.77 69.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.202 -0.936 . . . . 0.0 109.422 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLY . . . . . 0.46 ' O ' ' OD1' ' A' ' 103' ' ' ASP . . . -65.45 146.32 49.66 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.425 ' O ' ' HB2' ' A' ' 102' ' ' LYS . 50.1 Cg_endo -69.95 158.11 57.81 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.699 2.266 . . . . 0.0 111.849 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.486 ' HB3' ' CG2' ' A' ' 105' ' ' VAL . 62.6 mttp 61.63 53.32 3.31 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.301 -0.874 . . . . 0.0 109.499 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 100' ' ' GLY . 98.5 m-20 -59.85 -35.52 74.95 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.169 -0.957 . . . . 0.0 109.554 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 88.0 mt -63.64 -31.54 53.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.486 ' CG2' ' HB3' ' A' ' 102' ' ' LYS . 53.4 t -63.91 -40.61 89.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.471 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -94.64 109.99 46.66 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.298 -0.876 . . . . 0.0 109.487 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.9 52.93 1.09 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.654 2.236 . . . . 0.0 111.816 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -71.32 -33.04 69.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.446 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 29.3 m -72.53 138.79 80.73 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.597 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.8 Cg_endo -70.18 146.89 58.89 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.736 2.291 . . . . 0.0 111.854 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' TYR . . . . . 0.445 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 15.7 m-85 -108.76 161.15 24.68 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.877 . . . . 0.0 109.411 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' PRO . . . . . 0.445 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 47.5 Cg_endo -68.93 136.09 34.25 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.713 2.275 . . . . 0.0 111.765 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.4 -8.82 60.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -85.82 159.51 19.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.206 -1.173 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.559 ' HB3' HD21 ' A' ' 162' ' ' LEU . 24.6 mttm -87.3 145.52 26.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -0.899 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.995 HG21 HD23 ' A' ' 141' ' ' LEU . 14.1 m -132.98 152.18 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.428 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.467 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.8 tp -122.0 140.71 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.281 -0.887 . . . . 0.0 109.55 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.459 HD12 ' HB3' ' A' ' 123' ' ' PHE . 73.4 mt -92.68 132.88 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.252 -0.905 . . . . 0.0 109.405 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 54.7 p -111.01 0.16 16.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.248 -0.908 . . . . 0.0 109.6 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.439 ' HA ' ' OE1' ' A' ' 120' ' ' GLU . 71.7 mm-40 -143.52 155.73 44.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.174 -0.954 . . . . 0.0 109.484 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.35 164.26 39.65 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.74 -18.71 64.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -1.147 . . . . 0.0 109.473 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.752 ' CD1' HD13 ' A' ' 143' ' ' LEU . 96.9 m-85 -82.93 8.69 11.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.918 . . . . 0.0 109.535 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.0 tt0 -62.7 138.96 58.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.23 0.11 80.68 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -102.99 137.54 41.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.466 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -89.44 143.08 27.1 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.398 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.731 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.2 160.36 40.4 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.214 -0.929 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.2 mm -116.16 137.13 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.278 -0.889 . . . . 0.0 109.528 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' PHE . . . . . 0.676 ' CE2' HG11 ' A' ' 116' ' ' VAL . 24.7 m-85 -58.77 106.2 0.38 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.584 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.4 p -77.55 -33.64 54.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.256 -0.903 . . . . 0.0 109.249 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.05 96.53 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.428 -0.795 . . . . 0.0 109.326 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.43 123.52 10.29 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.71 2.274 . . . . 0.0 111.773 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -67.94 -33.03 73.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -150.24 174.71 29.58 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -69.57 -29.04 66.5 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.421 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.86 -74.16 0.13 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.161 -0.962 . . . . 0.0 109.344 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 33.0 ptt-85 -89.87 158.14 17.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.326 -0.859 . . . . 0.0 109.72 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 6.1 m -142.7 159.49 42.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' MET . . . . . 0.857 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.0 mtp -101.31 120.13 39.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.344 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.995 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -118.13 148.79 41.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.605 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' LEU . . . . . 0.741 HD13 ' HG2' ' A' ' 151' ' ' LYS . 48.9 tp -99.6 123.9 44.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.3 -0.875 . . . . 0.0 109.515 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.752 HD13 ' CD1' ' A' ' 123' ' ' PHE . 41.8 mt -98.18 110.84 23.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.95 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 20.1 p-10 -78.58 120.83 23.83 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.185 -0.947 . . . . 0.0 109.551 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' LEU . . . . . 0.843 HD11 HD13 ' A' ' 150' ' ' ILE . 67.9 mt -111.19 142.2 43.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.186 -0.946 . . . . 0.0 109.546 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.455 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.7 pt -51.63 -31.11 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.453 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASN . . . . . 0.52 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 87.2 m-20 -75.83 -55.57 5.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.465 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' LYS . . . . . 0.52 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 23.2 mttt -158.98 171.92 19.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.176 -0.952 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -88.34 130.03 35.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.325 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ILE . . . . . 0.843 HD13 HD11 ' A' ' 145' ' ' LEU . 42.4 pt -124.1 151.74 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.741 ' HG2' HD13 ' A' ' 142' ' ' LEU . 90.8 mttt -109.18 128.52 55.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.302 -0.874 . . . . 0.0 109.379 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -141.27 132.18 25.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.549 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 46.1 p -77.94 140.35 39.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.32 -0.862 . . . . 0.0 109.471 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.566 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.4 t -134.82 148.39 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.545 ' CD ' ' HG2' ' A' ' 158' ' ' GLU . 16.2 ptmt -91.27 139.96 30.24 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.227 -0.921 . . . . 0.0 109.625 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.583 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 44.7 m-80 -46.34 -27.27 1.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.397 -0.814 . . . . 0.0 110.067 -179.592 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' THR . . . . . 0.522 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 15.8 p -79.83 -21.02 44.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 0.0 109.766 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' GLU . . . . . 0.545 ' HG2' ' CD ' ' A' ' 155' ' ' LYS . 46.3 mm-40 -87.67 -20.51 26.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.052 -1.03 . . . . 0.0 109.229 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 39.3 p90 -136.17 168.68 18.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.339 -0.851 . . . . 0.0 109.667 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -133.09 159.7 39.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -82.51 118.0 22.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.433 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' LEU . . . . . 0.559 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.492 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.406 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 28.0 m-85 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.406 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.34 129.37 17.91 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.723 2.282 . . . . 0.0 111.773 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 104.26 -13.53 51.74 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -69.49 156.69 38.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -1.104 . . . . 0.0 109.445 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.487 ' HB2' HD12 ' A' ' 162' ' ' LEU . 18.2 mttp -86.42 139.63 30.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.561 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.04 HG21 HD23 ' A' ' 141' ' ' LEU . 4.4 m -127.17 154.14 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -0.911 . . . . 0.0 109.402 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.577 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.7 tp -122.44 139.83 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.57 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 83.6 mt -92.58 139.4 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.482 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.435 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 70.9 p -115.14 -10.8 12.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.458 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.38 157.26 43.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.08 162.08 38.01 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.9 -13.46 45.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.145 . . . . 0.0 109.437 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.461 ' CD1' HD23 ' A' ' 143' ' ' LEU . 96.4 m-85 -86.59 12.67 10.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.435 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.3 tt0 -63.42 137.93 58.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.12 -0.81 76.26 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -102.45 139.3 38.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.576 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -91.48 146.72 23.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.72 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -140.68 162.24 35.87 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.448 HD13 ' O ' ' A' ' 128' ' ' ALA . 35.6 mm -117.48 135.01 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.194 -0.941 . . . . 0.0 109.582 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.631 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.6 m-85 -58.55 104.41 0.22 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.523 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 55.4 p -79.79 -32.1 40.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.897 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 163.68 93.62 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.437 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 126.74 13.37 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.667 2.245 . . . . 0.0 111.723 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -66.82 -24.89 66.21 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.251 -0.906 . . . . 0.0 109.539 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.03 -179.41 40.56 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -72.64 -24.94 61.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -1.136 . . . . 0.0 109.452 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -75.29 -51.45 13.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.471 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 55.5 mtt85 -110.52 151.33 27.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 57.1 m -139.74 156.16 46.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.924 . . . . 0.0 109.507 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.821 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 mtp -106.76 119.39 39.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.04 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -116.3 154.03 30.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.509 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.865 HD12 ' O ' ' A' ' 150' ' ' ILE . 51.5 tp -106.04 124.95 50.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.216 -0.927 . . . . 0.0 109.464 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.841 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -99.19 116.67 31.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -82.73 129.23 34.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.638 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.743 HD11 HD13 ' A' ' 150' ' ' ILE . 42.6 mt -121.09 142.12 50.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.398 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.45 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -49.94 -30.6 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.517 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.45 ' N ' HG13 ' A' ' 146' ' ' ILE . 92.9 m-20 -79.24 -47.71 15.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.27 -0.894 . . . . 0.0 109.681 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.529 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 40.2 ttpt -168.77 168.1 10.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.459 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.529 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.9 mt-10 -87.55 137.29 32.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.252 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.865 ' O ' HD12 ' A' ' 142' ' ' LEU . 36.1 pt -126.34 149.16 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.202 -0.936 . . . . 0.0 109.774 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.823 ' HG2' HD13 ' A' ' 142' ' ' LEU . 62.1 mttp -110.45 131.46 55.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -0.882 . . . . 0.0 109.191 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -142.38 140.62 32.1 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.177 -0.952 . . . . 0.0 109.681 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 21.6 p -88.45 122.0 31.46 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.347 -0.846 . . . . 0.0 109.217 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.724 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.3 p -124.07 149.99 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.595 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.3 mttt -76.64 150.5 36.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.881 . . . . 0.0 109.482 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.567 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.9 m-80 -59.69 -23.49 63.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.335 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 74.8 p -81.62 -25.96 35.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.268 -0.895 . . . . 0.0 109.428 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.601 ' OE1' HG23 ' A' ' 154' ' ' VAL . 88.6 mt-10 -75.03 -24.81 58.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 0.0 109.519 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.724 ' CE2' HD21 ' A' ' 141' ' ' LEU . 31.9 p90 -136.36 170.78 15.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.43 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -134.23 159.64 40.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.226 -0.921 . . . . 0.0 109.53 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -83.63 146.76 28.09 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 117' ' ' ILE . 23.8 mt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.436 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 53.1 m-85 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.3 Cg_endo -69.92 135.16 29.4 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.663 2.242 . . . . 0.0 111.795 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.12 -9.04 65.29 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.436 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 82.8 m-20 -81.27 146.74 30.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -1.172 . . . . 0.0 109.523 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.676 ' C ' HD12 ' A' ' 162' ' ' LEU . 29.4 mtmt -80.51 144.48 32.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 0.0 109.417 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.977 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.4 m -133.47 152.63 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.196 -0.94 . . . . 0.0 109.595 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.69 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.8 tp -121.74 139.51 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.421 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.557 HD12 ' HB3' ' A' ' 123' ' ' PHE . 67.7 mt -92.78 130.76 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 70.4 p -116.72 4.04 13.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -0.925 . . . . 0.0 109.624 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 157' ' ' THR . 92.5 mt-10 -137.7 155.73 48.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 87.54 -168.04 37.74 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.6 -7.07 51.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -1.135 . . . . 0.0 109.502 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.557 ' HB3' HD12 ' A' ' 118' ' ' ILE . 80.4 m-85 -88.86 15.81 7.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.418 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 95.8 mt-10 -61.18 135.07 57.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.64 0.71 69.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -102.95 131.96 49.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -1.207 . . . . 0.0 109.488 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -92.61 140.46 29.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.229 -0.92 . . . . 0.0 109.45 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.778 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -136.77 167.01 22.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.176 -0.952 . . . . 0.0 109.536 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.519 HD13 ' O ' ' A' ' 128' ' ' ALA . 30.7 mm -118.31 138.14 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.3 m-85 -58.49 102.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.254 -0.904 . . . . 0.0 109.579 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.524 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 40.9 p -75.8 -33.39 60.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.6 OUTLIER 163.49 95.41 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.308 -0.87 . . . . 0.0 109.347 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.76 117.31 5.0 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.695 2.264 . . . . 0.0 111.791 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 18.1 p-10 -66.91 -31.56 72.23 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -0.935 . . . . 0.0 109.573 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.432 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -155.32 172.85 33.55 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -70.15 -28.85 65.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.307 -1.114 . . . . 0.0 109.485 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.67 -53.6 15.13 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.53 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.44 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 79.4 mtt180 -111.86 146.25 38.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.286 -0.883 . . . . 0.0 109.506 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.8 m -134.34 157.94 45.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.472 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.937 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.9 mtp -102.07 124.8 48.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.468 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.977 HD23 ' CG2' ' A' ' 116' ' ' VAL . 6.3 mp -127.22 143.91 51.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.209 -0.932 . . . . 0.0 109.551 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.809 HD12 ' O ' ' A' ' 150' ' ' ILE . 45.4 tp -93.79 121.19 34.99 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.955 . . . . 0.0 109.519 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.801 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.5 mp -93.03 129.62 38.9 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.429 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -103.59 106.98 17.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.882 . . . . 0.0 109.482 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.492 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 7.0 mp -75.03 -175.7 2.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.207 -0.933 . . . . 0.0 109.477 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.54 HG13 ' N ' ' A' ' 147' ' ' ASN . 10.9 pt -60.44 -46.09 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.18 -0.95 . . . . 0.0 109.449 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.54 ' N ' HG13 ' A' ' 146' ' ' ILE . 28.7 p-10 -139.38 23.1 2.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.286 -0.884 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.452 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 40.8 mttt -140.29 151.14 44.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.742 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -120.63 134.13 55.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.33 -0.856 . . . . 0.0 108.992 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.809 ' O ' HD12 ' A' ' 142' ' ' LEU . 37.0 pt -133.6 154.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.125 -0.984 . . . . 0.0 109.892 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.747 ' HG2' HD13 ' A' ' 142' ' ' LEU . 51.5 mttt -123.16 124.79 43.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.34 -0.85 . . . . 0.0 109.286 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -153.19 150.93 29.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 47.9 p -80.14 140.28 36.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.304 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.506 HG12 ' HD1' ' A' ' 159' ' ' PHE . 14.1 t -122.69 155.67 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.492 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 31.0 mttt -91.16 143.99 26.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.434 ' O ' ' O ' ' A' ' 159' ' ' PHE . 1.0 OUTLIER -51.4 -29.44 15.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.511 179.864 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 120' ' ' GLU . 45.9 p -82.57 -22.82 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.526 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -78.4 -19.99 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.254 -0.904 . . . . 0.0 109.531 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.575 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.4 p90 -145.09 162.25 37.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.938 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -131.83 136.47 47.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.535 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -60.86 134.46 57.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.69 HD21 ' HB ' ' A' ' 117' ' ' ILE . 9.2 mt . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.472 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.468 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 48.2 m-85 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.01 137.48 34.82 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.702 2.268 . . . . 0.0 111.829 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.78 -10.07 68.47 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.468 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.8 m-20 -82.39 145.48 29.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.252 -1.146 . . . . 0.0 109.461 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.464 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 30.5 mttm -75.83 142.23 42.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.912 HG21 HD23 ' A' ' 141' ' ' LEU . 4.5 m -132.45 150.97 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.444 ' HB ' HD11 ' A' ' 162' ' ' LEU . 4.5 tp -123.43 141.75 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.491 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.535 HD12 ' HB3' ' A' ' 123' ' ' PHE . 61.2 mt -92.59 131.12 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.236 -0.915 . . . . 0.0 109.443 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.451 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.2 p -106.95 -8.39 16.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.6 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -137.37 157.29 46.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.23 -0.919 . . . . 0.0 109.572 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.21 165.14 37.75 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.67 -19.87 65.25 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.445 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.535 ' HB3' HD12 ' A' ' 118' ' ' ILE . 94.3 m-85 -86.38 13.48 8.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.454 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 87.0 tt0 -66.25 137.88 57.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.471 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.51 0.26 73.23 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -106.4 134.72 49.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -1.162 . . . . 0.0 109.484 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -79.93 147.62 31.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.222 -0.924 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.33 163.63 32.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.676 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.0 mm -121.29 139.23 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -0.875 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.615 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 42.2 m-85 -60.92 114.41 3.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.192 -0.943 . . . . 0.0 109.442 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.519 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.3 p -87.37 -30.76 20.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 163.79 82.2 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.896 . . . . 0.0 109.455 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.417 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.07 130.74 19.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.723 2.282 . . . . 0.0 111.827 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -67.83 -32.72 73.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.291 -0.88 . . . . 0.0 109.475 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -170.54 -177.48 40.65 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.62 -29.46 70.47 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.272 -1.134 . . . . 0.0 109.521 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -63.68 -60.41 3.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.165 -0.96 . . . . 0.0 109.438 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.453 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.2 mtt180 -112.72 155.74 24.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 53.4 m -146.5 149.07 32.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.434 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.932 ' C ' HD12 ' A' ' 141' ' ' LEU . 82.1 mmm -95.31 125.14 39.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.389 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.932 HD12 ' C ' ' A' ' 140' ' ' MET . 6.3 mp -125.46 140.4 52.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.163 -0.961 . . . . 0.0 109.631 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.604 HD12 ' HG2' ' A' ' 151' ' ' LYS . 6.0 tt -96.04 123.9 39.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.322 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.858 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.6 mp -99.51 113.65 26.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.652 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -89.52 124.27 34.37 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.703 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.5 mm? -85.27 175.22 9.06 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.152 -0.967 . . . . 0.0 109.392 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.501 HG13 ' N ' ' A' ' 147' ' ' ASN . 17.6 pt -58.93 -38.12 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.501 ' N ' HG13 ' A' ' 146' ' ' ILE . 24.2 m120 -138.89 19.61 2.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.958 . . . . 0.0 109.407 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 85.7 mttt -143.64 156.56 44.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.26 -0.9 . . . . 0.0 109.631 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -121.38 124.9 45.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.196 -0.94 . . . . 0.0 109.191 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 145' ' ' LEU . 32.8 pt -128.73 156.03 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.918 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.604 ' HG2' HD12 ' A' ' 142' ' ' LEU . 22.7 mttt -131.56 132.18 43.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.339 -0.851 . . . . 0.0 109.27 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 153' ' ' SER . 57.8 t-80 -152.28 144.79 24.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.141 -0.974 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.429 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 45.9 p -68.7 142.61 54.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.33 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.832 ' HB ' HD13 ' A' ' 141' ' ' LEU . 19.7 t -129.85 150.78 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.537 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 158' ' ' GLU . 90.5 mttt -94.11 139.12 31.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.33 -0.856 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.0 p30 -46.0 -29.06 1.32 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.169 -0.957 . . . . 0.0 109.582 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 57.9 p -82.24 -21.92 36.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 109.595 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.2 mt-10 -81.22 -20.6 40.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.658 ' CD2' HD21 ' A' ' 141' ' ' LEU . 27.7 p90 -140.74 172.14 13.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -0.937 . . . . 0.0 109.561 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -130.85 147.73 52.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -78.57 133.54 37.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.273 -0.892 . . . . 0.0 109.504 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.444 HD11 ' HB ' ' A' ' 117' ' ' ILE . 15.9 mt . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.468 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.443 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 6.5 m-85 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.64 131.52 23.07 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.73 2.286 . . . . 0.0 111.712 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.65 -11.98 59.5 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.6 m-20 -77.44 157.43 30.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -1.155 . . . . 0.0 109.497 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.568 ' HB3' HD21 ' A' ' 162' ' ' LEU . 55.9 mttt -80.35 142.12 34.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.299 -0.876 . . . . 0.0 109.448 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.011 HG21 HD23 ' A' ' 141' ' ' LEU . 5.8 m -127.59 159.48 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.836 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.3 tp -123.37 147.32 27.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.607 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.2 mm -91.45 131.63 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.264 -0.897 . . . . 0.0 109.475 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.429 ' C ' ' HG2' ' A' ' 124' ' ' GLU . 72.7 p -121.65 5.5 10.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.267 -0.896 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.426 ' N ' ' HG2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -141.73 151.16 42.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -0.936 . . . . 0.0 109.442 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 85.13 -170.27 44.94 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.73 -2.4 58.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -1.201 . . . . 0.0 109.625 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.607 ' HB2' HG21 ' A' ' 118' ' ' ILE . 93.1 m-85 -87.94 4.78 43.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.63 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 119' ' ' THR . 97.5 mt-10 -56.5 142.09 40.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.7 -3.46 83.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.594 ' O ' HD12 ' A' ' 117' ' ' ILE . 19.8 m-30 -102.36 147.71 26.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -1.17 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -100.17 151.03 21.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.387 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.966 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -146.74 161.34 40.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.227 -0.92 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.487 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 22.8 mm -114.02 140.54 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.484 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.5 m-85 -61.42 112.86 2.36 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.275 -0.891 . . . . 0.0 109.443 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 46.0 p -82.36 -32.13 29.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.457 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.8 mm-40 164.4 91.72 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.156 -0.965 . . . . 0.0 109.488 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.11 122.99 9.55 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.597 2.198 . . . . 0.0 111.771 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -65.81 -31.26 72.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.47 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -163.26 179.84 38.18 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.04 -26.85 63.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.218 -1.166 . . . . 0.0 109.541 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.36 -53.72 15.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.461 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 59.0 mtt180 -112.32 151.44 29.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.516 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 54.4 m -142.32 150.43 40.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.303 -0.873 . . . . 0.0 109.465 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.931 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.8 mtp -100.37 127.31 46.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.011 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -125.38 146.42 49.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.483 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.576 ' O ' ' HB1' ' A' ' 128' ' ' ALA . 9.7 tt -97.44 126.3 42.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.641 HD23 ' HB2' ' A' ' 128' ' ' ALA . 39.1 mt -97.93 109.88 22.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.542 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.625 ' C ' HD22 ' A' ' 145' ' ' LEU . 14.9 p-10 -84.63 122.6 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 0.0 109.621 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -111.23 141.43 44.77 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.383 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.499 HG13 ' N ' ' A' ' 147' ' ' ASN . 21.3 pt -50.03 -35.75 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.499 ' N ' HG13 ' A' ' 146' ' ' ILE . 61.3 t30 -72.42 -49.22 35.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.288 -0.882 . . . . 0.0 109.575 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.499 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 67.3 mttt -158.11 173.38 16.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.543 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -103.17 133.21 48.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.924 . . . . 0.0 109.312 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.451 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 17.2 pt -133.99 159.27 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.625 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.523 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 13.3 mttt -119.63 136.95 54.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.282 -0.886 . . . . 0.0 109.33 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -144.31 140.24 29.04 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.585 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 23.5 p -85.1 125.19 32.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.338 -0.851 . . . . 0.0 109.313 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.722 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.0 p -127.97 147.92 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.196 -0.94 . . . . 0.0 109.547 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.54 ' O ' ' CD2' ' A' ' 159' ' ' PHE . 88.8 mttt -76.08 155.27 34.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.231 -0.918 . . . . 0.0 109.464 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 20.3 m-80 -62.71 -27.09 69.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.453 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 64.7 p -77.33 -18.86 57.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.356 -0.84 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.536 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.3 mt-10 -87.72 -19.78 27.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.475 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.581 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 29.8 p90 -138.08 161.03 37.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -0.951 . . . . 0.0 109.583 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.836 ' O ' HG22 ' A' ' 117' ' ' ILE . 73.7 mtt180 -129.53 147.77 51.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.317 -0.864 . . . . 0.0 109.475 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 25.7 tttt -73.55 123.88 24.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.612 ' OXT' HD12 ' A' ' 162' ' ' LEU . 1.1 pp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.487 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.462 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 52.8 m-85 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 49.4 Cg_endo -70.2 135.01 28.37 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.675 2.25 . . . . 0.0 111.754 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.82 -10.11 66.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.462 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.2 m-20 -83.99 147.53 27.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -1.123 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.516 ' CB ' HD21 ' A' ' 162' ' ' LEU . 22.7 mttm -72.98 145.08 46.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.902 . . . . 0.0 109.456 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 141' ' ' LEU . 4.3 m -133.79 150.42 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.476 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 1.8 tp -119.95 139.29 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.461 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.585 HD11 HD21 ' A' ' 143' ' ' LEU . 58.8 mt -92.53 130.08 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.287 -0.883 . . . . 0.0 109.501 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.482 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 60.5 p -106.96 -10.26 16.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -132.87 157.36 45.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 109.522 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.66 166.85 36.33 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.59 -22.31 64.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 96.9 m-85 -82.51 8.13 12.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.224 -0.922 . . . . 0.0 109.52 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -57.64 139.9 52.51 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.297 -0.877 . . . . 0.0 109.522 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.53 -5.26 73.82 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.5 m-30 -99.99 145.79 27.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.247 -1.149 . . . . 0.0 109.464 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -94.55 146.45 24.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.935 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.812 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.21 160.18 40.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.299 -0.875 . . . . 0.0 109.42 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.71 140.06 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.48 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.625 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.8 m-85 -61.42 110.15 1.36 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.295 -0.878 . . . . 0.0 109.495 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.52 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 39.3 p -80.46 -32.5 37.18 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.317 -0.864 . . . . 0.0 109.477 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 164.32 86.58 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.267 -0.895 . . . . 0.0 109.398 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.79 128.56 16.17 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.773 2.316 . . . . 0.0 111.799 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -69.06 -29.34 67.45 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.517 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -167.92 174.81 42.87 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -62.07 -27.97 69.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.68 -64.93 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.164 -0.96 . . . . 0.0 109.476 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.402 ' O ' ' O ' ' A' ' 135' ' ' GLY . 49.9 mtm-85 -105.08 152.08 23.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.532 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 65.2 m -142.46 152.15 42.44 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.51 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.917 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.2 mmm -96.58 123.61 40.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -122.5 142.89 50.11 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.945 . . . . 0.0 109.636 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.833 HD13 ' HG2' ' A' ' 151' ' ' LYS . 15.1 tp -103.86 119.36 38.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.273 -0.892 . . . . 0.0 109.417 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -100.57 109.14 21.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.501 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.431 ' O ' ' CG ' ' A' ' 144' ' ' ASN . 11.3 p-10 -83.11 118.86 23.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.567 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.765 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -82.03 168.83 17.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.259 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.515 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.2 pt -54.15 -38.27 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.19 -0.944 . . . . 0.0 109.638 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.515 ' N ' HG13 ' A' ' 146' ' ' ILE . 30.3 p-10 -139.19 25.09 2.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -0.984 . . . . 0.0 109.787 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.461 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 76.0 mttt -152.61 157.41 40.97 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.0 109.815 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -128.11 130.86 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.383 -0.823 . . . . 0.0 109.112 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.618 ' O ' HD12 ' A' ' 142' ' ' LEU . 21.3 pt -131.45 145.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.134 -0.978 . . . . 0.0 109.835 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.833 ' HG2' HD13 ' A' ' 142' ' ' LEU . 19.6 mttp -118.53 126.79 52.75 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 0.0 109.298 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.494 ' CE1' ' O ' ' A' ' 153' ' ' SER . 52.5 t-80 -153.85 145.73 23.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.168 -0.958 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.494 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 52.5 p -74.48 141.48 44.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.216 -0.928 . . . . 0.0 109.356 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.601 HG12 ' HD1' ' A' ' 159' ' ' PHE . 21.3 t -124.78 150.4 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.442 ' HB2' ' HG3' ' A' ' 158' ' ' GLU . 61.3 mttp -86.06 138.46 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -49.96 -22.99 1.75 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.943 . . . . 0.0 109.494 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.7 p -86.62 -25.39 24.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.175 -0.953 . . . . 0.0 109.463 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG3' ' HB2' ' A' ' 155' ' ' LYS . 97.6 mt-10 -76.63 -23.39 53.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -0.865 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.926 ' CE2' HD21 ' A' ' 141' ' ' LEU . 22.7 p90 -140.62 160.95 38.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 109.491 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -128.89 142.15 51.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.219 -0.925 . . . . 0.0 109.512 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -70.43 124.99 25.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.208 -0.933 . . . . 0.0 109.422 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.516 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.496 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 65.9 m-85 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.2 Cg_endo -69.64 132.27 23.16 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.681 2.254 . . . . 0.0 111.756 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.54 -10.55 61.12 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.45 ' HB3' ' HE3' ' A' ' 161' ' ' LYS . 81.5 m-20 -77.85 150.72 34.15 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.176 -1.191 . . . . 0.0 109.451 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.549 ' HB3' HD21 ' A' ' 162' ' ' LEU . 28.8 mttt -84.81 141.51 30.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.47 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -129.04 158.89 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 160' ' ' ARG . 7.3 tp -126.59 148.73 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.151 -0.968 . . . . 0.0 109.505 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.453 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 25.9 mm -90.52 127.84 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 72.8 p -112.83 -5.36 13.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.275 -0.891 . . . . 0.0 109.502 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.468 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 85.2 tt0 -138.51 156.28 47.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.202 -0.936 . . . . 0.0 109.421 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.468 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 86.5 169.57 46.05 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.22 -14.63 63.13 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -1.163 . . . . 0.0 109.527 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.553 ' CD1' HD13 ' A' ' 143' ' ' LEU . 85.6 m-85 -82.78 6.85 16.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 84.5 tt0 -59.45 132.84 55.2 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.565 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 99.46 1.17 56.67 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.521 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -103.49 138.58 40.01 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.12 -1.224 . . . . 0.0 109.59 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -93.98 122.58 36.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.211 -0.931 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.922 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -118.52 165.77 13.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.58 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.525 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 41.9 mm -120.43 139.29 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.598 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.6 m-85 -58.65 101.37 0.09 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.906 . . . . 0.0 109.516 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.525 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 49.2 p -77.15 -30.52 55.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.286 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.2 mt-10 163.63 97.15 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.262 -0.899 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.85 114.63 3.78 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.707 2.272 . . . . 0.0 111.763 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -66.55 -33.6 76.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.492 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -145.01 163.0 28.11 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.66 -31.99 72.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -1.146 . . . . 0.0 109.184 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.17 -73.91 0.15 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.6 ptt-85 -84.96 158.32 20.55 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.285 -0.885 . . . . 0.0 109.611 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 71.1 m -145.79 144.58 30.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.871 ' C ' HD12 ' A' ' 141' ' ' LEU . 89.8 mmm -86.58 118.89 26.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.251 -0.906 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -122.61 146.07 47.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.521 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.72 HD12 ' CE ' ' A' ' 151' ' ' LYS . 9.4 tt -99.37 127.44 45.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.434 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.553 HD13 ' CD1' ' A' ' 123' ' ' PHE . 17.9 mt -96.8 115.04 26.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.863 ' C ' HD12 ' A' ' 145' ' ' LEU . 6.9 p30 -86.75 126.6 34.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.6 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.863 HD12 ' C ' ' A' ' 144' ' ' ASN . 9.6 mp -129.46 136.33 49.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.242 -0.911 . . . . 0.0 109.362 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.514 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -50.55 -35.09 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.888 . . . . 0.0 109.614 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.514 ' N ' HG13 ' A' ' 146' ' ' ILE . 47.7 t-20 -68.68 -47.56 66.16 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.915 . . . . 0.0 109.585 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.482 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 55.5 tttp -168.09 158.98 10.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.166 -0.959 . . . . 0.0 109.576 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.482 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 97.0 mt-10 -93.81 125.72 38.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.95 . . . . 0.0 109.5 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.474 HD11 ' CE1' ' A' ' 123' ' ' PHE . 27.8 pt -126.34 158.63 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.205 -0.935 . . . . 0.0 109.428 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.72 ' CE ' HD12 ' A' ' 142' ' ' LEU . 17.1 mttt -124.62 131.55 53.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.543 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -142.6 147.06 35.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 39.3 p -72.18 139.66 48.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.692 ' HB ' HD13 ' A' ' 141' ' ' LEU . 21.8 t -131.08 150.63 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 24.6 mttm -97.16 138.72 34.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.585 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 32.1 m-80 -45.06 -30.64 1.11 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 65.9 p -81.15 -25.21 37.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.287 -0.883 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 92.0 mt-10 -76.21 -23.67 54.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.642 ' HD1' HG12 ' A' ' 154' ' ' VAL . 27.5 p90 -137.41 167.05 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 117' ' ' ILE . 63.5 mtt85 -130.21 146.84 51.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . 0.45 ' HE3' ' HB3' ' A' ' 114' ' ' ASP . 73.8 tttt -72.8 117.23 14.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.436 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.549 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.466 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.47 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 43.7 m-85 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 133.61 25.19 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.69 2.26 . . . . 0.0 111.873 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.34 -10.69 61.52 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.47 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.6 m-20 -85.57 144.69 27.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.288 -1.124 . . . . 0.0 109.498 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -75.45 147.02 40.22 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 109.517 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.058 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -134.9 151.41 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.912 HG21 HD21 ' A' ' 162' ' ' LEU . 3.8 tp -123.94 141.07 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.446 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 61.8 mt -92.18 129.95 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.321 -0.862 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.508 HG21 ' CD ' ' A' ' 160' ' ' ARG . 75.0 p -105.65 -7.6 18.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.537 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.435 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 97.8 mt-10 -138.02 158.16 44.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.484 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.4 168.11 38.55 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.95 -22.7 65.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.222 -1.163 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.9 m-85 -83.47 9.46 11.17 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.244 -0.91 . . . . 0.0 109.417 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.502 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -61.76 140.89 58.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.96 -6.06 76.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.0 m-85 -99.89 149.8 23.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -1.153 . . . . 0.0 109.557 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -98.45 147.86 24.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.319 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.817 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.69 162.61 35.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.898 . . . . 0.0 109.502 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.41 HD13 ' O ' ' A' ' 128' ' ' ALA . 26.1 mm -113.47 143.87 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.635 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 33.6 m-85 -66.06 113.01 4.16 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.531 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 18.1 p -82.4 -33.17 28.78 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.952 . . . . 0.0 109.437 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.89 90.3 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.78 122.66 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.686 2.257 . . . . 0.0 111.799 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 21.3 p-10 -65.89 -31.21 72.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.664 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.509 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -164.66 178.6 39.79 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -67.61 -27.05 66.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.308 -1.113 . . . . 0.0 109.543 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.04 -63.2 1.14 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 58.1 mtt180 -108.37 158.53 17.42 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 109.548 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 72.6 m -145.28 155.38 43.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.394 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.896 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.6 mtp -102.21 124.27 47.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.058 HD23 HG21 ' A' ' 116' ' ' VAL . 6.2 mp -122.25 145.79 47.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 7.8 tt -104.8 120.82 42.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.915 . . . . 0.0 109.521 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.7 mp -96.37 136.1 37.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.44 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.498 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 92.7 m-20 -106.21 112.41 25.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.541 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 44.1 mt -100.24 148.08 25.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.512 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -51.13 -40.12 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.512 ' N ' HG13 ' A' ' 146' ' ' ILE . 45.8 t-20 -68.7 -48.08 64.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.54 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.505 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 28.3 ttpp -168.46 164.6 12.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.287 -0.883 . . . . 0.0 109.466 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.505 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 95.1 mt-10 -87.88 139.19 30.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.7 158.18 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.25 -0.906 . . . . 0.0 109.402 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.447 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.8 mttt -125.84 130.45 51.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.196 -0.94 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.411 ' ND1' ' O ' ' A' ' 153' ' ' SER . 56.5 t-80 -153.17 141.61 20.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 109.436 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.411 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 68.6 m -67.77 142.59 56.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -0.958 . . . . 0.0 109.438 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.651 ' HB ' HD13 ' A' ' 141' ' ' LEU . 16.8 t -131.03 151.6 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.418 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 9.5 mtpm? -92.04 137.29 32.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.893 . . . . 0.0 109.508 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.587 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.0 m-80 -50.66 -24.36 3.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 109.415 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.6 p -84.78 -22.49 29.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.907 . . . . 0.0 109.356 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG2' ' HB2' ' A' ' 155' ' ' LYS . 68.6 mm-40 -81.47 -20.7 39.66 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.623 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -139.14 178.29 7.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.508 ' CD ' HG21 ' A' ' 119' ' ' THR . 59.1 mtt-85 -134.65 146.63 49.71 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.871 . . . . 0.0 109.402 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -84.71 135.75 34.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.447 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.912 HD21 HG21 ' A' ' 117' ' ' ILE . 68.0 mt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.415 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.407 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 33.0 m-85 . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.17 134.04 28.21 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.693 2.262 . . . . 0.0 111.819 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.03 -17.55 54.0 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -68.47 162.71 24.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -1.151 . . . . 0.0 109.38 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.483 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 36.5 mttm -88.01 139.48 30.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.282 -0.886 . . . . 0.0 109.572 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -133.48 148.98 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.447 ' CG2' ' HB3' ' A' ' 162' ' ' LEU . 5.1 tp -116.67 141.45 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.556 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.443 HD11 HD21 ' A' ' 143' ' ' LEU . 72.6 mt -92.61 130.72 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.422 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.454 HG21 ' HD2' ' A' ' 160' ' ' ARG . 61.3 p -107.27 -5.02 18.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.472 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 83.9 tt0 -141.41 155.53 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.521 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 100.33 166.83 28.83 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.37 -22.22 64.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.578 ' CE1' HD11 ' A' ' 150' ' ' ILE . 77.8 m-85 -87.64 12.87 11.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.1 136.94 58.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.254 -0.904 . . . . 0.0 109.432 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.91 66.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -105.68 122.75 46.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -1.168 . . . . 0.0 109.541 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -72.05 137.35 47.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.298 -0.876 . . . . 0.0 109.306 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.83 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -133.68 158.52 43.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.208 -0.932 . . . . 0.0 109.563 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.5 mm -116.64 136.0 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.444 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.842 ' CE2' HG11 ' A' ' 116' ' ' VAL . 35.2 m-85 -58.61 101.77 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.519 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.467 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 44.8 p -75.05 -39.06 61.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.386 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 131' ' ' THR . 67.9 tt0 172.98 95.77 0.05 OUTLIER Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.9 . . . . 0.0 109.441 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.16 110.72 2.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.718 2.279 . . . . 0.0 111.848 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.5 p-10 -62.68 -34.42 77.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.504 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.417 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -141.85 178.06 20.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -76.91 -30.02 55.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -1.129 . . . . 0.0 109.406 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -69.46 -78.06 0.07 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.407 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 13.3 ptt180 -89.77 148.13 23.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.248 -0.907 . . . . 0.0 109.743 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.1 m -135.33 155.38 50.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 0.0 109.492 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.76 ' C ' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -89.92 115.55 27.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.1 mp -119.74 139.52 52.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.892 . . . . 0.0 109.481 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.603 HD12 ' N ' ' A' ' 143' ' ' LEU . 9.0 tp -97.48 122.16 40.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.776 HD23 ' HB2' ' A' ' 128' ' ' ALA . 22.1 mt -87.95 146.46 25.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.316 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.503 ' C ' HD12 ' A' ' 145' ' ' LEU . 99.2 m-20 -115.98 107.96 15.63 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.601 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.77 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.0 mp -105.23 141.18 37.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.938 . . . . 0.0 109.302 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.0 pt -50.39 -32.5 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.522 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.7 m-20 -73.12 -56.41 5.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.289 -0.882 . . . . 0.0 109.674 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.522 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 60.2 mttm -159.58 171.32 19.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.513 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.58 139.08 38.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.337 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.598 ' O ' HD12 ' A' ' 142' ' ' LEU . 20.1 pt -132.8 142.43 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.231 -0.918 . . . . 0.0 109.46 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.445 ' HG2' HD13 ' A' ' 142' ' ' LEU . 98.1 mttt -96.5 130.02 43.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.24 -0.913 . . . . 0.0 109.474 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -147.52 138.57 23.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.488 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 52.1 p -73.2 141.45 47.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.278 -0.889 . . . . 0.0 109.441 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.729 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.2 t -128.81 151.56 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -0.91 . . . . 0.0 109.56 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 45.4 mttp -100.87 138.36 38.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.376 -0.828 . . . . 0.0 109.423 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.1 p30 -46.04 -28.28 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.493 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 72.0 p -84.94 -19.64 31.88 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.25 -0.906 . . . . 0.0 109.629 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.6 mt-10 -83.23 -22.34 33.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.182 -0.949 . . . . 0.0 109.459 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.655 ' HD1' HG12 ' A' ' 154' ' ' VAL . 29.9 p90 -136.93 173.03 12.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.215 -0.928 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.454 ' HD2' HG21 ' A' ' 119' ' ' THR . 96.6 mtt180 -134.99 145.17 47.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.515 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -69.34 113.59 6.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.616 HD23 ' C ' ' A' ' 116' ' ' VAL . 1.9 pp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.406 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.7 138.22 37.48 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.722 2.281 . . . . 0.0 111.79 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.85 -11.61 66.12 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.99 151.7 40.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -1.144 . . . . 0.0 109.403 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.534 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.5 mttm -80.26 139.75 36.54 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.031 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -129.23 156.3 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.655 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.24 146.1 29.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.598 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 20.5 mm -90.13 120.27 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.394 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 58.1 p -103.03 -16.06 15.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.42 155.56 50.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.459 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.94 165.04 35.45 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.95 -15.35 62.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 0.0 109.441 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.698 ' HB3' HD23 ' A' ' 143' ' ' LEU . 88.7 m-85 -86.49 11.75 11.88 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.459 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.1 tt0 -59.04 134.74 57.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.97 67.18 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.475 ' CE2' ' HG ' ' A' ' 145' ' ' LEU . 40.7 m-85 -99.19 137.62 37.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.098 -1.236 . . . . 0.0 109.545 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -90.99 129.38 37.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.323 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.972 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -130.08 163.72 25.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.56 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 128' ' ' ALA . 31.0 mm -119.42 139.76 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.308 -0.87 . . . . 0.0 109.408 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.594 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 38.0 m-85 -58.6 101.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -0.933 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.501 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 41.0 p -77.58 -28.33 51.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.7 OUTLIER 164.93 98.01 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.484 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.0 Cg_endo -69.82 114.83 3.84 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.733 2.289 . . . . 0.0 111.805 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -60.94 -30.7 70.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 109.506 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -166.15 174.45 41.72 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -67.34 -22.81 65.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -1.144 . . . . 0.0 109.491 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.92 -64.63 1.01 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.452 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 57.5 mtm-85 -107.72 159.61 16.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 55.7 m -144.98 157.93 43.97 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -0.864 . . . . 0.0 109.471 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.893 ' C ' HD12 ' A' ' 141' ' ' LEU . 33.8 mtp -101.97 120.91 41.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.031 HD23 HG21 ' A' ' 116' ' ' VAL . 6.4 mp -120.31 147.31 45.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.772 HD13 ' HG2' ' A' ' 151' ' ' LYS . 11.9 tp -99.87 124.01 44.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.45 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.843 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.1 mp -100.89 109.51 21.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.195 -0.941 . . . . 0.0 109.457 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.726 ' C ' HD12 ' A' ' 145' ' ' LEU . 13.4 p-10 -83.24 125.44 31.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.908 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 144' ' ' ASN . 7.7 mp -118.3 141.87 48.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.16 -0.962 . . . . 0.0 109.468 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.44 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.4 pt -51.6 -30.93 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.478 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.506 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 95.6 m-20 -74.98 -55.24 5.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.263 -0.898 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.506 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 33.9 mttt -158.68 171.78 19.47 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.223 -0.923 . . . . 0.0 109.622 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -101.01 131.3 46.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.239 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 142' ' ' LEU . 6.9 pt -129.87 144.77 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.742 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.772 ' HG2' HD13 ' A' ' 142' ' ' LEU . 31.2 mttt -108.47 136.57 47.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.039 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.09 140.02 20.97 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.004 -1.06 . . . . 0.0 109.831 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.402 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.4 p -85.19 121.8 28.46 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.39 -0.819 . . . . 0.0 109.047 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.544 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 2.9 p -121.13 151.55 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.15 -0.969 . . . . 0.0 109.638 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 35.2 mttt -75.21 149.25 38.97 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.327 -0.858 . . . . 0.0 109.577 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.573 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.1 m-80 -60.56 -26.09 66.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.7 p -78.51 -20.69 50.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.293 -0.88 . . . . 0.0 109.53 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.544 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 72.8 mm-40 -83.28 -22.06 33.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.908 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.977 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.4 p90 -138.35 156.19 47.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.655 ' O ' HG22 ' A' ' 117' ' ' ILE . 17.3 ttt85 -127.93 137.08 52.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 16.8 pttt -72.19 161.03 31.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.174 -0.954 . . . . 0.0 109.405 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.791 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.079 -0.963 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.77 132.34 24.75 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.728 2.285 . . . . 0.0 111.824 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 106.83 -14.79 41.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.49 158.96 25.71 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -1.146 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -92.78 145.92 24.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.278 -0.889 . . . . 0.0 109.48 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.041 HG22 ' O ' ' A' ' 128' ' ' ALA . 17.4 m -128.71 152.48 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.662 ' HB ' HD11 ' A' ' 162' ' ' LEU . 7.3 tp -123.6 148.59 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.493 HG21 ' HB2' ' A' ' 123' ' ' PHE . 18.0 mm -92.58 132.51 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.23 -0.919 . . . . 0.0 109.463 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 52.2 p -121.32 5.39 10.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.196 -0.94 . . . . 0.0 109.619 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.424 ' OE1' ' HA ' ' A' ' 158' ' ' GLU . 94.0 mt-10 -141.36 152.14 44.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.14 -0.975 . . . . 0.0 109.501 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 84.25 -171.94 48.64 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.25 -5.72 59.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -1.146 . . . . 0.0 109.54 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.576 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 83.1 m-85 -85.46 7.7 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.578 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 121' ' ' GLY . 97.6 mt-10 -58.96 141.1 54.71 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 109.572 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.56 -6.83 80.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.612 ' O ' HD12 ' A' ' 117' ' ' ILE . 20.6 m-30 -96.97 147.62 23.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.224 -1.162 . . . . 0.0 109.614 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -104.54 154.19 20.23 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.356 -0.84 . . . . 0.0 109.334 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 1.041 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -147.88 162.05 40.06 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.595 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.9 mm -112.39 144.34 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.587 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.728 ' CE1' HD21 ' A' ' 141' ' ' LEU . 35.1 m-85 -66.48 103.33 1.03 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.382 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.604 HG21 ' HE2' ' A' ' 151' ' ' LYS . 43.8 p -76.29 -34.2 59.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.527 ' O ' ' CG ' ' A' ' 140' ' ' MET . 2.2 mt-10 165.14 89.79 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.164 -0.96 . . . . 0.0 109.731 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.1 130.78 19.5 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.608 2.205 . . . . 0.0 111.694 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -68.17 -30.57 69.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -171.18 177.96 43.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -63.45 -25.76 68.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.254 -1.145 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.08 -62.27 1.51 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.7 mtt180 -110.01 157.98 18.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.3 m -142.46 153.05 43.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.527 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 85.7 mmm -99.73 124.0 44.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.872 HD22 HG21 ' A' ' 116' ' ' VAL . 42.0 mt -122.94 145.89 48.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.948 HD12 ' HG2' ' A' ' 151' ' ' LYS . 2.7 tt -101.2 126.39 47.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.168 -0.958 . . . . 0.0 109.646 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.807 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.8 mp -99.55 104.37 16.16 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.223 -0.923 . . . . 0.0 109.157 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -77.54 125.56 29.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.127 -0.983 . . . . 0.0 109.335 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 69.1 mt -117.72 141.35 48.49 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.32 -0.863 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.434 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.5 pt -51.55 -29.04 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.495 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.3 m-20 -78.47 -53.08 7.62 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.495 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 83.5 mttt -158.29 172.57 18.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.3 -0.875 . . . . 0.0 109.469 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -100.89 125.16 47.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 32.2 pt -120.87 158.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.923 . . . . 0.0 109.5 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.948 ' HG2' HD12 ' A' ' 142' ' ' LEU . 3.2 mtpm? -125.27 132.25 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.428 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -144.67 141.33 29.26 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.505 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 38.5 p -73.33 141.22 47.1 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.887 . . . . 0.0 109.32 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.577 HG12 ' HD1' ' A' ' 159' ' ' PHE . 19.4 t -133.09 152.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.114 -0.991 . . . . 0.0 109.618 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 39.0 mtmt -91.28 141.46 28.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 18.5 m-80 -51.21 -26.2 6.66 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.3 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 45.6 p -83.83 -19.18 35.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.304 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.444 ' OE2' ' HE2' ' A' ' 155' ' ' LYS . 94.9 mt-10 -84.87 -13.42 50.97 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.353 -0.842 . . . . 0.0 109.45 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.577 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -148.74 173.5 13.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.208 -0.933 . . . . 0.0 109.398 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.471 ' O ' HG22 ' A' ' 117' ' ' ILE . 97.2 mtt180 -131.16 143.99 51.04 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.197 -0.939 . . . . 0.0 109.607 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -80.78 135.09 35.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.738 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.7 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.495 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.44 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 72.0 m-85 . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.513 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 47.9 Cg_endo -69.07 130.72 20.72 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.767 2.311 . . . . 0.0 111.783 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.23 -8.21 55.18 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 129' ' ' ILE . 76.6 m-20 -83.1 166.41 18.73 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -1.185 . . . . 0.0 109.577 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 28.8 mtpt -90.85 140.36 29.88 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.032 HG21 HD23 ' A' ' 141' ' ' LEU . 9.9 m -129.77 155.92 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.546 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.791 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.6 tp -120.55 145.19 27.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.343 -0.848 . . . . 0.0 109.475 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.504 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.0 mm -90.25 134.02 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.937 . . . . 0.0 109.463 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.45 HG21 ' HD3' ' A' ' 160' ' ' ARG . 44.4 p -120.67 -0.05 10.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.512 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.465 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 93.9 mt-10 -138.39 153.4 48.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.4 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.422 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.28 -171.51 44.16 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.95 -3.62 58.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -1.13 . . . . 0.0 109.603 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.573 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.2 m-85 -89.13 9.55 25.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.502 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.465 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 98.3 mt-10 -59.23 141.89 53.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.586 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 88.57 -3.59 85.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.573 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.7 m-30 -100.17 143.22 30.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.167 -1.196 . . . . 0.0 109.565 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . 0.413 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 93.6 mt-30 -93.22 149.76 20.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.252 -0.905 . . . . 0.0 109.375 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.976 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -142.23 160.8 39.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.463 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.99 136.52 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.18 -0.95 . . . . 0.0 109.453 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.62 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 34.8 m-85 -59.8 109.89 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.219 -0.926 . . . . 0.0 109.708 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.51 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 60.7 p -79.61 -34.85 40.34 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 109.34 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.98 96.9 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -70.83 109.27 2.47 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.653 2.235 . . . . 0.0 111.59 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . 0.418 ' OD1' ' HG3' ' A' ' 138' ' ' ARG . 24.7 p-10 -76.02 0.11 19.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.736 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -172.48 160.68 32.01 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -66.32 -41.85 89.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -1.152 . . . . 0.0 109.314 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -65.5 -77.51 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.288 -0.882 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.488 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.0 ptp180 -80.46 151.53 29.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.91 . . . . 0.0 109.564 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.768 ' OG ' HD11 ' A' ' 141' ' ' LEU . 88.7 p -145.57 156.71 43.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.528 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.848 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.7 mtp -100.2 119.25 38.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.032 HD23 HG21 ' A' ' 116' ' ' VAL . 5.1 mp -124.24 148.52 47.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.278 -0.888 . . . . 0.0 109.506 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.522 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.7 tt -97.52 126.74 42.97 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.352 -0.843 . . . . 0.0 109.397 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.53 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 35.3 mt -96.47 110.42 22.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.227 -0.921 . . . . 0.0 109.377 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.663 ' C ' HD22 ' A' ' 145' ' ' LEU . 15.5 p-10 -82.73 124.03 29.86 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.852 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.735 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -117.34 144.02 45.35 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.527 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.6 pt -50.08 -35.73 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.438 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.527 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.3 m-20 -71.35 -55.44 7.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.59 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 43.8 mttm -157.58 173.33 17.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.28 -0.887 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -99.12 128.79 45.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.259 -0.901 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.42 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 19.2 pt -125.5 158.02 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.522 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 24.0 mttp -119.26 135.58 54.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.382 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -144.91 145.92 31.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.58 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.2 p -86.17 121.28 28.54 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.349 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.866 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.7 p -124.92 147.86 29.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.208 -0.932 . . . . 0.0 109.591 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.573 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.2 mttt -75.76 150.97 37.67 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.349 -0.844 . . . . 0.0 109.657 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.568 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 13.9 m-80 -61.51 -24.17 66.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.4 p -79.58 -21.08 45.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.246 -0.909 . . . . 0.0 109.495 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.646 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.8 mt-10 -81.18 -22.65 38.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.554 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.881 ' CE2' HD21 ' A' ' 141' ' ' LEU . 41.7 p90 -138.47 170.51 15.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.925 . . . . 0.0 109.464 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . 0.548 ' O ' HG22 ' A' ' 117' ' ' ILE . 27.1 ptt180 -134.79 158.72 43.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.181 -0.949 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -88.59 139.26 30.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.791 HD11 ' HB ' ' A' ' 117' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.401 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 85.6 m-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 50.4 Cg_endo -69.98 134.04 26.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.722 2.281 . . . . 0.0 111.713 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 89.88 -8.99 78.77 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.594 ' O ' HG23 ' A' ' 129' ' ' ILE . 29.0 p-10 -68.22 -178.85 1.13 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -1.153 . . . . 0.0 109.384 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.458 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 26.9 mttp -103.0 139.75 38.17 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.933 HG21 HD23 ' A' ' 141' ' ' LEU . 7.9 m -134.41 154.51 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.865 . . . . 0.0 109.38 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.427 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 2.5 tp -121.6 139.35 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.869 . . . . 0.0 109.617 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 120' ' ' GLU . 66.7 mt -92.68 127.19 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 80.4 p -101.68 -11.77 18.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.421 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.49 ' O ' HG22 ' A' ' 118' ' ' ILE . 95.6 mt-10 -130.66 158.97 38.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.01 165.61 36.85 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.78 -27.8 68.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.45 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 97.1 m-85 -82.49 3.61 27.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.326 -0.859 . . . . 0.0 109.582 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -53.76 141.49 26.58 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.177 -0.952 . . . . 0.0 109.48 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 94.06 -9.83 72.35 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.45 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -97.93 148.46 23.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.207 -1.172 . . . . 0.0 109.47 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . 0.446 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 95.3 mt-30 -91.27 143.69 26.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.273 -0.892 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.885 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -135.51 160.36 38.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.594 HG23 ' O ' ' A' ' 114' ' ' ASP . 31.2 mm -117.86 136.6 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.649 ' HE1' HD11 ' A' ' 141' ' ' LEU . 19.6 m-85 -66.53 114.84 5.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 47.6 p -90.62 -29.93 17.48 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.337 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 175.46 87.53 0.09 OUTLIER Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.224 -0.922 . . . . 0.0 109.327 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.46 118.02 5.36 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.671 2.247 . . . . 0.0 111.791 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -60.32 -34.71 74.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -164.95 -160.12 12.03 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 70.3 mm-40 -83.41 -26.64 30.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -1.139 . . . . 0.0 109.354 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.29 -80.57 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.223 -0.923 . . . . 0.0 109.372 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.446 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 24.0 ptt180 -89.17 148.38 23.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.631 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 59.2 m -144.44 152.81 41.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.197 -0.939 . . . . 0.0 109.414 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.914 ' C ' HD12 ' A' ' 141' ' ' LEU . 39.5 mtp -96.97 122.33 39.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.44 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.933 HD23 HG21 ' A' ' 116' ' ' VAL . 6.3 mp -123.83 150.41 44.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.521 HD12 ' O ' ' A' ' 150' ' ' ILE . 32.1 tp -100.07 123.73 44.64 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 109.466 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.84 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -93.94 118.71 31.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.579 ' C ' HD22 ' A' ' 145' ' ' LEU . 21.9 p-10 -83.49 114.92 21.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.566 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.749 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.9 mm? -114.38 144.16 43.73 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 109.413 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -55.09 -29.07 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.306 -0.872 . . . . 0.0 109.29 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.417 ' N ' HG13 ' A' ' 146' ' ' ILE . 34.8 t30 -75.82 -54.29 7.15 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.342 -0.849 . . . . 0.0 109.441 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.52 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 24.7 tttm -168.57 164.84 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.229 -0.919 . . . . 0.0 109.6 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.52 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 93.9 mt-10 -87.94 127.79 35.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.521 ' O ' HD12 ' A' ' 142' ' ' LEU . 7.6 pt -122.23 136.01 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.283 -0.885 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.512 ' HG2' HD13 ' A' ' 142' ' ' LEU . 17.3 mttp -91.92 127.17 37.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.399 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -139.27 141.36 37.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.638 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.1 p -87.15 119.44 27.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.321 -0.862 . . . . 0.0 109.381 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.789 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.9 p -121.97 149.3 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 68.2 mttm -83.62 151.89 25.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 12.3 m-80 -59.45 -25.14 64.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.236 -0.915 . . . . 0.0 109.456 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.4 p -78.77 -20.29 50.21 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.622 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.2 mt-10 -82.09 -22.68 36.16 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.564 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.22 166.89 23.35 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.537 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 76.4 mtt85 -131.87 150.93 52.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -74.0 122.44 22.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.435 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.489 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.469 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.5 m-85 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.469 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.4 Cg_endo -69.53 128.94 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.663 2.242 . . . . 0.0 111.688 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.8 -11.15 59.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.45 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 79.3 m-20 -78.99 151.87 31.31 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -1.119 . . . . 0.0 109.457 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.462 ' CB ' HD21 ' A' ' 162' ' ' LEU . 97.2 mttt -80.15 142.0 35.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.034 HG21 HD23 ' A' ' 141' ' ' LEU . 6.1 m -131.9 160.57 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 6.8 tp -124.6 142.19 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.509 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.477 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 69.4 mt -92.64 125.59 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.469 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.3 p -102.38 -10.66 19.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.432 ' O ' HG22 ' A' ' 118' ' ' ILE . 94.4 mt-10 -131.38 158.44 40.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.525 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 92.68 166.85 39.05 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.53 -19.78 63.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -1.133 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.546 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 95.9 m-85 -83.54 9.48 11.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.47 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.477 ' HG3' ' O ' ' A' ' 118' ' ' ILE . 85.5 tt0 -58.32 140.41 53.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.391 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.87 -6.04 73.09 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -99.06 142.36 30.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.475 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -86.71 125.92 34.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.937 . . . . 0.0 109.352 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.949 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -110.57 153.0 25.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.298 -0.876 . . . . 0.0 109.456 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.582 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.2 mm -118.06 130.67 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.498 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.847 ' CE2' HG11 ' A' ' 116' ' ' VAL . 32.7 m-85 -62.31 101.7 0.25 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -0.942 . . . . 0.0 109.542 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.478 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 43.3 p -78.43 -36.34 45.72 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.225 -0.922 . . . . 0.0 109.262 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 131' ' ' THR . 17.2 tp10 171.36 99.35 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.419 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.0 113.86 3.55 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.62 2.213 . . . . 0.0 111.461 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 29.2 p-10 -74.95 -6.3 48.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.628 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.19 169.67 41.6 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -75.3 -26.25 58.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.477 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -76.1 -73.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 109.341 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.438 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 9.9 ptp85 -89.32 147.62 23.99 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.483 ' HB2' HD11 ' A' ' 141' ' ' LEU . 65.0 m -134.68 144.91 48.06 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.232 -0.917 . . . . 0.0 109.5 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.709 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 ttm -87.98 109.66 19.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.224 -0.922 . . . . 0.0 109.504 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.034 HD23 HG21 ' A' ' 116' ' ' VAL . 5.5 mp -115.59 151.61 34.6 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.831 HD12 ' O ' ' A' ' 150' ' ' ILE . 48.1 tp -93.47 127.99 39.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.373 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.5 mt -90.73 137.45 32.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -104.16 106.16 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.0 109.432 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.414 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 49.5 mt -104.33 140.88 37.25 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -50.97 -31.47 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.238 -0.914 . . . . 0.0 109.423 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.49 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 17.1 t-20 -74.17 -56.15 5.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.635 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.49 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 19.9 mttt -158.81 166.75 31.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -0.954 . . . . 0.0 109.489 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -92.83 131.93 37.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -0.893 . . . . 0.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.831 ' O ' HD12 ' A' ' 142' ' ' LEU . 13.7 pt -132.56 155.53 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 109.6 -179.695 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.753 ' HG2' HD13 ' A' ' 142' ' ' LEU . 28.9 mttp -105.55 131.46 52.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -140.52 129.42 23.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.266 -0.896 . . . . 0.0 109.409 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 70.7 m -69.89 118.52 12.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.783 ' CG1' HD13 ' A' ' 141' ' ' LEU . 5.3 p -121.82 148.35 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.855 . . . . 0.0 109.53 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 33.0 mttp -81.8 151.92 27.17 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.566 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.0 m-80 -60.76 -21.34 62.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.914 . . . . 0.0 109.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.9 p -81.48 -21.58 38.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.629 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.8 mt-10 -81.52 -23.14 37.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.316 -0.865 . . . . 0.0 109.473 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.663 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.3 p90 -138.53 167.96 20.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.538 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 51.0 mtt-85 -131.12 155.37 47.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.547 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -76.84 125.06 28.64 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.495 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.462 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.472 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.453 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.4 m-85 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.71 130.75 19.95 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.609 2.206 . . . . 0.0 111.808 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.0 -15.14 56.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -69.45 153.88 42.86 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.196 -1.179 . . . . 0.0 109.51 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -90.04 147.5 23.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.797 HG22 ' O ' ' A' ' 128' ' ' ALA . 5.0 m -131.74 154.47 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.628 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.1 tp -124.48 146.98 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.275 -0.891 . . . . 0.0 109.478 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.461 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.1 mm -91.16 124.91 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.335 -0.853 . . . . 0.0 109.356 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.46 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 66.2 p -108.99 -8.57 15.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.531 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.92 157.4 45.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.121 -0.987 . . . . 0.0 109.463 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 88.88 166.54 42.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.44 -18.65 64.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.239 -1.154 . . . . 0.0 109.448 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.57 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 88.5 m-85 -82.56 5.75 19.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 109.506 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.46 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.6 tt0 -58.67 136.7 57.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.557 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.31 -3.43 66.3 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -101.11 150.09 23.29 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.17 -1.194 . . . . 0.0 109.48 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -102.21 149.27 24.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.47 166.22 25.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.305 -0.872 . . . . 0.0 109.423 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.501 HD13 ' O ' ' A' ' 128' ' ' ALA . 27.2 mm -116.63 137.66 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.206 -0.934 . . . . 0.0 109.535 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.698 ' CE2' HG12 ' A' ' 116' ' ' VAL . 36.0 m-85 -59.57 104.0 0.24 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.495 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 39.3 p -78.71 -38.89 37.92 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.344 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 131' ' ' THR . 1.0 OUTLIER 171.68 94.8 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.303 -0.873 . . . . 0.0 109.455 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.38 115.7 4.17 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.776 2.317 . . . . 0.0 111.744 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -61.16 -35.92 78.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.243 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -148.01 175.5 27.3 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.82 -27.43 64.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -1.151 . . . . 0.0 109.495 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.11 -73.54 0.29 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.309 -0.869 . . . . 0.0 109.384 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 21.3 ptt-85 -83.53 147.81 27.56 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.23 -0.919 . . . . 0.0 109.558 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 67.9 m -139.96 153.11 46.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.176 -0.952 . . . . 0.0 109.514 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.453 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 41.6 mtp -99.23 119.48 37.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.262 -0.899 . . . . 0.0 109.429 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.661 HD13 HG21 ' A' ' 116' ' ' VAL . 66.1 mt -117.85 147.73 42.78 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.255 -0.903 . . . . 0.0 109.471 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.612 HD12 ' CE ' ' A' ' 151' ' ' LYS . 8.4 tt -97.31 126.46 42.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.263 -0.898 . . . . 0.0 109.438 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.524 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 43.5 mt -97.69 113.87 25.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.183 -0.948 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.717 ' C ' HD22 ' A' ' 145' ' ' LEU . 8.4 p30 -83.45 121.21 26.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.283 -0.885 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.75 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -118.72 135.64 54.38 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.357 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.2 pt -49.74 -33.29 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.266 -0.896 . . . . 0.0 109.574 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.487 ' N ' HG13 ' A' ' 146' ' ' ILE . 94.2 m-20 -70.49 -46.44 63.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 30.3 tttm -168.49 160.75 11.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.527 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.0 mt-10 -87.85 127.24 35.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.927 . . . . 0.0 109.407 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.506 HG12 HD23 ' A' ' 145' ' ' LEU . 19.6 pt -127.67 162.12 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.424 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.612 ' CE ' HD12 ' A' ' 142' ' ' LEU . 20.9 mttt -125.72 130.25 51.14 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.446 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -139.12 148.14 42.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 29.7 p -82.7 141.89 32.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.578 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.7 t -130.91 153.64 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.35 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.501 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 41.3 mttt -91.11 138.3 31.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.913 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 1.6 p30 -47.75 -30.38 3.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 44.7 p -80.97 -22.18 39.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.898 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 155' ' ' LYS . 94.8 mt-10 -81.69 -19.7 41.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.439 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.584 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.6 p90 -140.45 169.01 18.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.372 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 87.0 mtt-85 -129.44 143.24 50.75 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -78.14 132.74 37.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.321 -0.862 . . . . 0.0 109.473 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.5 mp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.481 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.408 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 12.6 m-85 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 134.84 27.87 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.724 2.283 . . . . 0.0 111.797 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.21 -12.98 65.12 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 83.4 m-20 -69.97 147.91 49.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.515 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.3 mttm -75.05 139.74 43.05 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.036 HG21 HD23 ' A' ' 141' ' ' LEU . 6.0 m -127.33 155.67 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.942 . . . . 0.0 109.455 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.446 HD12 ' HA ' ' A' ' 117' ' ' ILE . 8.2 tp -123.82 147.69 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.235 -0.916 . . . . 0.0 109.48 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.466 ' HB ' ' HA ' ' A' ' 124' ' ' GLU . 21.6 mm -91.66 129.34 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.8 p -114.17 -7.34 13.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.486 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 46.8 tp10 -140.89 153.48 45.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.486 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 92.15 169.05 40.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.92 -15.9 63.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -1.188 . . . . 0.0 109.493 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.633 ' CD1' HD23 ' A' ' 143' ' ' LEU . 89.9 m-85 -84.93 11.06 10.1 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.2 -0.938 . . . . 0.0 109.451 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.466 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 85.0 tt0 -60.73 134.08 56.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.636 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.94 66.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.454 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.7 m-85 -98.26 140.48 32.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.143 -1.21 . . . . 0.0 109.472 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -94.13 126.52 39.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.525 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.994 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -126.35 161.42 27.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.938 . . . . 0.0 109.533 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.585 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.9 mm -120.12 136.96 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.254 -0.904 . . . . 0.0 109.451 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.586 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.5 m-85 -58.58 103.18 0.14 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 63.4 p -77.3 -31.45 54.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 164.74 91.37 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.188 -0.945 . . . . 0.0 109.53 -179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.47 125.99 12.37 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.63 2.22 . . . . 0.0 111.655 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.6 p-10 -68.66 -25.78 64.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 109.538 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -166.09 170.25 40.69 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -64.01 -27.59 69.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.43 -63.63 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.3 -0.875 . . . . 0.0 109.394 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 135' ' ' GLY . 57.7 mtt85 -107.48 153.6 22.59 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.197 -0.939 . . . . 0.0 109.468 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 68.8 m -138.8 156.64 47.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 109.46 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.819 ' C ' HD12 ' A' ' 141' ' ' LEU . 34.7 tpp -101.12 117.31 34.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.475 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.036 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -118.61 144.07 46.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 9.2 tt -101.52 123.51 45.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.452 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.835 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -91.4 138.51 31.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.923 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.684 ' C ' HD12 ' A' ' 145' ' ' LEU . 97.6 m-20 -110.86 113.38 25.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.768 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.3 mp -114.61 139.63 49.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.579 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.516 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.1 pt -50.28 -36.25 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.516 ' N ' HG13 ' A' ' 146' ' ' ILE . 15.3 t-20 -68.04 -52.89 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.488 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 19.3 tttt -166.66 155.11 10.3 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.541 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.47 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.4 mt-10 -89.86 140.21 29.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.4 pt -131.57 158.61 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.523 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.3 mttt -125.83 134.18 51.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.66 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.49 ' ND1' ' O ' ' A' ' 153' ' ' SER . 51.7 t-80 -158.31 146.45 18.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.422 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.49 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 42.0 p -69.77 141.34 53.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.924 . . . . 0.0 109.393 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.686 HG13 ' CD ' ' A' ' 158' ' ' GLU . 20.2 t -126.17 152.31 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.182 -0.949 . . . . 0.0 109.61 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.504 ' O ' ' HG2' ' A' ' 158' ' ' GLU . 86.4 mttt -91.17 131.64 36.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.276 -0.89 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.582 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 33.4 m-80 -53.41 -18.57 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 79.8 p -85.13 -29.66 24.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 110.141 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.686 ' CD ' HG13 ' A' ' 154' ' ' VAL . 10.9 pt-20 -82.84 -18.57 39.93 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.02 -1.05 . . . . 0.0 109.698 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.642 ' CE2' HD21 ' A' ' 141' ' ' LEU . 20.4 p90 -135.3 157.25 47.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.147 -0.97 . . . . 0.0 109.553 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.2 ttt-85 -124.07 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.267 -0.896 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 16.9 pttp -74.39 124.03 25.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.196 -0.94 . . . . 0.0 109.51 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.497 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.997 -1.002 . . . . 0.0 109.48 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.439 ' N ' ' OD2' ' A' ' 114' ' ' ASP . 50.9 m-85 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.1 Cg_endo -69.73 131.5 21.4 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.696 2.264 . . . . 0.0 111.79 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 98.83 -12.29 62.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' N ' ' A' ' 111' ' ' TYR . 81.5 m-20 -65.56 150.31 48.62 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -1.135 . . . . 0.0 109.491 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.508 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 96.5 mttt -77.98 140.14 39.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.897 . . . . 0.0 109.476 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.947 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.1 m -130.84 153.63 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 3.0 tp -122.65 140.67 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.473 HD12 ' HB3' ' A' ' 123' ' ' PHE . 69.4 mt -92.56 131.05 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.5 p -118.42 5.37 11.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.245 -0.909 . . . . 0.0 109.578 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.433 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -136.91 153.6 50.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 109.481 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.4 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.67 -171.08 42.9 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.87 -5.84 57.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -1.134 . . . . 0.0 109.587 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.557 ' CD1' HD23 ' A' ' 143' ' ' LEU . 80.2 m-85 -88.54 14.98 8.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.997 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.433 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 96.9 mt-10 -62.84 136.91 58.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.14 1.09 70.11 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -102.22 131.41 48.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.137 -1.213 . . . . 0.0 109.454 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -86.72 134.44 33.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.909 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.18 159.72 38.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.544 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.518 HD13 ' O ' ' A' ' 128' ' ' ALA . 33.4 mm -119.2 140.07 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.311 -0.868 . . . . 0.0 109.383 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.566 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.1 m-85 -58.58 101.47 0.09 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.538 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 68.9 p -75.04 -34.41 61.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.369 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.3 mt-10 163.75 88.84 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.294 -0.879 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.463 ' HB3' ' OG ' ' A' ' 139' ' ' SER . 49.9 Cg_endo -69.96 132.35 22.83 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.679 2.253 . . . . 0.0 111.81 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -67.82 -30.03 69.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -0.861 . . . . 0.0 109.444 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -165.18 -174.02 34.4 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -73.32 -26.79 61.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.295 -1.121 . . . . 0.0 109.453 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.82 -58.51 4.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.532 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -109.6 161.12 15.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.158 -0.964 . . . . 0.0 109.425 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 133' ' ' PRO . 4.1 m -147.36 155.38 41.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.262 -0.899 . . . . 0.0 109.566 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.906 ' C ' HD12 ' A' ' 141' ' ' LEU . 63.5 mtp -103.06 124.22 48.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.343 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.947 HD23 ' CG2' ' A' ' 116' ' ' VAL . 5.4 mp -126.19 140.78 52.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.175 -0.953 . . . . 0.0 109.607 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.569 HD23 ' C ' ' A' ' 142' ' ' LEU . 10.1 tt -96.59 125.82 41.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.304 -0.873 . . . . 0.0 109.413 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.829 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.6 mp -93.47 137.02 33.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.284 -0.885 . . . . 0.0 109.525 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.477 ' C ' HD12 ' A' ' 145' ' ' LEU . 28.4 m120 -108.57 104.19 13.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.905 . . . . 0.0 109.422 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.725 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.8 mp -104.45 139.6 39.14 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.149 -0.969 . . . . 0.0 109.56 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.2 pt -54.32 -35.09 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.445 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 52.0 t-20 -65.96 -46.57 77.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.393 -0.817 . . . . 0.0 109.512 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.1 pttt -168.64 169.54 10.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.204 -0.935 . . . . 0.0 109.555 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CG ' HD21 ' A' ' 142' ' ' LEU . 86.8 tt0 -98.2 132.32 43.82 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.1 pt -131.88 157.01 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.475 ' HG2' ' HG ' ' A' ' 142' ' ' LEU . 2.3 mtpm? -123.97 134.1 53.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.396 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.466 ' CE1' ' O ' ' A' ' 153' ' ' SER . 55.4 t-80 -152.26 143.73 23.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 41.6 p -81.66 137.07 35.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.512 HG12 ' HD1' ' A' ' 159' ' ' PHE . 16.4 t -127.6 151.09 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.406 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.528 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 0.6 OUTLIER -87.38 139.97 30.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.272 -0.893 . . . . 0.0 109.559 -179.935 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.515 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 27.4 m-80 -46.17 -27.98 1.12 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.357 -0.839 . . . . 0.0 110.272 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . 0.512 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 27.0 p -80.14 -19.93 46.1 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.97 -1.081 . . . . 0.0 109.983 -179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.528 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 48.5 mm-40 -89.85 -19.11 25.02 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.068 -1.02 . . . . 0.0 109.201 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.721 ' CE2' HD21 ' A' ' 141' ' ' LEU . 34.5 p90 -139.22 156.03 47.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.793 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 53.2 mtt180 -125.25 147.1 49.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.255 -0.903 . . . . 0.0 109.339 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . 0.477 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 15.9 pttp -82.44 121.52 26.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.492 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.489 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.4 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 53.0 m-85 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.5 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 46.2 Cg_endo -68.28 137.61 40.65 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.634 2.223 . . . . 0.0 111.701 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 90.82 -9.88 76.46 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.744 ' O ' HG23 ' A' ' 129' ' ' ILE . 36.6 p-10 -74.55 -177.85 3.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -1.149 . . . . 0.0 109.5 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.499 ' HA ' HD13 ' A' ' 129' ' ' ILE . 76.6 mttt -99.19 141.6 31.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -0.893 . . . . 0.0 109.426 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.927 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.2 m -138.18 158.1 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.239 -0.913 . . . . 0.0 109.529 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.2 tp -126.27 141.91 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.482 ' HA ' ' HB2' ' A' ' 159' ' ' PHE . 56.1 mt -92.29 129.91 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.209 -0.932 . . . . 0.0 109.695 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.525 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 58.0 p -105.08 -8.39 18.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.474 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 48.0 tp10 -136.26 156.84 48.08 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . 0.474 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 93.77 162.77 36.09 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.26 -19.4 65.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -1.115 . . . . 0.0 109.438 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.497 ' CD1' HD23 ' A' ' 143' ' ' LEU . 84.5 m-85 -86.26 13.16 8.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.379 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.525 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.8 tt0 -63.76 140.12 58.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.38 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 90.32 -0.15 77.63 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -104.99 138.89 40.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -1.193 . . . . 0.0 109.428 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -83.79 148.65 26.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.26 -0.9 . . . . 0.0 109.541 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.927 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -144.83 159.31 43.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.744 HG23 ' O ' ' A' ' 114' ' ' ASP . 27.2 mm -119.68 133.06 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.961 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.788 ' HE1' HD11 ' A' ' 141' ' ' LEU . 18.3 m-85 -58.57 115.84 3.29 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.368 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.516 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 44.0 p -84.18 -29.5 26.56 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.9 86.33 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.326 -0.859 . . . . 0.0 109.545 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.415 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.2 Cg_endo -70.0 130.64 19.38 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.694 2.263 . . . . 0.0 111.751 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -68.91 -26.61 65.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.905 . . . . 0.0 109.594 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -170.59 178.31 43.27 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -66.16 -25.94 67.19 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -1.121 . . . . 0.0 109.509 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.53 -63.68 1.01 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.476 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 75.4 mtt180 -107.11 156.89 18.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.43 ' HB3' ' CE1' ' A' ' 130' ' ' PHE . 69.0 m -148.58 152.42 36.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.175 -0.953 . . . . 0.0 109.51 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.806 ' C ' HD12 ' A' ' 141' ' ' LEU . 20.4 mtp -101.62 122.05 43.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.217 -0.927 . . . . 0.0 109.583 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.818 HD13 ' CG1' ' A' ' 154' ' ' VAL . 6.8 mp -114.21 147.32 39.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.875 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.926 HD21 ' OE2' ' A' ' 149' ' ' GLU . 34.5 tp -102.8 125.42 49.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.742 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.806 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -98.32 127.98 44.52 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.257 -0.902 . . . . 0.0 109.25 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -105.02 113.27 26.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.771 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.4 mm? -101.01 150.56 22.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.326 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 25.7 pt -65.13 -10.45 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.501 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 48.3 t30 -97.57 -47.55 5.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.59 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.501 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 77.7 mttt -158.55 165.39 34.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.93 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.926 ' OE2' HD21 ' A' ' 142' ' ' LEU . 78.4 tt0 -89.57 147.57 23.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.172 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 142' ' ' LEU . 30.9 pt -144.44 151.66 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.945 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.814 ' HG2' HD13 ' A' ' 142' ' ' LEU . 20.8 mttp -118.01 136.64 53.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.366 -0.834 . . . . 0.0 109.159 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -148.58 134.99 19.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.116 -0.99 . . . . 0.0 109.651 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.8 p -87.12 118.08 26.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.888 . . . . 0.0 109.326 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.818 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.3 p -120.05 150.59 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.565 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 28.0 mttt -77.01 153.69 34.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.891 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 9.7 m-80 -65.18 -14.95 61.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 70.5 p -88.17 -24.2 23.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.593 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.7 mt-10 -78.79 -22.62 46.05 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.258 -0.901 . . . . 0.0 109.51 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.769 ' CE2' HD21 ' A' ' 141' ' ' LEU . 38.3 p90 -135.95 174.04 11.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.414 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 52.6 mtp180 -139.45 164.59 29.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.57 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . 0.508 ' NZ ' ' OD2' ' A' ' 114' ' ' ASP . 55.4 tttp -85.59 126.32 33.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.487 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.475 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.519 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.404 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 50.3 m-85 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.96 130.89 19.87 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.63 2.22 . . . . 0.0 111.811 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 101.04 -14.77 58.42 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.483 ' CB ' ' HE2' ' A' ' 161' ' ' LYS . 80.4 m-20 -66.89 153.78 42.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.497 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 95.5 mttt -81.83 140.62 34.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.8 m -125.61 152.61 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.712 ' HB ' HD21 ' A' ' 162' ' ' LEU . 8.2 tp -122.64 145.43 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.538 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.48 HG12 ' O ' ' A' ' 126' ' ' PHE . 28.8 mm -91.24 128.82 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.293 -0.88 . . . . 0.0 109.499 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.453 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 69.1 p -114.92 -7.9 12.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.217 -0.927 . . . . 0.0 109.518 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -140.1 151.91 45.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.163 -0.961 . . . . 0.0 109.473 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.56 167.78 38.2 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.41 -13.78 62.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -1.155 . . . . 0.0 109.422 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.599 ' HB3' HD23 ' A' ' 143' ' ' LEU . 69.6 m-85 -87.98 13.93 9.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.475 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.8 tt0 -64.08 132.43 50.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.58 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.17 1.03 59.6 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.48 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.4 m-85 -98.95 136.52 38.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.1 -1.235 . . . . 0.0 109.594 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -88.79 136.07 33.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.291 -0.881 . . . . 0.0 109.279 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 1.018 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -137.95 165.73 25.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.597 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.7 mm -121.01 142.28 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CE2' HG12 ' A' ' 116' ' ' VAL . 40.5 m-85 -58.58 104.49 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.936 . . . . 0.0 109.558 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.462 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 71.1 p -78.07 -40.69 37.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' THR . 7.6 tt0 172.32 91.53 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 48.8 Cg_endo -70.1 124.46 10.97 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.718 2.279 . . . . 0.0 111.761 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 23.3 p-10 -75.23 -4.03 36.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.355 -0.84 . . . . 0.0 109.54 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 174.64 173.3 40.44 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.95 -30.48 67.87 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -1.125 . . . . 0.0 109.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.07 -60.03 2.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -0.915 . . . . 0.0 109.431 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.463 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 81.9 mtm180 -103.28 152.93 20.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.395 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 68.5 m -144.97 150.12 36.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.96 . . . . 0.0 109.491 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.941 ' C ' HD12 ' A' ' 141' ' ' LEU . 91.6 mmm -96.17 125.91 41.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.323 -0.861 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -128.32 141.27 51.49 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.236 -0.915 . . . . 0.0 109.622 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.527 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.9 tt -99.67 119.51 38.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.395 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -96.03 108.63 21.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.18 -0.95 . . . . 0.0 109.652 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 145' ' ' LEU . 5.8 p30 -88.7 127.5 35.59 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.32 -0.862 . . . . 0.0 109.631 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.793 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.1 mp -108.05 159.37 16.62 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.925 . . . . 0.0 109.425 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 23.6 pt -66.65 -10.22 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.418 ' CG ' ' N ' ' A' ' 148' ' ' LYS . 9.2 p30 -105.34 -45.54 4.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.514 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 62.1 tttm -158.48 147.96 19.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.29 -0.881 . . . . 0.0 109.563 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -87.89 141.23 28.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.371 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.564 HD11 ' CE1' ' A' ' 123' ' ' PHE . 28.7 pt -133.7 162.12 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.917 . . . . 0.0 109.572 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.527 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 29.6 mttt -125.16 136.52 53.68 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.291 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.29 148.47 28.21 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.183 -0.948 . . . . 0.0 109.694 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.49 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 21.9 p -86.88 122.77 31.21 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.251 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.986 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.2 p -125.06 148.93 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.493 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 45.0 mttt -79.59 153.53 29.38 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.493 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.8 m-80 -62.52 -19.73 63.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.344 -0.847 . . . . 0.0 109.474 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 63.1 p -82.26 -23.19 35.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.194 -0.941 . . . . 0.0 109.478 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.579 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.6 mt-10 -81.13 -21.11 40.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.226 -0.921 . . . . 0.0 109.524 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.874 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.8 p90 -139.53 158.94 43.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -122.15 148.49 44.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.205 -0.934 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . 0.483 ' HE2' ' CB ' ' A' ' 114' ' ' ASP . 64.1 tttm -76.44 135.37 39.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.923 . . . . 0.0 109.487 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.712 HD21 ' HB ' ' A' ' 117' ' ' ILE . 53.5 mt . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.912 -1.042 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -70.22 134.47 27.09 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.695 2.263 . . . . 0.0 111.784 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.24 -11.68 68.85 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.648 ' O ' HG23 ' A' ' 129' ' ' ILE . 23.9 p-10 -67.45 176.23 2.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.168 -1.195 . . . . 0.0 109.473 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.546 ' HA ' HD13 ' A' ' 129' ' ' ILE . 99.6 mttt -98.34 139.42 34.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.91 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.971 HG21 HD22 ' A' ' 141' ' ' LEU . 15.0 m -135.14 149.8 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.631 ' N ' HD11 ' A' ' 162' ' ' LEU . 6.4 tp -120.84 142.47 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.444 HD11 HD21 ' A' ' 143' ' ' LEU . 62.1 mt -92.37 129.78 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.192 -0.943 . . . . 0.0 109.416 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.487 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 62.7 p -105.6 -9.97 17.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.421 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 75.4 mm-40 -135.73 158.17 45.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.178 -0.951 . . . . 0.0 109.425 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.09 165.48 32.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.93 -20.78 65.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.174 . . . . 0.0 109.43 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.515 ' CG ' HD13 ' A' ' 143' ' ' LEU . 64.1 m-85 -88.12 15.0 8.02 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.487 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 83.2 tt0 -63.22 137.4 58.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.917 . . . . 0.0 109.469 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.7 0.96 62.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -105.67 128.43 53.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -78.04 135.29 37.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.227 -0.921 . . . . 0.0 109.417 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.843 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.89 164.35 27.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.237 -0.915 . . . . 0.0 109.593 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 114' ' ' ASP . 39.3 mm -122.8 137.81 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.462 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.833 ' CE1' HD21 ' A' ' 141' ' ' LEU . 10.6 m-85 -58.56 102.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.679 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 47.0 p -79.43 -36.01 39.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 109.322 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.454 ' O ' ' HG3' ' A' ' 140' ' ' MET . 1.0 OUTLIER 170.02 87.53 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.308 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . 0.406 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.5 Cg_endo -69.77 131.78 21.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.735 2.29 . . . . 0.0 111.871 -179.817 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -66.51 -32.36 73.66 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.374 -0.828 . . . . 0.0 109.415 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -163.44 -178.4 37.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -70.5 -29.1 65.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -1.165 . . . . 0.0 109.49 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.14 -59.14 4.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.236 -0.915 . . . . 0.0 109.388 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.505 ' HG3' ' NH1' ' A' ' 138' ' ' ARG . 6.8 mtt85 -109.46 157.81 18.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 109.35 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.406 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 35.6 m -146.38 156.8 43.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -0.986 . . . . 0.0 109.611 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.484 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 49.6 mtp -99.46 127.54 45.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.442 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.971 HD22 HG21 ' A' ' 116' ' ' VAL . 89.8 mt -126.27 135.73 51.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.524 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.0 tt -92.73 123.84 36.31 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.633 HD23 ' HB2' ' A' ' 128' ' ' ALA . 16.5 mt -97.1 109.06 21.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.922 . . . . 0.0 109.662 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.724 ' C ' HD12 ' A' ' 145' ' ' LEU . 12.8 p-10 -83.94 125.48 32.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.224 -0.922 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.724 HD12 ' C ' ' A' ' 144' ' ' ASN . 8.1 mp -119.24 145.73 45.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.17 -0.956 . . . . 0.0 109.441 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -53.44 -39.0 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.656 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.4 m-20 -67.98 -44.88 75.63 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HE3' ' CG2' ' A' ' 150' ' ' ILE . 11.8 pttt -167.17 173.41 9.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.589 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -104.13 129.37 51.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.435 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.451 ' CG2' ' HE3' ' A' ' 148' ' ' LYS . 25.8 pt -125.5 161.59 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.904 . . . . 0.0 109.427 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.524 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.6 mttt -125.34 133.02 52.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -145.87 142.72 29.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 44.9 p -77.17 140.96 40.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.553 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.463 HG12 ' HD2' ' A' ' 159' ' ' PHE . 14.6 t -137.62 146.48 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.534 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 1.3 ptpt -91.05 145.48 24.65 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.313 -0.867 . . . . 0.0 109.801 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.552 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 2.0 p30 -48.96 -29.21 4.52 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.344 -0.847 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . 0.496 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 17.1 p -78.98 -20.96 47.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.105 -0.997 . . . . 0.0 109.975 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.534 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 44.0 mm-40 -87.64 -20.4 26.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.02 -1.05 . . . . 0.0 109.214 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.552 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 26.8 p90 -135.85 166.86 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.876 . . . . 0.0 109.607 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -130.26 136.96 49.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.469 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.3 pttp -77.45 147.18 36.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.267 -0.895 . . . . 0.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.775 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' TYR . . . . . 0.445 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 15.7 m-85 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' PRO . . . . . 0.445 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 47.5 Cg_endo -68.93 136.09 34.25 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.713 2.275 . . . . 0.0 111.765 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.4 -8.82 60.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -85.82 159.51 19.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.206 -1.173 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' LYS . . . . . 0.559 ' HB3' HD21 ' A' ' 162' ' ' LEU . 24.6 mttm -87.3 145.52 26.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -0.899 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.995 HG21 HD23 ' A' ' 141' ' ' LEU . 14.1 m -132.98 152.18 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.428 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.467 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.8 tp -122.0 140.71 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.281 -0.887 . . . . 0.0 109.55 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.459 HD12 ' HB3' ' A' ' 123' ' ' PHE . 73.4 mt -92.68 132.88 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.252 -0.905 . . . . 0.0 109.405 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 54.7 p -111.01 0.16 16.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.248 -0.908 . . . . 0.0 109.6 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLU . . . . . 0.439 ' HA ' ' OE1' ' A' ' 120' ' ' GLU . 71.7 mm-40 -143.52 155.73 44.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.174 -0.954 . . . . 0.0 109.484 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.35 164.26 39.65 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.74 -18.71 64.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -1.147 . . . . 0.0 109.473 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.752 ' CD1' HD13 ' A' ' 143' ' ' LEU . 96.9 m-85 -82.93 8.69 11.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.918 . . . . 0.0 109.535 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.0 tt0 -62.7 138.96 58.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.23 0.11 80.68 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -102.99 137.54 41.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.466 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -89.44 143.08 27.1 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.398 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.731 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.2 160.36 40.4 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.214 -0.929 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.2 mm -116.16 137.13 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.278 -0.889 . . . . 0.0 109.528 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' PHE . . . . . 0.676 ' CE2' HG11 ' A' ' 116' ' ' VAL . 24.7 m-85 -58.77 106.2 0.38 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.584 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.4 p -77.55 -33.64 54.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.256 -0.903 . . . . 0.0 109.249 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.05 96.53 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.428 -0.795 . . . . 0.0 109.326 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.43 123.52 10.29 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.71 2.274 . . . . 0.0 111.773 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -67.94 -33.03 73.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -150.24 174.71 29.58 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -69.57 -29.04 66.5 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.421 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.86 -74.16 0.13 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.161 -0.962 . . . . 0.0 109.344 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 33.0 ptt-85 -89.87 158.14 17.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.326 -0.859 . . . . 0.0 109.72 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 6.1 m -142.7 159.49 42.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' MET . . . . . 0.857 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.0 mtp -101.31 120.13 39.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.344 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.995 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -118.13 148.79 41.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.605 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' LEU . . . . . 0.741 HD13 ' HG2' ' A' ' 151' ' ' LYS . 48.9 tp -99.6 123.9 44.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.3 -0.875 . . . . 0.0 109.515 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.752 HD13 ' CD1' ' A' ' 123' ' ' PHE . 41.8 mt -98.18 110.84 23.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.95 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 20.1 p-10 -78.58 120.83 23.83 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.185 -0.947 . . . . 0.0 109.551 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' LEU . . . . . 0.843 HD11 HD13 ' A' ' 150' ' ' ILE . 67.9 mt -111.19 142.2 43.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.186 -0.946 . . . . 0.0 109.546 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.455 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.7 pt -51.63 -31.11 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.453 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.52 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 22.9 m120 -75.83 -55.57 5.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.465 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' LYS . . . . . 0.52 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 23.2 mttt -158.98 171.92 19.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.176 -0.952 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -88.34 130.03 35.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.325 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ILE . . . . . 0.843 HD13 HD11 ' A' ' 145' ' ' LEU . 42.4 pt -124.1 151.74 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.741 ' HG2' HD13 ' A' ' 142' ' ' LEU . 90.8 mttt -109.18 128.52 55.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.302 -0.874 . . . . 0.0 109.379 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -141.27 132.18 25.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.549 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 46.1 p -77.94 140.35 39.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.32 -0.862 . . . . 0.0 109.471 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.566 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.4 t -134.82 148.39 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.545 ' CD ' ' HG2' ' A' ' 158' ' ' GLU . 16.2 ptmt -91.27 139.96 30.24 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.227 -0.921 . . . . 0.0 109.625 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.583 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 44.7 m-80 -46.34 -27.27 1.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.397 -0.814 . . . . 0.0 110.067 -179.592 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' THR . . . . . 0.522 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 15.8 p -79.83 -21.02 44.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 0.0 109.766 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' GLU . . . . . 0.545 ' HG2' ' CD ' ' A' ' 155' ' ' LYS . 46.3 mm-40 -87.67 -20.51 26.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.052 -1.03 . . . . 0.0 109.229 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 39.3 p90 -136.17 168.68 18.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.339 -0.851 . . . . 0.0 109.667 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -133.09 159.7 39.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -82.51 118.0 22.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.433 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' LEU . . . . . 0.559 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.492 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.24 144.34 55.67 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -1.139 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 87.9 mtp -61.01 -38.77 87.25 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 109.432 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -81.63 147.96 27.2 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.42 136.7 31.86 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.692 2.261 . . . . 0.0 111.788 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 45.4 mttm -63.81 -34.99 79.14 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.931 . . . . 0.0 109.422 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 53.9 p30 -142.87 -179.93 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.202 -0.936 . . . . 0.0 109.396 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.31 -43.43 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 39.4 t -115.06 128.58 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.274 -0.891 . . . . 0.0 109.512 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -88.47 164.8 31.13 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.26 -0.9 . . . . 0.0 109.447 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.35 53.97 1.36 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.73 2.286 . . . . 0.0 111.807 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.0 -26.61 66.88 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.483 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 61.2 m -55.19 118.25 17.44 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.466 ' CG ' ' CE2' ' A' ' 130' ' ' PHE . 49.8 Cg_endo -70.39 142.34 44.91 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.633 2.222 . . . . 0.0 111.793 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.406 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 28.0 m-85 -76.87 161.24 74.49 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.406 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.34 129.37 17.91 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.723 2.282 . . . . 0.0 111.773 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 104.26 -13.53 51.74 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -69.49 156.69 38.47 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -1.104 . . . . 0.0 109.445 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.487 ' HB2' HD12 ' A' ' 162' ' ' LEU . 18.2 mttp -86.42 139.63 30.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.561 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.04 HG21 HD23 ' A' ' 141' ' ' LEU . 4.4 m -127.17 154.14 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.243 -0.911 . . . . 0.0 109.402 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.577 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.7 tp -122.44 139.83 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.57 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 83.6 mt -92.58 139.4 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.482 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.435 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 70.9 p -115.14 -10.8 12.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.458 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -131.38 157.26 43.88 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.08 162.08 38.01 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.9 -13.46 45.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.145 . . . . 0.0 109.437 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.461 ' CD1' HD23 ' A' ' 143' ' ' LEU . 96.4 m-85 -86.59 12.67 10.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.435 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.3 tt0 -63.42 137.93 58.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.428 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.12 -0.81 76.26 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -102.45 139.3 38.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.157 -1.202 . . . . 0.0 109.576 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -91.48 146.72 23.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.259 -0.901 . . . . 0.0 109.527 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.72 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -140.68 162.24 35.87 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.435 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.448 HD13 ' O ' ' A' ' 128' ' ' ALA . 35.6 mm -117.48 135.01 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.194 -0.941 . . . . 0.0 109.582 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.631 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 36.6 m-85 -58.55 104.41 0.22 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.523 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 55.4 p -79.79 -32.1 40.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.897 . . . . 0.0 109.49 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 163.68 93.62 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.326 -0.859 . . . . 0.0 109.437 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 126.74 13.37 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.667 2.245 . . . . 0.0 111.723 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -66.82 -24.89 66.21 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.251 -0.906 . . . . 0.0 109.539 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.03 -179.41 40.56 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -72.64 -24.94 61.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -1.136 . . . . 0.0 109.452 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -75.29 -51.45 13.21 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.471 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 55.5 mtt85 -110.52 151.33 27.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.459 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 57.1 m -139.74 156.16 46.93 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.221 -0.924 . . . . 0.0 109.507 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.821 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 mtp -106.76 119.39 39.2 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.363 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.04 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -116.3 154.03 30.9 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.209 -0.932 . . . . 0.0 109.509 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.865 HD12 ' O ' ' A' ' 150' ' ' ILE . 51.5 tp -106.04 124.95 50.39 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.216 -0.927 . . . . 0.0 109.464 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.841 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -99.19 116.67 31.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.245 -0.909 . . . . 0.0 109.53 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -82.73 129.23 34.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.281 -0.887 . . . . 0.0 109.638 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.743 HD11 HD13 ' A' ' 150' ' ' ILE . 42.6 mt -121.09 142.12 50.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.398 179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.45 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -49.94 -30.6 6.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.517 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.45 ' N ' HG13 ' A' ' 146' ' ' ILE . 92.9 m-20 -79.24 -47.71 15.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.27 -0.894 . . . . 0.0 109.681 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.529 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 40.2 ttpt -168.77 168.1 10.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.459 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.529 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.9 mt-10 -87.55 137.29 32.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.911 . . . . 0.0 109.252 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.865 ' O ' HD12 ' A' ' 142' ' ' LEU . 36.1 pt -126.34 149.16 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.202 -0.936 . . . . 0.0 109.774 -179.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.823 ' HG2' HD13 ' A' ' 142' ' ' LEU . 62.1 mttp -110.45 131.46 55.03 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.289 -0.882 . . . . 0.0 109.191 179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -142.38 140.62 32.1 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.177 -0.952 . . . . 0.0 109.681 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 21.6 p -88.45 122.0 31.46 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.347 -0.846 . . . . 0.0 109.217 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.724 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.3 p -124.07 149.99 28.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.241 -0.912 . . . . 0.0 109.595 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.3 mttt -76.64 150.5 36.4 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.29 -0.881 . . . . 0.0 109.482 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.567 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.9 m-80 -59.69 -23.49 63.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.253 -0.904 . . . . 0.0 109.335 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 74.8 p -81.62 -25.96 35.25 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.268 -0.895 . . . . 0.0 109.428 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.601 ' OE1' HG23 ' A' ' 154' ' ' VAL . 88.6 mt-10 -75.03 -24.81 58.37 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.213 -0.929 . . . . 0.0 109.519 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.724 ' CE2' HD21 ' A' ' 141' ' ' LEU . 31.9 p90 -136.36 170.78 15.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.2 -0.937 . . . . 0.0 109.43 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -134.23 159.64 40.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.226 -0.921 . . . . 0.0 109.53 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -83.63 146.76 28.09 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.259 -0.9 . . . . 0.0 109.431 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 117' ' ' ILE . 23.8 mt . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.421 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.12 -33.1 73.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.463 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.1 mtm -58.24 -38.42 76.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.3 -0.875 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -68.45 145.16 43.63 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -69.89 -27.19 26.14 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.673 2.249 . . . . 0.0 111.776 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 28.9 ttpp -55.3 -41.06 71.83 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -80.45 139.63 36.35 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.291 -0.88 . . . . 0.0 109.452 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 57.4 mt -131.78 143.23 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 14.7 p -133.3 137.93 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.216 -0.928 . . . . 0.0 109.446 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -78.01 119.77 78.68 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.338 -0.851 . . . . 0.0 109.577 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -72.24 50.51 1.56 Allowed 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.594 2.196 . . . . 0.0 111.818 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.25 -35.44 68.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.11 -0.994 . . . . 0.0 109.415 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 26.8 m -66.62 131.61 94.1 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.251 -0.906 . . . . 0.0 109.312 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.606 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 48.0 Cg_endo -69.45 149.6 69.07 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.577 2.185 . . . . 0.0 111.933 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.436 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 53.1 m-85 -109.4 160.99 25.68 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.336 -0.852 . . . . 0.0 109.517 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.3 Cg_endo -69.92 135.16 29.4 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.663 2.242 . . . . 0.0 111.795 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.12 -9.04 65.29 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.436 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 82.8 m-20 -81.27 146.74 30.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.208 -1.172 . . . . 0.0 109.523 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.676 ' C ' HD12 ' A' ' 162' ' ' LEU . 29.4 mtmt -80.51 144.48 32.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.218 -0.926 . . . . 0.0 109.417 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.977 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.4 m -133.47 152.63 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.196 -0.94 . . . . 0.0 109.595 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.69 ' HB ' HD21 ' A' ' 162' ' ' LEU . 2.8 tp -121.74 139.51 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.421 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.557 HD12 ' HB3' ' A' ' 123' ' ' PHE . 67.7 mt -92.78 130.76 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 70.4 p -116.72 4.04 13.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -0.925 . . . . 0.0 109.624 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.443 ' OE1' ' O ' ' A' ' 157' ' ' THR . 92.5 mt-10 -137.7 155.73 48.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 87.54 -168.04 37.74 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -91.6 -7.07 51.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -1.135 . . . . 0.0 109.502 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.557 ' HB3' HD12 ' A' ' 118' ' ' ILE . 80.4 m-85 -88.86 15.81 7.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.418 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 95.8 mt-10 -61.18 135.07 57.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.18 -0.95 . . . . 0.0 109.474 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.64 0.71 69.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -102.95 131.96 49.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -1.207 . . . . 0.0 109.488 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -92.61 140.46 29.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.229 -0.92 . . . . 0.0 109.45 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.778 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -136.77 167.01 22.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.176 -0.952 . . . . 0.0 109.536 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.519 HD13 ' O ' ' A' ' 128' ' ' ALA . 30.7 mm -118.31 138.14 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.639 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.3 m-85 -58.49 102.12 0.1 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.254 -0.904 . . . . 0.0 109.579 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.524 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 40.9 p -75.8 -33.39 60.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.266 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.6 OUTLIER 163.49 95.41 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.308 -0.87 . . . . 0.0 109.347 179.94 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.76 117.31 5.0 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.695 2.264 . . . . 0.0 111.791 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 18.1 p-10 -66.91 -31.56 72.23 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.204 -0.935 . . . . 0.0 109.573 -179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.432 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -155.32 172.85 33.55 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -70.15 -28.85 65.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.307 -1.114 . . . . 0.0 109.485 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.67 -53.6 15.13 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.53 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.44 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 79.4 mtt180 -111.86 146.25 38.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.286 -0.883 . . . . 0.0 109.506 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.8 m -134.34 157.94 45.08 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.315 -0.865 . . . . 0.0 109.472 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.937 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.9 mtp -102.07 124.8 48.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.468 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.977 HD23 ' CG2' ' A' ' 116' ' ' VAL . 6.3 mp -127.22 143.91 51.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.209 -0.932 . . . . 0.0 109.551 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.809 HD12 ' O ' ' A' ' 150' ' ' ILE . 45.4 tp -93.79 121.19 34.99 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.173 -0.955 . . . . 0.0 109.519 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.801 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.5 mp -93.03 129.62 38.9 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.429 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.1 m-20 -103.59 106.98 17.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.882 . . . . 0.0 109.482 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.492 ' N ' ' CD1' ' A' ' 145' ' ' LEU . 7.0 mp -75.03 -175.7 2.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.207 -0.933 . . . . 0.0 109.477 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.54 HG13 ' N ' ' A' ' 147' ' ' ASN . 10.9 pt -60.44 -46.09 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.18 -0.95 . . . . 0.0 109.449 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.54 ' N ' HG13 ' A' ' 146' ' ' ILE . 28.7 p-10 -139.38 23.1 2.54 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.286 -0.884 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.452 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 40.8 mttt -140.29 151.14 44.85 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.197 -0.939 . . . . 0.0 109.742 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -120.63 134.13 55.31 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.33 -0.856 . . . . 0.0 108.992 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.809 ' O ' HD12 ' A' ' 142' ' ' LEU . 37.0 pt -133.6 154.39 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.125 -0.984 . . . . 0.0 109.892 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.747 ' HG2' HD13 ' A' ' 142' ' ' LEU . 51.5 mttt -123.16 124.79 43.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.34 -0.85 . . . . 0.0 109.286 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -153.19 150.93 29.53 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 47.9 p -80.14 140.28 36.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.304 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.506 HG12 ' HD1' ' A' ' 159' ' ' PHE . 14.1 t -122.69 155.67 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.492 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 31.0 mttt -91.16 143.99 26.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.434 ' O ' ' O ' ' A' ' 159' ' ' PHE . 1.0 OUTLIER -51.4 -29.44 15.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.511 179.864 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . 0.443 ' O ' ' OE1' ' A' ' 120' ' ' GLU . 45.9 p -82.57 -22.82 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.526 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -78.4 -19.99 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.254 -0.904 . . . . 0.0 109.531 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.575 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.4 p90 -145.09 162.25 37.47 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.938 . . . . 0.0 109.433 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 13.3 ttt180 -131.83 136.47 47.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.535 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 5.2 ttpt -60.86 134.46 57.11 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.449 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.69 HD21 ' HB ' ' A' ' 117' ' ' ILE . 9.2 mt . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.472 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.56 -32.5 72.58 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.221 -1.164 . . . . 0.0 109.506 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.6 mtt -122.05 151.87 40.4 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.26 -0.9 . . . . 0.0 109.466 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -69.07 150.35 50.17 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.98 148.73 64.25 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.227 . . . . 0.0 111.821 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -83.57 150.88 25.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -54.13 -40.05 67.01 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.399 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.723 HG22 ' H ' ' A' ' 106' ' ' ASP . 55.6 mt -112.96 142.56 24.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.181 -0.949 . . . . 0.0 109.494 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 19.5 m -87.23 -16.76 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.566 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.723 ' H ' HG22 ' A' ' 104' ' ' ILE . 0.5 OUTLIER -57.98 135.22 83.8 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.208 -0.933 . . . . 0.0 109.557 179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.39 53.57 1.33 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.676 2.251 . . . . 0.0 111.742 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . 58.98 33.1 22.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.298 -0.876 . . . . 0.0 109.434 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 42.2 m -65.78 136.83 95.96 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.479 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.599 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.1 Cg_endo -69.91 147.34 61.71 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.72 2.28 . . . . 0.0 111.839 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.468 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 48.2 m-85 -111.1 160.28 29.56 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.265 -0.897 . . . . 0.0 109.461 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.01 137.48 34.82 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.702 2.268 . . . . 0.0 111.829 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.78 -10.07 68.47 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.468 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.8 m-20 -82.39 145.48 29.87 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.252 -1.146 . . . . 0.0 109.461 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.464 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 30.5 mttm -75.83 142.23 42.27 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.898 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.912 HG21 HD23 ' A' ' 141' ' ' LEU . 4.5 m -132.45 150.97 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.444 ' HB ' HD11 ' A' ' 162' ' ' LEU . 4.5 tp -123.43 141.75 42.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.233 -0.917 . . . . 0.0 109.491 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.535 HD12 ' HB3' ' A' ' 123' ' ' PHE . 61.2 mt -92.59 131.12 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.236 -0.915 . . . . 0.0 109.443 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.451 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.2 p -106.95 -8.39 16.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.213 -0.929 . . . . 0.0 109.6 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -137.37 157.29 46.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.23 -0.919 . . . . 0.0 109.572 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.21 165.14 37.75 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.67 -19.87 65.25 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.445 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.535 ' HB3' HD12 ' A' ' 118' ' ' ILE . 94.3 m-85 -86.38 13.48 8.15 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.454 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 87.0 tt0 -66.25 137.88 57.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.471 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.51 0.26 73.23 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -106.4 134.72 49.09 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -1.162 . . . . 0.0 109.484 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -79.93 147.62 31.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.222 -0.924 . . . . 0.0 109.501 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.796 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.33 163.63 32.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.676 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.0 mm -121.29 139.23 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.301 -0.875 . . . . 0.0 109.47 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.615 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 42.2 m-85 -60.92 114.41 3.05 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.192 -0.943 . . . . 0.0 109.442 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.519 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 44.3 p -87.37 -30.76 20.53 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 163.79 82.2 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.896 . . . . 0.0 109.455 -179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.417 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.8 Cg_endo -70.07 130.74 19.48 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.723 2.282 . . . . 0.0 111.827 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -67.83 -32.72 73.45 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.291 -0.88 . . . . 0.0 109.475 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -170.54 -177.48 40.65 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -64.62 -29.46 70.47 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.272 -1.134 . . . . 0.0 109.521 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -63.68 -60.41 3.35 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.165 -0.96 . . . . 0.0 109.438 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.453 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.2 mtt180 -112.72 155.74 24.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 53.4 m -146.5 149.07 32.92 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.239 -0.913 . . . . 0.0 109.434 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.932 ' C ' HD12 ' A' ' 141' ' ' LEU . 82.1 mmm -95.31 125.14 39.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.389 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.932 HD12 ' C ' ' A' ' 140' ' ' MET . 6.3 mp -125.46 140.4 52.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.163 -0.961 . . . . 0.0 109.631 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.604 HD12 ' HG2' ' A' ' 151' ' ' LYS . 6.0 tt -96.04 123.9 39.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.322 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.858 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.6 mp -99.51 113.65 26.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.652 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -89.52 124.27 34.37 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.703 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.5 mm? -85.27 175.22 9.06 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.152 -0.967 . . . . 0.0 109.392 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.501 HG13 ' N ' ' A' ' 147' ' ' ASN . 17.6 pt -58.93 -38.12 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.202 -0.936 . . . . 0.0 109.452 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.501 ' N ' HG13 ' A' ' 146' ' ' ILE . 24.2 m120 -138.89 19.61 2.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.958 . . . . 0.0 109.407 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 85.7 mttt -143.64 156.56 44.6 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.26 -0.9 . . . . 0.0 109.631 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -121.38 124.9 45.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.196 -0.94 . . . . 0.0 109.191 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.572 HG23 HD23 ' A' ' 145' ' ' LEU . 32.8 pt -128.73 156.03 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.918 . . . . 0.0 109.766 -179.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.604 ' HG2' HD12 ' A' ' 142' ' ' LEU . 22.7 mttt -131.56 132.18 43.92 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.339 -0.851 . . . . 0.0 109.27 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 153' ' ' SER . 57.8 t-80 -152.28 144.79 24.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.141 -0.974 . . . . 0.0 109.502 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.429 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 45.9 p -68.7 142.61 54.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.33 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.832 ' HB ' HD13 ' A' ' 141' ' ' LEU . 19.7 t -129.85 150.78 34.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.537 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.499 ' O ' ' N ' ' A' ' 158' ' ' GLU . 90.5 mttt -94.11 139.12 31.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.33 -0.856 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.0 p30 -46.0 -29.06 1.32 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.169 -0.957 . . . . 0.0 109.582 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 57.9 p -82.24 -21.92 36.07 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 109.595 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.499 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.2 mt-10 -81.22 -20.6 40.71 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.658 ' CD2' HD21 ' A' ' 141' ' ' LEU . 27.7 p90 -140.74 172.14 13.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.201 -0.937 . . . . 0.0 109.561 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -130.85 147.73 52.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -78.57 133.54 37.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.273 -0.892 . . . . 0.0 109.504 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.444 HD11 ' HB ' ' A' ' 117' ' ' ILE . 15.9 mt . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.468 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.48 -33.03 73.08 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.172 -1.193 . . . . 0.0 109.526 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.6 mtt -125.35 154.4 41.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.925 . . . . 0.0 109.417 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -67.94 151.69 52.11 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.12 -9.08 25.17 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.669 2.246 . . . . 0.0 111.743 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.419 ' O ' ' HB3' ' A' ' 103' ' ' ASP . 93.5 mttt -63.57 -31.22 72.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.6 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.431 ' O ' ' C ' ' A' ' 104' ' ' ILE . 46.6 t0 67.0 26.82 8.96 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.292 -0.88 . . . . 0.0 109.39 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 103' ' ' ASP . 78.3 mt -42.98 -37.38 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.265 -0.897 . . . . 0.0 109.631 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 43.5 t -108.25 135.74 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.243 -0.911 . . . . 0.0 109.487 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 106' ' ' ASP . 25.8 p30 -106.89 156.37 37.44 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.894 . . . . 0.0 109.477 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -69.99 63.22 1.93 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.742 2.295 . . . . 0.0 111.854 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -66.52 -34.28 77.57 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.47 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.42 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 32.6 m -64.93 138.2 97.4 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.29 -0.881 . . . . 0.0 109.409 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.42 ' HD2' ' CG2' ' A' ' 109' ' ' THR . 49.9 Cg_endo -70.12 147.07 59.75 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.764 2.309 . . . . 0.0 111.833 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.443 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 6.5 m-85 -111.03 161.29 25.62 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.324 -0.86 . . . . 0.0 109.368 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.64 131.52 23.07 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.73 2.286 . . . . 0.0 111.712 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.65 -11.98 59.5 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 77.6 m-20 -77.44 157.43 30.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -1.155 . . . . 0.0 109.497 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.568 ' HB3' HD21 ' A' ' 162' ' ' LEU . 55.9 mttt -80.35 142.12 34.76 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.299 -0.876 . . . . 0.0 109.448 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.011 HG21 HD23 ' A' ' 141' ' ' LEU . 5.8 m -127.59 159.48 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.476 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.836 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.3 tp -123.37 147.32 27.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.45 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.607 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.2 mm -91.45 131.63 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.264 -0.897 . . . . 0.0 109.475 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.429 ' C ' ' HG2' ' A' ' 124' ' ' GLU . 72.7 p -121.65 5.5 10.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.267 -0.896 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.426 ' N ' ' HG2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -141.73 151.16 42.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.203 -0.936 . . . . 0.0 109.442 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 85.13 -170.27 44.94 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.73 -2.4 58.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -1.201 . . . . 0.0 109.625 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.607 ' HB2' HG21 ' A' ' 118' ' ' ILE . 93.1 m-85 -87.94 4.78 43.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.63 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 119' ' ' THR . 97.5 mt-10 -56.5 142.09 40.28 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.211 -0.93 . . . . 0.0 109.594 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.7 -3.46 83.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.594 ' O ' HD12 ' A' ' 117' ' ' ILE . 19.8 m-30 -102.36 147.71 26.37 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.211 -1.17 . . . . 0.0 109.596 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -100.17 151.03 21.9 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.349 -0.845 . . . . 0.0 109.387 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.966 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -146.74 161.34 40.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.227 -0.92 . . . . 0.0 109.516 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.487 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 22.8 mm -114.02 140.54 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.484 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.5 m-85 -61.42 112.86 2.36 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.275 -0.891 . . . . 0.0 109.443 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 46.0 p -82.36 -32.13 29.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.273 -0.892 . . . . 0.0 109.457 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.8 mm-40 164.4 91.72 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.156 -0.965 . . . . 0.0 109.488 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.11 122.99 9.55 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.597 2.198 . . . . 0.0 111.771 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 79.1 m-20 -65.81 -31.26 72.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.231 -0.918 . . . . 0.0 109.47 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -163.26 179.84 38.18 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.04 -26.85 63.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.218 -1.166 . . . . 0.0 109.541 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.36 -53.72 15.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.461 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 59.0 mtt180 -112.32 151.44 29.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.516 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 54.4 m -142.32 150.43 40.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.303 -0.873 . . . . 0.0 109.465 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.931 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.8 mtp -100.37 127.31 46.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.244 -0.91 . . . . 0.0 109.446 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.011 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -125.38 146.42 49.6 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.483 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.576 ' O ' ' HB1' ' A' ' 128' ' ' ALA . 9.7 tt -97.44 126.3 42.62 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.29 -0.881 . . . . 0.0 109.411 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.641 HD23 ' HB2' ' A' ' 128' ' ' ALA . 39.1 mt -97.93 109.88 22.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.542 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.625 ' C ' HD22 ' A' ' 145' ' ' LEU . 14.9 p-10 -84.63 122.6 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.295 -0.878 . . . . 0.0 109.621 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -111.23 141.43 44.77 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.383 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.499 HG13 ' N ' ' A' ' 147' ' ' ASN . 21.3 pt -50.03 -35.75 11.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.499 ' N ' HG13 ' A' ' 146' ' ' ILE . 61.3 t30 -72.42 -49.22 35.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.288 -0.882 . . . . 0.0 109.575 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.499 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 67.3 mttt -158.11 173.38 16.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.543 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -103.17 133.21 48.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.924 . . . . 0.0 109.312 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.451 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 17.2 pt -133.99 159.27 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.27 -0.894 . . . . 0.0 109.625 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.523 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 13.3 mttt -119.63 136.95 54.17 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.282 -0.886 . . . . 0.0 109.33 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 49.1 t-80 -144.31 140.24 29.04 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.164 -0.96 . . . . 0.0 109.585 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 23.5 p -85.1 125.19 32.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.338 -0.851 . . . . 0.0 109.313 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.722 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.0 p -127.97 147.92 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.196 -0.94 . . . . 0.0 109.547 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.54 ' O ' ' CD2' ' A' ' 159' ' ' PHE . 88.8 mttt -76.08 155.27 34.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.231 -0.918 . . . . 0.0 109.464 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 20.3 m-80 -62.71 -27.09 69.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.453 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 64.7 p -77.33 -18.86 57.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.356 -0.84 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.536 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 97.3 mt-10 -87.72 -19.78 27.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.475 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.581 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 29.8 p90 -138.08 161.03 37.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -0.951 . . . . 0.0 109.583 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.836 ' O ' HG22 ' A' ' 117' ' ' ILE . 73.7 mtt180 -129.53 147.77 51.37 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.317 -0.864 . . . . 0.0 109.475 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.405 ' NZ ' ' HA ' ' A' ' 110' ' ' PRO . 25.7 tttt -73.55 123.88 24.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.429 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.612 ' OXT' HD12 ' A' ' 162' ' ' LEU . 1.1 pp . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.934 -1.031 . . . . 0.0 109.487 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.48 146.02 52.7 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.281 -1.129 . . . . 0.0 109.48 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.8 mtm -111.5 143.21 42.71 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.288 -0.883 . . . . 0.0 109.454 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -74.6 150.77 42.09 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.02 147.53 61.4 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.708 2.272 . . . . 0.0 111.789 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 23.4 tttp -84.24 134.03 34.55 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -68.32 146.83 52.92 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -0.915 . . . . 0.0 109.528 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' A' ' 105' ' ' VAL . 54.6 mt -116.81 138.51 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.202 -0.936 . . . . 0.0 109.468 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.462 ' O ' ' O ' ' A' ' 104' ' ' ILE . 50.8 t 58.99 114.89 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.247 -0.908 . . . . 0.0 109.458 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -62.69 138.43 96.83 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.208 -0.932 . . . . 0.0 109.473 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.1 53.64 1.23 Allowed 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.75 2.3 . . . . 0.0 111.799 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.04 -32.04 72.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.904 . . . . 0.0 109.5 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.522 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 3.0 m -68.05 140.7 93.65 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.248 -0.908 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.589 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.1 Cg_endo -69.98 144.45 52.89 Favored 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.679 2.253 . . . . 0.0 111.754 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.462 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 52.8 m-85 -111.55 160.89 27.79 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.499 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 49.4 Cg_endo -70.2 135.01 28.37 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.675 2.25 . . . . 0.0 111.754 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.82 -10.11 66.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.462 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.2 m-20 -83.99 147.53 27.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -1.123 . . . . 0.0 109.482 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.516 ' CB ' HD21 ' A' ' 162' ' ' LEU . 22.7 mttm -72.98 145.08 46.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.256 -0.902 . . . . 0.0 109.456 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 141' ' ' LEU . 4.3 m -133.79 150.42 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.476 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 1.8 tp -119.95 139.29 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.15 -0.969 . . . . 0.0 109.461 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.585 HD11 HD21 ' A' ' 143' ' ' LEU . 58.8 mt -92.53 130.08 42.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.287 -0.883 . . . . 0.0 109.501 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.482 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 60.5 p -106.96 -10.26 16.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -132.87 157.36 45.25 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 109.522 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.66 166.85 36.33 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.59 -22.31 64.46 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.58 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 96.9 m-85 -82.51 8.13 12.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.224 -0.922 . . . . 0.0 109.52 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.482 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -57.64 139.9 52.51 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.297 -0.877 . . . . 0.0 109.522 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.53 -5.26 73.82 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.5 m-30 -99.99 145.79 27.46 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.247 -1.149 . . . . 0.0 109.464 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -94.55 146.45 24.11 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.203 -0.935 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.812 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.21 160.18 40.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.299 -0.875 . . . . 0.0 109.42 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.71 140.06 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.227 -0.921 . . . . 0.0 109.48 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.625 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 41.8 m-85 -61.42 110.15 1.36 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.295 -0.878 . . . . 0.0 109.495 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.52 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 39.3 p -80.46 -32.5 37.18 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.317 -0.864 . . . . 0.0 109.477 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.52 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 164.32 86.58 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.267 -0.895 . . . . 0.0 109.398 -179.941 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.79 128.56 16.17 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.773 2.316 . . . . 0.0 111.799 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.8 m-20 -69.06 -29.34 67.45 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.517 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -167.92 174.81 42.87 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . 0.41 ' HG3' HG23 ' A' ' 109' ' ' THR . 82.7 tt0 -62.07 -27.97 69.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.68 -64.93 0.75 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.164 -0.96 . . . . 0.0 109.476 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.402 ' O ' ' O ' ' A' ' 135' ' ' GLY . 49.9 mtm-85 -105.08 152.08 23.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.532 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 65.2 m -142.46 152.15 42.44 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.2 -0.938 . . . . 0.0 109.51 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.917 ' C ' HD12 ' A' ' 141' ' ' LEU . 66.2 mmm -96.58 123.61 40.31 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 116' ' ' VAL . 6.5 mp -122.5 142.89 50.11 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.945 . . . . 0.0 109.636 -179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.833 HD13 ' HG2' ' A' ' 151' ' ' LYS . 15.1 tp -103.86 119.36 38.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.273 -0.892 . . . . 0.0 109.417 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.85 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.9 mp -100.57 109.14 21.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.501 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.431 ' O ' ' CG ' ' A' ' 144' ' ' ASN . 11.3 p-10 -83.11 118.86 23.85 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.567 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.765 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -82.03 168.83 17.4 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.178 -0.951 . . . . 0.0 109.259 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.515 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.2 pt -54.15 -38.27 38.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.19 -0.944 . . . . 0.0 109.638 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.515 ' N ' HG13 ' A' ' 146' ' ' ILE . 30.3 p-10 -139.19 25.09 2.49 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.125 -0.984 . . . . 0.0 109.787 -179.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.461 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 76.0 mttt -152.61 157.41 40.97 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.14 -0.975 . . . . 0.0 109.815 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -128.11 130.86 48.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.383 -0.823 . . . . 0.0 109.112 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.618 ' O ' HD12 ' A' ' 142' ' ' LEU . 21.3 pt -131.45 145.22 35.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.134 -0.978 . . . . 0.0 109.835 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.833 ' HG2' HD13 ' A' ' 142' ' ' LEU . 19.6 mttp -118.53 126.79 52.75 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.38 -0.825 . . . . 0.0 109.298 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.494 ' CE1' ' O ' ' A' ' 153' ' ' SER . 52.5 t-80 -153.85 145.73 23.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.168 -0.958 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.494 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 52.5 p -74.48 141.48 44.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.216 -0.928 . . . . 0.0 109.356 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.601 HG12 ' HD1' ' A' ' 159' ' ' PHE . 21.3 t -124.78 150.4 29.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.442 ' HB2' ' HG3' ' A' ' 158' ' ' GLU . 61.3 mttp -86.06 138.46 31.93 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -49.96 -22.99 1.75 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.943 . . . . 0.0 109.494 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.7 p -86.62 -25.39 24.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.175 -0.953 . . . . 0.0 109.463 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG3' ' HB2' ' A' ' 155' ' ' LYS . 97.6 mt-10 -76.63 -23.39 53.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.316 -0.865 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.926 ' CE2' HD21 ' A' ' 141' ' ' LEU . 22.7 p90 -140.62 160.95 38.9 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.269 -0.894 . . . . 0.0 109.491 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -128.89 142.15 51.05 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.219 -0.925 . . . . 0.0 109.512 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -70.43 124.99 25.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.208 -0.933 . . . . 0.0 109.422 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.516 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.1 pp . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 118.001 -0.999 . . . . 0.0 109.496 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.9 143.93 57.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.253 -1.145 . . . . 0.0 109.424 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.1 mtp -56.36 -36.34 68.7 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.459 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -102.37 131.05 10.45 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.94 141.86 45.59 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.639 2.226 . . . . 0.0 111.825 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -58.21 -39.51 79.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.893 . . . . 0.0 109.516 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -84.52 139.24 32.28 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.475 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 54.3 mt -109.12 141.19 25.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.501 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 46.5 t -137.5 155.49 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.209 -0.932 . . . . 0.0 109.566 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.456 ' HB2' ' HD2' ' A' ' 107' ' ' PRO . 3.4 p30 -66.76 160.67 67.11 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.433 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . 0.456 ' HD2' ' HB2' ' A' ' 106' ' ' ASP . 49.0 Cg_endo -69.94 66.59 1.87 Allowed 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.634 2.223 . . . . 0.0 111.818 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -61.61 -31.54 71.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 32.3 m -55.71 129.16 70.67 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 109.42 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.603 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.3 Cg_endo -70.24 148.17 61.41 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.637 2.225 . . . . 0.0 111.754 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.441 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 65.9 m-85 -109.24 161.11 25.11 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.282 -0.886 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.414 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.2 Cg_endo -69.64 132.27 23.16 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.681 2.254 . . . . 0.0 111.756 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.54 -10.55 61.12 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.45 ' HB3' ' HE3' ' A' ' 161' ' ' LYS . 81.5 m-20 -77.85 150.72 34.15 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.176 -1.191 . . . . 0.0 109.451 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.549 ' HB3' HD21 ' A' ' 162' ' ' LEU . 28.8 mttt -84.81 141.51 30.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.47 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -129.04 158.89 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.464 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 160' ' ' ARG . 7.3 tp -126.59 148.73 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.151 -0.968 . . . . 0.0 109.505 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.453 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 25.9 mm -90.52 127.84 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 72.8 p -112.83 -5.36 13.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.275 -0.891 . . . . 0.0 109.502 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.468 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 85.2 tt0 -138.51 156.28 47.65 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.202 -0.936 . . . . 0.0 109.421 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.468 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 86.5 169.57 46.05 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.22 -14.63 63.13 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.222 -1.163 . . . . 0.0 109.527 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.553 ' CD1' HD13 ' A' ' 143' ' ' LEU . 85.6 m-85 -82.78 6.85 16.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.517 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 84.5 tt0 -59.45 132.84 55.2 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.565 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 99.46 1.17 56.67 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.521 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -103.49 138.58 40.01 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.12 -1.224 . . . . 0.0 109.59 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -93.98 122.58 36.63 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.211 -0.931 . . . . 0.0 109.45 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.922 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -118.52 165.77 13.52 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.58 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.525 ' CD1' ' HA ' ' A' ' 115' ' ' LYS . 41.9 mm -120.43 139.29 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -0.911 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.603 ' CE2' ' HB2' ' A' ' 110' ' ' PRO . 37.6 m-85 -58.65 101.37 0.09 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.251 -0.906 . . . . 0.0 109.516 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.525 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 49.2 p -77.15 -30.52 55.05 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.255 -0.903 . . . . 0.0 109.286 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.525 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.2 mt-10 163.63 97.15 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.262 -0.899 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.85 114.63 3.78 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.707 2.272 . . . . 0.0 111.763 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -66.55 -33.6 76.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.238 -0.914 . . . . 0.0 109.492 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -145.01 163.0 28.11 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.66 -31.99 72.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.252 -1.146 . . . . 0.0 109.184 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -70.17 -73.91 0.15 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.331 -0.855 . . . . 0.0 109.438 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.6 ptt-85 -84.96 158.32 20.55 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.285 -0.885 . . . . 0.0 109.611 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 71.1 m -145.79 144.58 30.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.871 ' C ' HD12 ' A' ' 141' ' ' LEU . 89.8 mmm -86.58 118.89 26.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.251 -0.906 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -122.61 146.07 47.78 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.521 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.72 HD12 ' CE ' ' A' ' 151' ' ' LYS . 9.4 tt -99.37 127.44 45.4 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 109.434 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.553 HD13 ' CD1' ' A' ' 123' ' ' PHE . 17.9 mt -96.8 115.04 26.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.222 -0.924 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.863 ' C ' HD12 ' A' ' 145' ' ' LEU . 6.9 p30 -86.75 126.6 34.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.19 -0.944 . . . . 0.0 109.6 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.863 HD12 ' C ' ' A' ' 144' ' ' ASN . 9.6 mp -129.46 136.33 49.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.242 -0.911 . . . . 0.0 109.362 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.514 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.3 pt -50.55 -35.09 12.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.888 . . . . 0.0 109.614 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.514 ' N ' HG13 ' A' ' 146' ' ' ILE . 47.7 t-20 -68.68 -47.56 66.16 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.915 . . . . 0.0 109.585 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.482 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 55.5 tttp -168.09 158.98 10.72 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.166 -0.959 . . . . 0.0 109.576 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.482 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 97.0 mt-10 -93.81 125.72 38.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.179 -0.95 . . . . 0.0 109.5 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.474 HD11 ' CE1' ' A' ' 123' ' ' PHE . 27.8 pt -126.34 158.63 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.205 -0.935 . . . . 0.0 109.428 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.72 ' CE ' HD12 ' A' ' 142' ' ' LEU . 17.1 mttt -124.62 131.55 53.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.272 -0.893 . . . . 0.0 109.543 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -142.6 147.06 35.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.215 -0.928 . . . . 0.0 109.441 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 39.3 p -72.18 139.66 48.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.283 -0.885 . . . . 0.0 109.438 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.692 ' HB ' HD13 ' A' ' 141' ' ' LEU . 21.8 t -131.08 150.63 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.184 -0.947 . . . . 0.0 109.354 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 24.6 mttm -97.16 138.72 34.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.585 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 32.1 m-80 -45.06 -30.64 1.11 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.199 -0.938 . . . . 0.0 109.468 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 65.9 p -81.15 -25.21 37.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.287 -0.883 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 92.0 mt-10 -76.21 -23.67 54.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.642 ' HD1' HG12 ' A' ' 154' ' ' VAL . 27.5 p90 -137.41 167.05 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.206 -0.934 . . . . 0.0 109.529 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.49 ' O ' HG22 ' A' ' 117' ' ' ILE . 63.5 mtt85 -130.21 146.84 51.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.459 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.45 ' HE3' ' HB3' ' A' ' 114' ' ' ASP . 73.8 tttt -72.8 117.23 14.25 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.208 -0.932 . . . . 0.0 109.436 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.549 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.9 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.466 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -60.65 -31.23 70.45 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.248 -1.148 . . . . 0.0 109.526 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 67.6 mtm -117.18 154.35 31.26 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.505 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -108.98 159.23 14.19 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.6 -21.07 30.09 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.801 2.334 . . . . 0.0 111.719 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -58.3 -38.43 77.04 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.919 . . . . 0.0 109.515 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -90.3 133.37 35.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 49.8 mt -124.87 140.2 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.186 -0.947 . . . . 0.0 109.512 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 41.8 t -138.63 146.24 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.367 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -105.69 164.17 15.57 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -75.78 45.0 1.38 Allowed 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.624 2.216 . . . . 0.0 111.995 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -83.28 -27.38 29.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.094 -1.004 . . . . 0.0 109.189 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 18.0 m -49.74 125.36 17.02 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.307 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.618 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 48.6 Cg_endo -69.99 154.77 66.49 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.701 2.267 . . . . 0.0 111.917 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.47 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 43.7 m-85 -120.01 159.45 46.99 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.27 -0.894 . . . . 0.0 109.442 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.18 133.61 25.19 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.69 2.26 . . . . 0.0 111.873 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.34 -10.69 61.52 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.47 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 78.6 m-20 -85.57 144.69 27.75 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.288 -1.124 . . . . 0.0 109.498 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 22.6 mttp -75.45 147.02 40.22 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 109.517 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.058 HG21 HD23 ' A' ' 141' ' ' LEU . 4.8 m -134.9 151.41 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.25 -0.906 . . . . 0.0 109.45 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.912 HG21 HD21 ' A' ' 162' ' ' LEU . 3.8 tp -123.94 141.07 45.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.446 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 120' ' ' GLU . 61.8 mt -92.18 129.95 42.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.321 -0.862 . . . . 0.0 109.427 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.508 HG21 ' CD ' ' A' ' 160' ' ' ARG . 75.0 p -105.65 -7.6 18.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.537 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.435 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 97.8 mt-10 -138.02 158.16 44.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.266 -0.896 . . . . 0.0 109.484 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.4 168.11 38.55 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.95 -22.7 65.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.222 -1.163 . . . . 0.0 109.502 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.528 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.9 m-85 -83.47 9.46 11.17 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.244 -0.91 . . . . 0.0 109.417 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.502 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.9 tt0 -61.76 140.89 58.17 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.167 -0.958 . . . . 0.0 109.459 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.96 -6.06 76.29 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.528 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.0 m-85 -99.89 149.8 23.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.241 -1.153 . . . . 0.0 109.557 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -98.45 147.86 24.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 109.319 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.817 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.69 162.61 35.53 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.898 . . . . 0.0 109.502 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.41 HD13 ' O ' ' A' ' 128' ' ' ALA . 26.1 mm -113.47 143.87 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.635 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 33.6 m-85 -66.06 113.01 4.16 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.484 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.531 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 18.1 p -82.4 -33.17 28.78 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.952 . . . . 0.0 109.437 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.519 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.89 90.3 0.01 OUTLIER Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.78 122.66 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.686 2.257 . . . . 0.0 111.799 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 21.3 p-10 -65.89 -31.21 72.01 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.273 -0.892 . . . . 0.0 109.664 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.509 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -164.66 178.6 39.79 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -67.61 -27.05 66.57 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.308 -1.113 . . . . 0.0 109.543 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.04 -63.2 1.14 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.2 -0.938 . . . . 0.0 109.499 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 58.1 mtt180 -108.37 158.53 17.42 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 109.548 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 72.6 m -145.28 155.38 43.18 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.394 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.896 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.6 mtp -102.21 124.27 47.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.305 -0.872 . . . . 0.0 109.538 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.058 HD23 HG21 ' A' ' 116' ' ' VAL . 6.2 mp -122.25 145.79 47.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.531 ' HB2' ' CG2' ' A' ' 131' ' ' THR . 7.8 tt -104.8 120.82 42.3 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.915 . . . . 0.0 109.521 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.849 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.7 mp -96.37 136.1 37.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.44 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.498 ' OD1' ' CD2' ' A' ' 142' ' ' LEU . 92.7 m-20 -106.21 112.41 25.43 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.541 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.425 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 44.1 mt -100.24 148.08 25.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.281 -0.887 . . . . 0.0 109.392 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.512 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -51.13 -40.12 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.512 ' N ' HG13 ' A' ' 146' ' ' ILE . 45.8 t-20 -68.7 -48.08 64.77 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.292 -0.88 . . . . 0.0 109.54 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.505 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 28.3 ttpp -168.46 164.6 12.69 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.287 -0.883 . . . . 0.0 109.466 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.505 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 95.1 mt-10 -87.88 139.19 30.77 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.863 . . . . 0.0 109.453 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 29.4 pt -124.7 158.18 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.25 -0.906 . . . . 0.0 109.402 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.447 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.8 mttt -125.84 130.45 51.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.196 -0.94 . . . . 0.0 109.462 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.411 ' ND1' ' O ' ' A' ' 153' ' ' SER . 56.5 t-80 -153.17 141.61 20.72 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.301 -0.874 . . . . 0.0 109.436 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.411 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 68.6 m -67.77 142.59 56.18 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.167 -0.958 . . . . 0.0 109.438 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.651 ' HB ' HD13 ' A' ' 141' ' ' LEU . 16.8 t -131.03 151.6 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.226 -0.921 . . . . 0.0 109.418 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 9.5 mtpm? -92.04 137.29 32.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.27 -0.893 . . . . 0.0 109.508 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.587 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.0 m-80 -50.66 -24.36 3.28 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 109.415 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.6 p -84.78 -22.49 29.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.907 . . . . 0.0 109.356 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.442 ' HG2' ' HB2' ' A' ' 155' ' ' LYS . 68.6 mm-40 -81.47 -20.7 39.66 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.623 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -139.14 178.29 7.28 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.508 ' CD ' HG21 ' A' ' 119' ' ' THR . 59.1 mtt-85 -134.65 146.63 49.71 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.307 -0.871 . . . . 0.0 109.402 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 18.9 tttm -84.71 135.75 34.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.924 . . . . 0.0 109.447 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.912 HD21 HG21 ' A' ' 117' ' ' ILE . 68.0 mt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.415 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 98' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 97' ' ' GLY . . . 63.67 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.206 -1.173 . . . . 0.0 109.481 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.0 mmm -60.58 -36.96 79.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.227 -0.92 . . . . 0.0 109.442 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -68.66 145.9 44.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.37 -14.93 34.65 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.707 2.272 . . . . 0.0 111.786 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.4 mttt -57.22 -36.27 70.68 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.322 -0.862 . . . . 0.0 109.458 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -79.79 135.65 36.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.198 -0.939 . . . . 0.0 109.562 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.74 142.26 37.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.473 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.73 154.99 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.231 -0.918 . . . . 0.0 109.445 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -74.26 122.37 87.38 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.1 57.84 1.67 Allowed 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.687 2.258 . . . . 0.0 111.779 179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.1 75.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.311 -0.868 . . . . 0.0 109.551 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 77.0 m -99.93 126.89 35.18 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.234 -0.916 . . . . 0.0 109.411 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.25 135.12 28.51 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.697 2.265 . . . . 0.0 111.846 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.407 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 33.0 m-85 -77.58 161.23 72.78 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.323 -0.861 . . . . 0.0 109.479 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.17 134.04 28.21 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.693 2.262 . . . . 0.0 111.819 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.03 -17.55 54.0 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -68.47 162.71 24.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -1.151 . . . . 0.0 109.38 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.483 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 36.5 mttm -88.01 139.48 30.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.282 -0.886 . . . . 0.0 109.572 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.007 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -133.48 148.98 30.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.309 -0.869 . . . . 0.0 109.307 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.447 ' CG2' ' HB3' ' A' ' 162' ' ' LEU . 5.1 tp -116.67 141.45 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.177 -0.952 . . . . 0.0 109.556 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.443 HD11 HD21 ' A' ' 143' ' ' LEU . 72.6 mt -92.61 130.72 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.297 -0.877 . . . . 0.0 109.422 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.454 HG21 ' HD2' ' A' ' 160' ' ' ARG . 61.3 p -107.27 -5.02 18.11 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.206 -0.934 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.472 ' HG2' ' N ' ' A' ' 121' ' ' GLY . 83.9 tt0 -141.41 155.53 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.521 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.472 ' N ' ' HG2' ' A' ' 120' ' ' GLU . . . 100.33 166.83 28.83 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.37 -22.22 64.67 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.578 ' CE1' HD11 ' A' ' 150' ' ' ILE . 77.8 m-85 -87.64 12.87 11.54 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.211 -0.931 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.1 136.94 58.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.254 -0.904 . . . . 0.0 109.432 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.91 66.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -105.68 122.75 46.7 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -1.168 . . . . 0.0 109.541 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -72.05 137.35 47.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.298 -0.876 . . . . 0.0 109.306 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.83 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -133.68 158.52 43.04 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.208 -0.932 . . . . 0.0 109.563 -179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.5 mm -116.64 136.0 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.444 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.842 ' CE2' HG11 ' A' ' 116' ' ' VAL . 35.2 m-85 -58.61 101.77 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.319 -0.863 . . . . 0.0 109.519 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.467 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 44.8 p -75.05 -39.06 61.16 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.386 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 131' ' ' THR . 67.9 tt0 172.98 95.77 0.05 OUTLIER Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.9 . . . . 0.0 109.441 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -70.16 110.72 2.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.718 2.279 . . . . 0.0 111.848 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.5 p-10 -62.68 -34.42 77.08 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.504 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.417 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -141.85 178.06 20.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -76.91 -30.02 55.95 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.281 -1.129 . . . . 0.0 109.406 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -69.46 -78.06 0.07 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.207 -0.933 . . . . 0.0 109.407 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.48 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 13.3 ptt180 -89.77 148.13 23.42 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.248 -0.907 . . . . 0.0 109.743 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.1 m -135.33 155.38 50.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.217 -0.927 . . . . 0.0 109.492 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.76 ' C ' HD12 ' A' ' 141' ' ' LEU . 93.6 mmm -89.92 115.55 27.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.478 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.1 mp -119.74 139.52 52.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.892 . . . . 0.0 109.481 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.603 HD12 ' N ' ' A' ' 143' ' ' LEU . 9.0 tp -97.48 122.16 40.22 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.244 -0.91 . . . . 0.0 109.545 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.776 HD23 ' HB2' ' A' ' 128' ' ' ALA . 22.1 mt -87.95 146.46 25.52 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.252 -0.905 . . . . 0.0 109.316 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.503 ' C ' HD12 ' A' ' 145' ' ' LEU . 99.2 m-20 -115.98 107.96 15.63 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.601 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.77 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.0 mp -105.23 141.18 37.21 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.2 -0.938 . . . . 0.0 109.302 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.0 pt -50.39 -32.5 9.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.522 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.7 m-20 -73.12 -56.41 5.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.289 -0.882 . . . . 0.0 109.674 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.522 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 60.2 mttm -159.58 171.32 19.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.513 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.58 139.08 38.64 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.337 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.598 ' O ' HD12 ' A' ' 142' ' ' LEU . 20.1 pt -132.8 142.43 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.231 -0.918 . . . . 0.0 109.46 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.445 ' HG2' HD13 ' A' ' 142' ' ' LEU . 98.1 mttt -96.5 130.02 43.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.24 -0.913 . . . . 0.0 109.474 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -147.52 138.57 23.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.488 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 52.1 p -73.2 141.45 47.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.278 -0.889 . . . . 0.0 109.441 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.729 ' HB ' HD13 ' A' ' 141' ' ' LEU . 12.2 t -128.81 151.56 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.243 -0.91 . . . . 0.0 109.56 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 158' ' ' GLU . 45.4 mttp -100.87 138.36 38.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.376 -0.828 . . . . 0.0 109.423 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.581 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 2.1 p30 -46.04 -28.28 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.187 -0.946 . . . . 0.0 109.493 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 72.0 p -84.94 -19.64 31.88 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.25 -0.906 . . . . 0.0 109.629 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 155' ' ' LYS . 95.6 mt-10 -83.23 -22.34 33.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.182 -0.949 . . . . 0.0 109.459 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.655 ' HD1' HG12 ' A' ' 154' ' ' VAL . 29.9 p90 -136.93 173.03 12.14 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.215 -0.928 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.454 ' HD2' HG21 ' A' ' 119' ' ' THR . 96.6 mtt180 -134.99 145.17 47.86 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.242 -0.911 . . . . 0.0 109.515 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -69.34 113.59 6.81 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.616 HD23 ' C ' ' A' ' 116' ' ' VAL . 1.9 pp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.406 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -65.31 140.44 58.69 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.277 -1.131 . . . . 0.0 109.445 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 71.7 mtm -60.48 -36.34 78.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.282 -0.886 . . . . 0.0 109.47 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -157.34 130.25 2.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.39 -9.24 25.46 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.682 2.255 . . . . 0.0 111.755 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 47.6 mttm -57.24 -33.18 67.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.3 -0.875 . . . . 0.0 109.474 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -63.94 141.77 58.65 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.443 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.6 -41.76 89.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 33.7 m -131.08 150.0 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.439 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 -107.65 136.06 19.7 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.285 -0.884 . . . . 0.0 109.377 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.37 54.11 1.0 Allowed 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.722 2.282 . . . . 0.0 111.729 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.53 -34.67 77.57 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.223 -0.923 . . . . 0.0 109.532 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 38.0 m -76.52 123.49 87.73 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.559 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 49.8 Cg_endo -70.08 139.55 39.38 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.689 2.259 . . . . 0.0 111.856 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 10.9 m-85 -88.26 161.08 44.22 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.903 . . . . 0.0 109.525 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.7 138.22 37.48 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.722 2.281 . . . . 0.0 111.79 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 96.85 -11.61 66.12 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -73.99 151.7 40.23 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.255 -1.144 . . . . 0.0 109.403 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.534 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.5 mttm -80.26 139.75 36.54 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.92 . . . . 0.0 109.474 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.031 HG21 HD23 ' A' ' 141' ' ' LEU . 4.7 m -129.23 156.3 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.255 -0.903 . . . . 0.0 109.43 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.655 HG22 ' O ' ' A' ' 160' ' ' ARG . 8.2 tp -123.24 146.1 29.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.598 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.465 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 20.5 mm -90.13 120.27 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.233 -0.917 . . . . 0.0 109.394 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 58.1 p -103.03 -16.06 15.91 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 109.456 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.42 155.56 50.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.287 -0.883 . . . . 0.0 109.459 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.94 165.04 35.45 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.95 -15.35 62.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.228 -1.16 . . . . 0.0 109.441 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.698 ' HB3' HD23 ' A' ' 143' ' ' LEU . 88.7 m-85 -86.49 11.75 11.88 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.249 -0.907 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.459 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.1 tt0 -59.04 134.74 57.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.466 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.97 67.18 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.475 ' CE2' ' HG ' ' A' ' 145' ' ' LEU . 40.7 m-85 -99.19 137.62 37.44 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.098 -1.236 . . . . 0.0 109.545 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -90.99 129.38 37.0 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 109.323 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.972 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -130.08 163.72 25.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.249 -0.907 . . . . 0.0 109.56 -179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 128' ' ' ALA . 31.0 mm -119.42 139.76 45.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.308 -0.87 . . . . 0.0 109.408 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.594 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 38.0 m-85 -58.6 101.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.207 -0.933 . . . . 0.0 109.409 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.501 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 41.0 p -77.58 -28.33 51.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.501 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.7 OUTLIER 164.93 98.01 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.484 179.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 50.0 Cg_endo -69.82 114.83 3.84 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.733 2.289 . . . . 0.0 111.805 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.1 m-20 -60.94 -30.7 70.37 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -0.889 . . . . 0.0 109.506 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -166.15 174.45 41.72 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -67.34 -22.81 65.57 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -1.144 . . . . 0.0 109.491 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.92 -64.63 1.01 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.222 -0.924 . . . . 0.0 109.568 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.452 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 57.5 mtm-85 -107.72 159.61 16.35 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.303 -0.873 . . . . 0.0 109.498 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 55.7 m -144.98 157.93 43.97 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -0.864 . . . . 0.0 109.471 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.893 ' C ' HD12 ' A' ' 141' ' ' LEU . 33.8 mtp -101.97 120.91 41.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.274 -0.891 . . . . 0.0 109.425 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.031 HD23 HG21 ' A' ' 116' ' ' VAL . 6.4 mp -120.31 147.31 45.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.173 -0.954 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.772 HD13 ' HG2' ' A' ' 151' ' ' LYS . 11.9 tp -99.87 124.01 44.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.225 -0.922 . . . . 0.0 109.45 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.843 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.1 mp -100.89 109.51 21.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.195 -0.941 . . . . 0.0 109.457 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.726 ' C ' HD12 ' A' ' 145' ' ' LEU . 13.4 p-10 -83.24 125.44 31.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.908 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 144' ' ' ASN . 7.7 mp -118.3 141.87 48.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.16 -0.962 . . . . 0.0 109.468 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.44 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.4 pt -51.6 -30.93 11.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.271 -0.893 . . . . 0.0 109.478 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.506 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 95.6 m-20 -74.98 -55.24 5.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.263 -0.898 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.506 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 33.9 mttt -158.68 171.78 19.47 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.223 -0.923 . . . . 0.0 109.622 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -101.01 131.3 46.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.239 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.544 ' O ' HD12 ' A' ' 142' ' ' LEU . 6.9 pt -129.87 144.77 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.742 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.772 ' HG2' HD13 ' A' ' 142' ' ' LEU . 31.2 mttt -108.47 136.57 47.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.329 -0.857 . . . . 0.0 109.039 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.09 140.02 20.97 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.004 -1.06 . . . . 0.0 109.831 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.402 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.4 p -85.19 121.8 28.46 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.39 -0.819 . . . . 0.0 109.047 179.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.544 ' CG2' ' HB2' ' A' ' 158' ' ' GLU . 2.9 p -121.13 151.55 24.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.15 -0.969 . . . . 0.0 109.638 -179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 35.2 mttt -75.21 149.25 38.97 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.327 -0.858 . . . . 0.0 109.577 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.573 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 23.1 m-80 -60.56 -26.09 66.67 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.7 p -78.51 -20.69 50.24 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.293 -0.88 . . . . 0.0 109.53 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.544 ' HB2' ' CG2' ' A' ' 154' ' ' VAL . 72.8 mm-40 -83.28 -22.06 33.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.908 . . . . 0.0 109.456 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.977 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.4 p90 -138.35 156.19 47.84 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.242 -0.911 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.655 ' O ' HG22 ' A' ' 117' ' ' ILE . 17.3 ttt85 -127.93 137.08 52.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.418 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 16.8 pttt -72.19 161.03 31.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.174 -0.954 . . . . 0.0 109.405 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.791 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 118.079 -0.963 . . . . 0.0 109.501 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.63 -31.07 71.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -1.138 . . . . 0.0 109.414 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 89.1 mtp -117.58 149.0 41.39 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.302 -0.874 . . . . 0.0 109.461 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -65.29 155.56 49.17 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.23 141.65 43.86 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 122.684 2.256 . . . . 0.0 111.833 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 53.0 tttm -57.82 -39.95 78.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.275 -0.891 . . . . 0.0 109.346 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.11 137.94 47.41 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 62.9 mt -113.89 141.36 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.178 -0.951 . . . . 0.0 109.542 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 36.8 t -119.15 126.84 75.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.216 -0.927 . . . . 0.0 109.394 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.447 ' N ' ' OD1' ' A' ' 106' ' ' ASP . 0.4 OUTLIER -98.8 119.66 60.61 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.631 -179.864 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -77.13 42.32 1.1 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.601 2.201 . . . . 0.0 111.999 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -80.77 -31.72 35.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.129 -0.982 . . . . 0.0 109.451 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 21.1 m -58.17 129.92 83.25 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.331 -0.856 . . . . 0.0 109.515 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.638 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 48.5 Cg_endo -70.32 145.14 53.08 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.639 2.226 . . . . 0.0 111.789 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 31.3 m-85 -109.03 161.33 24.13 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.253 -0.904 . . . . 0.0 109.528 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.77 132.34 24.75 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.728 2.285 . . . . 0.0 111.824 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 106.83 -14.79 41.25 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.49 158.96 25.71 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -1.146 . . . . 0.0 109.595 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -92.78 145.92 24.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.278 -0.889 . . . . 0.0 109.48 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.041 HG22 ' O ' ' A' ' 128' ' ' ALA . 17.4 m -128.71 152.48 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.443 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.662 ' HB ' HD11 ' A' ' 162' ' ' LEU . 7.3 tp -123.6 148.59 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.493 HG21 ' HB2' ' A' ' 123' ' ' PHE . 18.0 mm -92.58 132.51 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.23 -0.919 . . . . 0.0 109.463 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 52.2 p -121.32 5.39 10.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.196 -0.94 . . . . 0.0 109.619 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.424 ' OE1' ' HA ' ' A' ' 158' ' ' GLU . 94.0 mt-10 -141.36 152.14 44.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.14 -0.975 . . . . 0.0 109.501 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 84.25 -171.94 48.64 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.25 -5.72 59.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -1.146 . . . . 0.0 109.54 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.576 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 83.1 m-85 -85.46 7.7 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.906 . . . . 0.0 109.578 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 121' ' ' GLY . 97.6 mt-10 -58.96 141.1 54.71 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.217 -0.927 . . . . 0.0 109.572 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.56 -6.83 80.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.612 ' O ' HD12 ' A' ' 117' ' ' ILE . 20.6 m-30 -96.97 147.62 23.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.224 -1.162 . . . . 0.0 109.614 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -104.54 154.19 20.23 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.356 -0.84 . . . . 0.0 109.334 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 1.041 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -147.88 162.05 40.06 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.595 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 23.9 mm -112.39 144.34 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.587 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.728 ' CE1' HD21 ' A' ' 141' ' ' LEU . 35.1 m-85 -66.48 103.33 1.03 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.25 -0.906 . . . . 0.0 109.382 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.604 HG21 ' HE2' ' A' ' 151' ' ' LYS . 43.8 p -76.29 -34.2 59.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.527 ' O ' ' CG ' ' A' ' 140' ' ' MET . 2.2 mt-10 165.14 89.79 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.164 -0.96 . . . . 0.0 109.731 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.1 130.78 19.5 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.608 2.205 . . . . 0.0 111.694 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -68.17 -30.57 69.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -171.18 177.96 43.83 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 74.9 tt0 -63.45 -25.76 68.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.254 -1.145 . . . . 0.0 109.491 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.08 -62.27 1.51 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' O ' ' O ' ' A' ' 135' ' ' GLY . 55.7 mtt180 -110.01 157.98 18.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 70.3 m -142.46 153.05 43.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.52 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.527 ' CG ' ' O ' ' A' ' 132' ' ' GLU . 85.7 mmm -99.73 124.0 44.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.237 -0.914 . . . . 0.0 109.465 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.872 HD22 HG21 ' A' ' 116' ' ' VAL . 42.0 mt -122.94 145.89 48.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.233 -0.917 . . . . 0.0 109.449 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.948 HD12 ' HG2' ' A' ' 151' ' ' LYS . 2.7 tt -101.2 126.39 47.91 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.168 -0.958 . . . . 0.0 109.646 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.807 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.8 mp -99.55 104.37 16.16 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.223 -0.923 . . . . 0.0 109.157 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -77.54 125.56 29.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.127 -0.983 . . . . 0.0 109.335 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 69.1 mt -117.72 141.35 48.49 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.32 -0.863 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.434 HG13 ' N ' ' A' ' 147' ' ' ASN . 25.5 pt -51.55 -29.04 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.464 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.495 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 94.3 m-20 -78.47 -53.08 7.62 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.243 -0.911 . . . . 0.0 109.479 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.495 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 83.5 mttt -158.29 172.57 18.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.3 -0.875 . . . . 0.0 109.469 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -100.89 125.16 47.42 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.261 -0.899 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 32.2 pt -120.87 158.22 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -0.923 . . . . 0.0 109.5 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.948 ' HG2' HD12 ' A' ' 142' ' ' LEU . 3.2 mtpm? -125.27 132.25 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.428 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -144.67 141.33 29.26 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.292 -0.88 . . . . 0.0 109.505 -179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.514 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 38.5 p -73.33 141.22 47.1 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.887 . . . . 0.0 109.32 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.577 HG12 ' HD1' ' A' ' 159' ' ' PHE . 19.4 t -133.09 152.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.114 -0.991 . . . . 0.0 109.618 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.478 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 39.0 mtmt -91.28 141.46 28.76 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.394 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 18.5 m-80 -51.21 -26.2 6.66 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.3 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 45.6 p -83.83 -19.18 35.38 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.304 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.444 ' OE2' ' HE2' ' A' ' 155' ' ' LYS . 94.9 mt-10 -84.87 -13.42 50.97 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.353 -0.842 . . . . 0.0 109.45 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.577 ' HD1' HG12 ' A' ' 154' ' ' VAL . 36.0 p90 -148.74 173.5 13.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.208 -0.933 . . . . 0.0 109.398 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.471 ' O ' HG22 ' A' ' 117' ' ' ILE . 97.2 mtt180 -131.16 143.99 51.04 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.197 -0.939 . . . . 0.0 109.607 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 32.8 ttpt -80.78 135.09 35.91 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.738 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.7 mp . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.495 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.13 143.79 56.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.236 -1.155 . . . . 0.0 109.512 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.5 mtt -124.02 150.7 44.6 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.429 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -78.72 161.26 47.82 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.16 -16.74 35.95 Favored 'Trans proline' 0 C--O 1.214 -0.712 0 C-N-CA 122.673 2.248 . . . . 0.0 111.754 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 105' ' ' VAL . 37.1 mttt -62.29 -32.78 73.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -0.905 . . . . 0.0 109.44 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -60.07 -26.99 66.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.206 -0.934 . . . . 0.0 109.44 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 85.3 mt -55.97 -44.49 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.264 -0.897 . . . . 0.0 109.499 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' A' ' 102' ' ' LYS . 46.7 t -129.52 148.87 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.478 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.9 m-20 -84.05 140.69 40.0 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.485 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.06 42.75 1.03 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.712 2.275 . . . . 0.0 112.081 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -78.87 -32.76 46.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.072 -1.018 . . . . 0.0 109.124 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.452 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 26.5 m -58.09 138.84 83.85 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.603 ' HB2' ' CZ ' ' A' ' 130' ' ' PHE . 48.9 Cg_endo -69.73 148.04 64.4 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.662 2.242 . . . . 0.0 111.958 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.44 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 72.0 m-85 -118.39 161.18 36.58 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.319 -0.863 . . . . 0.0 109.341 179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.513 ' HA ' ' CB ' ' A' ' 130' ' ' PHE . 47.9 Cg_endo -69.07 130.72 20.72 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.767 2.311 . . . . 0.0 111.783 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.23 -8.21 55.18 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 129' ' ' ILE . 76.6 m-20 -83.1 166.41 18.73 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.186 -1.185 . . . . 0.0 109.577 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 28.8 mtpt -90.85 140.36 29.88 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.263 -0.898 . . . . 0.0 109.47 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.032 HG21 HD23 ' A' ' 141' ' ' LEU . 9.9 m -129.77 155.92 41.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.546 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.791 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.6 tp -120.55 145.19 27.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.343 -0.848 . . . . 0.0 109.475 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.504 HG21 ' HB2' ' A' ' 123' ' ' PHE . 15.0 mm -90.25 134.02 30.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.202 -0.937 . . . . 0.0 109.463 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.45 HG21 ' HD3' ' A' ' 160' ' ' ARG . 44.4 p -120.67 -0.05 10.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -0.899 . . . . 0.0 109.512 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.465 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 93.9 mt-10 -138.39 153.4 48.92 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.214 -0.929 . . . . 0.0 109.4 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.422 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.28 -171.51 44.16 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -87.95 -3.62 58.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.279 -1.13 . . . . 0.0 109.603 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.573 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 98.2 m-85 -89.13 9.55 25.11 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.24 -0.912 . . . . 0.0 109.502 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.465 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 98.3 mt-10 -59.23 141.89 53.18 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.217 -0.927 . . . . 0.0 109.586 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 88.57 -3.59 85.12 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.573 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 19.7 m-30 -100.17 143.22 30.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.167 -1.196 . . . . 0.0 109.565 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . 0.413 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 93.6 mt-30 -93.22 149.76 20.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.252 -0.905 . . . . 0.0 109.375 179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.976 ' HB3' ' CG2' ' A' ' 116' ' ' VAL . . . -142.23 160.8 39.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.464 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.463 HD13 ' O ' ' A' ' 128' ' ' ALA . 25.8 mm -114.99 136.52 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.18 -0.95 . . . . 0.0 109.453 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.62 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 34.8 m-85 -59.8 109.89 1.03 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.219 -0.926 . . . . 0.0 109.708 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.51 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 60.7 p -79.61 -34.85 40.34 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.338 -0.851 . . . . 0.0 109.34 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.51 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.98 96.9 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.199 -0.938 . . . . 0.0 109.526 -179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -70.83 109.27 2.47 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.653 2.235 . . . . 0.0 111.59 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . 0.418 ' OD1' ' HG3' ' A' ' 138' ' ' ARG . 24.7 p-10 -76.02 0.11 19.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.257 -0.902 . . . . 0.0 109.736 -179.853 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -172.48 160.68 32.01 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -66.32 -41.85 89.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -1.152 . . . . 0.0 109.314 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -65.5 -77.51 0.06 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.288 -0.882 . . . . 0.0 109.46 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.488 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 14.0 ptp180 -80.46 151.53 29.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.91 . . . . 0.0 109.564 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.768 ' OG ' HD11 ' A' ' 141' ' ' LEU . 88.7 p -145.57 156.71 43.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.216 -0.928 . . . . 0.0 109.528 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.848 ' C ' HD12 ' A' ' 141' ' ' LEU . 48.7 mtp -100.2 119.25 38.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.032 HD23 HG21 ' A' ' 116' ' ' VAL . 5.1 mp -124.24 148.52 47.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.278 -0.888 . . . . 0.0 109.506 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.522 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.7 tt -97.52 126.74 42.97 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.352 -0.843 . . . . 0.0 109.397 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.53 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 35.3 mt -96.47 110.42 22.8 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.227 -0.921 . . . . 0.0 109.377 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.663 ' C ' HD22 ' A' ' 145' ' ' LEU . 15.5 p-10 -82.73 124.03 29.86 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.336 -0.852 . . . . 0.0 109.495 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.735 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -117.34 144.02 45.35 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.257 -0.902 . . . . 0.0 109.506 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.527 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.6 pt -50.08 -35.73 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.438 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.527 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.3 m-20 -71.35 -55.44 7.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.59 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 43.8 mttm -157.58 173.33 17.03 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.28 -0.887 . . . . 0.0 109.399 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -99.12 128.79 45.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.259 -0.901 . . . . 0.0 109.42 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.42 ' O ' ' HG ' ' A' ' 142' ' ' LEU . 19.2 pt -125.5 158.02 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.26 -0.9 . . . . 0.0 109.455 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.522 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 24.0 mttp -119.26 135.58 54.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 109.382 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -144.91 145.92 31.78 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.58 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.2 p -86.17 121.28 28.54 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.349 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.866 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.7 p -124.92 147.86 29.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.208 -0.932 . . . . 0.0 109.591 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.573 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 43.2 mttt -75.76 150.97 37.67 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.349 -0.844 . . . . 0.0 109.657 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.568 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 13.9 m-80 -61.51 -24.17 66.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.213 -0.93 . . . . 0.0 109.456 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 60.4 p -79.58 -21.08 45.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.246 -0.909 . . . . 0.0 109.495 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.646 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.8 mt-10 -81.18 -22.65 38.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.554 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.881 ' CE2' HD21 ' A' ' 141' ' ' LEU . 41.7 p90 -138.47 170.51 15.88 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.925 . . . . 0.0 109.464 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . 0.548 ' O ' HG22 ' A' ' 117' ' ' ILE . 27.1 ptt180 -134.79 158.72 43.46 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.181 -0.949 . . . . 0.0 109.542 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 49.3 tttm -88.59 139.26 30.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.791 HD11 ' HB ' ' A' ' 117' ' ' ILE . 5.2 mp . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 98' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.475 ' HB3' ' O ' ' A' ' 97' ' ' GLY . . . 64.04 -89.02 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.166 -1.196 . . . . 0.0 109.469 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 70.0 mtm -62.21 -36.94 83.47 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.298 -0.876 . . . . 0.0 109.5 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -80.28 160.43 44.08 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.84 144.57 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.637 2.225 . . . . 0.0 111.841 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -58.16 -37.12 74.08 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -0.927 . . . . 0.0 109.421 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 104' ' ' ILE . 51.4 t0 -160.55 168.64 24.6 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.279 -0.888 . . . . 0.0 109.504 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.547 HG22 ' H ' ' A' ' 106' ' ' ASP . 70.3 mt -110.07 146.13 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.921 . . . . 0.0 109.52 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.51 -36.51 77.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.306 -0.871 . . . . 0.0 109.516 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.547 ' H ' HG22 ' A' ' 104' ' ' ILE . 3.8 m-20 -62.96 121.58 69.62 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.198 -0.939 . . . . 0.0 109.537 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -71.17 51.44 1.34 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.707 2.271 . . . . 0.0 111.885 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.96 -34.78 66.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.203 -0.935 . . . . 0.0 109.315 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.0 m -87.37 130.55 47.15 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.231 179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.431 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 47.6 Cg_endo -68.58 137.89 40.36 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.595 2.197 . . . . 0.0 111.949 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.401 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 85.6 m-85 -77.84 157.63 78.98 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 109.486 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.401 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 50.4 Cg_endo -69.98 134.04 26.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.722 2.281 . . . . 0.0 111.713 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 89.88 -8.99 78.77 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.594 ' O ' HG23 ' A' ' 129' ' ' ILE . 29.0 p-10 -68.22 -178.85 1.13 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.239 -1.153 . . . . 0.0 109.384 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.458 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 26.9 mttp -103.0 139.75 38.17 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.261 -0.9 . . . . 0.0 109.471 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.933 HG21 HD23 ' A' ' 141' ' ' LEU . 7.9 m -134.41 154.51 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.315 -0.865 . . . . 0.0 109.38 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.427 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 2.5 tp -121.6 139.35 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.309 -0.869 . . . . 0.0 109.617 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 120' ' ' GLU . 66.7 mt -92.68 127.19 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 80.4 p -101.68 -11.77 18.91 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.421 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.49 ' O ' HG22 ' A' ' 118' ' ' ILE . 95.6 mt-10 -130.66 158.97 38.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.215 -0.928 . . . . 0.0 109.435 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 94.01 165.61 36.85 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.78 -27.8 68.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -1.133 . . . . 0.0 109.471 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.45 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 97.1 m-85 -82.49 3.61 27.64 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.326 -0.859 . . . . 0.0 109.582 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -53.76 141.49 26.58 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.177 -0.952 . . . . 0.0 109.48 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 94.06 -9.83 72.35 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.45 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -97.93 148.46 23.43 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.207 -1.172 . . . . 0.0 109.47 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . 0.446 ' HA ' ' O ' ' A' ' 116' ' ' VAL . 95.3 mt-30 -91.27 143.69 26.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.273 -0.892 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.885 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -135.51 160.36 38.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.436 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.594 HG23 ' O ' ' A' ' 114' ' ' ASP . 31.2 mm -117.86 136.6 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.268 -0.895 . . . . 0.0 109.501 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.649 ' HE1' HD11 ' A' ' 141' ' ' LEU . 19.6 m-85 -66.53 114.84 5.81 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.207 -0.933 . . . . 0.0 109.543 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 47.6 p -90.62 -29.93 17.48 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.337 179.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 175.46 87.53 0.09 OUTLIER Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.224 -0.922 . . . . 0.0 109.327 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.46 118.02 5.36 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.671 2.247 . . . . 0.0 111.791 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -60.32 -34.71 74.2 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.597 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -164.95 -160.12 12.03 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 70.3 mm-40 -83.41 -26.64 30.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -1.139 . . . . 0.0 109.354 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -74.29 -80.57 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.223 -0.923 . . . . 0.0 109.372 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.446 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 24.0 ptt180 -89.17 148.38 23.67 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.631 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 59.2 m -144.44 152.81 41.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.197 -0.939 . . . . 0.0 109.414 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.914 ' C ' HD12 ' A' ' 141' ' ' LEU . 39.5 mtp -96.97 122.33 39.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.44 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.933 HD23 HG21 ' A' ' 116' ' ' VAL . 6.3 mp -123.83 150.41 44.58 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.521 HD12 ' O ' ' A' ' 150' ' ' ILE . 32.1 tp -100.07 123.73 44.64 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 109.466 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.84 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -93.94 118.71 31.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.579 ' C ' HD22 ' A' ' 145' ' ' LEU . 21.9 p-10 -83.49 114.92 21.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.22 -0.925 . . . . 0.0 109.566 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.749 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.9 mm? -114.38 144.16 43.73 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.169 -0.957 . . . . 0.0 109.413 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -55.09 -29.07 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.306 -0.872 . . . . 0.0 109.29 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.417 ' N ' HG13 ' A' ' 146' ' ' ILE . 34.8 t30 -75.82 -54.29 7.15 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.342 -0.849 . . . . 0.0 109.441 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.52 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 24.7 tttm -168.57 164.84 12.45 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.229 -0.919 . . . . 0.0 109.6 -179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.52 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 93.9 mt-10 -87.94 127.79 35.37 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.521 ' O ' HD12 ' A' ' 142' ' ' LEU . 7.6 pt -122.23 136.01 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.283 -0.885 . . . . 0.0 109.44 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.512 ' HG2' HD13 ' A' ' 142' ' ' LEU . 17.3 mttp -91.92 127.17 37.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.399 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -139.27 141.36 37.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.638 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 22.1 p -87.15 119.44 27.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.321 -0.862 . . . . 0.0 109.381 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.789 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.9 p -121.97 149.3 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 68.2 mttm -83.62 151.89 25.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 12.3 m-80 -59.45 -25.14 64.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.236 -0.915 . . . . 0.0 109.456 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 69.4 p -78.77 -20.29 50.21 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 109.487 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.622 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.2 mt-10 -82.09 -22.68 36.16 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.564 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 36.0 p90 -139.22 166.89 23.35 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.228 -0.92 . . . . 0.0 109.537 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 76.4 mtt85 -131.87 150.93 52.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.217 -0.927 . . . . 0.0 109.564 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.426 ' HD2' ' HB3' ' A' ' 110' ' ' PRO . 63.8 tttt -74.0 122.44 22.62 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.435 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.489 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.23 -33.41 74.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.194 -1.18 . . . . 0.0 109.467 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 9.1 tpt -57.79 -35.6 71.03 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.286 -0.884 . . . . 0.0 109.426 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.53 149.24 5.07 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.26 -37.19 10.73 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.699 2.266 . . . . 0.0 111.726 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 60.8 mttm 58.14 42.97 21.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.244 -0.91 . . . . 0.0 109.647 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 84.8 m-20 45.59 -165.77 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.568 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.0 mt -109.28 141.51 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.263 -0.898 . . . . 0.0 109.499 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 40.3 t -131.83 135.78 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.24 -0.913 . . . . 0.0 109.522 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.97 137.56 97.14 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.303 -0.873 . . . . 0.0 109.641 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . 0.468 ' HG2' ' OG1' ' A' ' 109' ' ' THR . 53.0 Cg_endo -73.67 49.97 1.94 Allowed 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.716 2.277 . . . . 0.0 111.76 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.421 ' C ' ' O ' ' A' ' 107' ' ' PRO . . . 43.88 37.47 1.71 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.885 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.468 ' OG1' ' HG2' ' A' ' 107' ' ' PRO . 11.6 m -64.32 130.41 94.6 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.485 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.601 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.0 Cg_endo -70.13 147.72 61.13 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.644 2.229 . . . . 0.0 111.822 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.469 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.5 m-85 -99.55 160.17 28.11 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.469 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.4 Cg_endo -69.53 128.94 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.663 2.242 . . . . 0.0 111.688 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 100.8 -11.15 59.15 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.45 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 79.3 m-20 -78.99 151.87 31.31 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.298 -1.119 . . . . 0.0 109.457 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.462 ' CB ' HD21 ' A' ' 162' ' ' LEU . 97.2 mttt -80.15 142.0 35.19 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.034 HG21 HD23 ' A' ' 141' ' ' LEU . 6.1 m -131.9 160.57 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.127 -0.983 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 6.8 tp -124.6 142.19 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.27 -0.894 . . . . 0.0 109.509 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.477 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 69.4 mt -92.64 125.59 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.238 -0.914 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.469 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 60.3 p -102.38 -10.66 19.25 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.432 ' O ' HG22 ' A' ' 118' ' ' ILE . 94.4 mt-10 -131.38 158.44 40.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.525 -179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 92.68 166.85 39.05 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.53 -19.78 63.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -1.133 . . . . 0.0 109.419 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.546 ' HA ' ' CE2' ' A' ' 126' ' ' PHE . 95.9 m-85 -83.54 9.48 11.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.311 -0.868 . . . . 0.0 109.47 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.477 ' HG3' ' O ' ' A' ' 118' ' ' ILE . 85.5 tt0 -58.32 140.41 53.49 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.239 -0.913 . . . . 0.0 109.391 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.87 -6.04 73.09 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE2' ' HA ' ' A' ' 123' ' ' PHE . 19.6 m-30 -99.06 142.36 30.64 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.284 -1.127 . . . . 0.0 109.475 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -86.71 125.92 34.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.2 -0.937 . . . . 0.0 109.352 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.949 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -110.57 153.0 25.76 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.298 -0.876 . . . . 0.0 109.456 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.582 HD13 ' O ' ' A' ' 128' ' ' ALA . 24.2 mm -118.06 130.67 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.498 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.847 ' CE2' HG11 ' A' ' 116' ' ' VAL . 32.7 m-85 -62.31 101.7 0.25 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -0.942 . . . . 0.0 109.542 179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.478 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 43.3 p -78.43 -36.34 45.72 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.225 -0.922 . . . . 0.0 109.262 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 131' ' ' THR . 17.2 tp10 171.36 99.35 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.419 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.0 113.86 3.55 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.62 2.213 . . . . 0.0 111.461 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 29.2 p-10 -74.95 -6.3 48.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.263 -0.898 . . . . 0.0 109.628 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -168.19 169.67 41.6 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -75.3 -26.25 58.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.31 -1.112 . . . . 0.0 109.477 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -76.1 -73.9 0.25 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 109.341 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.438 ' HA ' ' HA ' ' A' ' 155' ' ' LYS . 9.9 ptp85 -89.32 147.62 23.99 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.174 -0.954 . . . . 0.0 109.422 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.483 ' HB2' HD11 ' A' ' 141' ' ' LEU . 65.0 m -134.68 144.91 48.06 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.232 -0.917 . . . . 0.0 109.5 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.709 ' C ' HD12 ' A' ' 141' ' ' LEU . 56.2 ttm -87.98 109.66 19.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.224 -0.922 . . . . 0.0 109.504 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.034 HD23 HG21 ' A' ' 116' ' ' VAL . 5.5 mp -115.59 151.61 34.6 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.831 HD12 ' O ' ' A' ' 150' ' ' ILE . 48.1 tp -93.47 127.99 39.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.235 -0.915 . . . . 0.0 109.373 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 51.5 mt -90.73 137.45 32.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.229 -0.919 . . . . 0.0 109.504 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -104.16 106.16 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.231 -0.918 . . . . 0.0 109.432 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.414 ' HB2' ' O ' ' A' ' 148' ' ' LYS . 49.5 mt -104.33 140.88 37.25 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 109.456 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.483 HG13 ' N ' ' A' ' 147' ' ' ASN . 29.1 pt -50.97 -31.47 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.238 -0.914 . . . . 0.0 109.423 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.49 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 17.1 t-20 -74.17 -56.15 5.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.635 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.49 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 19.9 mttt -158.81 166.75 31.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -0.954 . . . . 0.0 109.489 -179.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -92.83 131.93 37.44 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -0.893 . . . . 0.0 109.216 179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.831 ' O ' HD12 ' A' ' 142' ' ' LEU . 13.7 pt -132.56 155.53 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 109.6 -179.695 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.753 ' HG2' HD13 ' A' ' 142' ' ' LEU . 28.9 mttp -105.55 131.46 52.93 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.225 -0.922 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -140.52 129.42 23.25 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.266 -0.896 . . . . 0.0 109.409 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . . . . . . . . . 70.7 m -69.89 118.52 12.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.783 ' CG1' HD13 ' A' ' 141' ' ' LEU . 5.3 p -121.82 148.35 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.333 -0.855 . . . . 0.0 109.53 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 33.0 mttp -81.8 151.92 27.17 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.566 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.0 m-80 -60.76 -21.34 62.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.237 -0.914 . . . . 0.0 109.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 71.9 p -81.48 -21.58 38.64 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.629 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.8 mt-10 -81.52 -23.14 37.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.316 -0.865 . . . . 0.0 109.473 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.663 ' CE2' HD21 ' A' ' 141' ' ' LEU . 33.3 p90 -138.53 167.96 20.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.25 -0.906 . . . . 0.0 109.538 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 51.0 mtt-85 -131.12 155.37 47.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.248 -0.907 . . . . 0.0 109.547 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 17.6 tttm -76.84 125.06 28.64 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.495 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.462 HD21 ' CB ' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.472 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -144.05 152.19 40.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -1.127 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 94.7 mmm -58.99 -35.2 72.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 152.67 130.93 1.6 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.26 148.67 62.36 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.732 2.288 . . . . 0.0 111.784 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 83.3 tttt -54.83 -36.87 65.48 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -0.923 . . . . 0.0 109.432 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 105' ' ' VAL . 49.7 p30 -148.43 173.93 12.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.478 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 83.0 mt -59.83 -41.64 86.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.221 -0.925 . . . . 0.0 109.543 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.416 ' O ' ' OD1' ' A' ' 103' ' ' ASP . 40.6 t -117.09 126.68 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' A' ' 106' ' ' ASP . 7.5 p30 -59.2 135.5 88.14 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.632 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -78.41 38.62 0.71 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.653 2.235 . . . . 0.0 112.075 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -80.76 -36.68 31.59 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.088 -1.007 . . . . 0.0 109.237 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 88.4 m -75.61 129.54 81.46 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.33 -0.856 . . . . 0.0 109.325 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.628 ' CB ' ' CZ ' ' A' ' 130' ' ' PHE . 50.5 Cg_endo -70.26 138.05 35.38 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.638 2.225 . . . . 0.0 111.866 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.453 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 22.4 m-85 -88.5 160.92 43.9 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.207 -0.933 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 48.9 Cg_endo -69.71 130.75 19.95 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.609 2.206 . . . . 0.0 111.808 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 102.0 -15.14 56.95 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -69.45 153.88 42.86 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.196 -1.179 . . . . 0.0 109.51 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -90.04 147.5 23.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.267 -0.895 . . . . 0.0 109.48 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.797 HG22 ' O ' ' A' ' 128' ' ' ALA . 5.0 m -131.74 154.47 40.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.628 ' HB ' HD11 ' A' ' 162' ' ' LEU . 8.1 tp -124.48 146.98 29.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.275 -0.891 . . . . 0.0 109.478 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.461 ' HB ' ' O ' ' A' ' 123' ' ' PHE . 18.1 mm -91.16 124.91 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.335 -0.853 . . . . 0.0 109.356 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.46 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 66.2 p -108.99 -8.57 15.18 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.19 -0.944 . . . . 0.0 109.531 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.92 157.4 45.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.121 -0.987 . . . . 0.0 109.463 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 88.88 166.54 42.29 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.44 -18.65 64.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.239 -1.154 . . . . 0.0 109.448 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.57 ' HA ' ' CD2' ' A' ' 126' ' ' PHE . 88.5 m-85 -82.56 5.75 19.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.198 -0.939 . . . . 0.0 109.506 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.46 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.6 tt0 -58.67 136.7 57.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.557 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.31 -3.43 66.3 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 123' ' ' PHE . 21.1 m-85 -101.11 150.09 23.29 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.17 -1.194 . . . . 0.0 109.48 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -102.21 149.27 24.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.275 -0.891 . . . . 0.0 109.364 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -143.47 166.22 25.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.305 -0.872 . . . . 0.0 109.423 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.501 HD13 ' O ' ' A' ' 128' ' ' ALA . 27.2 mm -116.63 137.66 49.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.206 -0.934 . . . . 0.0 109.535 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.698 ' CE2' HG12 ' A' ' 116' ' ' VAL . 36.0 m-85 -59.57 104.0 0.24 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.457 179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.495 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 39.3 p -78.71 -38.89 37.92 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.344 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 131' ' ' THR . 1.0 OUTLIER 171.68 94.8 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.303 -0.873 . . . . 0.0 109.455 179.921 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.38 115.7 4.17 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.776 2.317 . . . . 0.0 111.744 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -61.16 -35.92 78.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.243 -0.911 . . . . 0.0 109.452 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -148.01 175.5 27.3 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.82 -27.43 64.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.244 -1.151 . . . . 0.0 109.495 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.11 -73.54 0.29 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.309 -0.869 . . . . 0.0 109.384 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 21.3 ptt-85 -83.53 147.81 27.56 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.23 -0.919 . . . . 0.0 109.558 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 67.9 m -139.96 153.11 46.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.176 -0.952 . . . . 0.0 109.514 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.453 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 41.6 mtp -99.23 119.48 37.96 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.262 -0.899 . . . . 0.0 109.429 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.661 HD13 HG21 ' A' ' 116' ' ' VAL . 66.1 mt -117.85 147.73 42.78 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.255 -0.903 . . . . 0.0 109.471 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.612 HD12 ' CE ' ' A' ' 151' ' ' LYS . 8.4 tt -97.31 126.46 42.55 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.263 -0.898 . . . . 0.0 109.438 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.524 ' O ' ' CD2' ' A' ' 145' ' ' LEU . 43.5 mt -97.69 113.87 25.72 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.183 -0.948 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.717 ' C ' HD22 ' A' ' 145' ' ' LEU . 8.4 p30 -83.45 121.21 26.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.283 -0.885 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.75 ' N ' HD22 ' A' ' 145' ' ' LEU . 3.0 mm? -118.72 135.64 54.38 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.187 -0.945 . . . . 0.0 109.357 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.487 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.2 pt -49.74 -33.29 8.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.266 -0.896 . . . . 0.0 109.574 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.487 ' N ' HG13 ' A' ' 146' ' ' ILE . 94.2 m-20 -70.49 -46.44 63.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.895 . . . . 0.0 109.605 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.527 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 30.3 tttm -168.49 160.75 11.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.14 -0.975 . . . . 0.0 109.492 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.527 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.0 mt-10 -87.85 127.24 35.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.218 -0.927 . . . . 0.0 109.407 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.506 HG12 HD23 ' A' ' 145' ' ' LEU . 19.6 pt -127.67 162.12 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.26 -0.9 . . . . 0.0 109.424 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.612 ' CE ' HD12 ' A' ' 142' ' ' LEU . 20.9 mttt -125.72 130.25 51.14 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.446 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -139.12 148.14 42.87 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 29.7 p -82.7 141.89 32.08 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.388 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.578 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.7 t -130.91 153.64 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.35 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.501 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 41.3 mttt -91.11 138.3 31.7 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.913 . . . . 0.0 109.469 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 1.6 p30 -47.75 -30.38 3.86 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.277 -0.889 . . . . 0.0 109.371 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 44.7 p -80.97 -22.18 39.75 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.898 . . . . 0.0 109.491 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 155' ' ' LYS . 94.8 mt-10 -81.69 -19.7 41.04 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.939 . . . . 0.0 109.439 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.584 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 38.6 p90 -140.45 169.01 18.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.372 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 87.0 mtt-85 -129.44 143.24 50.75 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.157 -0.964 . . . . 0.0 109.477 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -78.14 132.74 37.78 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.321 -0.862 . . . . 0.0 109.473 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.679 HD12 ' N ' ' A' ' 162' ' ' LEU . 6.5 mp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.481 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -62.7 -31.73 72.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.303 -1.116 . . . . 0.0 109.445 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.6 mtp -58.36 -36.99 74.32 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 109.488 -179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -151.58 139.47 7.16 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.4 143.31 47.42 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.744 2.296 . . . . 0.0 111.755 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -112.39 144.76 41.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.261 -0.9 . . . . 0.0 109.523 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' A' ' 103' ' ' ASP . 45.6 p30 -74.5 151.83 39.47 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.243 -0.91 . . . . 0.0 109.494 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -122.88 143.58 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.25 -0.906 . . . . 0.0 109.523 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.6 t -115.92 134.09 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.251 -0.906 . . . . 0.0 109.505 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -67.01 130.59 93.87 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.276 -0.89 . . . . 0.0 109.628 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -71.71 50.59 1.4 Allowed 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.682 2.255 . . . . 0.0 111.875 179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.37 -27.65 59.22 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.196 -0.94 . . . . 0.0 109.376 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 23.1 m -63.9 127.15 91.35 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.353 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.414 ' HB3' ' HD2' ' A' ' 161' ' ' LYS . 49.3 Cg_endo -69.75 140.74 43.47 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.656 2.238 . . . . 0.0 111.797 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.408 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 12.6 m-85 -81.5 161.0 63.33 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.205 -0.934 . . . . 0.0 109.434 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 134.84 27.87 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.724 2.283 . . . . 0.0 111.797 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 97.21 -12.98 65.12 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.408 ' OD2' ' HB2' ' A' ' 111' ' ' TYR . 83.4 m-20 -69.97 147.91 49.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.515 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 68.3 mttm -75.05 139.74 43.05 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.244 -0.91 . . . . 0.0 109.527 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.036 HG21 HD23 ' A' ' 141' ' ' LEU . 6.0 m -127.33 155.67 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.192 -0.942 . . . . 0.0 109.455 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.446 HD12 ' HA ' ' A' ' 117' ' ' ILE . 8.2 tp -123.82 147.69 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.235 -0.916 . . . . 0.0 109.48 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.466 ' HB ' ' HA ' ' A' ' 124' ' ' GLU . 21.6 mm -91.66 129.34 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.42 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.8 p -114.17 -7.34 13.02 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.548 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.486 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 46.8 tp10 -140.89 153.48 45.71 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.422 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.486 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 92.15 169.05 40.67 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.92 -15.9 63.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.181 -1.188 . . . . 0.0 109.493 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.633 ' CD1' HD23 ' A' ' 143' ' ' LEU . 89.9 m-85 -84.93 11.06 10.1 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.2 -0.938 . . . . 0.0 109.451 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.466 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 85.0 tt0 -60.73 134.08 56.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.636 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 93.6 0.94 66.45 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.454 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.7 m-85 -98.26 140.48 32.49 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.143 -1.21 . . . . 0.0 109.472 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -94.13 126.52 39.41 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.525 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.994 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -126.35 161.42 27.87 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.938 . . . . 0.0 109.533 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.585 HD13 ' O ' ' A' ' 128' ' ' ALA . 29.9 mm -120.12 136.96 55.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.254 -0.904 . . . . 0.0 109.451 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.586 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.5 m-85 -58.58 103.18 0.14 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.257 -0.902 . . . . 0.0 109.428 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.517 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 63.4 p -77.3 -31.45 54.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.891 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.517 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.0 OUTLIER 164.74 91.37 0.02 OUTLIER Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.188 -0.945 . . . . 0.0 109.53 -179.987 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.47 125.99 12.37 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.63 2.22 . . . . 0.0 111.655 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 135' ' ' GLY . 16.6 p-10 -68.66 -25.78 64.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 109.538 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.466 ' N ' ' OD1' ' A' ' 134' ' ' ASP . . . -166.09 170.25 40.69 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -64.01 -27.59 69.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.298 -1.119 . . . . 0.0 109.416 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.43 -63.63 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.3 -0.875 . . . . 0.0 109.394 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.419 ' O ' ' O ' ' A' ' 135' ' ' GLY . 57.7 mtt85 -107.48 153.6 22.59 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.197 -0.939 . . . . 0.0 109.468 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 68.8 m -138.8 156.64 47.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.189 -0.944 . . . . 0.0 109.46 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.819 ' C ' HD12 ' A' ' 141' ' ' LEU . 34.7 tpp -101.12 117.31 34.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 109.475 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.036 HD23 HG21 ' A' ' 116' ' ' VAL . 6.8 mp -118.61 144.07 46.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.223 -0.923 . . . . 0.0 109.452 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 151' ' ' LYS . 9.2 tt -101.52 123.51 45.67 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.452 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.835 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -91.4 138.51 31.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.222 -0.923 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.684 ' C ' HD12 ' A' ' 145' ' ' LEU . 97.6 m-20 -110.86 113.38 25.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.768 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.3 mp -114.61 139.63 49.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.235 -0.916 . . . . 0.0 109.579 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.516 HG13 ' N ' ' A' ' 147' ' ' ASN . 23.1 pt -50.28 -36.25 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.257 -0.902 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.516 ' N ' HG13 ' A' ' 146' ' ' ILE . 15.3 t-20 -68.04 -52.89 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.488 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.47 ' HG2' ' N ' ' A' ' 149' ' ' GLU . 19.3 tttt -166.66 155.11 10.3 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.355 -0.841 . . . . 0.0 109.541 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.47 ' N ' ' HG2' ' A' ' 148' ' ' LYS . 94.4 mt-10 -89.86 140.21 29.83 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 109.451 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.4 pt -131.57 158.61 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.484 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.523 ' CE ' ' CD1' ' A' ' 142' ' ' LEU . 22.3 mttt -125.83 134.18 51.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.66 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.49 ' ND1' ' O ' ' A' ' 153' ' ' SER . 51.7 t-80 -158.31 146.45 18.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.303 -0.873 . . . . 0.0 109.422 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.49 ' O ' ' ND1' ' A' ' 152' ' ' HIS . 42.0 p -69.77 141.34 53.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.222 -0.924 . . . . 0.0 109.393 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.686 HG13 ' CD ' ' A' ' 158' ' ' GLU . 20.2 t -126.17 152.31 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.182 -0.949 . . . . 0.0 109.61 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.504 ' O ' ' HG2' ' A' ' 158' ' ' GLU . 86.4 mttt -91.17 131.64 36.59 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.276 -0.89 . . . . 0.0 109.552 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.582 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 33.4 m-80 -53.41 -18.57 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.155 -0.965 . . . . 0.0 109.643 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 79.8 p -85.13 -29.66 24.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.167 -0.958 . . . . 0.0 110.141 -179.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.686 ' CD ' HG13 ' A' ' 154' ' ' VAL . 10.9 pt-20 -82.84 -18.57 39.93 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.02 -1.05 . . . . 0.0 109.698 -179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.642 ' CE2' HD21 ' A' ' 141' ' ' LEU . 20.4 p90 -135.3 157.25 47.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.147 -0.97 . . . . 0.0 109.553 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.2 ttt-85 -124.07 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.267 -0.896 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 16.9 pttp -74.39 124.03 25.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.196 -0.94 . . . . 0.0 109.51 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.497 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.997 -1.002 . . . . 0.0 109.48 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.26 -31.09 70.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.48 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.4 mtt -121.43 156.21 33.2 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.129 -0.982 . . . . 0.0 109.444 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -122.37 167.24 14.85 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.99 -23.73 29.43 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.684 2.256 . . . . 0.0 111.841 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.2 tttm -77.3 133.49 38.78 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.9 . . . . 0.0 109.449 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 34.8 t0 -80.89 135.38 35.9 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.28 -0.888 . . . . 0.0 109.409 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 63.4 mt -125.81 143.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.454 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 25.8 m -126.57 160.36 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.231 -0.918 . . . . 0.0 109.475 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -64.29 130.37 94.57 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.914 . . . . 0.0 109.429 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.89 53.27 1.12 Allowed 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.729 2.286 . . . . 0.0 111.831 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . 46.03 26.23 0.39 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.297 -0.877 . . . . 0.0 109.406 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 45.1 m -107.09 124.73 34.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.238 -0.914 . . . . 0.0 109.444 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.23 143.84 49.77 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.682 2.255 . . . . 0.0 111.82 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.439 ' N ' ' OD2' ' A' ' 114' ' ' ASP . 50.9 m-85 -76.14 161.14 76.35 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.245 -0.91 . . . . 0.0 109.475 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 49.1 Cg_endo -69.73 131.5 21.4 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.696 2.264 . . . . 0.0 111.79 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 98.83 -12.29 62.57 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.439 ' OD2' ' N ' ' A' ' 111' ' ' TYR . 81.5 m-20 -65.56 150.31 48.62 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -1.135 . . . . 0.0 109.491 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.508 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 96.5 mttt -77.98 140.14 39.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.897 . . . . 0.0 109.476 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.947 ' CG2' HD23 ' A' ' 141' ' ' LEU . 4.1 m -130.84 153.63 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . . . . . . . . . 3.0 tp -122.65 140.67 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.218 -0.926 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.473 HD12 ' HB3' ' A' ' 123' ' ' PHE . 69.4 mt -92.56 131.05 40.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.42 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 72.5 p -118.42 5.37 11.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.245 -0.909 . . . . 0.0 109.578 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.433 ' HA ' ' OE2' ' A' ' 124' ' ' GLU . 75.3 mm-40 -136.91 153.6 50.69 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.115 -0.991 . . . . 0.0 109.481 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.4 ' O ' ' HG3' ' A' ' 124' ' ' GLU . . . 86.67 -171.08 42.9 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.87 -5.84 57.74 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -1.134 . . . . 0.0 109.587 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.557 ' CD1' HD23 ' A' ' 143' ' ' LEU . 80.2 m-85 -88.54 14.98 8.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.106 -0.997 . . . . 0.0 109.51 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.433 ' OE2' ' HA ' ' A' ' 120' ' ' GLU . 96.9 mt-10 -62.84 136.91 58.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 92.14 1.09 70.11 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -102.22 131.41 48.78 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.137 -1.213 . . . . 0.0 109.454 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -86.72 134.44 33.59 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.281 -0.887 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.909 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.18 159.72 38.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.237 -0.914 . . . . 0.0 109.544 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.518 HD13 ' O ' ' A' ' 128' ' ' ALA . 33.4 mm -119.2 140.07 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.311 -0.868 . . . . 0.0 109.383 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.566 ' CE2' ' CG1' ' A' ' 116' ' ' VAL . 37.1 m-85 -58.58 101.47 0.09 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.23 -0.919 . . . . 0.0 109.461 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.538 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 68.9 p -75.04 -34.41 61.86 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.25 -0.906 . . . . 0.0 109.369 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 131' ' ' THR . 3.3 mt-10 163.75 88.84 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.294 -0.879 . . . . 0.0 109.456 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.463 ' HB3' ' OG ' ' A' ' 139' ' ' SER . 49.9 Cg_endo -69.96 132.35 22.83 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.679 2.253 . . . . 0.0 111.81 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.3 m-20 -67.82 -30.03 69.33 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.322 -0.861 . . . . 0.0 109.444 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -165.18 -174.02 34.4 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -73.32 -26.79 61.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.295 -1.121 . . . . 0.0 109.453 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.82 -58.51 4.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 109.532 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -109.6 161.12 15.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.158 -0.964 . . . . 0.0 109.425 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 133' ' ' PRO . 4.1 m -147.36 155.38 41.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.262 -0.899 . . . . 0.0 109.566 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.906 ' C ' HD12 ' A' ' 141' ' ' LEU . 63.5 mtp -103.06 124.22 48.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.319 -0.863 . . . . 0.0 109.343 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.947 HD23 ' CG2' ' A' ' 116' ' ' VAL . 5.4 mp -126.19 140.78 52.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.175 -0.953 . . . . 0.0 109.607 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.569 HD23 ' C ' ' A' ' 142' ' ' LEU . 10.1 tt -96.59 125.82 41.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.304 -0.873 . . . . 0.0 109.413 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.829 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.6 mp -93.47 137.02 33.18 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.284 -0.885 . . . . 0.0 109.525 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.477 ' C ' HD12 ' A' ' 145' ' ' LEU . 28.4 m120 -108.57 104.19 13.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.905 . . . . 0.0 109.422 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.725 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.8 mp -104.45 139.6 39.14 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.149 -0.969 . . . . 0.0 109.56 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.2 pt -54.32 -35.09 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.445 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 52.0 t-20 -65.96 -46.57 77.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.393 -0.817 . . . . 0.0 109.512 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . . . . . . . . . 31.1 pttt -168.64 169.54 10.11 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.204 -0.935 . . . . 0.0 109.555 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CG ' HD21 ' A' ' 142' ' ' LEU . 86.8 tt0 -98.2 132.32 43.82 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.442 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . . . . . . . . . 30.1 pt -131.88 157.01 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.475 ' HG2' ' HG ' ' A' ' 142' ' ' LEU . 2.3 mtpm? -123.97 134.1 53.55 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.247 -0.908 . . . . 0.0 109.396 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.466 ' CE1' ' O ' ' A' ' 153' ' ' SER . 55.4 t-80 -152.26 143.73 23.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.252 -0.905 . . . . 0.0 109.52 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 41.6 p -81.66 137.07 35.48 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.512 HG12 ' HD1' ' A' ' 159' ' ' PHE . 16.4 t -127.6 151.09 34.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.406 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.528 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 0.6 OUTLIER -87.38 139.97 30.01 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.272 -0.893 . . . . 0.0 109.559 -179.935 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.515 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 27.4 m-80 -46.17 -27.98 1.12 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.357 -0.839 . . . . 0.0 110.272 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . 0.512 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 27.0 p -80.14 -19.93 46.1 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.97 -1.081 . . . . 0.0 109.983 -179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.528 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 48.5 mm-40 -89.85 -19.11 25.02 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.068 -1.02 . . . . 0.0 109.201 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.721 ' CE2' HD21 ' A' ' 141' ' ' LEU . 34.5 p90 -139.22 156.03 47.37 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.28 -0.888 . . . . 0.0 109.793 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 53.2 mtt180 -125.25 147.1 49.23 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.255 -0.903 . . . . 0.0 109.339 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.477 ' O ' ' HG3' ' A' ' 161' ' ' LYS . 15.9 pttp -82.44 121.52 26.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.492 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.2 pp . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.489 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.12 -36.3 79.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -1.173 . . . . 0.0 109.527 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 65.1 mtt -58.64 -35.19 72.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.257 -0.902 . . . . 0.0 109.426 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -144.93 130.4 3.87 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.17 140.67 41.65 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.736 2.29 . . . . 0.0 111.736 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -123.92 150.11 45.09 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -52.38 -36.8 54.83 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.31 -0.869 . . . . 0.0 109.413 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 59.2 mt -107.75 143.17 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.511 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 42.1 t -122.48 130.26 74.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.508 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -65.08 149.83 96.26 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.295 -0.878 . . . . 0.0 109.527 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -76.35 43.47 1.19 Allowed 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.633 2.222 . . . . 0.0 112.069 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.38 -42.74 61.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.05 -1.031 . . . . 0.0 109.109 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 53.3 m -103.24 120.39 52.18 Favored Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.366 -0.834 . . . . 0.0 109.187 179.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.4 149.47 69.2 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.663 2.242 . . . . 0.0 111.93 -179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.4 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 53.0 m-85 -102.8 161.46 23.11 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.313 -0.867 . . . . 0.0 109.448 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.5 ' HA ' ' HB2' ' A' ' 130' ' ' PHE . 46.2 Cg_endo -68.28 137.61 40.65 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.634 2.223 . . . . 0.0 111.701 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . 0.467 ' HA2' HG22 ' A' ' 129' ' ' ILE . . . 90.82 -9.88 76.46 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.744 ' O ' HG23 ' A' ' 129' ' ' ILE . 36.6 p-10 -74.55 -177.85 3.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.246 -1.149 . . . . 0.0 109.5 179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.499 ' HA ' HD13 ' A' ' 129' ' ' ILE . 76.6 mttt -99.19 141.6 31.75 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.271 -0.893 . . . . 0.0 109.426 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.927 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.2 m -138.18 158.1 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.239 -0.913 . . . . 0.0 109.529 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.2 tp -126.27 141.91 44.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.482 ' HA ' ' HB2' ' A' ' 159' ' ' PHE . 56.1 mt -92.29 129.91 42.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.209 -0.932 . . . . 0.0 109.695 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.525 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 58.0 p -105.08 -8.39 18.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.474 ' HG3' ' N ' ' A' ' 121' ' ' GLY . 48.0 tp10 -136.26 156.84 48.08 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.234 -0.916 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . 0.474 ' N ' ' HG3' ' A' ' 120' ' ' GLU . . . 93.77 162.77 36.09 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -64.26 -19.4 65.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -1.115 . . . . 0.0 109.438 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.497 ' CD1' HD23 ' A' ' 143' ' ' LEU . 84.5 m-85 -86.26 13.16 8.44 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.379 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.525 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 84.8 tt0 -63.76 140.12 58.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.209 -0.932 . . . . 0.0 109.38 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 90.32 -0.15 77.63 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -104.99 138.89 40.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -1.193 . . . . 0.0 109.428 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -83.79 148.65 26.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.26 -0.9 . . . . 0.0 109.541 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.927 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -144.83 159.31 43.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.361 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.744 HG23 ' O ' ' A' ' 114' ' ' ASP . 27.2 mm -119.68 133.06 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.961 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.788 ' HE1' HD11 ' A' ' 141' ' ' LEU . 18.3 m-85 -58.57 115.84 3.29 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.29 -0.881 . . . . 0.0 109.368 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.516 ' CG2' ' HB2' ' A' ' 142' ' ' LEU . 44.0 p -84.18 -29.5 26.56 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.2 OUTLIER 164.9 86.33 0.01 OUTLIER Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.326 -0.859 . . . . 0.0 109.545 -179.989 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.415 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.2 Cg_endo -70.0 130.64 19.38 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.694 2.263 . . . . 0.0 111.751 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 75.8 m-20 -68.91 -26.61 65.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.253 -0.905 . . . . 0.0 109.594 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -170.59 178.31 43.27 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -66.16 -25.94 67.19 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -1.121 . . . . 0.0 109.509 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -67.53 -63.68 1.01 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.476 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 75.4 mtt180 -107.11 156.89 18.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.43 ' HB3' ' CE1' ' A' ' 130' ' ' PHE . 69.0 m -148.58 152.42 36.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.175 -0.953 . . . . 0.0 109.51 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.806 ' C ' HD12 ' A' ' 141' ' ' LEU . 20.4 mtp -101.62 122.05 43.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.217 -0.927 . . . . 0.0 109.583 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.818 HD13 ' CG1' ' A' ' 154' ' ' VAL . 6.8 mp -114.21 147.32 39.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.299 -0.875 . . . . 0.0 109.511 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.926 HD21 ' OE2' ' A' ' 149' ' ' GLU . 34.5 tp -102.8 125.42 49.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.223 -0.923 . . . . 0.0 109.742 -179.802 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.806 HD12 ' N ' ' A' ' 143' ' ' LEU . 4.7 mp -98.32 127.98 44.52 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.257 -0.902 . . . . 0.0 109.25 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . . . . . . . . . 85.2 m-20 -105.02 113.27 26.77 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.228 -0.92 . . . . 0.0 109.631 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.771 ' N ' HD22 ' A' ' 145' ' ' LEU . 2.4 mm? -101.01 150.56 22.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.254 -0.904 . . . . 0.0 109.326 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 25.7 pt -65.13 -10.45 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.505 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.501 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 48.3 t30 -97.57 -47.55 5.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.191 -0.943 . . . . 0.0 109.59 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.501 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 77.7 mttt -158.55 165.39 34.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.93 . . . . 0.0 109.604 -179.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.926 ' OE2' HD21 ' A' ' 142' ' ' LEU . 78.4 tt0 -89.57 147.57 23.87 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.172 179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.805 ' O ' HD12 ' A' ' 142' ' ' LEU . 30.9 pt -144.44 151.66 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.193 -0.942 . . . . 0.0 109.945 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.814 ' HG2' HD13 ' A' ' 142' ' ' LEU . 20.8 mttp -118.01 136.64 53.4 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.366 -0.834 . . . . 0.0 109.159 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -148.58 134.99 19.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.116 -0.99 . . . . 0.0 109.651 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 22.8 p -87.12 118.08 26.29 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.888 . . . . 0.0 109.326 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.818 ' CG1' HD13 ' A' ' 141' ' ' LEU . 4.3 p -120.05 150.59 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.565 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 28.0 mttt -77.01 153.69 34.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.891 . . . . 0.0 109.53 179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 9.7 m-80 -65.18 -14.95 61.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.21 -0.931 . . . . 0.0 109.525 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 70.5 p -88.17 -24.2 23.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.593 ' OE1' HG23 ' A' ' 154' ' ' VAL . 99.7 mt-10 -78.79 -22.62 46.05 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.258 -0.901 . . . . 0.0 109.51 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.769 ' CE2' HD21 ' A' ' 141' ' ' LEU . 38.3 p90 -135.95 174.04 11.05 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.414 179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 52.6 mtp180 -139.45 164.59 29.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.57 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.508 ' NZ ' ' OD2' ' A' ' 114' ' ' ASP . 55.4 tttp -85.59 126.32 33.8 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.487 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.475 HD21 ' HB3' ' A' ' 115' ' ' LYS . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.519 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -64.69 142.05 58.56 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.229 -1.159 . . . . 0.0 109.405 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 65.1 mtt -61.58 -34.15 75.1 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.282 -0.886 . . . . 0.0 109.538 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -110.94 173.82 16.37 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.77 152.43 69.26 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.748 2.299 . . . . 0.0 111.818 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 105' ' ' VAL . 94.1 mttt -83.28 145.73 28.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.515 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -61.56 -32.65 72.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.197 -0.94 . . . . 0.0 109.353 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 83.9 mt -49.25 -45.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.238 -0.914 . . . . 0.0 109.517 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' A' ' 102' ' ' LYS . 18.0 m -130.44 143.23 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.295 -0.878 . . . . 0.0 109.435 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.464 ' HB2' ' HD2' ' A' ' 107' ' ' PRO . 1.8 p30 -98.7 164.49 16.87 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.239 -0.913 . . . . 0.0 109.399 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' A' ' 106' ' ' ASP . 55.8 Cg_endo -80.57 34.04 0.53 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.725 2.283 . . . . 0.0 112.052 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -99.54 -26.71 14.01 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.122 -0.986 . . . . 0.0 109.447 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 76.7 m -66.39 132.09 94.3 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.353 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.605 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 51.1 Cg_endo -70.19 131.95 21.65 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.916 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.404 ' HB2' ' OD2' ' A' ' 114' ' ' ASP . 50.3 m-85 -79.75 157.93 73.72 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.917 . . . . 0.0 109.379 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -69.96 130.89 19.87 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.63 2.22 . . . . 0.0 111.811 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 101.04 -14.77 58.42 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.483 ' CB ' ' HE2' ' A' ' 161' ' ' LYS . 80.4 m-20 -66.89 153.78 42.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.497 ' HA ' ' CD1' ' A' ' 129' ' ' ILE . 95.5 mttt -81.83 140.62 34.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.307 -0.871 . . . . 0.0 109.415 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 1.018 HG22 ' O ' ' A' ' 128' ' ' ALA . 11.8 m -125.61 152.61 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.712 ' HB ' HD21 ' A' ' 162' ' ' LEU . 8.2 tp -122.64 145.43 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.538 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.48 HG12 ' O ' ' A' ' 126' ' ' PHE . 28.8 mm -91.24 128.82 42.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.293 -0.88 . . . . 0.0 109.499 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.453 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 69.1 p -114.92 -7.9 12.56 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.217 -0.927 . . . . 0.0 109.518 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -140.1 151.91 45.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.163 -0.961 . . . . 0.0 109.473 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 93.56 167.78 38.2 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.41 -13.78 62.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.237 -1.155 . . . . 0.0 109.422 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.599 ' HB3' HD23 ' A' ' 143' ' ' LEU . 69.6 m-85 -87.98 13.93 9.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.432 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.475 ' HA ' ' HB ' ' A' ' 118' ' ' ILE . 84.8 tt0 -64.08 132.43 50.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.58 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.17 1.03 59.6 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.48 ' O ' HG12 ' A' ' 118' ' ' ILE . 42.4 m-85 -98.95 136.52 38.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.1 -1.235 . . . . 0.0 109.594 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 91.1 mt-30 -88.79 136.07 33.2 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.291 -0.881 . . . . 0.0 109.279 179.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 1.018 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -137.95 165.73 25.82 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.597 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.7 mm -121.01 142.28 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.257 -0.902 . . . . 0.0 109.339 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.647 ' CE2' HG12 ' A' ' 116' ' ' VAL . 40.5 m-85 -58.58 104.49 0.22 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.936 . . . . 0.0 109.558 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.462 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 71.1 p -78.07 -40.69 37.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.217 -0.927 . . . . 0.0 109.486 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 131' ' ' THR . 7.6 tt0 172.32 91.53 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.408 ' HA ' ' HA ' ' A' ' 139' ' ' SER . 48.8 Cg_endo -70.1 124.46 10.97 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.718 2.279 . . . . 0.0 111.761 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 23.3 p-10 -75.23 -4.03 36.61 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.355 -0.84 . . . . 0.0 109.54 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 174.64 173.3 40.44 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -69.95 -30.48 67.87 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.287 -1.125 . . . . 0.0 109.496 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.07 -60.03 2.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -0.915 . . . . 0.0 109.431 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.463 ' HG2' ' HG2' ' A' ' 155' ' ' LYS . 81.9 mtm180 -103.28 152.93 20.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.395 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 133' ' ' PRO . 68.5 m -144.97 150.12 36.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.96 . . . . 0.0 109.491 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.941 ' C ' HD12 ' A' ' 141' ' ' LEU . 91.6 mmm -96.17 125.91 41.03 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.323 -0.861 . . . . 0.0 109.498 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 1.007 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -128.32 141.27 51.49 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.236 -0.915 . . . . 0.0 109.622 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.527 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 7.9 tt -99.67 119.51 38.22 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.253 -0.904 . . . . 0.0 109.395 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.857 HD12 ' N ' ' A' ' 143' ' ' LEU . 3.5 mp -96.03 108.63 21.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.18 -0.95 . . . . 0.0 109.652 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 145' ' ' LEU . 5.8 p30 -88.7 127.5 35.59 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.32 -0.862 . . . . 0.0 109.631 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.793 HD12 ' N ' ' A' ' 145' ' ' LEU . 6.1 mp -108.05 159.37 16.62 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.219 -0.925 . . . . 0.0 109.425 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 23.6 pt -66.65 -10.22 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.287 -0.883 . . . . 0.0 109.518 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.418 ' CG ' ' N ' ' A' ' 148' ' ' LYS . 9.2 p30 -105.34 -45.54 4.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.514 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 145' ' ' LEU . 62.1 tttm -158.48 147.96 19.37 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.29 -0.881 . . . . 0.0 109.563 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -87.89 141.23 28.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.371 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.564 HD11 ' CE1' ' A' ' 123' ' ' PHE . 28.7 pt -133.7 162.12 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.232 -0.917 . . . . 0.0 109.572 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.527 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 29.6 mttt -125.16 136.52 53.68 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.291 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 48.7 t-80 -151.29 148.47 28.21 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.183 -0.948 . . . . 0.0 109.694 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.49 ' CB ' ' SD ' ' A' ' 140' ' ' MET . 21.9 p -86.88 122.77 31.21 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.241 -0.912 . . . . 0.0 109.251 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.986 ' CG1' HD13 ' A' ' 141' ' ' LEU . 3.2 p -125.06 148.93 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.493 -179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.518 ' O ' ' CD1' ' A' ' 159' ' ' PHE . 45.0 mttt -79.59 153.53 29.38 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.493 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.584 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 14.8 m-80 -62.52 -19.73 63.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.344 -0.847 . . . . 0.0 109.474 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . . . . . . . . . 63.1 p -82.26 -23.19 35.41 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.194 -0.941 . . . . 0.0 109.478 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.579 ' OE1' HG23 ' A' ' 154' ' ' VAL . 97.6 mt-10 -81.13 -21.11 40.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.226 -0.921 . . . . 0.0 109.524 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.874 ' CE2' HD21 ' A' ' 141' ' ' LEU . 35.8 p90 -139.53 158.94 43.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.42 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 33.2 ttt180 -122.15 148.49 44.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.205 -0.934 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.483 ' HE2' ' CB ' ' A' ' 114' ' ' ASP . 64.1 tttm -76.44 135.37 39.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.923 . . . . 0.0 109.487 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.712 HD21 ' HB ' ' A' ' 117' ' ' ILE . 53.5 mt . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 117.912 -1.042 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -63.05 143.7 57.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.263 -1.139 . . . . 0.0 109.479 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 71.4 mtm -57.73 -37.75 74.1 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -79.4 163.83 48.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.07 140.2 40.97 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.699 2.266 . . . . 0.0 111.744 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 11.0 mtmt -107.28 141.85 37.97 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.202 -0.936 . . . . 0.0 109.494 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -81.58 138.5 35.37 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.305 -0.872 . . . . 0.0 109.424 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 81.9 mt -62.86 -36.27 74.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 44.3 t -122.55 130.54 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.476 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 63.0 m-20 -78.99 146.9 68.99 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.264 -0.898 . . . . 0.0 109.496 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.08 65.24 1.99 Allowed 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.706 2.271 . . . . 0.0 111.783 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -58.27 -38.49 77.06 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.495 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 12.0 m -71.42 130.66 87.32 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.244 -0.91 . . . . 0.0 109.406 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.468 ' HB3' ' HD2' ' A' ' 161' ' ' LYS . 49.9 Cg_endo -70.05 151.97 67.63 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.754 2.303 . . . . 0.0 111.879 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -90.99 158.8 41.21 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.251 -0.906 . . . . 0.0 109.366 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -70.22 134.47 27.09 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.695 2.263 . . . . 0.0 111.784 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 95.24 -11.68 68.85 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.648 ' O ' HG23 ' A' ' 129' ' ' ILE . 23.9 p-10 -67.45 176.23 2.43 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.168 -1.195 . . . . 0.0 109.473 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.546 ' HA ' HD13 ' A' ' 129' ' ' ILE . 99.6 mttt -98.34 139.42 34.14 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.245 -0.91 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.971 HG21 HD22 ' A' ' 141' ' ' LEU . 15.0 m -135.14 149.8 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.631 ' N ' HD11 ' A' ' 162' ' ' LEU . 6.4 tp -120.84 142.47 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.498 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.444 HD11 HD21 ' A' ' 143' ' ' LEU . 62.1 mt -92.37 129.78 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.192 -0.943 . . . . 0.0 109.416 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.487 ' CA ' ' HG3' ' A' ' 124' ' ' GLU . 62.7 p -105.6 -9.97 17.09 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.194 -0.941 . . . . 0.0 109.483 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.421 ' O ' ' CG2' ' A' ' 118' ' ' ILE . 75.4 mm-40 -135.73 158.17 45.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.178 -0.951 . . . . 0.0 109.425 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 97.09 165.48 32.6 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.93 -20.78 65.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.205 -1.174 . . . . 0.0 109.43 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.515 ' CG ' HD13 ' A' ' 143' ' ' LEU . 64.1 m-85 -88.12 15.0 8.02 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.487 ' HG3' ' CA ' ' A' ' 119' ' ' THR . 83.2 tt0 -63.22 137.4 58.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.917 . . . . 0.0 109.469 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 95.7 0.96 62.13 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -105.67 128.43 53.65 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -1.173 . . . . 0.0 109.443 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -78.04 135.29 37.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.227 -0.921 . . . . 0.0 109.417 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.843 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -132.89 164.35 27.09 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.237 -0.915 . . . . 0.0 109.593 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.648 HG23 ' O ' ' A' ' 114' ' ' ASP . 39.3 mm -122.8 137.81 55.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.315 -0.865 . . . . 0.0 109.462 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.833 ' CE1' HD21 ' A' ' 141' ' ' LEU . 10.6 m-85 -58.56 102.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.679 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.423 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 47.0 p -79.43 -36.01 39.65 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.361 -0.837 . . . . 0.0 109.322 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.454 ' O ' ' HG3' ' A' ' 140' ' ' MET . 1.0 OUTLIER 170.02 87.53 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.325 -0.86 . . . . 0.0 109.308 179.899 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . 0.406 ' HB3' ' CB ' ' A' ' 139' ' ' SER . 49.5 Cg_endo -69.77 131.78 21.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.735 2.29 . . . . 0.0 111.871 -179.817 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -66.51 -32.36 73.66 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.374 -0.828 . . . . 0.0 109.415 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 138' ' ' ARG . . . -163.44 -178.4 37.11 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -70.5 -29.1 65.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -1.165 . . . . 0.0 109.49 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -66.14 -59.14 4.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.236 -0.915 . . . . 0.0 109.388 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.505 ' HG3' ' NH1' ' A' ' 138' ' ' ARG . 6.8 mtt85 -109.46 157.81 18.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 109.35 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.406 ' CB ' ' HB3' ' A' ' 133' ' ' PRO . 35.6 m -146.38 156.8 43.58 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.122 -0.986 . . . . 0.0 109.611 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.484 ' HA ' ' HA ' ' A' ' 153' ' ' SER . 49.6 mtp -99.46 127.54 45.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.905 . . . . 0.0 109.442 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.971 HD22 HG21 ' A' ' 116' ' ' VAL . 89.8 mt -126.27 135.73 51.91 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.524 ' CD1' ' HG2' ' A' ' 151' ' ' LYS . 8.0 tt -92.73 123.84 36.31 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.258 -0.901 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.633 HD23 ' HB2' ' A' ' 128' ' ' ALA . 16.5 mt -97.1 109.06 21.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.226 -0.922 . . . . 0.0 109.662 -179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.724 ' C ' HD12 ' A' ' 145' ' ' LEU . 12.8 p-10 -83.94 125.48 32.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.224 -0.922 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.724 HD12 ' C ' ' A' ' 144' ' ' ASN . 8.1 mp -119.24 145.73 45.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.17 -0.956 . . . . 0.0 109.441 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.511 HG13 ' N ' ' A' ' 147' ' ' ASN . 18.6 pt -53.44 -39.0 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.656 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.511 ' N ' HG13 ' A' ' 146' ' ' ILE . 95.4 m-20 -67.98 -44.88 75.63 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.451 ' HE3' ' CG2' ' A' ' 150' ' ' ILE . 11.8 pttt -167.17 173.41 9.1 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.589 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -104.13 129.37 51.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.435 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.451 ' CG2' ' HE3' ' A' ' 148' ' ' LYS . 25.8 pt -125.5 161.59 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.904 . . . . 0.0 109.427 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.524 ' HG2' ' CD1' ' A' ' 142' ' ' LEU . 20.6 mttt -125.34 133.02 52.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.473 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -145.87 142.72 29.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.464 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 44.9 p -77.17 140.96 40.32 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.553 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.463 HG12 ' HD2' ' A' ' 159' ' ' PHE . 14.6 t -137.62 146.48 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.293 -0.88 . . . . 0.0 109.482 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.534 ' HG2' ' CG ' ' A' ' 158' ' ' GLU . 1.3 ptpt -91.05 145.48 24.65 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.313 -0.867 . . . . 0.0 109.801 -179.89 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.552 ' HA ' ' CE2' ' A' ' 159' ' ' PHE . 2.0 p30 -48.96 -29.21 4.52 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.344 -0.847 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . 0.496 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 17.1 p -78.98 -20.96 47.81 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.105 -0.997 . . . . 0.0 109.975 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.534 ' CG ' ' HG2' ' A' ' 155' ' ' LYS . 44.0 mm-40 -87.64 -20.4 26.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.02 -1.05 . . . . 0.0 109.214 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.552 ' CE2' ' HA ' ' A' ' 156' ' ' ASN . 26.8 p90 -135.85 166.86 22.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.876 . . . . 0.0 109.607 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 37.1 ttt180 -130.26 136.96 49.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.469 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . 0.468 ' HD2' ' HB3' ' A' ' 110' ' ' PRO . 18.3 pttp -77.45 147.18 36.07 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.267 -0.895 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.775 HD12 ' N ' ' A' ' 162' ' ' LEU . 5.4 mp . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.03 -0.986 . . . . 0.0 109.46 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.471 -1.451 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -61.57 -34.32 75.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.252 -1.146 . . . . 0.0 109.466 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 72.7 mtm -56.12 -37.77 69.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.202 -0.936 . . . . 0.0 109.422 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . 0.46 ' O ' ' OD1' ' A' ' 103' ' ' ASP . . . -65.45 146.32 49.66 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.425 ' O ' ' HB2' ' A' ' 102' ' ' LYS . 50.1 Cg_endo -69.95 158.11 57.81 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.699 2.266 . . . . 0.0 111.849 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.486 ' HB3' ' CG2' ' A' ' 105' ' ' VAL . 62.6 mttp 61.63 53.32 3.31 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.301 -0.874 . . . . 0.0 109.499 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 100' ' ' GLY . 98.5 m-20 -59.85 -35.52 74.95 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.169 -0.957 . . . . 0.0 109.554 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 88.0 mt -63.64 -31.54 53.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.486 ' CG2' ' HB3' ' A' ' 102' ' ' LYS . 53.4 t -63.91 -40.61 89.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.471 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -94.64 109.99 46.66 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.298 -0.876 . . . . 0.0 109.487 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.9 52.93 1.09 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.654 2.236 . . . . 0.0 111.816 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -71.32 -33.04 69.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.446 ' CG2' ' HD2' ' A' ' 110' ' ' PRO . 29.3 m -72.53 138.79 80.73 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.229 -0.919 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.597 ' HB2' ' CE2' ' A' ' 130' ' ' PHE . 50.8 Cg_endo -70.18 146.89 58.89 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.736 2.291 . . . . 0.0 111.854 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' TYR . . . . . 0.445 ' HB3' ' HD2' ' A' ' 112' ' ' PRO . 15.7 m-85 -108.76 161.15 24.68 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.877 . . . . 0.0 109.411 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' PRO . . . . . 0.445 ' HD2' ' HB3' ' A' ' 111' ' ' TYR . 47.5 Cg_endo -68.93 136.09 34.25 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.713 2.275 . . . . 0.0 111.765 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 99.4 -8.82 60.61 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 77.5 m-20 -85.82 159.51 19.7 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.206 -1.173 . . . . 0.0 109.467 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.559 ' HB3' HD21 ' A' ' 162' ' ' LEU . 24.6 mttm -87.3 145.52 26.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.262 -0.899 . . . . 0.0 109.487 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.995 HG21 HD23 ' A' ' 141' ' ' LEU . 14.1 m -132.98 152.18 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.291 -0.881 . . . . 0.0 109.428 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.467 ' HB ' ' HB3' ' A' ' 162' ' ' LEU . 3.8 tp -122.0 140.71 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.281 -0.887 . . . . 0.0 109.55 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.459 HD12 ' HB3' ' A' ' 123' ' ' PHE . 73.4 mt -92.68 132.88 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.252 -0.905 . . . . 0.0 109.405 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.468 ' HA ' ' HG3' ' A' ' 124' ' ' GLU . 54.7 p -111.01 0.16 16.88 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.248 -0.908 . . . . 0.0 109.6 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.439 ' HA ' ' OE1' ' A' ' 120' ' ' GLU . 71.7 mm-40 -143.52 155.73 44.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.174 -0.954 . . . . 0.0 109.484 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . 90.35 164.26 39.65 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -63.74 -18.71 64.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -1.147 . . . . 0.0 109.473 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.752 ' CD1' HD13 ' A' ' 143' ' ' LEU . 96.9 m-85 -82.93 8.69 11.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.918 . . . . 0.0 109.535 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.468 ' HG3' ' HA ' ' A' ' 119' ' ' THR . 86.0 tt0 -62.7 138.96 58.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.249 -0.907 . . . . 0.0 109.465 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 89.23 0.11 80.68 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . . . . . . . . . 50.5 m-85 -102.99 137.54 41.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.466 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -89.44 143.08 27.1 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.884 . . . . 0.0 109.398 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.731 ' O ' HG22 ' A' ' 116' ' ' VAL . . . -142.2 160.36 40.4 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.214 -0.929 . . . . 0.0 109.482 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.486 HD13 ' O ' ' A' ' 128' ' ' ALA . 28.2 mm -116.16 137.13 50.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.278 -0.889 . . . . 0.0 109.528 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' PHE . . . . . 0.676 ' CE2' HG11 ' A' ' 116' ' ' VAL . 24.7 m-85 -58.77 106.2 0.38 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.238 -0.914 . . . . 0.0 109.584 179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.531 ' O ' ' CB ' ' A' ' 132' ' ' GLU . 43.4 p -77.55 -33.64 54.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.256 -0.903 . . . . 0.0 109.249 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.531 ' CB ' ' O ' ' A' ' 131' ' ' THR . 0.1 OUTLIER 163.05 96.53 0.01 OUTLIER Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.428 -0.795 . . . . 0.0 109.326 179.968 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -69.43 123.52 10.29 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.71 2.274 . . . . 0.0 111.773 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ASP . . . . . . . . . . . . . 78.8 m-20 -67.94 -33.03 73.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -150.24 174.71 29.58 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -69.57 -29.04 66.5 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.421 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -68.86 -74.16 0.13 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.161 -0.962 . . . . 0.0 109.344 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 33.0 ptt-85 -89.87 158.14 17.58 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.326 -0.859 . . . . 0.0 109.72 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 6.1 m -142.7 159.49 42.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.244 -0.91 . . . . 0.0 109.554 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' MET . . . . . 0.857 ' C ' HD12 ' A' ' 141' ' ' LEU . 64.0 mtp -101.31 120.13 39.8 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.272 -0.892 . . . . 0.0 109.344 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.995 HD23 HG21 ' A' ' 116' ' ' VAL . 6.6 mp -118.13 148.79 41.99 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.248 -0.908 . . . . 0.0 109.605 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' LEU . . . . . 0.741 HD13 ' HG2' ' A' ' 151' ' ' LYS . 48.9 tp -99.6 123.9 44.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.3 -0.875 . . . . 0.0 109.515 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.752 HD13 ' CD1' ' A' ' 123' ' ' PHE . 41.8 mt -98.18 110.84 23.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.95 . . . . 0.0 109.463 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 144' ' ' ASN . 20.1 p-10 -78.58 120.83 23.83 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.185 -0.947 . . . . 0.0 109.551 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' LEU . . . . . 0.843 HD11 HD13 ' A' ' 150' ' ' ILE . 67.9 mt -111.19 142.2 43.7 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.186 -0.946 . . . . 0.0 109.546 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.455 HG13 ' N ' ' A' ' 147' ' ' ASN . 24.7 pt -51.63 -31.11 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.453 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.52 ' O ' ' CG ' ' A' ' 148' ' ' LYS . 22.9 m120 -75.83 -55.57 5.5 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.465 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' LYS . . . . . 0.52 ' CG ' ' O ' ' A' ' 147' ' ' ASN . 23.2 mttt -158.98 171.92 19.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.176 -0.952 . . . . 0.0 109.474 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -88.34 130.03 35.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.22 -0.925 . . . . 0.0 109.325 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ILE . . . . . 0.843 HD13 HD11 ' A' ' 145' ' ' LEU . 42.4 pt -124.1 151.74 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.254 -0.904 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.741 ' HG2' HD13 ' A' ' 142' ' ' LEU . 90.8 mttt -109.18 128.52 55.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.302 -0.874 . . . . 0.0 109.379 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -141.27 132.18 25.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.549 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 140' ' ' MET . 46.1 p -77.94 140.35 39.24 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.32 -0.862 . . . . 0.0 109.471 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.566 HG12 ' HD1' ' A' ' 159' ' ' PHE . 13.4 t -134.82 148.39 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.254 -0.904 . . . . 0.0 109.55 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.545 ' CD ' ' HG2' ' A' ' 158' ' ' GLU . 16.2 ptmt -91.27 139.96 30.24 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.227 -0.921 . . . . 0.0 109.625 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.583 ' HA ' ' CE1' ' A' ' 159' ' ' PHE . 44.7 m-80 -46.34 -27.27 1.0 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.397 -0.814 . . . . 0.0 110.067 -179.592 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' THR . . . . . 0.522 ' OG1' ' CD ' ' A' ' 155' ' ' LYS . 15.8 p -79.83 -21.02 44.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.118 -0.989 . . . . 0.0 109.766 -179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' GLU . . . . . 0.545 ' HG2' ' CD ' ' A' ' 155' ' ' LYS . 46.3 mm-40 -87.67 -20.51 26.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.052 -1.03 . . . . 0.0 109.229 179.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' PHE . . . . . 0.583 ' CE1' ' HA ' ' A' ' 156' ' ' ASN . 39.3 p90 -136.17 168.68 18.94 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.339 -0.851 . . . . 0.0 109.667 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ARG . . . . . . . . . . . . . 15.3 mtp180 -133.09 159.7 39.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.258 -0.902 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -82.51 118.0 22.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.433 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' LEU . . . . . 0.559 HD21 ' HB3' ' A' ' 115' ' ' LYS . 1.5 pp . . . . . 0 N--CA 1.489 1.524 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.492 -179.981 . . . . . . . . 1 1 . 1 stop_ save_